Applications of magnetic particles for oligidendrocyte precursor cell transplantation strategies by Jenkins, SB
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is protected by copyright and other intellectual property rights and 
duplication or sale of all or part is not permitted, except that material may be 
duplicated by you for research, private study, criticism/review or educational 
purposes. Electronic or print copies are for your own personal, non-
commercial use and shall not be passed to any other individual. No quotation 
may be published without proper acknowledgement. For any other use, or to 
quote extensively from the work, permission must be obtained from the 
copyright holder/s. 
 
Applications of magnetic particles 
for oligodendrocyte precursor cell 
transplantation strategies 
 
 
 
Stuart Iain Jenkins 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy 
June 2013 
Keele University  
 
 
SUBMISSION OF THESIS FOR A RESEARCH DEGREE 
Degree for which thesis being submitted Doctor of Philosophy 
Title of thesis Applications of magnetic particles for 
oligodendrocyte precursor cell transplantation 
strategies 
This thesis contains confidential information and is subject to the protocol 
set down for the submission and examination of such a thesis?  NO  
Date of submission  04 February 2013  
Original registration date 12 January 2009 
Name of candidate  Stuart Iain Jenkins 
Research Institute  Institute for Science and Technology in Medicine 
Name of Lead Supervisor Dr Divya Maitreyi Chari 
I certify that: 
i. The thesis being submitted for examination is my own account of my own 
research 
ii. My research has been conducted ethically. Where relevant a letter from 
the approving body confirming that ethical approval has been given has 
been bound in the thesis as an Annex 
iii. The data and results presented are the genuine data and results actually 
obtained by me during the conduct of the research 
iv. Where I have drawn on the work, ideas and results of others this has been 
appropriately acknowledged in the thesis 
v. Where any collaboration has taken place with one or more other 
researchers, I have included within an ‘Acknowledgments’ section in the 
thesis a clear statement of their contributions, in line with the relevant 
statement in the Code of Practice (see Note overleaf). 
vi. The greater portion of the work described in the thesis has been 
undertaken subsequent to my registration for the higher degree for which I 
am submitting for examination 
vii. Where part of the work described in the thesis has previously been 
incorporated in another thesis submitted by me for a higher degree (if any), 
this has been identified and acknowledged in the thesis 
viii. The thesis submitted is within the required word limit as specified in the 
Regulations 
Total words in submitted thesis (including text and footnotes, but excluding references and 
appendices) ……………… 48,988 
Signature of candidate ………………………………… Date ………… 
 i 
 
Abstract: 
Oligodendrocyte precursor cells (OPCs) are a major transplant population to 
promote myelin repair and central nervous system (CNS) regeneration in conditions such 
as Multiple Sclerosis and spinal cord injury. Magnetic particles (MPs) can offer a 
multifunctional platform for cell therapies, facilitating labelling for cell tracking (e.g. by 
MRI and histopathology); biomolecule delivery (including nonviral gene delivery, 
enhanceable by novel ‘magnetofection’ strategies); and magnetic cell targeting of 
transplant populations. However, MP-based applications for neural tissue engineering have 
received limited attention to date.  
This thesis demonstrates that ~60% of OPCs (derived from a primary source) can 
be safely labelled using two well-characterised MP formulations, including a novel 
multimodal MP with transfection plus cell labelling capabilities. A rapid, technically 
simple, high-throughput ultrastructural imaging technique, OTOTO SEM, has been 
developed to study the surface interactions of MPs with precursor cells. Safe MP-mediated 
transfection of OPCs was demonstrated, including with multiple and therapeutic genes. 
Transfection efficiency was enhanced by static/oscillating ‘magnetofection’ techniques 
(~21%; competitive with nonviral alternatives). Organotypic cerebellar slice cultures were 
developed as a model of ‘host’ neural tissue, and ‘magnetofected’ OPCs exhibited normal 
migration, proliferation and differentiation profiles following transplantation onto such 
slices. 
Safe labelling (~45%) and transfection (enhanced by static/oscillating 
magnetofection strategies: ~6%) of oligodendrocytes was achieved utilising identical 
protocols to those developed for OPCs. A comparative intralineage analysis demonstrated 
that MP-uptake and amenability to transfection were significantly lower in 
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oligodendrocytes compared to OPCs. Inter-cellular comparisons of MP-handling by the 
four major CNS glial subtypes (viz. OPCs, oligodendrocytes, astrocytes, microglia; derived 
from the same primary source) revealed major differences in the rate/extent of MP uptake, 
amenability to transfection, optimal magnetofection frequency, and MP-associated 
toxicity. Finally, a stoichiometrically-defined glial co-culture model was developed and 
utilised to test the hypothesis that microglia represent an ‘extracellular barrier’ to MP 
uptake by other glia. 
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Chapter 1: General introduction 
 
  
 2 
 
1.1 Myelin loss is common to Multiple Sclerosis and spinal cord injury 
The adult mammalian central nervous system (CNS; the brain and spinal cord) has 
a limited capacity for regeneration. As a result, disease or injury is often associated with 
permanent neurological deficits, with poor clinical prognoses and potentially severe 
personal and socioeconomic costs. Two of the most common neurological conditions in 
young adults are Multiple Sclerosis (MS) and spinal cord injury (SCI).
1–3
 MS is the most 
prevalent progressive neurological condition in young adults, with onset typically 
occurring at 20 – 40 years of age, and it is the second most common cause of disability in 
young people in the Western world, after trauma;
4
 SCI can occur at any age, but is most 
frequent at 16 – 30 years of age, often leading to life-long disability.5 Consequently, there 
is a major need for repair-promoting therapies, as current treatments for such conditions 
attempt to alleviate symptoms and limit progression of the condition, rather than instigate 
significant regeneration.  
In both MS and SCI, impairment or loss of neurological function is due to the loss 
of nerve fibres and/or the loss of myelin (the fatty insulating sheath around nerve fibres).
6
 
Myelin is produced and maintained by oligodendrocytes, which are the myelinating cells 
of the CNS. These cells produce vast quantities of specialised membrane which forms 
highly compacted myelin sheaths around axons and, as there is very limited water content, 
myelin functions as an excellent insulating material.
7,8
 Approximately 70% (dry weight) of 
myelin is composed of lipids, predominantly cholesterol and glycosphingolipids [notably 
galactosylceramide (GalC)], with ~30% protein, and the majority of these components are 
unique to myelin.
9,10
 Myelin sheaths are separated by exposed regions of axon known as 
nodes of Ranvier, at which ion channels are clustered, and this facilitates rapid and 
efficient saltatory conduction of electrical impulses (action potentials); this conduction is 
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diminished or even abolished as a consequence of myelin damage/loss.
11–13
 Further, myelin 
has been shown to be essential for the long-term survival and normal function of axons, 
including the provision of metabolic support.
14–18
  
 
1.2 Remyelination is a rare example of CNS regeneration 
Although the CNS has a poor intrinsic capacity for regeneration, a notable 
exception to this is the phenomenon of ‘remyelination’: a regenerative event that involves 
the production of new myelin sheaths that can restore saltatory conduction to demyelinated 
axons.
1,6
 The concept of remyelination in the CNS had been proposed in the 1950s, and 
was shown by Bunge et al. (1960, 1961) to occur following experimental demyelination of 
the spinal cord.
19,20
 Although these and subsequent reports showed that remyelination of 
CNS axons was possible, it was characterised by thinner sheaths and shorter internodes 
than normal, leading to doubts about whether this could support impulse conduction.
21,22
 It 
was not until a seminal 1979 report that remyelination was shown to restore axonal 
conduction and neurological function in the CNS.
23,24
 It is now known that following most 
insults, including SCI
25
 and MS,
1
 CNS lesions exhibit some evidence of remyelination, 
which can facilitate functional recovery. Importantly in the context of disease progression, 
myelin is neuroprotective, and demyelinated axons are vulnerable to environmental 
stressors, which can lead to axonal atrophy and degeneration, with concomitant loss of 
neurological function.
14–18
 Therefore, strategies to activate and enhance remyelination 
are currently a key goal of experimental neurology.  
The development of remyelination enhancing strategies is critically dependent upon 
a clear understanding of the biology of myelin genesis; valuable insights into this process 
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have been gained from an understanding of the process of developmental myelination in 
mammals. During this process, a population of highly proliferative and migratory 
precursor/stem cells called oligodendrocyte precursor cells (or OPCs, which as their name 
suggests are the parent cells of the oligodendrocytes) arise in defined CNS regions, and in 
several waves, populating the brain and spinal cord separately.
26
 An OPC population arises 
in the ventral ventricular zone of the spinal cord involving sonic hedgehog (Shh) 
signalling, and these cells start to populate the entire spinal cord, before a second wave 
arises in the dorsal spinal cord from radial glia, which competes largely unsuccessfully 
with the first wave, eventually generating ~10 – 15% of spinal cord oligodendrocytes.26 In 
the brain, OPCs first arise in the medial ganglionic eminence and the anterior 
entopeduncular area of the ventral forebrain, populating the entire telencephalon and 
cortex. However, a second wave of OPCs arises in the lateral and/or caudal ganglionic 
eminences, almost completely replacing the first wave. Finally a third wave arises in the 
cortex (postnatal in rodents), which competes with the second wave.
27
 Experimental 
ablation of each of these waves in mice has shown that each alone can populate the entire 
brain with oligodendrocytes and result in normal myelination.
27
 Eventually, OPCs receive 
temporally- and spatially-controlled signals that halt migration and stimulate most (but not 
all) OPCs to differentiate into oligodendrocytes (an OPC subpopulation persists into 
adulthood hence both cell types are present in the adult CNS, with the OPCs representing 5 
– 8% of CNS cells).28 
In the next stage of the process, the OPCs lose their characteristic bipolar 
morphology (becoming multipolar), lose their migratory capacity, and undergo a sequence 
of antigenic shifts as they progress through several developmental stages, eventually 
becoming mature myelinating oligodendrocytes (Figure 1).
9,29
 Early oligodendrocytes 
extend membrane processes to make contact with numerous axons (reports vary, with 10 to 
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60 axons per oligodendrocyte being suggested) within ~30 µm of the cell body.
9,10
 As they 
mature, oligodendrocytes form myelin sheaths, in a tightly temporally-regulated event that 
appears to occur within an 18 h window; such regulation depends on several factors, 
including electrical activity in neurons, and the expression of complementary cell adhesion 
molecules by oligodendrocyte processes and axons.
7,30
 
The leading edge of the oligodendrocyte process then wraps once around the axon, 
and forms a spiral by growing between the continuously extending process and the axon. 
After approximately three wraps/layers are formed, the process of lamellar compaction 
begins, aided by myelin basic protein (MBP), which links the layers (lamellae) in tight 
apposition forming what are known as the major dense lines, and extruding the cytoplasm 
to the less tightly compacted lamellae at the paranodes abutting the nodes of Ranvier.
31
 
Oligodendrocytes and axons engage in extensive cross-talk during myelination, which 
mutually influences their development. For example, the number of wraps determines the 
myelin thickness, which in turn is proportional to the axon diameter; this is likely 
controlled by axonal signalling, as individual oligodendrocytes can myelinate axons of 
differing diameters, resulting in differing numbers of lamellae.
10
 In turn, the presence of 
myelin prevents the aberrant sprouting of new branches from axons during development.
31
 
This cross-talk illustrates that highly coordinated events are necessary for the generation of 
functional myelin sheaths, and this is followed by continuous turnover of myelin 
components,
32,33
 a process which is critical to neuronal survival and function. 
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Figure 1: Schematic illustrating the developmental stages of the oligodendroglial 
lineage. OPCs are proliferative cells, which generate oligodendrocytes during 
developmental myelination (through the stages indicated), and also leave a residual 
population of ‘adult’ OPCs. Following activation, adult OPCs engage in proliferation. 
Antigenic profiles are indicated for each stage.
9,34,35
 Blue arrows indicate proliferating cell 
types. 
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The vast majority of what is known about the oligodendroglial lineage and developmental 
myelination of the CNS has been derived from rodent models, but what is known from 
equivalent human biology is largely in agreement, including the sequence of events in 
myelination, the broad rostro-caudal sequence in which CNS regions are myelinated 
(Table 1), and the antigenic markers of the oligodendroglia.
34,36,37
 Various therapeutic 
molecules (e.g. fingolimod, FTY720)
38
 that enhance survival or promote differentiation in 
rodent oligodendroglia produce the same effects in human oligodendroglia, further 
suggesting that rodent models of myelination serve as good models of human myelination, 
of relevance to basic research studies that aim to develop myelin repair strategies.  
Table 1: Age at which myelination begins in various brain regions for human and rat.  
Brain Region Human age (Postnatal 
months; GM = 
Gestational month) 
Rat age 
(Postnatal days) 
Cerebellar peduncles GM 7 7 
Lateral lemniscus GM 6 9 
Medial lemniscus GM 6 10 
Brachium, superior colliculus GM 8 10 
Internal capsule 1 10 
Stria medullaris 4 10 
Habenula-peduncular GM 6 12 
Brachium, inferior colliculus GM 7 12 
Fornix 6 12 
Corpus callosum & corticospinal tract GM 7 14 
Olfactory tract 2 14 
Anterior commissure 3 17 
50% of adult myelination complete 18 25 
100% of adult myelination complete 20-30 years 90-100 
Adapted from Yakovlev et al.
11
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1.3 Remyelination recapitulates developmental myelination 
It is important to note here that the process of remyelination broadly recapitulates 
the process of developmental myelination. As in CNS development, the OPCs play critical 
roles in generating new oligodendrocytes that subsequently mediate the remyelination 
process; the appearance of remyelinating oligodendrocytes in lesions is preceded by the 
appearance of a population of OPCs, which have now been proven by fate-mapping to 
generate remyelinating oligodendrocytes.
39
 Remyelination has been proposed to consist of 
three stages:
28
 (i) activation of OPCs, with subsequent proliferation and colonisation of 
lesion sites, (ii) differentiation of these OPCs to generate oligodendrocytes which associate 
with demyelinated axons, and (iii) the formation of functional myelin sheaths by these 
oligodendrocytes. Each of these stages is associated with temporally-specific growth factor 
expression, and the expression (and downregulation) of each factor must occur in an 
appropriate sequence in order to orchestrate the relevant stages of remyelination (for 
example, see Figure 2).
40,41
 
Remyelination failure: Remyelination in rodent models can be extensive, 
however, human remyelination frequently does not proceed to completion and ultimately 
fails in the majority of patients and lesions.
28,42,43
 The reasons for remyelination failure are 
still unclear, and a detailed discussion is beyond the scope of this introduction, but in brief, 
the prevailing theories suggest: (i) depletion of the repair mediating OPC population, (ii) 
the limited migratory capacity of adult OPCs, and ‘temporal mismatches’ between the 
presence of a repair-promoting environment and lesion colonisation by OPCs, (iii) the 
failure of quiescent OPCs to generate myelinating oligodendrocytes, and (iv) the 
unreceptive nature of mature axons for (re)myelination.
1,28
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Figure 2: Stages of remyelination and associated growth factor expression. Focal 
demyelination was induced by lysolecithin injection into the spinal cord of adult rats (day 
0). By 2 days post-lesion, demyelinated fibres were apparent, by 5 days demyelination was 
widespread, peaking at 10 days. Remyelinated fibres were apparent from day 10, the peak 
rate of remyelination was from days 14 – 21, and remyelination was complete by day 28. 
Shapes labelled IGF-1 (insulin-like growth factor-I), TGF-β1 (transforming growth factor-
β1), PDGF-A and FGF2 indicate increased mRNA expression of these growth factors. The 
recruitment phase is associated with upregulation of PDGF-A and FGF2, whereas peak 
IGF-1 and TGF-β1 expression coincides with the onset of remyelination, suggesting their 
involvement in the differentiation phase, which may also require downregulation of FGF2. 
Adapted from published data.
40,41
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1.4 OPCs are a major transplant population to promote myelin repair 
Given our knowledge of the remyelination process, it is clear that OPCs play a 
pivotal role in myelin repair and that one of two strategies can be adopted to enhance this 
important regenerative event: (i) activate and enhance intrinsic repair mechanisms, or (ii) 
bypass intrinsic repair by cell transplantation. The latter is likely to be the more feasible 
strategy from a practical and clinical (translational) perspective,
28
 and will be considered in 
more detail in this thesis. The potential for transplanted OPCs (derived from a variety of 
sources) to enhance myelin repair has been demonstrated by their transplantation into 
animal models.
44–46
 These reports can be broadly divided into (a) developmental studies, 
involving myelination of previously unmyelinated axons, and (b) injury studies, involving 
remyelination of demyelinated axons.  
As examples of the former, transplantation of OPCs into dysmyelinating/ 
hypomyelinating mutant rodents has resulted in myelination throughout the CNS, and 
rescue of individuals from typically lethal conditions. A widely used example is the 
hypomyelinated shiverer mouse, which is MBP-deficient, allowing the identification of the 
transplant-derived oligodendrocytes as MBP
+
.
47
 For example, Windrem et al. transplanted 
human OPCs into newborn shiverer mice, demonstrating extensive myelination, 
neurological improvement and enhanced survival in ~26% of the mice receiving 
transplants (with the suggestion of complete rescue of several animals), whereas all control 
mice died at an early timepoint.
48
 Of greater relevance to promoting remyelination, OPC 
transplant populations have also been successfully tested in demyelination models.
46,49
 
Givogri et al. transplanted primary OPCs into the ventricle of a neonatal mouse model of 
metachromatic leukodystrophy, a genetic disorder leading to demyelination and extensive 
loss of oligodendrocytes.
50
 These OPCs generated myelinating oligodendrocytes, which 
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were identifiable one year post-transplantation, and motor function was significantly 
improved compared to animals without transplants. Keirstead et al. transplanted human 
embryonic stem cell (ESC)-derived OPCs into adult rodent models of SCI, demonstrating 
remyelination and associated improvement in motor function.
51
 The developing CNS is a 
far more favourable environment for regeneration and for the survival of transplanted cells, 
and therefore the latter study is significant in that functional improvements were shown 
after cells were transplanted into the adult CNS. OPCs do not survive when transplanted 
into the normal adult (myelinated) CNS, but do survive when transplanted in the vicinity of 
demyelinated lesions in the adult CNS.
52,53
 All of these studies support the concept that 
OPCs represent a major transplant population for promoting remyelination. 
OPC transplant populations can be derived from a variety of sources [including 
foetal tissue, adult tissue, neural stem cells (NSCs) and ESCs], and ESC, NSC and OPC 
populations can all be expanded in vitro, suggesting the potential for clinical 
translation.
11,34,54,55
 Indeed, a phase I clinical trial has been approved for transplantation of 
human ESC-derived OPCs into SCI.
56
 This trial has stopped enrolling new patients, a 
decision taken on financial grounds, but the current subjects will continue to be monitored, 
and no adverse effects of the transplants have been reported.
57,58
 Further evidence of the 
safety of OPC transplantation was provided by a recent review of preclinical OPC 
transplant studies for SCI models, which noted that across 24 separate studies there were 
no recorded instances of teratomas, systemic toxicity, allodynia (pain resulting from 
aberrant integration of the transplant cells), increased mortality or allogeneic immune 
responses.
56
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1.5 ‘Combinatorial’ approaches are required for CNS regeneration 
Despite the positive outcomes from the above studies and the enhanced 
remyelination seen following OPC transplantation, it seems likely that the repair capability 
of transplant populations will require augmentation in order to further enhance CNS 
regeneration, for example by introducing growth factors or other therapeutic molecules 
into the lesion site, typically achieved by intravenous or intrathecal injection, or 
implantation of an osmotic pump.
45,59,60
 ‘Combinatorial therapies’ that combine multiple 
strategies, particularly when in an appropriate sequence for appropriate periods of time, 
have produced more promising results than singular therapies, and are widely considered 
to be necessary for CNS repair in general.
43,59
 Studies using a variety of cell types and 
disease/injury models lend support to this notion, including the demonstration of 
synergistic effects of multiple treatments.
45,59,60
 For example, Karimi-Abdolrezaee et al. 
produced a rodent SCI model, then compared the functional recovery due to a variety of 
therapies [intrathecal chondroitinase ABC; intrathecal PDGF-AA, FGF2 and epidermal 
growth factor (EGF); NSC transplantation] delivered individually and in combination.
59
 
Both the chondroitinase- and growth factor-treated groups (with cell transplantation) 
showed significantly greater transplant cell survival and migration distance, and a greater 
proportion of NSCs underwent oligodendroglial differentiation compared to control 
animals, which received cell transplants without supplementary treatments. Importantly, 
the authors report that significant locomotor recovery (13 – 15 weeks post-injury; 6 – 8 
weeks post-treatment) occurred only when all three treatments were combined. 
With respect to combinatorial therapies involving OPCs, Milward et al. 
transplanted CG4 cells (an oligodendroglial cell line originally derived from neonatal rat 
cortex), along with a neuroblastoma cell line (B104) intended to provide growth factors for 
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the CG4 cells, into the spinal cord of hypomyelinated mutant rats.
61
 The authors concluded 
that this stimulated more proliferation of the CG4 cells than transplantation of CG4 cells 
alone.
61
 However, the transplantation of tumour cells is not a suitable strategy for 
translation to the clinic. By applying gene therapy approaches to cells prior to 
transplantation, for so-called 'ex vivo gene delivery', transplanted cells can serve as 
delivery vehicles for therapeutic biomolecules. This technique can overcome many of the 
problems inherent to other drug delivery methods, including the short half-life of proteins, 
which necessitates costly production and repeated applications.
62
 These combinatorial 
approaches could be harnessed to manipulate multiple aspects of the remyelination process 
to promote more effective regeneration.
43,59
 Magy et al. made the first report of genetically 
modified OPCs showing a functional effect, by transfecting CG4 cells to express FGF2 and 
selecting stably transfected clones.
63
 The transgenic cells were shown to enhance the 
production of myelin-associated proteins and myelin sheaths when co-cultured with 
dissociated cortical tissue containing neurons. Two studies by Cao et al. have gone further, 
and investigated the transplantation (into in vivo models of SCI) of primary OPCs 
genetically modified to express neurotrophic factors [ciliary neurotrophic factor (CNTF) in 
one study,
60
 and a multineurotrophin (D15A, with both brain-derived neurotrophin factor, 
BDNF, and neurotrophin-3, NT3, activity) in the other
64
]. In both cases, transplanted cells 
were shown to generate remyelinating oligodendrocytes within the lesions, which were 
associated with restored impulse conduction and functional improvements. It is critical to 
note that these improvements were significantly greater than were observed following 
transplantation of unmodified OPCs, transplantation of fibroblasts secreting the same 
neurotrophin, or in vivo gene therapy with the same neurotrophin (adenoviral delivery of 
D15A; D15A experiment only). This demonstrates the effectiveness of genetically 
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engineering an appropriate transplant population as a combinatorial approach to 
remyelination-promoting therapy. 
 
1.6 Testing the therapeutic potential of cell therapies: Organotypic neural slice 
models for transplantation biology 
Cell transplantation studies such as those detailed above are necessary to facilitate 
translation to the clinic, but progress in transplant biology is hampered by a heavy reliance 
on live animal experimentation for such studies, which require large numbers of animals 
(for sufficient statistical power, and for sham surgical controls), surgical expertise, 
considerable time and financial costs, and raise ethical concerns, especially with respect to 
injury/disease models. These factors have fuelled a major international drive to develop 
alternatives to live animal experimentation. To address these issues and with reference to 
the reduction element of the 3Rs principle (the Replacement, Reduction and Refinement of 
the use of animal models),
65
 there is significant interest in developing high-throughput in 
vitro models of the CNS (including injury/disease models) in order to test therapeutic 
interventions. 
66–68
 
One promising approach in this regard is the use of organotypic slice cultures, 
which can be prepared from various regions of the CNS through a simple slicing 
technique, and then maintained in culture on a piece of membrane for up to seven months. 
69–72
 These slice cultures offer major advantages which may serve to bridge the gap 
between isolated cell and pre-clinical animal experimentation, including low costs,
73,74
 
technical simplicity,
69,70,75
 the potential for high throughput assays,
73
 reduced experimental 
variability due to the ability to use slices from the same animal for both treatment and 
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control assays, preservation of neural cytoarchitecture,
70,75,76
 and the ability to produce 
injury
74,77
 and disease
38,78–80
 models in slices. The most appropriate CNS regions for the 
establishment of slice cultures are those with lamellar structure, with the main axonal tracts 
in a single plane (e.g. spinal cord and cerebellum).
73
 Such regions can be sectioned parallel 
to these tracts, preserving the cytoarchitecture of particular neural circuits.
73
 The 
distribution of oligodendrocytes
81
 and the expression of MBP
82
 in neural slice cultures has 
been reported to closely mimic in vivo observations. In particular, rodent cerebellar slice 
cultures offer an appropriate environment for the study of transplanted OPCs, as large 
tracts of Purkinje nerve fibres descending from the cerebellar folia to the deep cerebellar 
nuclei (DCN) are preserved, with these tracts undergoing myelination in vitro,
83
 mimicking 
in vivo myelination of the cerebellum, which occurs postnatally in rodents.
84
 
Synaptic connections are preserved in slice cultures, as evidenced by spontaneous 
electrical activity,
71
 and electrophysiological recordings can be obtained from nerve fibre 
tracts.
85
 Rodent cerebellar slices have been used as in vitro models of alcohol-related 
disorders,
86
 tumour invasion,
87
 and cerebellar ataxia,
80
 in order to screen therapies such as 
drug delivery.
73
 These neural slices can also be used as models of 
demyelination/remyelination, and the ability to culture them for several months enables 
‘transplant’ studies to be performed, with the slice as ‘host’ tissue.78,88 When neonatal 
neural tissue is placed in contact with cerebellar slices (from hypomyelinated mutants, or 
pretreated with cytosine arabinoside to prevent oligodendrocyte differentiation), OPCs will 
migrate from this tissue into the cerebellar slice, resulting in cerebellar myelination.
89
 
Purified, dissociated OPCs have also been transplanted onto cerebellar slice cultures 
(cytosine arabinoside treated), resulting in remyelination.
90
 Recently, Zhang et al. 
transplanted OPCs (lentivirally transduced to express green fluorescent protein, GFP) onto 
mouse cerebellar slices and found that they produced GFP
+
 myelin sheaths.
4
 These 
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experiments demonstrate the utility of organotypic cerebellar slice cultures as a high 
throughput screening system for testing the effects of OPC transplantation on 
remyelination without the use of a live animal injury/disease model, before proceeding to 
pre-clinical animal testing. 
 
1.7 Technical challenges in cell transplant studies and translational considerations 
A variety of cell transplantation therapies (both neural and non-neural) are 
currently the subject of active research globally, and they face many of the same technical 
challenges with respect to the testing of their efficacy and suitability for translation to the 
clinic: (i) Cells must be non-invasively tracked post-transplantation, (ii) transplanted cells 
must be identifiable by histology, post-mortem, (iii) for the development of combinatorial 
therapies, the need to genetically engineer a transplant population must be met, (iv) cells 
must be delivered/targeted to lesions, and (v) all of these processes must be demonstrably 
safe for both the transplant population and the host. These will now be considered in turn. 
 
1.7.1 Non-invasive imaging of transplanted cells 
A non-invasive imaging technique to track transplanted cells is essential to 
accurately correlate functional neurological recovery with the biodistribution of transplant 
cells in particular lesion sites in real-time.
91,92
 Non-invasive imaging would enable long-
term studies to be performed, and such a technique could be employed clinically.
93,94
 . 
Magnetic resonance imaging (MRI) is a major candidate technique for this purpose, and is 
being extensively tested in cell transplant studies, including with OPC cell lines.
95–98
 This 
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technique requires that the transplant population is labelled with a suitable contrast agent, 
such as a compound including a heavy metal (e.g. iron, gadolinium). MRI has a resolution 
of ~500 µm in current clinical scanners, but high magnetic field (up to 9 T) research 
scanners have demonstrated a resolution of ~10 µm,
99
 with recent refinements allowing the 
identification of individual cells.
100
 Although MRI is currently the most widely used non-
invasive imaging technique, optoacoustic, computed tomography (CT) and fluorescence 
imaging have been developed, which can be used to track gold particle-labelled cells 
(optoacoustic and CT imaging) and fluorophore-labelled cells (fluorescence imaging).
99
 
Optoacoustic imaging is achieved by causing expansion of gold nanoparticles through 
infra-red irradiation and detecting the resulting soundwaves.
99
 Non-invasive fluorescence 
imaging involves changing the electron energy levels in fluorophores through illumination, 
and detecting the emitted light as the fluorophore returns to its original activation state.
99
 
Positron emission tomography (PET) has been employed for tracking radionuclide-labelled 
cells, but this technique is unlikely to be applied to cell transplant imaging due to the short 
half-life of such radio-isotopes,
99
 and PET has poor spatial resolution, of approximately 1 – 
3 mm.
92,101
 Although MRI has lower sensitivity than optoacoustic and fluorescence 
imaging, it has the advantages: (i) of providing detailed anatomical imaging (e.g. allowing 
identification of inflammation and assessment of lesion size) in parallel to the detection of 
the labelled cells;
92,99
 (ii) of not using potentially harmful radiation (in contrast to CT and 
PET scanners);
92
 and (iii) significant infrastructure and expertise is in place at clinics 
worldwide. 
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1.7.2 Histopathological detection of transplanted cells 
Post-mortem histological analyses are required to assess transplant cell survival, 
rejection, differentiation profiles and integration, including for example the extent of 
remyelination.
91,94,102
 A diverse range of approaches have been utilised to address the 
problem of graft detection. Identifying the transplant population may rely on the selection 
of a distinguishable donor and host (e.g. different gender or species,
103
 GFP
+
 cells from a 
mutant donor;
104
 these approaches may require immune suppression of the host,
105
 and can 
be predicted to have limited translational potential), or will require effective labelling of 
the cells pre-transplantation.
97
 The labelling of a cell transplant population for histological 
detection can be achieved by staining cells with a dye (e.g. carbocyanine),
106
 incorporation 
of a contrast agent,
93,107
 incorporation of a fluorophore,
106
 or transduction/transfection with 
a transgene that will render the cells identifiable.
97
 A common gene delivery technique 
involves transduction with the lacZ gene, which encodes the β-galactosidase enzyme. 
Successfully modified cells (LacZ
+
) are then histochemically-detected post-transplantation 
by incubation with the X-gal enzyme substrate (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside), resulting in an intense blue product.
108
 There are a range of drawbacks 
associated with these labelling approaches. For example, labelling cells with a dye is 
generally unreliable, as the dye can leach from the transplanted cells and stain endogenous 
cells, post-transplantation.
95
 Delivery of a reporter gene, such as lacZ, is not ideal for 
tracking transplant populations in the CNS since microglia exhibit high endogenous levels 
of β-galactosidase, increasing the risk of obtaining false-positive results.108 Finally, the 
gene delivery technique used, for example viral delivery, can have unwanted toxic effects 
(section 1.7.3 will discuss viral toxicity). 
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1.7.3 Gene delivery to cell transplant populations 
Free nucleic acids are not readily taken up by cells, as their size and negative 
charge hinder membrane interactions.
109
 Although this can be overcome by direct 
microinjection into cells, electroporation, or gene gun (ballistic) delivery,
110,111
 these 
techniques have limited clinical potential, with the latter two techniques being associated 
with adverse effects including membrane damage, abnormal cell physiology and 
substantial cell death (up to 80% cell loss in OPCs),
110,111
 necessitating the use of viral or 
nonviral vectors to facilitate nucleic acid transport into cells.
109
 Gene delivery to neural 
cells is largely achieved using viral vectors (a process termed ‘transduction’), which 
include adenovirus, adeno-associated virus (AAV), an amplicon based on the herpes 
simplex virus (HSV), and various retroviruses (Table 2).
60,64,112,113
 Whilst viral methods 
can mediate gene delivery to a significant proportion of a cell population (up to 90% has 
been shown with OPCs,
50
 although results are highly variable), and have yielded valuable 
information in experimental studies on myelin repair, they are associated with significant 
drawbacks, primarily safety concerns including direct toxicity, inflammatory responses, 
nonspecific cellular uptake and oncogenic effects leading to abnormal cellular 
growth.
110,112,114–117
 For example, adenoviral vectors are typically highly efficient for gene 
delivery, but are also highly immunogenic, prompting adaptive immune responses against 
the viral capsid proteins, which possibly leads to the suppression of transgene 
expression.
118
 Adenoviruses can trigger cellular immune responses which cause viral 
clearance and humoral immune responses which make re-administration of the vectors 
ineffective.
118
 There is also evidence that viral vectors are directly toxic to oligodendroglial 
cells, altering OPC proliferation and differentiation, causing oligodendrocyte death, and 
damaging myelin.
114,119
 There are major limitations with viral transduction in terms of 
limited plasmid insert size, and the infrastructure necessary to achieve large scale 
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production for clinical applications (which includes biological safety cabinets), and it 
should be noted that the safest viral option (AAV) is also the least efficient,
120
 leading to a 
major international drive to develop nonviral alternatives for gene delivery.
116,117
 A number 
of nonviral transfection methods have been tested with OPCs, including calcium phosphate 
precipitation and liposomes, but these also have significant disadvantages, including 
typically lower levels of transfection efficiency than viral methods, and toxicity, with 
calcium phosphate precipitation in particular resulting in a 10% viability rate.
108,111
 As a 
consequence, physical gene delivery techniques have been applied, such as biolistic 
transfection (gene gun)
111
 and electroporation,
108
 with adverse consequences as mentioned 
at the outset of this section.  
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Table 2: Comparison of viral vectors for gene delivery, with associated drawbacks. 
Viral 
vector 
Genome 
vector 
size 
(nm) 
Insert 
size 
(kb) 
Transduction 
efficiency 
Large scale 
production 
Pathogenicity 
Stable insertion/ 
Insertional 
mutagenesis 
Adeno-
associated 
virus 
(AAV) 
 
 
ssDNA 
 
 
~20 
 
 
~4.5 Low Yes 
 
 
Low 
 
 
Low 
~2.2 Low, but 
greater than 
4.5 kb AAV 
~8* Low* 
Retrovirus 
(e.g. 
MoMuLV, 
lentivirus) 
ssDNA ~100 ~8 High, but 
requires 
mitosis121 
Yes, but only 
of 
moderately-
pure vector 
Initial exposure 
can be toxic 
Yes; vectors 
typically modified 
to limit this 
Adenovirus dsDNA 70-
100 
~36 High Yes, but with 
helper virus 
contamination 
Yes, immune 
response to 
adenovirus and 
helper virus 
Low 
 
Amplicon 
(HSV-
based 
plasmid in 
HSV coat) 
dsDNA ~186 ~150 No data 
available; can 
infect non-
dividing cells 
No Cytotoxicity and 
immune 
response to 
helper HSV 
contamination 
Low 
 All data refers to replication-deficient, modified viruses. ssDNA = single stranded DNA; dsDNA = double-stranded DNA; 
MoMuLV = Moloney murine leukaemia virus; HSV = herpes simplex virus. Details from Lentz et al.120 and Neve & 
Carlezon.122 *Requires co-transduction with two inserts which are then joined within the cell. 
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1.7.4 Targeting of transplant cells to lesion sites 
In order to be effective, transplant populations must be delivered or targeted to 
lesions. However, direct injection into a lesion, or the CNS parenchyma, will likely cause 
secondary physical damage including disruption of the blood brain barrier (BBB) risking 
inflammation, haemorrhage and embolism formation.
1
 Alternatively, cells can be 
introduced intravenously, intraventricularly or intrathecally, methods which are more 
likely to be used clinically than parenchymal injection.
95
 However, it is probable that these 
approaches will result in many cells diffusing away from the target site, and it would be 
beneficial to develop strategies to localise or target the transplant cells to the desired area 
to facilitate attachment and integration, particularly to minimise cell loss in situations 
where a limited cell source exists. One possibility is the implantation of a synthetic 
scaffold pre-seeded with cells,
123,124
 with such technology being the subject of extensive 
preclinical testing, which has demonstrated functional improvements in a rat model of 
SCI.
125
 However, delivery of a scaffold would likely involve highly invasive surgery to 
expose the CNS for implantation.  
 
1.7.5 Safety of cellular engineering and transplant procedures 
The requirement that transplantation of a genetically modified cell population is 
safe, encompasses a wide variety of factors. The transplant cells must be pathogen-free,
1
 
and the cell type chosen must not be tumourigenic (as ESCs have been shown to be) or 
immunogenic.
126,127
 In this context, human ESC-derived OPCs have been shown to retain 
some of the immunological properties of ESCs which confer immunological privileges, 
preventing adverse immune responses, and hence graft rejection, but do not demonstrate 
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the tumourigenic potential of ESCs.
128
 The risk of introducing pathogens (bacterial, viral, 
or simply xenogeneic material from culture or engineering procedures)
55
 into the transplant 
population increases with multi-step manipulations, for example separate labelling and 
gene delivery procedures. Multiple manipulations also increase the risk of unintended 
alterations to the cells, and immune cells can mount responses to cells that they determine 
to be abnormal.
129
 It is important to ensure a high rate of survival of labelled cells, as dying 
cells will release their labelling agent, which is then likely to be taken up by host cells, as 
has been shown following rejection of cell grafts, leading to a false detection rate of 
transplanted cells.
130
 The techniques employed to engineer the transplant cells, including 
labelling and gene delivery, must not cause unwanted side effects, such as prolonged cell 
cycle
131
 or oncogenesis.
132
  
 
1.8 Magnetic particles can satisfy many technical requirements of cell 
transplantation 
It is clear from the above section that the development and testing of cell therapies 
is associated with a range of technical issues that can hamper the rate of discovery in this 
field. In this context, magnetic particles (MPs) can serve as a multifunctional engineering 
platform, which can be harnessed to meet the technical requirements detailed in section 1.7 
(Figure 3). The term MP encompasses a variety of synthetic particles, of various physico-
chemical properties, with the common element being the incorporation of a magnetic 
component. The following section will briefly outline the synthesis of iron oxide MPs. 
There are numerous ways to synthesise these particles, allowing the design to be tailored to 
specific applications. 
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Figure 3: Schematic illustrating various technical issues in transplant biology, and the 
properties of MPs that can address these issues. See section 1.7 for details of the 
technical problems faced by transplant biologists, and see section 1.8 for details of how 
MPs can provide solutions to these problems. 
 
Although other materials can be used as the core (e.g. polystyrene), with iron oxide 
crystals incorporated as a layer, the iron oxide component is typically synthesised first and 
used as the core of the particle. Iron oxide particles (5 – 100 nm core) can be prepared by 
precipitation from iron salt solutions through the use of a base, and this procedure can be 
tailored to produce the particular size and consistency required.
133
 When iron oxide 
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crystals form certain structures (e.g. magnetite, Fe3O4, or maghemite, γ-Fe2O3), and remain 
smaller than approximately 30 nm, they exhibit superparamagnetism, which is desirable as 
such particles become magnetised only in the presence of a magnetic field, losing this 
magnetism once the field is removed.
134
 This allow the particles to be manipulated by 
external fields (including MRI), but prevents aggregation due to permanent magnetisation 
of the particles. 
As iron oxide does not readily attach to organic molecules and as iron ions (Fe
2+
) 
can cause oxidative stress through free radical production,
135–137
 a biocompatible coating is 
applied to protect the core and facilitate either further coating or functionalisation. 
Typically, a natural biocompatible polymer is employed for this layer, for example 
dextran, starch or chitosan.
138
 As these cannot be covalently bound to the iron oxide core, 
they are cross-linked in a network, surrounding the core with cages of polymers.
133
 These 
polymers help to prevent aggregation, and have active groups [e.g. dextran presents 
hydroxyl groups (-OH); chitosan presents hydroxyl and amine groups (-NH2)] which 
facilitate biomolecule attachment.
138
 Alternative coatings include synthetic polymers, such 
as poly-L-lactic acid (PLA), polyethylene glycol (PEG) and polyglycolic acid (PGA), 
which are all considered biocompatible. However, these polymers are not readily 
functionalised as they lack active groups, and introducing active groups requires that the 
polymer skeleton is broken and hence shortened.
133
 All of the synthetic and natural 
polymers mentioned can leach, which means that particles constructed in this manner can 
degrade. Therefore, an alternative method of coating the core has been developed, which 
involves silanisation: using alkoxysilanes to covalently attach a stable layer of silica (-Fe-
O-Si-), offering the core some protection from corrosion by physiological electrolytes, and 
providing a surface composed of readily functionalised organic groups.
133
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Unifunctional MPs are simple to synthesise by sequential layering over the core 
material, resulting in an outer layer of functional molecules. However, as more 
sophisticated particles are required for multimodal applications, the synthesis process 
requires that consideration be given to the coexistence of functional groups.
133
 For 
example, it is possible to exploit the inefficiency of certain organic chemical reactions 
when performed at a solid/liquid interface. The incomplete transformation of primary 
amine groups at the particle surface to imines (aldehyde end groups) when reacted with 
glutaraldehyde means that both groups will be present after the reaction, to which different 
functional molecules can then be attached.
139
 This principle has been demonstrated by the 
transformation of ~30% of amine groups at the particle surface into carboxyl groups, 
allowing the particles to be functionalised with both a fluorophore and an antibody.
139
 The 
development of such multifunctional particles is especially desirable in the context of 
cell transplantation, as although MPs have been shown to facilitate each of the 
applications listed in section 1.7, no single particle is available which can mediate all of 
them. Such a particle would be of great value for research, as current transplant studies 
either neglect certain aspects (e.g. gene delivery without real-time imaging) or require cells 
to undergo multiple manipulations (e.g. separate gene delivery and cell labelling 
procedures). 
MPs have been exploited for a variety of biomedical applications so far, in a 
number of physiological systems,
135,140–142
 raising interest in their potential utility for 
neural engineering, but this has received limited attention. There is significant interest in 
using MPs as contrast agents to track neural transplant populations using MRI,
92,143
 and a 
small number of studies have investigated the potential for magnetic targeting of MP-
labelled transplant populations, using external/implanted magnets.
144,145
 The applications 
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of MPs relevant to cell transplantation in general will now be detailed, with reference to 
OPC applications where such data is available. 
 
1.8.1 Intracellular MPs serve as contrast agents for non-invasive imaging 
MPs may be synthesised using elements such as gadolinium, cobalt, iron or nickel, 
with gadolinium being the most widely used as a contrast agent.
146,147
 These materials 
provide contrast for MRI through high magnetic moments,
148
 which disturb local magnetic 
field homogeneities.
146
 This results in short proton relaxivity times in water protons in the 
immediate vicinity of the particles, leading to loss of signal in T2*-weighted MRI, which is 
beneficial for imaging purposes.
149,150
 The relaxation rate of these protons (i.e. the contrast 
generated) is proportional to the quantity of metal, and is inversely proportional to the 
distance between the metal and the water protons.
99
 Therefore, particles designed with 
large quantities of iron and/or iron near their surface are likely to provide enhanced 
contrast, which may be achieved by synthesis of a small particle with high iron content, or 
a particle with a layer of iron immediately beneath the outer (ideally hydrophilic) layer.
99
 
Iron-based MPs have been used as systemically delivered MRI contrast agents, as well as 
cell-labelling agents for tracking individual cells.
151
  
For example, Ben-Hur et al. have demonstrated in vivo MRI tracking (for one 
month) of MP-labelled [poly-L-lysine (PLL)-coated Feridex] mouse NSCs following 
transplantation into a mouse MS model.
152
 Lepore et al. labelled co-cultures of NSCs and 
glial precursor cells (from mutant rats expressing human alkaline phosphatase) with 
Feridex MPs and transplanted these cells into adult rat spinal cord.
95
 After 5 weeks, the 
spinal cord was extracted and ex vivo MRI showed coincidence of MP contrast with both 
Perls’ iron staining (for MPs) and with alkaline phosphatase staining (for transplant cells). 
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Feridex-labelled human NSCs have been transplanted into monkey brain and human brain, 
without neurological effects or seizures, and successfully detected in vivo by MRI.
153
 
Focke et al. labelled human embryonic NSCs with iron oxide MPs (8 nm) and transplanted 
these cells into rat striatum, before successfully tracking them in vivo with a clinical (1.5 
T) scanner.
154
 Several studies have used MRI to track MP-labelled OPCs (CG4 cell line) 
post-transplantation,
94,143,155
 and these will be discussed in detail in section 2.1. 
 
1.8.2 Histological detection of MP-labelled cells 
Many MPs can be readily detected due to their metal content, for example by 
simple histochemical staining to detect iron,
102,155
 and this has been demonstrated post-
mortem with NSCs
153,154
 and OPCs.
94,143
 For particles not amenable to metal-based 
detection (e.g. due to low iron content), fluorophores can be incorporated,
92,102,156
 either 
internally or attached to the surface, to facilitate post-mortem detection by fluorescence 
microscopy. This has been demonstrated using gadolinium-based MPs incorporating a red 
fluorophore, which were used to label a hippocampal cell line, before transplantation into a 
rat model of global ischaemia.
157
 Following in vivo MRI imaging, cells labelled with these 
fluorescent MPs were identified in post-mortem brain tissue by fluorescence microscopy. 
Kircher et al. have demonstrated detection of a cyanine dye (Cy5.5)-tagged dextran-coated 
iron oxide MP through fluorescence microscopy of post-mortem tissue, although this 
particle was delivered intravenously to delineate a brain tumour, rather than being used to 
label a cell transplant population.
158
 By these methods, MP-labelled cells can be detected 
post-mortem, and iron staining has been shown to correlate well with MRI observations, 
including studies with OPC cell lines.
95,143,159
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1.8.3 MP-mediated gene delivery: The use of novel ‘magnetofection’ strategies 
MPs can be functionalised to facilitate the addition of nucleic acids to their surface, 
and can then serve as gene delivery vectors. This can be achieved using nonviral 
transfection agents [e.g. polyethyleneimine (PEI), PLL] with subsequent nucleic acid 
binding, but MPs can also be conjugated with viral vectors, typically by biotinylating the 
viral particles and conjugating (strept)avidin to the MPs, or vice versa.
160,161
 Alternatively, 
viral vectors or nucleic acids can be bound to cationic MPs by electrostatic interactions, or 
MPs with hydrophobic surface regions can associate with viral particles/nucleic acids 
through hydrophobic interactions.
161
  
Nonviral MP-mediated gene delivery has been demonstrated in a wide range of cell 
lines, and primary cells including neurons,
162
 NSCs,
163
 and astrocytes.
164
 Such vector-
mediated delivery of DNA to cells in culture must overcome a number of obstacles: (1) 
vector-cell contact; (2) transport across the cell membrane; (3) endosomal escape, if the 
vectors are internalised within vesicles; (4) transport to the nucleus; and (5) delivery of 
DNA into the nucleus.
165,166
 With respect to the first barrier (1), cell contact is largely 
diffusion-limited for nanoscale vectors (viruses and most synthetic alternatives, including 
MPs), and a number of attempts have been made to facilitate more rapid vector-cell 
contact, rather than relying on Brownian motion. For example, Luo and Saltzman exploited 
gravitational effects on high density particles to cause sedimentation of DNA onto adherent 
cells, increasing transfection efficiency.
167
 When the same technique was used with cells 
cultured on an elevated membrane with 3 µm pores (allowing sedimenting particles to pass 
through), the enhanced transfection effect was abolished. Centrifugal force has also been 
successfully used to increase vector-cell contact.
168
 The fact that heavier nucleic acid 
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vectors are more likely to sediment onto adherent cells may explain why some large 
vectors have proven more efficient than smaller particles.
169
  
For MPs with a sufficient magnetic component, the rate and extent of vector-cell 
interactions can be enhanced by employing the ‘magnetofection’ technique, with the first 
reports in the literature of such magnet-assisted gene delivery being those of Mah et al.
170
 
(using polystyrene magnetite microspheres complexed with AAV vectors) and Plank et 
al.
171
 In a recent review, Plank et al. defined magnetofection as “...nucleic acid delivery 
under the influence of a magnetic field acting on nucleic acid vectors that are associated 
with magnetic (nano)particles.”161 In such protocols, a magnetic field is placed beneath a 
culture plate, increasing the rate of MP-nucleic acid complex sedimentation, and thereby 
enhancing transfection efficiency by exploiting the magnetic properties of these 
particles.
161
 For the rest of this thesis, the term magnetofection will refer only to nonviral 
gene delivery. 
Although originally developed to employ a static magnetic field, the 
magnetofection concept has been refined by several groups, notably by Professor Jon 
Dobson’s group, which introduced lateral motion to the particles in addition to the 
sedimentation effect, through horizontal oscillation of the array of magnets beneath the 
culture plate, while the plate remains stationary.
172
 The Dobson group has demonstrated 
enhanced transfection efficiency for oscillating field conditions compared to static field 
conditions in various cell lines, and published a number of reports addressing the 
optimisation of the system, for example through varying the oscillation frequency and 
amplitude,
172
 or by altering the arrangement of the magnetic fields in relation to the cells 
(e.g. vertical separation).
173
 The mechanisms of enhanced transfection efficiency through 
magnetofection techniques will be discussed further in section 3.4. 
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With respect to the second barrier (2), crossing the plasma membrane, this is 
typically achieved through endocytosis, such that the vectors are contained within 
endosomes, which may be subject to acidification, and trafficking to lysosomes for 
enzymatic digestion of the contents, preventing gene delivery. Endocytosis will be 
discussed in more detail in section 1.9. The third barrier (3), endosomal escape can 
reportedly be achieved through the ‘proton sponge effect’,174 made possible by 
functionalising particles with highly cationic molecules. For PEI, this is proposed to occur 
due to the secondary and tertiary amine groups of PEI buffering the acidification process in 
the endosome. This acidification process occurs as endosomal membrane pumps import 
protons into the endosome. The endosomal proton pumps continue to import protons, 
resulting in osmotic swelling and rupture of the endosome, releasing the vectors into the 
cytosol. Alternative approaches include the incorporation of chloroquine into the vector, 
which raises the pH of lysosomes, deactivating the lysosomal degradative enzymes and 
potentially rupturing the lysosome,
116
 or the inclusion of membrane-destabilising peptides 
(e.g. synthetic N-terminal peptides of Rhinovirus VP-1).
109
 The fourth barrier (4), transport 
to the nucleus, is poorly understood for nonviral vectors, but trafficking of PEI has been 
shown to be mediated by microtubule transport (which is exploited by some viruses).
116
 
However, it is not known whether this transport involved PEI within vesicles, and 
therefore may not apply to free PEI or PEI-coated MPs.
175
 The final barrier (5) is the 
nuclear envelope, as DNA must enter the nucleus for transgene expression to occur.
176
 In 
non-dividing cells, nuclear entry is regulated by nuclear pore complexes, and nuclear 
uptake is dependent on the size and sequence of the DNA, with smaller DNA molecules 
more efficiently gaining entry. The size is not only dependent on the length of the 
sequence, but also the conformation, as DNA has a smaller diameter when supercoiled 
than when open/circular, with the additional advantage that supercoiled DNA is more 
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transcriptionally active.
176
 Also, some DNA sequences demonstrate enhanced nuclear entry 
due to having binding sites for transcription factors [e.g. a region of simian virus (SV) 40], 
some of which may be cell type-dependent.
176
 Dividing cells undergo nuclear membrane 
breakdown,
176
 during which nucleic acids can potentially gain entry, and proliferative 
populations are frequently reported to be more amenable to transfection.
177–179
 Enhanced 
nuclear entry can be achieved using nuclear localisation signals (NLS; e.g. by conjugating 
importin β to either vector or DNA), which molecules larger than ~40 kDa require for 
active transport into the nucleus.
109,176,180
 The intracellular mechanisms that affect gene 
delivery are under intensive study, and various molecules are being tested to enhance gene 
delivery at each of the steps outlined here.
109,176
  
 
1.8.4 Magnetic cell targeting approaches 
Manipulation of MP-labelled cells following transplantation has been 
demonstrated,
144,145,181,182
 a technique that could facilitate the retention of transplant cells at 
a target site, and raises the possibility of magnetic ‘capture’ of transplanted cells from the 
circulation, following intravenous/intrathecal delivery at a distant site. For example, an 
implanted magnet has been employed to localise (limit dispersion of) MP-labelled cells at 
a rat spinal cord lesion following intrathecal delivery,
144,145
 and Kyrtatos et al. 
demonstrated localisation of intravenously delivered endothelial progenitor cells to the rat 
common carotid arteries using an externally applied magnetic field.
181
 The common carotid 
arteries are ~5 mm beneath the skin of the neck and subject to considerable hydrodynamic 
forces (systolic blood flow is up to 10 ml/min), which significantly reduced the number of 
transplanted cells remaining in this region in control animals, without the application of an 
external magnetic field. These magnetic targeting approaches may facilitate the 
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concentration of transplanted cells at lesion sites, of high relevance in situations where the 
cell source may be limited. 
 
1.8.5 Safety of iron oxide-based MPs for biomedical applications 
Of the MPs reported in the literature, those incorporating iron oxide (typically 
either magnetite or maghemite) have a good safety profile, and some formulations have 
been approved for clinical applications [e.g. Endorem
TM
, Resovist
®
 and Sinerem
TM
, as 
MRI contrast agents;
150,183
 NanoTherm
®
 for hyperthermic tumour therapy;
99
 ferumoxytol 
(Feraheme®) for iron-deficiency anaemia
184
], suggesting that iron oxide-based MPs may 
be suitable as non-toxic agents for the engineering of neural cells.
92,146
 The static 
magnetofection technology has been safely used by a large number of laboratories, and 
although fewer groups are exploiting the oscillating magnetofection technology, reports 
show that safe protocols can be developed.
140,172,185–188
 No adverse effects of magnetic 
targeting of MP-labelled cells have been noted.
144,145,181,182
 As they have received approval 
for clinical use, are widely available commercially, and can be readily synthesised, this 
thesis will focus on iron oxide-based MPs, formulations of which (typically unimodal MRI 
contrast agents) have been used successfully with neural transplant populations.
92,97,154
 
It should be noted here, that despite the demonstrable potential of MPs for cell 
transplant applications, there is a critical lack of neurocompatible multimodal MPs 
designed for these purposes, representing a major scientific and commercial gap. The 
development of such particles is hindered by the lack of data relating to MP handling by 
neural cells, data that is particularly lacking with respect to OPCs. Although a number of 
reports have shown MP uptake by neural cells, each of these studies typically employs a 
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physico-chemically different particle, which is rarely characterised in detail, barring an 
effective assessment of which parameters are desirable in a neurocompatible MP. An 
understanding of how various permutations of these physico-chemical characteristics 
affect cellular interactions will be essential for the development of multimodal MPs, which 
will likely possess heterogeneous surface properties due to the presence of multiple 
functional molecules (e.g. fluorophores, transfection agents and targeting molecules). 
 
1.9 Uptake of MPs is typically by endocytosis, but the relationship between 
physico-chemical properties and cell uptake is poorly understood in neural 
cells 
In general, mammalian cells appear to take up MPs by endocytosis,
156
 which 
encompasses a number of mechanisms, which vary in the specificity and size of their cargo 
(Figure 4).
189,190
 Phagocytosis is a form of endocytosis usually employed for the removal 
of pathogens, debris and apoptotic cells, and in the CNS is exhibited by microglia and 
astrocytes, with some controversy about whether oligodendrocytes have this capability.
191–
194
 Professional phagocytic cells (e.g. macrophages) readily take up most formulations of 
MPs, but ‘non-phagocytic cells’ are often reported to display little, or inefficient, MP 
uptake.
195,196
 Phagocytosis has the greatest payload capacity of any uptake mechanism, and 
macrophages have demonstrated phagocytosis of latex beads >20 µm in diameter.
197
 Other 
forms of endocytosis are referred to as pinocytosis (‘cell drinking’),198,199 which may be 
subdivided into macropinocytosis, and a collection of pit-based uptake mechanisms, 
together described as micropinocytotic uptake.
200
 After phagocytosis, macropinocytosis 
has the potential to internalise the largest payload, as the process involves forming ruffles 
(lamellipodia-like or circular) or ‘blebs’ in the membrane which extend from the cell 
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before collapsing back to the membrane and forming intracellular vesicles known as 
macropinosomes which may be 5 µm in diameter (Figure 4).
200
 This is a non-specific 
mechanism, and therefore extracellular molecules are internalised at the same 
concentration as found extracellularly (fluid-phase uptake), although it should be noted that 
membrane-bound particles are more likely to be endocytosed than unattached particles.
201
 
The other pinocytotic mechanisms [described as caveolae-dependent clathrin-dependent, or 
caveolae- and clathrin-independent (which includes at least four mechanisms; see Figure 
4)] involve the formation of pits in the membrane, which mediate uptake of molecules 
smaller than ~500 nm,
202
 giving rise to vesicles. Some of these micropinocytotic 
mechanisms are receptor-mediated (selectively internalising specific growth factors, for 
example), but others act non-specifically. Therefore, for non-phagocytic cells, any particle 
that can associate with the cell membrane can potentially be taken up by macropinocytosis, 
whereas micropinocytosis is limited to smaller particles (possibly <300 nm, although there 
are suggestions that multiple-pit complexes may facilitate uptake of larger entities)
198
 and 
may require specific receptor-binding for uptake. 
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Figure 4: Endocytotic mechanisms of MP uptake. The cell membrane is shown with 
endocytotic membrane extensions and pits, and uptake of various sizes of particle is 
illustrated. Uptake may result in transport to the nucleus, degradation in a lysosome, or 
exocytosis (not shown). Four clathrin- and caveolae-independent micropinocytotic uptake 
mechanisms are known: RhoA-. flotilin-, ARF6- and CDC42-dependent uptake. The cargo 
size limit for each mechanism is indicated, but these are largely unconfirmed. Some 
evidence suggests that multiple pits can cooperate to internalise larger molecules than a 
single pit can accommodate.
198
 Schematic adapted from Canton & Battaglia.
198
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The uptake of MPs is not only dependent upon cell-intrinsic factors, such as the 
particular endocytotic mechanisms employed by that cell type and their rates of activity, 
but is also dependent upon the physico-chemical characteristics of the MPs, including the 
size, shape and charge, which can significantly affect the uptake and processing of the 
particles.
203,204
 However, there are no studies in the literature systematically comparing 
OPC (or other neural cell) uptake of particles of differing sizes. One report has compared 
uptake of dextran-coated iron oxide nanoparticles in a non-phagocytic cell line, with 
particle sizes ranging from 33 nm to 1.5 µm, with identical surface properties.
204
 They 
report efficient uptake of all MPs (up to 300 nm), except for the 1.5 µm MPs, with a 107 
nm (highly cationic) particle producing the most effective cellular labelling for MRI 
purposes.
204
 Uptake of large MPs has been reported in various cell types, including cells 
that may not be expected to exhibit phagocytosis, for example, ~50% of a rat neuronal 
precursor cell population has been labelled with a 5.8 µm MP (magnetite core, 
carboxylated divinyl benzene/styrene polymer coating).
156
 In general, uptake of non-
targeted vector-nucleic acid complexes is reportedly size-dependent, with a recent review 
suggesting that 70 – 90 nm is the optimal size for transfection across various cell lines.109 
However, there are considerable inconsistencies in the literature, due in part to the sheer 
variety of particles and cell types tested, which hampers efforts to compare and contrast the 
available data. 
No data is available for OPC interactions with non-spherical MPs, but particle 
shape may be an important factor for engineering, as it can affect cellular uptake and even 
cellular responses, on a cell type-dependent basis. This has been shown for some neural 
cells by Hutter et al. who examined the uptake of gold nanoparticles (spheres, rods and 
‘urchins’: spheres with protrusions; respective dimensions: ~23 nm, ~43 x 12 nm, ~77 nm) 
by microglia and neurons.
205
 Neurons only showed uptake of rods, but microglia not only 
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internalised all three shapes, with a preference for the spiky urchins, but responded 
differently to each particle with respect to cytokine production.
205
 Cylindrical gold 
nanoparticles were less efficiently internalised by HeLa cells than were spherical particles 
and efficiency and rate of uptake decreased with increasing aspect ratio of the particles.
203
 
However, when studying the effect of aspect ratio on the uptake of gold nanorods, another 
group concluded that surface chemistry was more influential than shape.
206
 In a study by 
Gratton et al., cylinders demonstrated more efficient uptake by HeLa cells than did 
cubes,
196
 although it is not clear how best to perform a reasonable comparison between 
such differing morphologies. Influencing cellular uptake or behaviour through particle 
morphology may be possible, yet little is known about how shape affects cellular 
interactions, particularly with regard to iron oxide MPs. 
In general, it is not clear whether uptake is favoured by a positive (cationic), 
negative (anionic) or neutral surface charge, in part because it is difficult to manufacture 
particles that differ only in their surface charge, without confounding alterations in the 
surface chemistry. The plasma membrane is negatively charged, and therefore positively 
charged particles have a high affinity for the cell membrane, with this interaction being 
exploited for cellular delivery of therapeutic agents.
207
 However, the strong non-specific 
interactions of cationic particles with cell membranes and negatively charged proteins can 
lead to aggregation of the particles, and this has been associated with toxic effects.
208
 
Cytotoxic effects of positively charged iron oxide-based particles have also been suggested 
to be related to extensive, ‘uncontrolled’ uptake.204,209 In reviews of the subject, the general 
view has been stated that positively charged particles are more readily taken up by cells 
than neutral or negatively charged particles.
198,210
 However, negatively-charged particles 
have been reported to exhibit high levels of cellular uptake, sometimes to a greater extent 
than seen with similar-sized positively-charged particles.
146,211,212
 These contradictory 
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observations illustrate the need for a systematic review of particle handling by neural 
cells, which should be performed on a cell-by-cell basis. There is a requirement for 
cationic MPs, as transfection-grade MPs often utilise cationic surface groups in order to 
electrostatically bind nucleic acids. In these cases, the surface charge of the functionalised 
particle is likely to depend on the extent to which these cationic groups are occupied by 
nucleic acids, but complexes such as PEI-DNA and PLL-DNA can retain their overall 
cationic charge after nucleic acid binding.
109
 However, the influence of surface charge on 
uptake is clouded by the fact that once added to culture medium the MPs will typically 
develop a corona of proteins and other molecules, affecting the size, and potentially the 
shape and charge of the particles.
213,214
 In addition to these factors, the particular molecules 
that constitute the corona can be expected to influence interactions of the particles with the 
cell membrane, as coronal molecules (e.g. albumin, growth factors) may interact with cell 
surface receptors, facilitating attachment to the membrane, and possibly uptake.
214,215
 
The literature does not contain any reports of MP uptake by OPCs derived from 
primary sources, but does contain some reports of MP-labelling of OPC cell lines. 
However, the uptake demonstrated by these cell lines may not be a reliable indicator of the 
amenability of primary cells to MP-labelling, for reasons to be discussed in the next 
section, and therefore the question of whether OPCs from a primary source will take up 
MPs remains unresolved. 
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1.10 Are cell lines biologically relevant models for MP testing? 
Much of the research conducted so far investigating the cellular uptake and handling 
of MPs has used cell lines.
216–221
 Whilst such research has yielded valuable data, a number 
of studies have shown that cell line behaviour can differ markedly from the behaviour of 
primary cells, limiting its predictive value. For example, Pinkernelle et al. compared 
uptake of iron oxide MPs by primary neurons and the ‘neuron-like’ cell line (PC12).222 
PC12 cells were originally derived from a pheochromocytoma of the rat adrenal medulla, 
and possess only 40 chromosomes,
223
 but are commonly used as a model of neurons,
219,224
 
including for particle uptake studies.
131,219,225
 Uptake in the cell line (76.9 ± 11.8% 
standard deviation, SD) was six-fold greater than in the primary cells (12.8 ± 13.2% 
SD),
222
 illustrating the fact that cell lines can be poor models of primary cell behaviour.
222
 
More generally, warnings about cell line identity have been made since the 1950s, 
and many instances of published work have been shown to have been carried out in 
misidentified cell lines.
226,227
 Despite articles highlighting this, a 2004 survey of 483 cell 
culture workers by Buehring et al. indicated that 9% were inadvertently using HeLa 
contaminants, 33% never verified their cell lines, and 35% had acquired their cells from 
other laboratories, rather than through a cell line repository.
228
 The risk of cross-
contamination cannot be overstated, and is not a problem exclusive to laboratories 
handling multiple cell lines.
229–231
 Even if the provenance of a cell line has been 
established, other potential problems exist. The creation of cell lines involves either the 
selection of a naturally immortal cell (e.g. a cancer cell), or the transformation of a cell 
population to create immortal cells.
232–234
 In either situation, the cells possess an altered 
physiology compared with the corresponding primary cells - such alterations are not 
readily characterized in many situations. Once established, cell lines are subjected to 
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selection pressures, such that progeny with the highest proliferative potential numerically 
dominate subsequent passages.
235
 Therefore, cell lines behave in a relatively homogenous 
clonal manner being derived from a relatively small precursor cell population, and their 
properties may not be representative of the natural biological variations that exist in vivo. 
Such variations reflect factors such as the existence of cellular subtypes, ongoing cell 
proliferation and differentiation, presence of cells at different developmental stages and 
states of biological activation (of particular relevance in regions of neurological 
injury/disease), all of which will impact the outcomes of MP use. A further aspect common 
to many cell lines is their relatively high survival and proliferation rates and resistance to 
adverse stimuli, such as cell death signals. This robust culture growth also plays a role in 
cryptic (undetectable) contamination, often by mycoplasma.
232
 Such contamination may 
not be detected for several passages, but can result in alterations in cell structure, 
metabolism and growth characteristics.
232–234
 These considerations, in combination with 
the risk of cellular aneuploidy, can make cell lines a relatively poor model for toxicity 
testing.
232,235
 This is an issue of high relevance in the field of nanotechnology, where the 
neurotoxicity of a range of nano- and micro-sized particles is currently an issue of major 
public and scientific concern.
236
  
In terms of gathering clinically relevant data, a viable therapeutic cell transplant 
therapy is unlikely to utilise an immortalised cell line, as such cells are prone to tumour 
formation.
237
 The most likely sources of cells for transplantation are aborted human tissue 
or OPCs derived from either human ESCs or NSCs.
34
 Primary OPC populations, such as 
would be obtained from abortion tissue, have been shown to consist of various subclasses 
of cells,
238
 a characteristic which will not be adequately represented within a cell line, 
further limiting the relevance of data obtained from cell lines.
29,239
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1.11 Aims and objectives of the experimental chapters 
The development of cell transplantation and gene therapy strategies for promoting 
remyelination in the CNS offer the hope of recovery from debilitating conditions, in 
contrast to the majority of current CNS therapies, which are directed at managing 
symptoms. The first aim of this thesis is to address the utility of MPs as a tool for 
engineering OPC transplant populations. To this end, different formulations of MPs were 
tested as labelling and gene delivery agents for OPCs. These formulations were iron oxide-
based, for the reasons given in section 1.8.5. The efficiency and safety of these protocols 
were assessed, including the effectiveness of magnetofection protocols for enhancing MP-
mediated gene delivery; an organotypic cerebellar slice culture model was developed to 
test the behaviour of transplanted OPCs, serving as an assay of the safety of the genetic 
engineering procedures (the rationale for employing slice models is given in section 1.6). 
As a second aim, the amenability of oligodendrocytes to MP labelling and transfection was 
assessed, and contrasted with the amenability of OPCs, constituting an intralineage 
comparison of MP handling. Finally, the interesting results of the intralineage comparison 
prompted a cross-cellular comparison of MP handling by all of the major neuroglia. This 
was performed by collating the novel OPC and oligodendrocyte data with previously 
published data for astrocytes
164,240
 and microglia,
241
 the other major neuroglial cell types. 
All the experimental studies in this thesis utilised cells derived from a primary source, an 
approach I consider to be of higher relevance to future clinical transplantation than cell 
lines, for the reasons outlined in section 1.10. More detailed descriptions of the chapter 
objectives follow: 
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Chapter 2: Magnetic particle (MP) uptake in oligodendrocyte precursor cell (OPC) 
transplant populations 
The potential for MP-labelling of OPCs derived from a primary source was 
investigated in this chapter. The uptake dynamics of two physico-chemically different MPs 
were assessed, including a novel multimodal particle with cell labelling and gene delivery 
capabilities. An ultrastructural imaging technique was developed for future rapid, 
technically simple, high-throughput analysis of particle-cell surface interactions. 
 
Chapter 3: MP-mediated transfection of OPC transplant populations: effects of novel 
‘magnetofection’ techniques 
The potential for MP-mediated gene delivery to OPCs, and the effects of 
magnetofection protocols employing static and oscillating magnetic fields, were 
investigated in this chapter. The safety of the gene delivery procedures was tested by 
transplanting modified cells onto an organotypic cerebellar slice culture model. MP-
mediated delivery of multiple genes and a therapeutic gene were also tested. 
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Chapter 4: Labelling and gene delivery applications of MPs in oligodendrocytes: An 
intralineage comparison with OPCs 
The amenability of oligodendrocytes to MP labelling and MP-mediated 
transfection, and the safety of these procedures, were investigated in this chapter. These 
data were then collated with the OPC data obtained in chapters 2 and 3, in order to perform 
an intralineage analysis of oligodendroglial MP-handling. Differences in particle uptake 
and amenability to MP-mediated transfection were discussed in terms of biological 
differences between the OPC and oligodendrocyte cell types. 
 
Chapter 5: Differences in MP-handling by CNS glial subclasses: Competitive MP 
uptake in glial co-cultures 
This chapter first collated MP-handling data reported in chapters 2 – 4, for 
oligodendroglial cells, with data previously published by the host laboratory (pertaining to 
the other major CNS glial cell types: astrocytes and microglia) in order to perform a 
systematic cross-cellular comparison of particle uptake and processing, including 
amenability to MP-labelling and MP-mediated gene delivery, and presence of MP-related 
toxicity. Based on observations made during this comparison, a hypothesis was proposed 
that competitive microglial MP uptake will limit MP uptake by other glial cell types in 
mixed glial cultures. A glial co-culture model with defined cell stoichiometry was 
developed for the purpose of testing this hypothesis. 
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Chapter 2: Magnetic particle (MP) uptake 
in oligodendrocyte precursor cell (OPC) 
transplant populations 
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2.1 Introduction 
As discussed in section 1.3, endogenous OPCs mediate myelin repair following 
injury/disease, but the remyelination process is often incomplete.
1,6,42
 In attempts to 
address this problem through cell transplantation therapies, a range of studies prove that 
transplanted OPCs derived from a variety of sources can promote myelin repair.
45,242,243
 In 
parallel with the growth of the field of neural cell therapies, there is a significant and 
growing biomedical demand for technological methods and adjunct tools to facilitate 
research into the development of cell transplantation therapies in the CNS.
91,117
 This 
demand includes techniques to track cells post-transplantation, both non-invasively 
(especially for clinical studies) and histologically, to assess the safety and efficacy of the 
cell replacement procedures. Sections 1.7.1 and 1.7.2 discuss current labelling approaches, 
including associated drawbacks, and sections 1.8.1 and 1.8.2 detail how these may be 
addressed by the use of MPs as cellular labels. MPs have been shown to be broadly 
suitable for both non-invasive and histological imaging, serving as contrast agents for MRI 
and being readily detectable in post-mortem tissue.
96,97,101,240
  
This chapter will address a series of issues related to MP-labelling of OPCs derived 
from primary cultures. Previous studies have assessed the cellular labelling potential of 
iron oxide MPs by employing the oligodendroglial cell lines CG4 (considered an OPC line 
due to the behavioural and morphological similarities between these cells and primary 
OPCs)
53
 and OLN-93 (described as a “primary oligodendrocyte” line; these cells 
morphologically resemble bipolar OPCs and proliferate in culture, but stain A2B5
-
/MBP
+
 
and produce constituent molecules of myelin, which are characteristics of mature 
oligodendrocytes).
94,143,155,244
 Following reports that dextran-coated MPs do not efficiently 
label mammalian cells (other than professional phagocytes),
143
 Bulte et al. attempted to 
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label CG4 cells with dextran-coated MPs of 8 – 20 nm diameter.155 They report that no 
CG4 cells were labelled following 48 h incubation of MPs with cells. However, CG4 cells 
possess a high number of transferrin receptors, and by conjugating anti-transferrin-receptor 
antibodies to these MPs “significant” uptake by CG4 cells was achieved, though the 
percentage of cells labelled was not reported. Based on transmission electron microscope 
(TEM) analysis, the authors suggest that uptake was by receptor-mediated endocytosis. No 
MP-related toxicity data were provided, but a trypan blue exclusion assay showed “similar 
viability” to control cultures at all doses tested. Labelled cells were then transplanted into 
the spinal cord of postnatal day (P)7 myelin deficient (md) rats and normal littermates. 
Post-transplantation, fixed spinal cords were removed for ex vivo MRI analysis, which 
showed that transplanted cells had migrated from the injection site (up to 10 mm) and 
retained their MP label for up to 14 days post-transplantation. 
In contrast to the prior report, Franklin et al. successfully labelled CG4 cells with 
iron oxide MPs without the need to employ specific cell targeting strategies, and 
transplanted these labelled cells into adult rat ventricles.
94
 MP-labelled cells were detected 
by ex vivo MRI in tissue fixed at seven days post-transplantation. The particles were 
synthesised by the authors, based on a patent which reports the iron oxide core diameter as 
10 – 50 nm, and were coated with dextran. However, the overall particle size is not 
reported. Measurements of EM images in the article suggest that the particles are ~400 nm 
in diameter, although this figure could be based on agglomerations of particles. The 
authors report that >60% of cells contained at least one intracellular MP inclusion, but no 
safety/toxicity data is reported. 
A later report by Bulte et al. studied uptake of magnetodendrimers across a range 
of cell lines, including CG4, and also with OPCs derived from rat NSCs (it is not stated 
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whether these were derived from primary NSCs or a cell line).
93
 These magnetodendrimers 
were formed by attaching 7 – 8 nm iron oxide crystals to dendrimers (~100 iron oxide 
crystals per dendrimer; overall size not reported), and the resulting particles were used as 
transfection agents.
93,97
 The authors report comparable levels of uptake in these and other 
cell types, concluding that uptake is non-specific and not dependent on cell type.
93
 The 
extent of labelling was described as “remarkably high”, but the percentage of cells labelled 
was unreported. Unlabelled cells were determined to contain ~1 pg endogenous Fe, and 
following 48 h exposure to magnetodendrimers (at a concentration of 25 µg Fe/ml), 
labelled cells contained an average of 10 pg Fe/cell. There was no obvious decrease in 
labelling after one week in vitro, and proliferation capacity and viability “appeared 
unaffected”, although numerical data are not provided in this regard.93 In this and a related 
publication,
96
 reporting part of the same study, rat NSC-derived OPCs were labelled with 
the same magnetodendrimers (simultaneously transfecting the cells with lacZ) and 
transplanted into the ventricles of neonatal Long Evans shaker (les) rats. It was reported 
that these transplanted OPCs could be detected by in vivo MRI for up to six weeks post-
transplantation (the latest time-point assessed).
96
 Good anatomical correlation was reported 
between the MRI detection of particle contrast and the histological detection of LacZ
+
 
cells.
93,96
  
Frank et al. incubated CG4 cells with Feridex (also known as ferumoxides; 
dextran-coated iron oxide particles, 5 nm iron core diameter, 50 – 180 nm hydrodynamic 
diameter, zeta potential -31.3 mV in water)
150,245,246
 with and without a complexed 
transfection agent (Lipofectamine or PLL).
143
 In the absence of a transfection agent, 
Feridex labelling was reportedly “low” or not detectable using Perls’ Prussian blue iron 
stain. CG4 cells were successfully labelled when Feridex was combined with each of the 
transfection agents, and the average iron content per cell was reported to be significantly 
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greater than the iron content in control cultures, following 48 h exposure to the single 
concentration of each MP-transfection agent complex tested (in picograms per cell, 
control: 1.9 ± 0.9; Feridex-PLL: 3.8 ± 1.2; Feridex-Lipofectamine: 14.7 ± 1.7). However, 
the percentage of cells labelled was not reported, and no toxicity data were provided. 
 
2.1.1 Knowledge gap: Which MP characteristics are relevant for labelling primary 
OPC transplant populations? 
The literature pertaining to MP-OPC interactions is limited, and contains 
contradictory information regarding the ability of OPC cell lines to take up MPs without 
conjugation of cell targeting molecules or transfection agents (e.g. data of Bulte
143,155
 
versus Franklin
94
). From the review presented here, a number of substantial gaps in the 
literature are apparent: (i) only one report provides even an approximation of the 
percentage of cells which can be labelled, and none report the extent to which the cells can 
be loaded with particles, beyond an average iron content per cell measurement,
93,143
 which 
may mask heterogeneity of particle accumulation within a cell population;
240,247–249
 (ii) 
although two of these four studies report a lack of MP-associated cytotoxicity, no 
numerical viability/safety data have been presented, which is a significant shortcoming as 
these data will be vital to the development of safe particles and related protocols and in 
order to assess the clinical potential of MPs; and (iii) the MPs employed by these studies, 
as with many synthetic materials used with other cell types, are typically not fully 
characterised by the authors, yet these details are essential to the development and 
optimisation of MP-based cell engineering. For example, most studies of iron oxide MP 
interactions with mammalian cells report that particle uptake does not require specific 
targeting, but the reasons behind the exceptions to this (e.g. Bulte et al.,
155
 Frank et al.
143
) 
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are not clear, and are difficult to address in the absence of detailed particle characterisation. 
There has been little attempt so far to systematically determine which specific physico-
chemical properties of MPs are associated with greater or lesser particle uptake by OPCs, a 
matter of high relevance from a cell labelling perspective. Indeed, no previous studies have 
systematically compared how the physico-chemical properties of MPs affect their 
interactions with OPCs in any context; knowledge that will aid the development of MPs for 
specific applications in OPCs.  
 A further point to note here is that to the best of my knowledge, the literature does 
not contain any studies of MP interactions with OPCs derived from primary cultures, an 
approach that will be of greater biological and translational relevance than the widely 
employed cell lines (discussed in detail in section 1.10).  
 
2.1.2 Knowledge gap: How do MPs interact with the OPC membrane? 
In the context of studying cellular interactions with sub-micron sized particles, 
ultrastructural analyses are inevitably required for a high resolution analysis of particle-
membrane associations and to obtain evidence of endocytosis of particles. From a technical 
perspective, TEM analysis is a commonly used method for studying cell-particle 
interactions,
131,219,250
 but requires considerable expertise, time and expense to analyse a 
large number of cells. Therefore there is a significant need to develop alternative, cost 
effective and rapid methods to study the interactions of neural precursor cells and 
nanomaterials, to optimise the use of such platforms for transplant therapies. One such 
possibility is the use of scanning electron microscopy (SEM) techniques, which are 
frequently employed to study particles in the absence of cells.
251
 Ultrastructural analyses 
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can be performed using electron or ion beams to produce high resolution images, but 
electrically non-conductive samples (typical of biological specimens) are not readily 
visualised by such techniques, as they become charged. Therefore, biological samples are 
commonly post-fixed with osmium tetroxide (OsO4) to preserve the sample and enable 
conductivity in the sample, allowing electron microscopical analysis.
252
 However, this 
single osmium treatment often results in poor osmium penetration, leading to suboptimal 
sample preservation and inferior conductivity.
253
 Overcoating the osmicated sample with 
thiocarbohydrazide allows further overcoating with OsO4, and this OTO technique 
improves sample conductivity and secondary electron generation by completely and evenly 
coating the sample with metal.
252,253
 By coating a sample with further alternating layers of 
thiocarbohydrazide and OsO4 (the OTOTO technique) specimen charging can be 
eliminated, reducing artefacts.
252,254,255
 As a ‘non-coating’ technique (not employing 
relatively thick, 12 – 25 nm, layers of metal), OTOTO results in optimal internal and 
external fixation and an even conductive layer, ensuring that fine structures can be 
visualised at comparably high resolution to TEM.
256
 Some neuroscientists have exploited 
the OTOTO method, particularly as the affinity of osmium for unsaturated lipids provides 
enhanced mass-density in myelin,
254,257
 and the technique has been employed for analysis 
of the structures of the inner ear.
256,258,259
 Although SEM in general has been used to 
visualise particles in non-neural cell cultures,
251,260–262
 identification of endocytotic activity 
has rarely been reported.
260,262
 These studies did not utilise an OTOTO protocol, which 
may allow more detailed analysis at high magnification, with improved definition of 
particles and endocytotic processes, which would facilitate the study of membrane surface 
interactions of neural precursor cells with biomaterials; to the best of my knowledge, this 
technique has not previously been used for this purpose. The OTOTO SEM technique is 
rarely utilised for the study of neural cells or for studying the interactions of synthetic 
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materials with cells, yet it may offer a simple, high-throughput alternative to conventional 
TEM studies of particle-cell interactions. 
 
2.1.3 Objectives 
The principle aim of this chapter is to assess how OPCs derived from primary 
cultures interact with MPs, and determine whether OPCs can be efficiently labelled with 
such particles. The second aim of this chapter is to develop a high throughput 
ultrastructural imaging technique, OTOTO SEM, for the analysis of MP-OPC membrane 
interactions. 
 In the first part of this chapter, the main ‘test’ MP (termed SpheroTM) will be 
characterised and the following questions addressed: (i) Do OPCs exhibit uptake of these 
MPs? (ii) Is the rate and extent of MP uptake by OPCs time- and/or concentration-
dependent? (iii) Does exposure to these MPs result in acute cytotoxicity in OPCs? (iv) Do 
the differentiated progeny of MP-labelled OPCs safely inherit the particles? (v) Over what 
period of time are particles retained in daughter cells? 
In the second part of this chapter, OPC labelling will be tested using a novel 
multimodal MP, which has significantly different physico-chemical properties to the ‘test’ 
particle above, including notable differences in size, iron content and the layering of its 
constituent parts (e.g. surface rather than core-bound fluorophores, an iron oxide core 
rather than a polystyrene core). The following questions will then be addressed in OPC 
cultures: (i) Are OPC populations amenable to labelling with these particles? (ii) Is 
labelling of OPCs with these MPs concentration-dependent? (iii) Does exposure to these 
MPs result in acute cytotoxicity in OPCs? 
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The final part of this chapter will explore the potential for studying MP-OPC 
interactions using the SEM technique known as OTOTO, developing the technique and 
applying it to OPCs incubated with MPs. The ability to detect MPs and identify 
endocytotic processes in OPC cultures will be assessed.  
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2.2 Methods and materials 
The care and use of animals was in accordance with the Animals (Scientific 
Procedures) Act of 1986 (United Kingdom) with approval by the local ethics committee. 
Reagents and equipment: Tissue culture-grade plastics, media, and media 
supplements were from Fisher Scientific (Loughborough, UK) and Sigma-Aldrich (Poole, 
UK). Recombinant human platelet-derived growth factor (PDGF-AA) and basic fibroblast 
growth factor (FGF2) were from Peprotech (London, UK). Monoclonal rat anti-MBP was 
from Serotech (Kidlington, UK), monoclonal mouse anti-A2B5 was from Sigma-Aldrich 
(Poole, UK), and secondary antibodies [Fluorescein isothiocyanate (FITC)-conjugated] 
were from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA). Mounting 
medium (with and without DAPI, 4’,6-diamidino-2-phenylindole) was from Vector 
Laboratories (Peterborough, UK). Chemicals for Perls’ staining (potassium 
hexacyanoferrate and HCl) were from Sigma-Aldrich (Poole, UK). 
OPC cultures: Primary mixed glial cultures were prepared from cerebral cortices of 
Sprague-Dawley rats at P1 – 3, based on an established protocol.263 Cultures were 
maintained in D10 medium [Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum, 2 mM glutaMAX-I, 1 mM sodium pyruvate, 50 U/ml 
penicillin, and 50 µg/ml streptomycin] at 37°C in 5% CO2/95% humidified air for 8 – 10 
days, then shaken for 2 h on a rotary shaker at 200 rpm. This medium (containing largely 
microglia) was discarded, fresh D10 medium was added and allowed to re-gas, then the 
flasks were shaken overnight at 200 rpm. The resulting medium, containing largely OPCs, 
was transferred to non-tissue-culture grade petri dishes, to which microglia readily attach, 
reducing residual microglial contamination. After 30 min, unattached cells were 
resuspended in OPC maintenance medium (OPC-MM: DMEM supplemented with 2 mM 
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glutaMAX-I, 1 mM sodium pyruvate, 10 nM biotin, 10 nM hydrocortisone, 30 nM sodium 
selenite, 50 µg/ml transferrin, 5 µg/ml insulin, 0.1% bovine serum albumin, 50 U/ml 
penicillin, 50 µg/ml streptomycin, 10 ng/ml PDGF-AA, and 10 ng/ml FGF2) then plated 
onto poly-D-lysine (PDL) coated glass coverslips in 24-well plates (0.3 ml/well, at 3 x 10
4
 
cells/cm
2
). OPC cultures were maintained for 24 h before incubation with MPs, to allow 
cell adherence and re-growth of processes.  
Sphero MPs: Sphero
TM
 MPs (diameter 200 – 390 nm, iron content 15 – 20% w/v) 
were obtained from Spherotech Inc. (Lake Forest, Illinois, USA). These particles are 
prepared by the manufacturer as described in the results and comprise a polystyrene core 
(stained with the fluorophore nile red) surrounded by a layer of polystyrene and magnetite, 
over which carboxyl groups have been bound using an undisclosed monomer linker. 
Although these particles have been previously analysed in this laboratory by scanning 
electron microscopy (SEM),
241
 batch-to-batch variability can occur during MP synthesis, 
and particle size and shape are important factors in cellular uptake and processing.
212,264
 
Therefore, Sphero MPs were analysed by SEM for size and shape assessments. We have 
observed that their fluorophore does not leach, and their emission spectra remain stable 
following long periods of storage.
240,241
 The stability of the fluorophore (due to its 
incorporation into the polystyrene core, as opposed to conjugation at the particle surface 
where it would be more prone to oxidation, quenching or detachment) was a significant 
factor in selecting these MPs, as pilot experiments (involving MP-labelling of 
neuroblastoma cells and astrocytes) employed transfection grade MPs with surface-bound 
fluorophores (FluoMag, OZ Biosciences) demonstrating dye-related toxicity (unpublished 
observations, Dr Divya Chari, Dr Mark Pickard, Keele University, UK). Sphero MPs can 
be readily visualised by MRI, with the higher concentrations used here (20 and 50 µg/ml) 
demonstrating concentration-dependent contrast in agar gel when visualised using a 1.5 T 
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clinical MRI scanner,
240
 and Sphero-labelled mouse NSCs transplanted into rodent spinal 
cord could be detected using a 7 T scanner (unpublished data, this laboratory). Although 
the Sphero particles are relatively large, it should be noted that particles up to 1 µm 
diameter have been employed to image transplanted cells in the CNS without demonstrable 
effects on even complex biological functions such as myelination,
98 
and other particles, 
including functionalised transfection grade particles, are of comparable diameter,
100,265
 
justifying their use here.  
Fe3O4-PEI-RITC MPs: In collaboration with Professor M J Rosseinsky, novel 
multimodal MPs were synthesised at the University of Liverpool by Dr H H P Yiu (now at 
Heriot-Watt University, Edinburgh, UK).
102
 These Fe3O4-PEI-RITC particles comprise a 
magnetite core, surrounded by a covalently attached PEI layer, onto which a red 
fluorophore (rhodamine isothiocyanate, RITC) is bound. These particles have previously 
been characterised in detail, with TEM analyses indicating a uniform spherical shape and a 
core diameter of 24.3 ± 5.7 nm.
102
 These particles have been formulated with a higher iron 
content than typically found in commercial particles (~58%, compared to <30% in typical 
commercial particles; uncoated magnetite is ~72.4% iron) in order to provide superior MRI 
contrast at lower particle doses.
102
 The number of particles in 1 µg of the prepared MP 
suspension is calculated to be approximately 19.2 billion (Dr H H P Yiu, personal 
communication; calculation included in Appendix 1). Table 1 compares the characteristics 
of these particles with the Sphero MPs, and Figure 1 provides a schematic comparison of 
the components and layers.  
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Table 1. Comparison of physico-chemical characteristics of Sphero and Fe3O4-PEI-
RITC MPs 
Physico-chemical 
property 
Sphero MPs Fe3O4-PEI-RITC MPs
102
 
Iron oxide crystal size 
~18.5 nm (layer of crystals 
around polystyrene core)† 
24.3 ± 5.7 nm (core, TEM) 
25.5 nm (core, XRD) 
Magnetisation Not evaluated 80 emu/g 
Coating material 
1.63 x 10
6
 carboxyl groups per 
particle* 
PEI (MW = 1800) 
Fe content (w/v) 15 – 20%* ~58% 
Zeta potential (mV) -23.13* +18.6 
r2 relaxivity values 
(7T MRI scanner) 
Not evaluated 199 mM
-1
s
-1
 
Particles per µg 25.9 x 10
6* 19.2 x 109† 
*Data provided by manufacturer, Spherotech Inc.; †Data gathered by Dr H H P Yiu 
(Heriot-Watt University, Edinburgh, UK). All Fe3O4-PEI-RITC data taken from Yiu et 
al.
102
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Figure 1: Schematic diagrams of idealised Sphero and Fe3O4-PEI-RITC particles. (a) 
Idealised Sphero MP. Illustrates the polystyrene core stained with nile red fluorophores, 
surrounded by a layer of magnetite (Fe3O4) and polystyrene to which carboxyl groups 
have been attached using an undisclosed monomer linker. (b) Idealised Fe3O4-PEI-RITC 
MP. Illustrates the magnetite core (Fe3O4) within a silica shell (achieved through 
silanisation). The shell is functionalised with short chain polyethyleneimine (PEI; to which 
nucleic acids can be electrostatically bound),
188
 which is in turn functionalised with a 
RITC fluorophore. Schematic (a) was produced by Dr H H P Yiu, and (b) is adapted from 
Yiu et al.;
102
 particles and layers not drawn to scale.  
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Fourier transform infrared (FTIR) spectroscopic analysis of Sphero MPs: FTIR 
was carried out by Dr H H P Yiu (Heriot-Watt University, Edinburgh) using a Perkin 
Elmer Spectrum 100 spectrometer fitted with an attenuated total reflection (ATR) sampling 
unit. For the sample measurement, 32 scans in the region from 650 to 4000 cm
-1
 were 
accumulated with a resolution of 4 cm
-1
. This technique was used to identify the chemical 
groups at the particle surface. 
Powder XRD (X-ray diffraction) analysis of Sphero MPs: XRD analysis of the iron 
oxide component of the particles was carried out Dr H H P Yiu (Heriot-Watt University, 
Edinburgh, UK) using a Bruker D8 Advance diffractometer with Cu Kα1 radiation (λ = 
1.542 Å). This technique allows the identification of the structure of crystalline 
components.
266
 The diffraction pattern was collected from 2θ = 5° to 80°, at a step size of 
0.009° and a step time of 120 s. The particle size of iron oxide was estimated using 
Scherrer analysis on the most intense peak (311). This calculation estimates the mean 
domain size rather than the physical size of the particle, and is used as a complementary 
technique to TEM size analysis.
266
 
Sphero uptake experiments: At 24 h after plating, OPCs were incubated with 2 – 50 
µg/ml MPs for 1 – 24 h. Control cultures were treated with equal volumes of fresh 
medium, without MPs. Samples were washed with phosphate buffered saline (PBS), then 
fixed and either immunostained, or processed for Perl's Prussian blue histochemical 
staining. OPC cultures are not strongly adherent to PDL-coated coverslips and this 
presented a methodological problem for particle uptake experiments with regard to the 
removal of extracellular particles when terminating incubations. In previous work with 
astrocytes
240
 and microglia,
241
 extensive washing with PBS was necessary to reduce non-
specific binding of MPs to minimal levels, and this was well tolerated by microglial and 
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astrocyte cultures, resulting in minimal cell detachment. In the present study a similar 
washing protocol resulted in the loss of many OPCs, even without the prior addition of 
MPs (i.e. control cultures). Consequently, to minimize the loss of cells, several washes 
were performed by gently applying PBS to the walls of culture wells. 
Differentiation potential of MP-labelled OPCs: OPCs (plated in OPC-MM 24 h 
previously) were pulse-labelled with Sphero MPs for 24 h (20 µg/ml) then washed with 
PBS and the medium replaced with Sato medium [DMEM supplemented with 2 mM 
glutaMAX-I, 1 mM sodium pyruvate, 1x N2 supplement (insulin, human transferrin, 
progesterone, putrescin, selenite),
267
 30 nM thyroxine, 30 nM triiodothyronine, 50 U/ml 
penicillin, and 50 µg/ml streptomycin] to induce differentiation. Cultures were maintained 
for 30 days (medium changes every 2 – 3 days) then either immunostained for MBP or 
subjected to Perls’ staining. 
Fe3O4-PEI-RITC uptake experiments: At 24 h after plating, OPCs were incubated 
with 5 or 20 µg/ml MPs for 24 h. Control cultures were treated with equal volumes of fresh 
medium, without MPs. Samples were washed with PBS, then fixed and either 
immunostained, or processed for Perl's Prussian blue histochemical staining.  
Immunocytochemistry: In all cases, washed cells were fixed with 4% 
paraformaldehyde [PFA; room temperature (RT); 25 min] then washed again (PBS). For 
staining, cells were incubated with blocking solution (5% serum in PBS, with 0.3% Triton 
X-100 for MBP; RT; 30 min), then with primary antibody in blocking solution (A2B5 
1:200; MBP 1:200; 4°C; overnight). Cells were then washed with PBS, incubated with 
blocking solution (RT; 30 min), and incubated with the appropriate FITC-conjugated 
secondary antibody in blocking solution (1:200; RT; 2 h). Finally, coverslips were washed 
with PBS and mounted with the nuclear stain DAPI.  
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Perls’ Prussian blue iron staining: Fixed OPCs were incubated with 2% potassium 
ferricyanide in 2% HCl for 10 min, washed three times with distilled water and then 
mounted in glycerol-based mounting medium without DAPI. 
Fluorescence microscopy: Samples were imaged using fixed exposure settings on 
an Axio Scope A1 fluorescence microscope (Carl Zeiss MicroImaging GmbH, Goettingen, 
Germany), and the images merged using Adobe Photoshop CS3 (version 10.0.1).  
Z-stack fluorescence microscopy: Z-stack fluorescence images of samples were 
created using fixed exposure settings on a Nikon Eclipse 80i microscope fitted with a 
CA742-95 camera (Hamamatsu Photonics, Hamamatsu, Japan), with manual focus 
stepping at 0.5 or 1.0 µm, and the image manipulations performed using Nikon NIS 
Elements (version 3.00). 
Confocal fluorescence microscopy: Confocal fluorescence images of samples were 
taken using a BioRad MRC1024 confocal laser scanning microscope. This employed a 
krypton-argon laser with excitation at 488 nm and emission filters of 522/535 nm. 
Scanning electron microscopy (SEM; Sphero MPs): For analysis of MPs without 
cells, Sphero particles in OPC-MM were air-dried onto aluminium stubs and visualised 
uncoated using a high resolution field emission SEM (Hitachi S4500) operated at an 
accelerating voltage of 5 kV.  
SEM (OTOTO): For analysis of MP-OPC interactions, OPCs in OPC-MM were 
plated onto PDL-coated glass coverslips (13 mm), then incubated with 20 µg/ml Sphero 
MPs for 24 h before OTOTO processing as follows (RT): Samples were fixed in 2.5% 
glutaraldehyde [in 0.1 M sodium cacodylate buffer containing 2 mM CaCl2, pH 7.4 (SCB; 
2 h)], washed with SCB, post-fixed with 1% OsO4 in SCB (1 h), and washed with SCB 
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again. Samples were washed thoroughly with distilled water after each of the following 
incubations: thiocarbohydrazide (in water, saturated solution; 20 min), 1% OsO4 (2 h), 
thiocarbohydrazide (20 min), 1% OsO4 (2 h). Samples were then dehydrated through a 
graded series of ethanol, before critical point drying (2 h). Coverslips were finally mounted 
on aluminium stubs using carbon pads, and visualised using a high resolution field 
emission SEM (Hitachi S4500) operated at an accelerating voltage of 5kV. To determine 
OPC shrinkage due to sample processing, the longest axis of the cell body was measured in 
OTOTO samples and compared to the longest axis of the cell body in samples prepared for 
fluorescence microscopy. Bipolar OPCs were identified for these measurements (12 cells 
for each microscopic technique) and the longest axis was the distance across the cell body 
between the two processes. 
Transmission electron microscopy (TEM): OPC cultures were established for 24 h 
on polyornithine-coated aclar sheet, previously cut to fit a 24-well plate (0.3 ml/well, at 6 x 
10
4
 cells/cm
2
), then incubated with 20 µg/ml MPs for 24 h. Samples were fixed with 2.5% 
glutaraldehyde (in SCB; RT; 2 h), then washed with SCB. Samples were postfixed with 
1% OsO4 in SCB for 1 h, washed with SCB, dehydrated in a graded series of ethanol, then 
infiltrated with Spurr resin, before polymerization at 60°C for 16 h. To obtain sections, the 
block was trimmed to expose the aclar sheet which was peeled off, leaving the cells in the 
resin. Ultrathin sections were then cut parallel to the original plane of the sheet on a 
Reichert Ultracut E ultramicrotome, mounted on 200 mesh thin bar copper grids, and 
stained with 2% uranyl acetate in 70% ethanol (RT; 20 min) and 2% Reynolds lead citrate 
(RT; <5 min). Sections were examined using a JEOL 100-CX transmission electron 
microscope operated at 100 kV. Images were acquired using a SIS systems Megaview III 
digital camera (Olympus). 
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Culture purity analysis: The purity of each culture was determined by scoring at 
least 100 DAPI-stained nuclei for coincidence with A2B5 staining in fluorescence 
micrographs.  
Sphero uptake/toxicity analysis: For uptake studies, fluorescence micrographs were 
used to assess the proportion of A2B5
+
 OPCs with coincident nile red fluorescence, 
scoring the extent of uptake in each cell as ‘low’, ‘medium’ or ‘high’ (see: semi-
quantitative assessment of MP uptake), and recording whether each MP-labelled cell 
exhibiting any perinuclear MPs (minimum 100 DAPI-stained nuclei for each concentration 
and time point). Initial experiments used a 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTS) assay to assess MP toxicity in OPCs, by comparing 
cellular metabolic activity, a technique previously used with astrocytes
240
 and microglia.
241
 
However, typically low levels of MTS reduction to formazan were consistently found in 
both control and MP-treated OPC cultures, which was not deemed sufficiently sensitive to 
accurately assess toxicity. Therefore, fluorescence micrographs were used to count the 
pyknotic and total (healthy plus pyknotic) nuclei per microscopic field, as measures of MP-
related toxicity (minimum five microscopic fields for each concentration and time point). 
Fe3O4-PEI-RITC uptake/toxicity analysis: OPCs were identified in Perls’ stained 
cultures by phase contrast microscopy, and judged to be labelled if intracellular Perls’ 
staining was apparent (minimum 100 DAPI-stained nuclei for each concentration and time 
point). The extent of uptake by each cell was judged as ‘low’, ‘medium’ or ‘high’ (see: 
semi-quantitative assessment of MP uptake). Duplicate coverslips (plated and treated 
identically) were immunostained for A2B5 and mounted with DAPI. Toxicity was 
determined by assessing the percentage of pyknotic nuclei, as judged by DAPI-staining 
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(shrunken, fragmenting nuclei were classed as pyknotic). Minimum five microscopic fields 
for each concentration and time point. 
Semi-quantitative assessment of MP uptake: The level of MP uptake in individual 
cells was assessed in a semi-quantitative manner by comparison with the average cross-
sectional area of an OPC nucleus, and scored as either ‘low’ (<10% of the area of an 
average nucleus), ‘medium’ (10 – 50%), or ‘high’ (>50%). It was deemed unsuitable to 
assess levels of uptake by means of a fluorescence plate reader, or in terms of incorporated 
iron per cell, as these techniques quantify the total fluorescence or iron present in a culture, 
and therefore assume an even distribution between cells. Such techniques would not enable 
the determination of uptake heterogeneity within the cell population, as observed in these 
cultures. A flow cytometry approach was also considered and rejected, as it is likely that 
extracellular MPs adherent to the plasma membrane would lead to a number of ‘false 
positives' and this technique cannot distinguish cytoplasmic versus nuclear accumulations 
of particles within cells. Microscopic cell counting analysis was therefore considered the 
most appropriate method to assess whether MPs were intracellular, or merely 
extracellularly attached to plasma membrane, and detailed microscopic assessment of MP 
uptake was considered to more accurately reflect the heterogeneity that is typically found 
in primary cell cultures. A minimum of 100 DAPI-stained nuclei were assessed for each 
concentration and time point. 
Statistical analysis: Data were analysed using GraphPad Prism statistical analysis 
software. All data are expressed as mean ± SEM. The number of experiments (n) refers to 
the number of mixed glial cultures from which OPC cultures were derived, with each 
primary culture being established from a different rat litter. Sphero MP analysis: for (i) 
the percentage of cells labelled, (ii) percentage of cells exhibiting perinuclear particles, 
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percentage of labelled cells demonstrating (iii) ‘low’ or (iv) ‘medium’ uptake, (v) total 
nuclei per microscopic field, and (vi) percentage of pyknotic nuclei per microscopic field, 
data were analysed by two-way ANOVA for concentration- and time-dependence, with 
Bonferroni’s post-tests for (i), (ii), (iii) and (iv). Fe3O4-PEI-RITC MP analysis: for (i) the 
percentage of cells labelled, (ii) the percentage of cells exhibiting ‘medium’ uptake, and 
(iii) the percentage of cells exhibiting ‘medium’ uptake plus the percentage of cells 
exhibiting ‘high’ uptake, data were analysed by unpaired two-tailed t-tests; for OPCs per 
microscopic field and percentage of pyknotic nuclei, data were analysed by one-way 
ANOVA. 
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2.3 Results 
 
2.3.1 OPC culture characterisation 
Phase contrast microscopy of untreated and MP-treated cultures revealed phase-
bright cells with the bipolar morphologies characteristic of OPCs (Figure 2a). 
Fluorescence microscopy showed that high purity cultures of OPCs were routinely derived 
from primary mixed glial cultures, as assessed by immunostaining for the OPC marker 
A2B5 (95.4 ± 0.9%; n = 4), and DAPI-staining showed typical round or oval nuclei 
(Figure 2b). 
 
 
Figure 2: Characterisation of OPC cultures. (a) Typical phase-contrast micrograph of 
OPCs. (b) Counterpart fluorescence micrograph of (a) showing A2B5 staining and DAPI-
stained nuclei. 
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2.3.2 Sphero MP characterisation 
SEM data were consistent with previous findings, showing that the particles used 
were regular in shape, and within the size range reported by the manufacturer (Figure 3). 
The FTIR spectrum of these particles was dominated by the polystyrene component 
(Figure 4a) with a small number of carboxylic groups, shown as νC=O (C=O stretching) at 
1707 cm
-1
. The powder XRD pattern (Figure 4b) revealed that the iron oxide crystallites in 
the particles are of an inverse spinel structure, e.g. Fe3O4 (magnetite) or γ-Fe2O3 
(maghemite), consistent with the inclusion of magnetite stated by the manufacturer. 
However, due to the small crystal size or low crystallinity of the iron oxide, the diffraction 
peaks are broad and of low intensity. This is also partly due to the predominant amount of 
polystyrene (ca. 80%) present in the particles. The average crystal size was estimated to be 
approximately 18.5 nm in diameter using Scherrer analysis on the most prominent 
diffraction peak (311).  
 
 
Figure 3: Characterisation of Sphero MPs by SEM. Scanning electron micrograph of 
an individual particle, showing typical size and shape. 
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Figure 4: Characterisation of Sphero MPs by FTIR and XRD analyses. (b) FTIR 
spectroscopic analysis of Sphero MPs shows a major polystyrene component characterised 
by peaks in the ranges of 3083 – 3025 cm-1 (C-H stretch, aliphatic) and 2923 – 2851 cm-1 
(C-H stretch, aromatic ring). The peaks within the fingerprint region 1601, 1492 and 1452 
cm
-1
 correspond to the C=C stretch in an aromatic system. The strong peaks at 755 and 
696 cm
-1
 correspond to the C-H bending mode of the benzene ring. A small number of 
carboxylic acid groups were detected at 1707 cm
-1
 (C=O stretching; arrow). (c) Powder 
XRD pattern of particles showing an inverse spinel structure of iron oxide crystallites in 
particles, consistent with the presence of magnetite. The average diameter of an individual 
crystal was estimated to be 18.5 nm, based on Scherrer analysis of diffraction peak 311.  
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2.3.3 Sphero MPs can be detected within OPCs by both fluorescence and iron 
staining 
Perls’ Prussian blue iron staining of cells labelled for 24 h with Sphero MPs 
revealed the presence of iron coincident with nile red fluorescence (Figure 5). Analyses of 
cultures which had been pulse-labelled for 24 h then maintained in Sato medium showed 
that Perls’ staining was still coincident with nile red fluorescence after 30 days in culture. 
This demonstrates the reliability of fluorescence as an indicator of Sphero MP presence, 
and suggests the stability of MPs in both the culture media and the cells. No blue staining 
was observed after Perls’ staining of control cultures, presumably due to the low levels of 
endogenous iron. 
 
  
Figure 5: Sphero particle visualisation by fluorescence and histochemical staining. (a) 
Phase-contrast micrograph, showing Perls’ Prussian blue staining of iron within an OPC 
(24 h incubation with 20 µg/ml Sphero MPs). (b) Counterpart fluorescence micrograph 
image to (a) showing nile red fluorescence is coincident with iron accumulations. 
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2.3.4 Sphero uptake and perinuclear localisation is concentration- and time-
dependent in OPCs 
Fluorescence microscopy, including z-stack and confocal analyses, confirmed the 
intracellular presence of Sphero MPs in OPCs (Figure 6a-b). Both cytoplasmic and 
perinuclear particle accumulations were observed, with the typical diameter of these 
accumulations being <2 µm; z-stack analyses revealed accumulations to be typically 
spherical. MP uptake was time- and concentration-dependent, with the highest dose and 
longest exposure tested resulting in MP-labelling of ca. 60% of A2B5
+
 cells (Figure 7a). 
Concentrations of 20 and 50 µg/ml resulted in the labelling of a significantly greater 
percentage of A2B5
+
 cells than 2 µg/ml, at all time points (Figure 7a). Heterogeneity was 
apparent in the extent of MP-uptake by individual cells. Under all conditions, the majority 
of MP-labelled OPCs were judged to exhibit a ‘low’ level of particle accumulation (Table 
2). The proportion of labelled OPCs exhibiting ‘medium’ levels of MP accumulation was 
both time- (F2,36 = 14.2; p < 0.001) and concentration-dependent (F3,36 = 15.2; p < 0.001; 
two-way ANOVA; n = 4). ‘High’ levels of uptake by OPCs were rarely observed (Table 
2). With respect to MP-labelled OPCs, the percentage of cells with perinuclear MPs was 
found to be time- and concentration-dependent (Figure 7b). Perinuclear, but not 
intranuclear, particles were observed using confocal and z-stack analyses (Figure 6). 
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Figure 6: Uptake and perinuclear localisation of Sphero MPs by OPCs was confirmed 
by confocal and z-stack microscopy. (a) Series of confocal fluorescence micrographs of 
cells incubated with 20 µg/ml MPs for 24 h, then stained for A2B5. Arrows indicate nile 
red fluorescence within a cell. The intracellular nature of particles is inferred by the fact 
that the cell and particles are in focus within the same planes. (b) Z-stack fluorescence 
analysis of cells incubated with 5 µg/ml MPs for 4 h, then stained for A2B5. Nile red 
fluorescence reveals MPs in cytoplasmic accumulations (blue arrow), perinuclear 
accumulations (crosshairs), and attached to the substratum (white arrow). 
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Figure 7: Uptake and perinuclear localisation of Sphero MPs by OPCs is time-and 
concentration-dependent. (a) Bar chart showing the percentage of OPCs labelled with 
MPs. The percentage of MP-labelled cells is related to particle concentration (F3,36 = 
29.2; p < 0.001) and incubation time (F2,36 = 35.1; p < 0.001; two-way ANOVA; n = 4). 
(b) Bar chart showing the percentage of MP-labelled OPCs with perinuclear MPs. The 
percentage of cells exhibiting perinuclear MP localisation was related to both particle 
concentration (F3,36 = 8.22; p < 0.001) and incubation time (F2,36 = 50.8; p < 0.001; two-
way ANOVA; n = 4). For (a) and (b), *p < 0.05 versus 2 µg/ml at the same timepoint; 
+
p 
< 0.05 versus the same concentration at 1 h (Bonferroni’s post-tests). 
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Table 2. Semi-quantitative analysis of the extent of Sphero MP uptake by OPCs. 
Incubation 
time (h) 
MP concentration 
(µg Sphero/ml) 
Level of particle accumulation in MP-labelled 
OPCs (%) 
‘Low’ ‘Medium’ ‘High’ 
1 2 100.0 0.0 0.0 
5 100.0 0.0 0.0 
20 100.0 0.0 0.0 
50 95.0 ± 1.0 5.0 ± 1.0 0.0 
4 2 99.6 ± 0.5 0.4 ± 0.5 0.0 
5 96.7 ± 2.6 3.3 ± 2.6 0.0 
20 88.2 ± 4.1
**
 11.8 ± 4.1
**/††
 0.0 
50 87.0 ± 3.1
†
 12.1 ± 2.2
††
 0.9 ± 1.0 
24 2 97.3 ± 1.9 2.7 ± 1.9 0.0 
5 95.9 ± 2.2 4.1 ± 2.2 0.0 
20 86.8 ± 4.3
**/††
 12.2 ± 3.6
***/†
 1.1 ± 0.7 
50 85.1 ± 4.3
*/†††
 13.3 ± 3.0
††
 1.6 ± 1.5 
*
p < 0.05, 
**
p < 0.01, 
***
p < 0.001 versus same concentration at 1 h; 
†
p < 0.05, 
††
p < 0.01, 
†††
p < 0.001 versus 2 µg/ml at the same time-point; Bonferroni’s post-tests; n = 4. 
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2.3.5 Sphero MPs are not acutely toxic to OPCs 
At all concentrations and incubation times tested, no significant effects of Sphero 
MPs were observed in OPC cultures with respect to (a) cell adherence, as judged by 
number of DAPI-labelled nuclei (either healthy or pyknotic) per microscopic field (one-
way ANOVA at each timepoint; 1 h: F4,15 = 0.314, ns; 4 h: F4,15 = 0.921, ns; 24 h: F4,15 = 
0.261, ns; n = 4; Figure 8a), and (b) cell death, as judged by the percentage of cells 
exhibiting pyknotic nuclei (i.e. shrunken or fragmenting morphologies; one-way ANOVA 
at each timepoint; 1 h: F4,15 = 0.913, ns; 4 h: F4,15 = 1.41, ns; 24 h: F4,15 = 0.0444, ns; n = 
4; Figure 8b). For all concentrations and incubation times, OPC cultures appeared 
morphologically similar to controls at 24 h.  
 
 
Figure 8: Incubation of OPCs with Sphero MPs at a range of concentrations does not 
result in acute cytotoxicity. Bar graphs of OPC time course experiments showing (a) total 
(healthy plus pyknotic) nuclei per microscopic field, and (b) percentage of nuclei with 
pyknotic features (n = 4 for both graphs). 
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2.3.6 Oligodendrocytes inherit MPs from labelled OPC parent cells without obvious 
long term toxicity 
When OPCs were pulse-labelled with Sphero MPs for 24 h then cultured for 30 
days in differentiation medium, no differences were observed in treated versus control 
cultures with respect to the number of cells, percentage of cells staining for MBP, or 
morphology. Accumulations of MPs were evident within approximately 60% of 
oligodendroglial cells (Figure 9). Occasional dense rings of MPs were present within 
MBP
-
 cells, which morphologically resembled microglia. Heterogeneity in the extent of 
cellular MP accumulation was apparent (Figure 9). 
 
2.3.7 Fe3O4-PEI-RITC MPs can be detected within OPCs by both fluorescence and 
iron staining 
Whereas the Sphero particles contain a relatively small proportion of iron (15 – 
20% w/v), the Fe3O4-PEI-RITC particles have a high iron content (~58% w/v), and 
therefore uptake was assessed by Perls’ Prussian blue iron stain which was found to 
robustly label even small (<1 µm diameter) accumulations of particles (Figure 10a). Red 
fluorescence attributable to the RITC fluorophore could also be detected within OPCs 
using confocal and z-stack microscopy, confirming that the particles were intracellular 
rather than merely adherent to the plasma membrane (Figure 10b). Both cytoplasmic and 
perinuclear accumulations of particles were observed (Figure 10b). 
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Figure 9: Sphero particles are stably retained within oligodendrocytes generated 
from labelled OPCs for up to 30 days. OPCs were pulse-treated with Sphero particles 
(24 h incubation with 20 µg/ml Sphero MPs) then maintained in differentiation medium for 
30 days, generating an enriched oligodendrocyte culture. (a) Dark field micrograph 
showing Perls’ iron stain of Sphero MPs within cells identified morphologically as 
oligodendrocytes. (b) Counterpart fluorescence micrograph to (a) showing nile red 
fluorescence of Sphero MPs. Orange arrow indicates the same large accumulation of MPs 
in both images, located within a multipolar oligodendrocyte. White arrows indicate the 
same intracellular accumulations of Sphero particles in both images. Note that MPs are 
frequently located at the edge of the nucleus, which can be identified as a dark circle or 
oval in the centre of each cell. (c) Fluorescence micrograph of a culture stained with the 
late-stage oligodendrocyte marker MBP. White arrows indicate example accumulations of 
Sphero particles within cells. Note the heterogeneity in the extent of particle uptake, and 
the intense MP fluorescence. 
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Figure 10: Fe3O4-PEI-RITC particle visualisation by histochemical staining and 
fluorescence microscopy. (a) Phase-contrast micrograph, showing Perls’ Prussian blue 
staining of iron within OPCs (24 h incubation with 20 µg/ml Fe3O4-PEI-RITC MPs). 
Arrows indicate intracellular particle accumulations. (b) Z-stack fluorescence micrograph 
of OPCs (identified by the OPC marker A2B5) following 24 h incubation with 20 µg/ml 
Fe3O4-PEI-RITC MPs. RITC fluorescence indicates the intracellular presence of particles, 
with perinuclear (crosshairs and dashed arrow) and cytoplasmic (white arrow) 
accumulations apparent. Arrowhead indicates an extracellular particle accumulation. 
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2.3.8 Uptake of Fe3O4-PEI-RITC particles by OPCs is concentration-dependent 
Concentration-dependent labelling of OPCs with Fe3O4-PEI-RITC particles was 
apparent, with >50% of OPCs demonstrating either ‘medium’ or ‘high’ levels of particle 
uptake at 24 h with the highest concentration tested (Figure 11a). At both concentrations 
tested, no significant effects of Fe3O4-PEI-RITC MPs were observed in OPC cultures with 
respect to: (a) cell adherence, as judged by the number of OPCs per microscopic field 
(Figure 11b), and (b) cytotoxicity, as judged by the percentage of cells exhibiting pyknotic 
nuclei (i.e. shrunken or fragmenting morphologies in duplicate cultures labelled with DAPI 
and A2B5, but without Perls’ staining; Figure 11c). For both concentrations, OPC cultures 
appeared morphologically similar to controls after 24 h incubation. The percentage of 
OPCs exhibiting perinuclear accumulations was not specifically counted in the Perls’ 
analyses as DAPI-staining is not compatible with Perls’ staining. However, perinuclear 
particle accumulations were frequently observed using fluorescence microscopy, and could 
be inferred by the characteristic Perls’ staining of particles in arcs or curves around the 
centre of cells (see Figure 10a for examples). From these assessments, the approximate 
percentage of cells exhibiting these perinuclear patterns (~70% for both 5 and 20 µg/ml, 24 
h) was comparable to that observed with Sphero MPs. 
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Figure 11: Fe3O4-PEI-RITC MPs label OPCs in a concentration-dependent manner 
and do not exhibit acute toxicity. (a) Bar graph illustrating the concentration-dependent 
uptake of Fe3O4-PEI-RITC MPs by OPCs following 24 h incubation (*p < 0.05). The 
stacked bars indicate the proportions of labelled OPCs which exhibited ‘low’, ‘medium’ or 
‘high’ levels of MP accumulation. The proportion of OPCs exhibiting ‘medium’ levels of 
MP accumulation was concentration-dependent (p < 0.05). The percentage of OPCs 
exhibiting ’medium’-to-‘high’ MP uptake was concentration-dependent (p < 0.05). Bar 
graphs illustrating no differences in (b) the number of OPCs per microscopic field (F2,6 = 
0.602; ns; one-way ANOVA; n = 3) and (c) the percentage of pyknotic cells per 
microscopic field (F2,6 = 0.559; ns; one-way ANOVA; n = 3) following incubation of OPC 
cultures with or without Fe3O4-PEI-RITC MPs for 24 h. For (b) and (c), OPCs and 
pyknotic nuclei were identified by A2B5 and DAPI staining of identically treated sister 
cultures, without Perls’ staining; n = 3 for all graphs. 
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2.3.9 OTOTO SEM facilitates the identification of MP-cell interactions and 
endocytotic processes 
Samples demonstrated good cell adherence, with few cells exhibiting membrane 
fractures (<5%). Membrane features could be readily identified in the high resolution 
images obtained, revealing cellular interactions with MPs (Figure 12). Control cultures 
showed no evidence of MPs (Figure 12a), and OPCs were readily identifiable by their 
characteristic bipolar morphologies, with small cell bodies and fine processes (Figure 
12b). Cells with proliferative morphologies could be observed in MP-treated samples 
(Figure 12c). Based on the measurement of the longest axis of the cell body, OTOTO-
processed OPCs appear to shrink to ~80% of the size of OPCs fixed for fluorescence 
microscopy, but the lack of obvious fractures in the membrane attributable to shrinkage 
suggests no cells were damaged by this shrinkage. Sphero MPs could be identified by their 
regular spherical morphology and size, in agreement with SEM of particles without cells, 
and the absence of similar structures from control cultures, and these MPs could be found 
in association with cell membranes (Figure 12d-f; Figure 13a). Small ‘blebs’ of 
membrane were observed projecting from the cell surface, of slightly larger diameter than 
the MPs, although it was not apparent from these analyses whether MPs were inside these 
‘blebs’ (Figure 12d-e). Many cells displayed large numbers of microvilli and/or pits, 
indicating highly active endocytotic membrane (Figure 12d-e; contrast with regions of 
‘smooth’ membrane in Figure 12a-c. Some cell-associated MPs were observed to be 
within membrane depressions, which may indicate the early stages of endocytotic pit 
formation (Figure 12f), and in close proximity to pit-like structures, suggestive of 
endocytotic activity (Figure 13a). Macropinocytotic membrane elaborations could also be 
seen near MPs (Figure 13a), suggesting that OTOTO SEM may allow identification of the 
same endocytotic activity as was observed using TEM analysis (Figure 13b).  
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Figure 12: Particle-cell interactions visualised by OTOTO SEM. Scanning electron 
micrographs of OPC cultures, incubated without (a) and with (b-f) Sphero MPs (24 h, 20 
µg/ml). (a) Cell surface without particles. (b) Cells with the small, bipolar morphologies 
and fine processes typical of OPCs (arrows). (c) Cells demonstrating a mitotic profile 
(arrows indicate two daughter cells about to complete mitosis). (d) Sphero MPs associated 
with a cell surface (white arrows). Black arrows indicate membrane projections, ‘blebs’, 
which may be wrapped around individual MPs. Note the numerous microvilli projecting 
from the cell surface, suggesting a highly active region of membrane. (e) Enlarged image 
from (d), with arrows indicating the same features. (f) Membrane-associated MP which 
appears to be situated within a depressed region of membrane, suggestive of endocytotic 
pit-formation, illustrating that this technique can facilitate the identification of such 
features.  
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Figure 13: OTOTO SEM and TEM images illustrating the potential to identify the 
same endocytotic events. OPC cultures were incubated with Sphero MPs (24 h, 20 µg/ml) 
(a) SEM image of a Sphero MP (white arrow) associated with OPC membrane. An 
endocytotic pit (black arrow) may be forming in the vicinity of the particle, and 
macropinocytotic membrane elaboration is apparent (dashed arrow). (b) TEM image of an 
OPC. A small cluster of MPs is apparent (white arrows), and they appear to be associated 
with macropinocytotic membrane (black arrows). This can be compared with the SEM 
image of macropinocytotic membrane in (a).  
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2.4 Discussion 
 
2.4.1 OPCs are amenable to labelling with physico-chemically different MP 
formulations 
This is the first report of MP-labelling of high purity OPC cultures derived from a 
primary source. As detailed in section 1.10, data from primary cultures will be of greater 
biological relevance for informing clinical MP-based engineering than will data from cell 
lines. Labelling was successfully achieved using two MP formulations with very different 
physico-chemical properties. For the given concentrations used in this study (5 and 20 
µg/ml at 24 h), the smaller MP (Fe3O4-PEI-RITC) labelled a greater percentage of OPCs, 
consistent with a number of other reports in different cell types suggesting greater uptake 
of smaller particles.
204,268–270
 At the highest concentrations and incubation times tested, 
both particles labelled ~60% of OPCs. The time- and concentration-dependence observed 
with the Sphero particles, and the concentration-dependence observed with the Fe3O4-PEI-
RITC particles suggest that labelling of a higher percentage of OPCs may be achieved by 
simply increasing the concentration and/or incubation time, although such an approach 
would entail further toxicity assessment. 
However, it should be noted that the concentrations reported here were based on 
equal weights of particles (µg/ml) rather than equal numbers of particles (particles/ml). 
The disparity in particle number is such that the highest Sphero concentration (50 µg/ml) 
contains 1.3 billion particles/ml, whereas the lowest Fe3O4-PEI-RITC concentration (5 
µg/ml) contains 96 billion particles/ml, a ratio of 1:74 (Appendix 1). As incubation with 
this far larger number of particles did not result in labelling of more than 60% of the 
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population, it is possible that this represents an intrinsic labelling limit in the OPC cultures. 
This further suggests the presence of an OPC sub-population which is intransigent to MP 
uptake, and may require specific cell-targeting approaches to achieve labelling. For 
transplantation applications, labelled cells could be purified using a magnetic cell 
separation step;
271
 it would additionally be of high biological interest to separate the 
labelled/unlabelled subpopulations and compare their gene expression, or endocytotic 
profiles. The particles also differ in their coating material and zeta potential, each of which 
could influence cellular uptake. The Fe3O4-PEI-RITC particles have previously been tested 
in cultures of astrocytes, for labelling purposes (as used here) and also as transfection 
agents (particles incubated with plasmid DNA to form complexes).
102
 The percentage of 
MP-labelled astrocytes was not found to differ between particles with and without 
complexed DNA at the three concentrations tested (MPs at 7, 21 and 67 µg/ml, 24 h). As 
the addition of DNA would alter the surface groups and presumably the charge, this 
suggests that the coating and charge do not significantly affect cellular uptake of the 
Fe3O4-PEI-RITC particles, although equivalent assays would be required to demonstrate 
that this is also the case for OPCs. Formation of a particle-plasmid complex will of course 
also increase the size, and although these complexes are not anticipated to approach the 
size of the Sphero particles, it will be important to determine the physico-chemical 
properties of MP-plasmid complexes before conclusions can be drawn regarding the 
specific factors that may influence cellular uptake of these particles. 
Some iron oxide MPs are reported to require specific cellular targeting to result in 
cellular uptake, for example by conjugation of anti-transferrin-receptor antibodies to the 
particles.
155
 Even for particles that are taken up by cells without targeting, attempts are 
frequently made to increase the extent of labelling by complexing the particles with 
transfection agents, such as Lipofectamine 2000.
131
 It is of note that cell targeting 
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techniques such as these were not required for OPC uptake of the Sphero particles tested 
here, but it remains possible that incorporating such a targeting technique could yield 
greater levels of OPC labelling, in terms of both percentage of cells and extent of 
accumulation, and this warrants further investigation. It may also be possible to enhance 
MP-labelling of OPCs by employing a magnetic field, placed beneath the culture plate, to 
enhance particle sedimentation and therefore particle-cell interactions.
217
 
 
2.4.2 MP-labelled OPCs retain this label when differentiated into oligodendrocytes 
As a transplant population of MP-labelled OPCs is intended to eventually 
differentiate into mature oligodendrocytes as part of a regeneration-enhancing strategy, it is 
important to assess whether MPs are retained within the differentiated cells (for imaging 
applications), and whether any adverse effects become apparent post-differentiation. When 
pulse-labelled OPCs (24 h, 20 µg/ml Sphero) were cultured in differentiation medium for 
30 days, MPs were clearly visible within MBP
+
 oligodendrocytes, although it is not 
apparent whether these particles (i) were present within the same cells for the entire 
duration of the experiment, (ii) were only endocytosed during the prolonged incubation 
period (beyond the 24 h pulse-labelling period; cultures were washed after 24 h, but some 
residual extracellular MPs would be expected), or (iii) were exocytosed and subsequently 
endocytosed by another cell. Approximately 60% of oligodendroglia were MP-labelled at 
30 days, compared to ~38% of OPCs at 24 h exposure to the same concentration. There are 
several possible explanations for these observations. If cells unlabelled at 24 h did not later 
become labelled, and assuming equal survival and proliferative capacity of the initial 
labelled and unlabelled subpopulations, the percentage of labelled cells would be expected 
to remain steady. If MP-labelled cells experienced impaired survival or proliferative 
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capacity, then the percentage of labelled cells would be expected to diminish. Therefore, 
this increase in the percentage of cells labelled supports both option (i), which suggests 
that proliferation of labelled OPCs resulted in particle inheritance in both daughters and 
also that MP-labelled OPCs retained at least some of their particles during differentiation 
into oligodendrocytes, and option (ii) which suggests that cells unlabelled at 24 h exhibited 
particle uptake at some later time-point, without precluding an effect due to option (iii).  
Longer term MP retention studies will be necessary in order to determine the length 
of time over which oligodendroglial cells retain MPs and to assess their ultimate fate. For 
example, it will be of value to determine whether an OPC transplant population may 
exocytose intact MPs, or MP breakdown products, over time. It will also be important to 
assess how MP-labelling is diluted by mitosis, given that OPCs are a proliferative cell 
population. The retention study reported here used oligodendrocyte differentiation medium 
in order to determine whether the labelled cells could produce mature oligodendrocytes 
and to assess the extent of particle retention in the differentiated progeny of labelled OPCs, 
but a similar study could be performed with proliferative medium, passaging the OPCs and 
monitoring the dilution of the MP-label. Proliferation of particle-labelled cells is reported 
to typically result in random and asymmetric inheritance by daughter cells.
272
 Although 
large-scale culture of OPCs may become part of a future therapeutic procedure, it is 
unlikely that cells would be labelled prior to a significant expansion of the cultures, as this 
would be expected to dilute the labelling effect. Rather, it is to be anticipated that an 
eventual clinical labelling procedure would label cells close to the time of transplantation, 
limiting dilution due to proliferation.  
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2.4.3 MP-labelling of OPCs is safe 
In order to develop MPs for clinical applications it is of paramount importance to 
assess potential cytotoxic effects associated with particle uptake and/or breakdown. 
Oligodendroglial cells contain more iron than any other CNS cell type, but are also the 
most vulnerable to excess iron, which typically leads to an increase in oxidative stress due 
to reactive oxygen species (ROS) produced by the Fenton reaction.
273
 Oxidative stress is of 
particular concern in the CNS as it is associated with neurodegenerative disease, and has 
been associated with oligodendrocyte damage in MS.
274
 Therefore, it is important to 
determine whether it is safe to introduce iron-based particles into oligodendroglial cells. In 
addition, MPs could impair cellular function through a wide variety of other mechanisms, 
including physically disrupting the cytoskeleton/cell membrane
131,225
 or intracellular 
trafficking processes,
275
 directly damaging intracellular structures/organelles, or by 
producing toxic substances, potentially by particle degradation releasing iron
219
 or 
fluorophores. Through these or other mechanisms, MP uptake could also perturb cellular 
behaviour, including capacity for migration or proliferation.
276
 
Limited MP-related safety/toxicity data is available for glia, but Soenen et al. have 
shown some cytoskeletal effects of MP accumulation in human blood outgrowth 
endothelial cells (hBOECs). These effects were only present at high concentrations of MPs 
[>400 µg Fe/ml for Endorem (4 – 10 nm iron oxide core, dextran coating, 80 – 150 nm 
hydrodynamic diameter, neutral zeta potential),
150,277
 and >300 µg Fe/ml for Resovist (4.2 
nm iron oxide core, dextran coating, 60 nm hydrodynamic diameter, neutral zeta 
potential)
131
], and were typically transient.
131
 No morphological perturbations were 
apparent during the experiments reported here, but more detailed analyses would be 
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required to exclude the possibility that either MP tested can produce adverse effects in 
OPCs, or at least to establish a safe dose, which avoids such effects. 
The lack of MP-associated toxicity in OPCs reported here is in general agreement 
with Hohnholt et al., who employed a battery of assays [lactate dehydrogenase (LDH) 
activity; propidium iodide/nigrosin infiltration; cellular protein content (Lowry assay); 
counting nuclei per mm
2
; MTT reduction assay; intracellular ROS (rhodamine 123)] to test 
the toxicity of dimercaptosuccinic acid (DMSA)-coated iron oxide MPs (5 – 20 nm iron 
oxide core, 60 nm hydrodynamic diameter, -26 mV zeta potential) in the OLN-93 cell 
line.
273
 They found no evidence of acute cytotoxicity (up to 72 h exposure), even at high 
concentrations (1000 µM Fe; 55 µg Fe/ml), although the authors noted a “trend” towards a 
reduction in proliferative capacity at the highest dose, which was not found to be 
significant. In the current studies, OPC proliferation was unaffected by MP-labelling using 
either Sphero or Fe3O4-PEI-RITC particles, and no intranuclear MPs were observed at any 
time-point, suggesting no adverse effects on mitosis, including the exclusion of MPs from 
the nucleus even during nuclear membrane breakdown. Although it has been shown here 
that Sphero MP-labelling does not impair OPC differentiation into oligodendrocytes, it will 
be important to determine whether the progeny of MP-labelled OPCs are competent to 
remyelinate axons. In vitro assays could be performed to address this issue in order to 
compare, for example, the rate of myelin production, the thickness of myelin sheaths, and 
the internode lengths of sheaths produced by labelled versus unmodified cells. 
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2.4.4 OTOTO SEM analyses reveal MP-cell interactions and endocytotic processes 
The development of MP-based cellular applications will benefit greatly from 
insights into the cellular uptake mechanisms that result in MP internalisation, and in order 
to facilitate such future studies a powerful but not widely utilised histological technique 
has for the first time been brought to the study of neural stem/progenitor cells and the 
interactions of cells with synthetic materials.  
Ultrastructural analyses such as TEM enable direct observation of the uptake 
process, allowing the identification of specific endocytotic processes by visualisation of 
endocytotic structures and vesicle formation. However, this is a time- and labour-intensive 
process,
278
 and few uptake events may be observed in an individual sample, consisting as it 
does of an ultrathin section (typically 30 – 100 nm, rarely exceeding 150 nm, as electrons 
less readily pass through biological material of this thickness)
279
 containing a limited 
sample of membrane from each cell. Artefacts may be introduced into TEM samples due to 
damage during the sectioning process, which can be a particular problem for the study of 
cellular interactions with synthetic materials, as the interface between ‘soft’ biological 
material and ‘hard’ synthetic particles can be altered.255 An advantage of TEM analyses 
over SEM analyses is the ability to observe intracellular processing, including vesicular 
trafficking and association of particles with intracellular structures. However, by 
employing backscatter detection, it may be possible to detect MPs immediately beneath the 
cell membrane, including within macropinocytotic membrane.
280
 A significant advantage 
of OTOTO processing for analysis of synthetic particles, including nanoparticles, is that 
the need for a gold coating of the sample (after critical point drying) is avoided. Gold 
coating can potentially obscure small diameter MPs, and is not compatible with backscatter 
electron detection, which can be used to detect iron oxide particles.
279
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OTOTO-preparation of samples for SEM provides a greater number of cells per 
sample than is possible for TEM samples, and a greater proportion of each cell’s 
membrane is available for study. Following OTOTO processing, a whole coverslip (13 mm 
diameter) can be placed into a scanning electron microscope allowing an entire culture to 
be analysed. By comparison, for TEM samples, cells are cultured on a 13 mm diameter 
aclar disc (which must first be cut from an aclar sheet) and the sample processed in resin, 
yielding a single ~13 mm disc of resin containing the cells. However, the resin must then 
be broken into smaller pieces to be amenable to ultrathin sectioning. A single piece of resin 
must be mounted in the correct orientation, which requires some expertise, and then 
sections must be taken from this, which also requires significant training in order to 
generate high quality specimens – sections prepared by inexperienced personnel commonly 
contain score-lines, and are often torn during the necessary process of mounting the 
sections on copper grids. Ultrathin sections will contain far fewer cells than an SEM 
specimen, even if sectioned parallel to the original cell monolayer, which is a more 
difficult technique than sectioning perpendicular to the monolayer. Many sections would 
need to be analysed in order to build up a profile of the extent of endocytosis occurring in a 
single cell, as a single section may be unrepresentative. It is common during TEM resin 
sectioning to obtain a semi-thin section (typically 0.5 – 2.0 µm) for light microscopy, in 
order to assess the current position and orientation of the sample, and such a section can 
constitute a significant proportion of the total sample in a monolayer of cells, which then 
cannot be analysed by TEM. Each time a new ultrathin section is taken from a sample, 
there is a risk of damage to, or even loss of, the rest of that sample. Finally, the sections 
commonly undergo a further, lengthy staining process (e.g. uranyl acetate and lead citrate) 
individually, which when performed by a non-expert commonly results in unwanted 
artefacts. It should also be noted that only a small number of ultrathin sections can be 
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studied by TEM at a time, and these will commonly all have been obtained from a single 
face of a single fragment of the original resin-embedded sample. All of this processing 
makes TEM analyses more expensive and time-consuming than OTOTO SEM.
257
 
Further benefits of the OTOTO SEM method include the ability to combine it with 
techniques such as backscatter detection of iron oxide particles and stereo image analysis, 
involving a red/green anaglyph, which produces three-dimensional images and facilitates 
the measurement of the depth of membrane depressions/pits. Such data can enable the 
identification of the mechanisms responsible for cellular uptake of particles, and reveal 
which particular mechanisms a particular cell type is capable of employing. There is the 
potential to develop a high-throughput assay for counting ‘particle uptake events’ by cells, 
by identifying and scoring instances of endocytosis. Bases on these advantages, the 
OTOTO protocol described here can provide significantly more quantifiable data than is 
achievable with TEM analyses, given the same resources in terms of time and expense. As 
such, I consider that development of this method will therefore provide a rapid and simple 
methodology for use in the field of bio-nanotechnology, to evaluate interactions of neural 
cells with biomaterials, currently an area of high scientific interest. 
Endocytotic pits, macropinocytotic membrane and cell-associated Sphero MPs 
could be identified in OTOTO-processed samples of OPC cultures. These observations 
provide proof-of-principle that that such morphological/microstructural data can be further 
quantified for detailed analysis of the extent of membrane activity and particle association. 
It can be predicted that this will be of high relevance to investigations into the underlying 
mechanisms of magnetofection, effects of physico-chemical properties of particles on 
endocytotic uptake and the specific mechanisms associated with the latter. 
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2.4.5 Conclusions and future directions 
Although MP-labelling of OPCs has been previously reported (for cell 
lines),
93,94,96,97,143,155
 detailed data (relating to uptake dynamics, intracellular particle fate 
and MP-associated toxicity, all with reference to the properties of the specific particle 
used) are lacking, representing critical knowledge gaps in the literature, which must be 
addressed in a systematic manner to allow the development of this field. The OTOTO 
SEM samples obtained indicate significant potential for the development of a high-
throughput screening process for studying and quantifying MP-cell interactions, although 
early data will need to be compared with parallel TEM studies to verify the efficacy of the 
OTOTO approach. This will consist of attempts to confirm that each specific endocytotic 
mechanism (and related particle uptake) observed in one technique is also observed in the 
other, and with comparable frequency. Measurements should also be made of particles and 
structures such as nuclei (possible for SEM samples through techniques such as freeze-
fracture), to compare the effects of sample shrinkage during processing. 
The finding that ~60% of OPCs from a primary culture were safely labelled with 
two physico-chemically differing MPs (that have demonstrated MRI contrast capability) 
without the need for a specific cell targeting or purification strategy shows significant 
potential for the translation of MP-labelling approaches, as these data suggest that the 
majority of cells from a primary OPC population could be detected both non-invasively 
and histologically post-transplantation. Further studies will be necessary to confirm that 
cells labelled with each of these particles can be detected by MRI in vivo, including after 
transplantation into neurological injury sites. It can be predicted that the Fe3O4-PEI-RITC 
prototype particles will have the greater translational potential to serve as a cell labelling 
agent for transplant studies, as T2 proton relaxivity is predicted to decrease in a linear 
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fashion with increasing concentration of the contrast agent (iron oxide), providing 
increasing imaging contrast.
245,281
 However, when tested in vivo, compartmentalisation of 
contrast agents within cells/tissues often causes this linear relationship to fail, and the 
relative MRI contrast capability of these and indeed any MPs must be verified in vivo.
281
 A 
further advantage is that the versatile design of these particles enables simple surface 
modification to functionalise the particles for biological applications. For example, 
alternative fluorophores can readily replace the RITC tag by attachment to the PEI layer, 
such as the succinimidyl ester- or isothiocyanate- (ITC) derivatives of common dyes (e.g. 
the Alexa Fluor family). The PEI skeleton can also be further functionalised by, for 
example, the incorporation of an anti-transferrin receptor antibody to enhance cellular 
uptake and the extent of cell labelling (as transferrin receptors are recycled to the cell 
surface within minutes of endocytosis, facilitating rapid uptake)
155
 for transplantation 
applications.  
Based on these findings, it is clear that further studies will be required to evaluate 
interactions of OPCs with MPs possessing a wider range of physico-chemical properties, in 
order to inform the development of MPs tailored to specific biomedical applications. Such 
investigations should typically include: (i) ultrastructural analyses of particle-cell 
interactions, intracellular processing and fate; (ii) endocytotic blocker studies to establish 
the relative contribution of each endocytotic mechanism to the uptake of differently-
configured particles; (iii) microarray and proteomic analyses to detect alterations in gene 
and protein expression following MP-treatment, providing detailed toxicity analyses; (iv) 
vesicle tracking analyses to inform the development of MPs with the potential for 
endosomal escape, or suggest the specific endocytotic mechanism to which MPs should be 
preferentially targeted; and (v) functional assays of the migratory and myelinating capacity 
of transplanted labelled cells, for example by 'galvanotaxis' studies of cell migration or co-
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culture with unmyelinated/demyelinated axons. The fact that OPCs demonstrate uptake 
and perinuclear localisation of MPs implies that MPs could be exploited as gene delivery 
vectors for engineering of OPCs, and this possibility will be explored in the next chapter.
a
  
                                                 
a
 Most of the Sphero-related data in this chapter have now been published. The article is reproduced here as 
Appendix 3. 
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Chapter 3: MP-mediated transfection of 
OPC transplant populations: effects of 
novel ‘magnetofection’ techniques 
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3.1 Introduction 
In order to treat CNS injury or disease, there is reason to believe that therapeutic 
benefit can be derived by genetically engineering a cell transplant population to release 
therapeutic factors.
117,118,282
 This may involve delivering growth factors to promote 
migration, proliferation or differentiation of particular cell types, introducing 
immunomodulatory molecules, or otherwise manipulating a lesion site, for example by 
down-regulating molecules that inhibit axonal growth (e.g. Nogo).
283
 Such modifications 
can facilitate ‘combinatorial’ approaches to regeneration (e.g. delivery of cells plus 
therapeutic biomolecules to lesions; section 1.5 discusses combinatorial therapies) which 
are increasingly believed to be necessary to mediate repair in the CNS.
59
 With particular 
reference to promoting remyelination in MS or SCI lesions, these therapeutic factors could 
be chosen to manipulate the lesion site, making it a more favourable milieu for 
regeneration, or to stimulate differentiation of endogenous OPCs, which are typically 
present within or adjacent to injury sites, but in a ‘quiescent’ state that limits or even 
prevents the replacement of lost oligodendrocytes/myelin.
284–287
  
In this context, genetic engineering of OPC transplant populations to release 
therapeutic factors post-transplantation may be a suitable combinatorial therapy to promote 
remyelination following CNS injury/disease. This has been demonstrated in animal 
models, with two reports of genetically modified OPC transplants demonstrating enhanced 
remyelination and functional recovery
60,64
 (detailed in section 1.5), but in both these 
studies, as with the majority of genetic manipulations of OPCs, viral gene vectors were 
used, which are associated with various problems that may prevent translation to the clinic, 
chiefly safety concerns (detailed in section 1.7.3). However, the nonviral alternatives tested 
in OPCs so far have also demonstrated drawbacks, including safety concerns, inefficient 
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gene delivery and lack of potential for clinical translation (section 1.7.3). With respect to 
transfection of primary rodent OPCs, the most efficient technique reported is 
electroporation, with ~49%
288
 and ~43%
289
 of cells being transfected. However, both of 
these reports are from company websites rather than peer-reviewed publications, and both 
show significant reductions in cell viability (to ~78% and ~60%, respectively). The only 
other nonviral techniques tested, lipofection
110,267,290
 and calcium phosphate 
precipitation,
108,110
 have reported less than 5% transfection efficiency, and significant 
toxicity. It should be noted that many reports of OPC transfection do not provide details of 
transfection efficiency, and there is an even more frequent lack of detail relating to 
safety/toxicity, hindering efforts to compare gene delivery techniques, and assess their 
potential for clinical translation. 
 
3.1.1 Knowledge gap: Are OPCs amenable to MP-mediated transfection, including 
magnetofection strategies? 
An alternative nonviral transfection technique which has not been tested with OPCs 
is the use of MPs as nucleic acid vectors. Several studies have demonstrated successful 
MP-mediated transfection of neural cell types, mainly neurons and NSCs, but also 
astrocytes.
102,161–164,291,292
 Furthermore, the amenability of MPs to magnetofection 
techniques for enhanced gene delivery highlights one of the additional benefits of this 
multifunctional engineering platform (see sections 1.8.3 for details of magnetofection, and 
1.8 for further benefits of MPs in the context of cell transplantation). Several papers have 
reported that magnetofection techniques can result in increased transfection efficiency, 
including a report of enhanced transfection efficiency in astrocytes.
164,172
 Despite the 
potential of this approach, the efficacy of MPs as nucleic acid vectors and the application 
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of magnetofection techniques have not been assessed to date with OPCs, and addressing 
this knowledge gap will be the principle aim of this chapter.  
A further point to note here is that safety is a primary concern for the development 
of therapeutic strategies, and represents a major impetus behind the development of 
nonviral gene delivery technologies. Therefore, the safety of MPs as gene delivery agents 
for transplant populations must be assessed in detail. However, in order to test the safety 
and efficacy of cell transplantation, live animal models are typically used as hosts. These in 
vivo cell transplantation studies have significant drawbacks, as they are technically 
demanding, expensive, time-consuming and raise ethical concerns.
293
 As discussed in 
section 1.6, organotypic cerebellar slice cultures offer major advantages which may serve 
to bridge the gap between isolated cell studies and pre-clinical animal experimentation.  
It should also be noted that while OPCs have previously been transplanted onto 
cerebellar slices in order to study myelination/remyelination,
90,294,295
 only one report exists 
of genetically engineered OPCs being transplanted onto a slice culture: Zhang et al. used a 
lentivirus to transduce mouse OPCs, resulting in GFP expression (transfection efficiency 
and toxicity not reported), then pipetted these cells onto demyelinated organotypic neural 
slices; transplanted cells were shown to generate remyelinating oligodendrocytes.
4
 
Critically, the same group conducted a comparison of remyelination-enhancing therapies in 
demyelination models using co-cultures versus slice cultures, showing that results in slices 
more closely correlated with findings from lesion models in vivo.
4
 By contrast, results 
in co-culture models often contradicted in vivo results, suggesting slice cultures represent a 
superior model of in vivo conditions.
4
 These data demonstrate the feasibility and utility of 
organotypic neural slice cultures as ‘host’ tissue for cell transplantation studies. Therefore, 
transplantation of modified OPCs onto cerebellar slice cultures will be tested in this 
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chapter with a view to developing a toxicity assay to monitor the behaviour of MP-
engineered OPCs.  
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3.1.2 Objectives 
Having established that two different MP formulations are internalised by OPCs 
(Chapter 2), the principle aim of this chapter is to assess the potential for MPs to serve as 
gene delivery vectors for OPCs, by addressing the following questions using a different 
(transfection grade) MP formulation: 
(i) Do MP-nucleic acid complexes and/or magnetic fields have acute toxic 
effects on OPCs? 
(ii) Does the application of a static or oscillating magnetic field 
(magnetofection) result in enhanced MP-mediated transfection efficiency in 
OPCs? 
(iii) Does MP-mediated transfection of OPCs affect their capacity for 
proliferation or differentiation? 
(iv) Can multiple genes be delivered to an OPC population using MP vectors? 
(v) Can therapeutic genes be delivered to an OPC population using MP 
vectors? 
The second aim of this chapter is to establish and characterise organotypic 
cerebellar slice cultures, and assess their potential to serve as ‘host’ tissue for transplanted 
modified OPCs. The survival and behaviour of genetically engineered OPCs will be 
monitored following transplantation onto these slices, to assess the safety of the 
transfection procedures. Four key parameters will be evaluated with respect to the 
transplanted OPCs, namely survival, proliferation, migration and differentiation into 
oligodendrocytes.  
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3.2 Methods and materials 
Reagents and equipment: The pmaxGFP plasmid (3.5 kb in size; encodes GFP; 
map shown in Figure 1) was from Amaxa Biosciences (Cologne, Germany), pCMV-
DsRed-Express2 plasmid [4.6 kb; encodes red fluorescent protein (RFP); herein termed 
pDsRed] from Clontech (Saint-Germain-en-Laye, France), the pCMV6-FGF2-GFP 
plasmid (7.4 kb; encodes the open reading frame of human FGF2 with a carboxy-terminal 
turboGFP tag; herein termed pFGF2-GFP; map shown in Figure 1) and the recommended 
control plasmid, pCMV6-AN-GFP (6.6 kb; herein termed pAN-GFP), were from OriGene 
Technologies (Rockville, MD, USA), as was the anti-FGF2 antibody (clone 3D9; mouse 
IgG2b anti-human FGF2). Polyclonal rabbit anti-glial fibrillary acidic protein (GFAP; a 
marker for astrocytes) was from DakoCytomation (Ely, UK). Anti-calbindin antibody was 
from Santa Cruz (CA, USA); calbindin is a calcium-binding protein common to many 
classes of neuron
86
 but within cerebellar slices stains only Purkinje cells, the axons of 
which provide the main myelinating tracts.
80,85
 Cy3-conjugated secondary antibodies were 
from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA, USA). Anti-NG2 
antibody, Millicell culture inserts and Omnipore membrane were from Millipore (Watford, 
UK). Accutase was from Sigma-Aldrich (Poole, UK). DNase I was from Roche 
Diagnostics Ltd. (Burgess Hill, UK). The McIlwain tissue chopper was from The Mickle 
Laboratory Engineering Co. (Guildford, UK). 
OPC culture: As described in section 2.2, OPCs were derived from mixed glial 
cultures and plated on coverslips (0.3 ml/well, at 3 x 10
4
 cells/cm
2
). Once cells had 
attached, medium was replaced with 225 µl fresh medium, and cultured for 24 – 48 h (to 
allow cells to recover from plating and extend processes) before transfection. 
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Figure 1: Plasmid maps for pmaxGFP and pFGF2-GFP. PCMV represents the 
cytomegalovirus promoter which drives heterologous expression in mammalian cells 
(although post-transcriptional and regulatory effects may affect the protein expression 
levels on a cell type-dependent basis). ColE1 is the bacterial origin of replication. SV40 
ori is the simian virus 40 origin of replication, which allows for replication in mammalian 
cells. f1 ori is the filamentous phage origin of replication which allows for the recovery of 
single stranded plasmids. puC ori: origin of replication for propagation in Escherichia 
coli. Kanamycin/ampicillin resistance allows the selection of E. coli which contain the 
plasmid of interest during plasmid production. Neomycin resistance allows the selection of 
stably transfected mammalian cells by culturing cells in medium containing G418 
(geneticin), which will kill cells that have not stably incorporated the transgene into their 
genome, leaving stably transfected colonies. PolyA is the human growth hormone (hGH) 
polyadenylation signal, which protects the mRNA from degradation by exonucleases. 
Kozak: Kozak consensus sequence, facilitates initiation of translation of eukaryotic mRNA. 
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Choice of MPs for transfection: A commercially-available transfection-grade MP 
(Neuromag) was employed for these studies (OZ Biosciences, Marseille, France). These 
particles have an average diameter of 160 nm (range 140 – 200 nm), contain ~0.5% Fe, and 
a positive zeta potential (though undisclosed for these commercial particles).
292
 They are 
reported to bind DNA non-covalently through electrostatic and hydrophobic 
interactions.
292
 DNA binding curves showed that these particles bind DNA effectively with 
pmaxGFP binding increasing the hydrodynamic diameter of the particles by 35%, as 
assessed using a Malvern Zetasizer 3000.
164
 These Neuromag particles were developed for 
gene delivery to primary neurons, which are typically difficult to transfect, and the 
particles have demonstrated minimal toxicity with such cells.
291,292,296
 These particles have 
also been used in this laboratory to successfully transfect astrocytes,
164
 NSCs,
163
 and 
olfactory ensheathing cells (OECs; unpublished data), generally with greater transfection 
efficiencies than achieved with other transfection grade MPs, such as various commercial 
PolyMag formulations (tested in this laboratory, unpublished data). The magnefect-nano
TM
 
magnetofection device: The magnefect-nano oscillating magnetic array system, used for 
both static and oscillating magnetofection methods, was from nanoTherics Ltd. (Stoke-on-
Trent, UK; commercially available since 2009; Figure 2). This system allows 24-well 
culture plates to be placed over a horizontal array of 24 neodymium (NdFeB) magnets, 
grade N42, which match the plate configuration. The magnetic array can be programmed 
to oscillate laterally beneath the culture plate via a computerized motor; both the frequency 
(up to 5 Hz) and the amplitude (10 µm to 1 mm) of oscillation can be varied. The field 
strength at the face of each magnet is 421 ± 20 mT (nanoTherics Ltd., personal 
communication). In static mode (frequency, F = 0 Hz), this system has been shown to 
produce similar transfection efficiencies in astrocytes to commercially available magnetic 
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plates in routine use for static magnetofection,
164
 and it is the only commercially available 
device for oscillating magnetofection applications. 
 
Figure 2: The magnefect-nano system (nanoTherics Ltd., Stoke-on-Trent, UK). A 
laptop with software is pictured above the computerised motor that drives an oscillating 
magnetic array, situated to the left of this image and configured for a 96-well plate. Image 
courtesy of nanoTherics Ltd. 
 
Transfection (magnetofection) protocols: It was necessary to determine the 
maximum safe dose of Neuromag-plasmid complexes for transfection of OPCs, and to 
determine whether magnetofection conditions affected toxicity. Neuromag MPs are 
recommended for use with neurons at a final concentration of 7 μl/ml in medium (referred 
to here as a 1.0x dose), but lower concentrations have been required for safe use with other 
neural cells (astrocytes,
164
 NSCs
163,297
). The DNA-binding capacity of Neuromag MPs is 
maximal at a ratio of 3.5 μl Neuromag to 1 μg DNA;164 this ratio was therefore routinely 
used in the present study.  
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In preliminary experiments, transfection complexes were prepared at 1.0x and 0.1x 
doses. A 1.0x dose was prepared by mixing 600 ng plasmid in 75 μl DMEM base medium, 
then gently mixing this with 2.1 μl Neuromag. For control wells, plasmid was mixed in 
DMEM, but no Neuromag was included. After 20 min incubation, the entire complex mix 
was added dropwise to cells, whilst gently swirling the plate. Complexes (1.0x and 0.1x) 
were incubated with cells for a total of 1 h (the first 30 min in the presence of a magnetic 
field, when appropriate) then the medium was replaced, as incubation times >1 h had 
demonstrated toxicity in astrocytes.
164
 However, very limited transgene expression was 
observed in OPCs with or without application of magnetic fields (typically <1%, cultures 
monitored for 72 h). Therefore, complexes (1.0x and 0.1x) were applied to cultures and 
GFP expression was monitored continuously for 72 h without complex removal. This 
resulted in greater transgene expression, with peak expression occurring at approximately 
48 h post-transfection. Plasmid-based transfection is often reported to result in peak 
expression at approximately 48 h,
111,164,267
 and as continuous incubation with particle-
plasmid complexes for 48 h was without obvious effects on cell morphology or adherence 
(0.1x preliminary experiments), complexes were not removed from the cultures in 
subsequent experiments and transgene expression was routinely assessed at 48 h. 
Following these preliminary experiments, it was decided to test 0.1x and 0.5x 
doses. Control cultures were treated with pmaxGFP plasmid alone, without Neuromag, at 
the highest concentration of plasmid used as a complex with Neuromag (equivalent to 
either 0.5x or 0.1x). For magnetofection, immediately following application of complexes 
to cells, the 24-well plate was placed above a 24-magnet array on the magnefect-nano 
device, which had been pre-warmed in the incubator. The array either remained static (F = 
0 Hz), or was programmed to oscillate at F = 1 or 4 Hz (amplitude 0.2 mm). It has been 
predicted by modelling that an incubation time of 20 min is sufficient for the accumulation 
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of 200 nm diameter particles at the surface of a cell monolayer, with larger particles likely 
to require shorter incubation times, and therefore 30 min was deemed a sufficient 
incubation time for these experiments.
298
 After 30 min, the plate was removed from the 
magnetic array. For the no field condition, plates were returned to the incubator without 
application of a magnetic field. Total Neuromag-plasmid incubation time for all conditions 
was 48 h, at which point cells were either fixed or switched to Sato medium for 
differentiation experiments. The established safe dose of 0.1x was prepared using 60 ng 
plasmid in 75 µl DMEM, then mixing this with 0.21 µl Neuromag. 
Assessment of toxicity: Several parameters of cytotoxicity were assessed by 
microscopy, specifically: (i) whether cells were phase bright, adherent and extending 
processes; (ii) the presence of pyknotic (fragmenting) nuclei, as judged by DAPI staining; 
(iii) expression of the OPC marker A2B5; and (iv) cell counts per microscopic field. As 
transfection grade MPs, Neuromag particles have no intended purpose without conjugation 
of nucleic acids, and the positive surface charge of naked Neuromag particles could result 
in differing uptake kinetics and/or toxicity compared to Neuromag-plasmid complexes. 
Therefore, it was not deemed appropriate to systematically assess their effects in the 
absence of plasmid, but pilot experiments were performed with 0.1x particles alone which 
showed no effects on OPC proliferation or differentiation (data not shown). 
Differentiation potential of transfected OPCs and long-term GFP-expression in 
oligodendrocyte progeny: At 48 h post-transfection, cells were washed with PBS, then 
switched to Sato medium to induce oligodendrocyte differentiation. Cells were monitored 
to assess the extent of cellular expression of GFP and to evaluate potential adverse effects 
on OPC differentiation for up to 3 weeks. Medium was changed every 2 – 3 days.  
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Co-transfection protocol: For co-transfection experiments, pmaxGFP and pDsRed 
plasmids were used at half the dose stated above (i.e. 0.05x, 30 ng each plasmid per 75 µl 
DMEM) producing a total plasmid dose equivalent to 0.1x, with the corresponding safe 
dose of Neuromag (0.1x, 0.21 µl per well) to maintain the plasmid:Neuromag ratio. Single 
transfection controls (either pmaxGFP or pDsRed only) were performed in parallel at 
0.05x (30 ng plasmid, with 0.105 µl Neuromag per 75 µl DMEM). Plasmid-only controls 
were treated with both pmaxGFP and pDsRed. 
Transfection with plasmid encoding therapeutic fusion protein: Experiments to 
assess the delivery of the plasmid pFGF2-GFP (which encodes a fusion protein consisting 
of FGF2 and turboGFP: FGF2-GFP), and the appropriate control plasmid pAN-GFP 
(which encodes turboGFP alone), were conducted as described for pmaxGFP (0.1x dose), 
with pFGF2-GFP used as the plasmid-only control. To detect the presence of the fusion 
protein, fixed cultures were immunostained with an anti-FGF2 antibody. 
Organotypic cerebellar slice cultures: This culture technique is based on the 
interface method described by Stoppini et al.
69
 Brains were extracted from P8 – 14 rats into 
ice-cold slicing medium [Earle’s balanced salt solution (EBSS) buffered with 25 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)]. Cerebella were dissected and 
meninges removed, then 350 – 400 µm parasagittal slices were prepared using a McIlwain 
tissue chopper. Slices were incubated in ice-cold slicing medium for 30 min, then 
transferred by wide-bore pipette to pieces of Omnipore membrane (‘confetti’, cut to be 
slightly larger than a cerebellar slice) on Millicell culture inserts in six-well plates 
containing slice culture medium [50% minimum essential medium (MEM), 25% heat-
inactivated horse serum, 25% EBSS, supplemented with 36 mM D-glucose, 50 U/ml 
penicillin and 50 µg/ml streptomycin]. Slices were incubated at 37°C in 5% CO2/95% 
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humidified air for at least 8 days before transplantation studies, live/dead staining or 
fixation and staining for slice characterisation, with medium changes every 2 – 3 days.  
Transplantation of transfected OPCs onto slice cultures: At 24 h post-
magnetofection (0.1x, F = 4 Hz), OPCs were washed with PBS, then enzymatically 
detached using accutase-DNase I. Cells were resuspended at 2 x 10
7
 cells/ml Sato 
differentiation medium, and 0.5 μl was pipetted onto cerebellar slice cultures. The passive 
spread of cells is the area covered by transplanted cells when delivered by pipette or 
syringe, and is due to the force of delivery. It is important to assess this to gauge whether 
focal delivery can be achieved; if cells can be reliably delivered to one end of a slice, then 
attempts can be made to assess the extent of migration. Passive spread due to the pipetting 
procedure was assessed by transferring cerebellar slices to a small quantity of PBS on a 
microscope slide, then transplanting cells onto these slices and viewing immediately using 
fluorescence microscopy. Transplants were performed with 15 slices in total from four 
animals. At the end of the transplant procedure, remaining cells were also plated at 2 x 10
5
 
cells/ml Sato medium on PDL-coated chamber slides. Samples were fixed and stained 24 – 
48 h post-transplantation to assess the survival and morphology of the transplanted and re-
plated cells. 
Immunocytochemistry: Cells and slices were incubated with blocking solution [5% 
serum in PBS with 0.3% Triton X-100; RT; 30 min], then with primary antibody in 
blocking solution (FGF2 1:100; NG2 1:150; GFAP 1:500; calbindin 1:5000; 4°C; 
overnight). Cells and slices were then washed with PBS, incubated with blocking solution 
(RT; 30 min), and incubated with the appropriate FITC- or Cy3-conjugated secondary 
antibody in blocking solution (1:200; RT; 2 h). Finally, coverslips, chamber slides and 
slices were washed with PBS and mounted with the nuclear stain DAPI. 
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Slice culture viability assays: Live slices were transferred to a 24-well plate, 
washed with PBS then incubated (15 min; 37°C) with ethidium bromide (12 µM) and 
calcein-AM (acetomethoxy derivate of calcein; 2 µM). Slices were then washed, mounted 
with DAPI and immediately visualised using fluorescence microscopy. Ethidium 
homodimer-1 is excluded from viable cells, but permeates dead/dying cells, which have 
lost membrane integrity, labelling them red; calcein-AM is transported across the plasma 
membrane and is converted to calcein by intracellular esterases, active only in live cells, 
labelling the cells green.
299,300
 
Fluorescence microscopy and image analysis: Samples were imaged using fixed 
exposure settings on an Axio Scope A1 fluorescence microscope (Carl Zeiss 
MicroImaging GmbH, Goettingen, Germany), and the images merged using Adobe 
Photoshop CS3 (version 10.0.1). For toxicity and transfection experiments, a minimum of 
200 nuclei per treatment per culture were scored for association with A2B5 or MBP 
staining (for OPC culture purity) and GFP expression (for transfection efficiency). For 
OPC differentiation experiments, a minimum of 100 nuclei per treatment per culture were 
scored for MBP expression. 
Statistical analysis: Data were analysed using GraphPad Prism statistical analysis 
software. Data are expressed as mean ± SEM. The number of experiments (n) refers to the 
number of OPC cultures used, each from a different rat litter. For toxicity analyses of the 
0.1x and 0.5x doses, with magnetic fields, a two-way ANOVA was performed with respect 
to the number of A2B5
+
 cells per field, with Bonferroni’s post tests. For transfection 
efficiency, the percentage of A2B5
+
 cells expressing GFP under each field condition was 
analysed by one-way ANOVA, with Bonferroni’s post tests. To determine whether 
transfection conditions affected the differentiation of OPCs into MBP
+
 oligodendrocytes, 
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the percentage of MBP
+
 cells in cultures without Neuromag and without application of a 
magnetic field was compared to magnetofected cultures (F = 4 Hz, 0.1x) using a two-tailed 
unpaired t-test. For co-transfection experiments, a two-way ANOVA was performed with 
respect to transfection efficiency with single and combined plasmids, with Bonferroni’s 
post tests, and a one-way ANOVA was performed with respect to the percentage of 
transfected cells in co-transfected cultures that expressed either a single transgene or both 
transgenes, with Bonferroni’s post tests. To compare transfection efficiency for different 
field conditions with pAN-GFP, a one-way ANOVA was performed with Bonferroni’s 
post-tests. An identical analysis was performed for pFGF2-GFP. To compare transfection 
efficiency achieved with the pmaxGFP, pAN-GFP and pFGF2-GFP plasmids, a two-way 
ANOVA was performed for the no field and F = 4 Hz conditions, with Bonferroni’s post 
tests. To determine the correlation between plasmid size and transfection efficiency, linear 
regression analyses were performed for pmaxGFP, pAN-GFP and pFGF2-GFP, for both 
the no field and F = 4 Hz conditions. 
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3.3 Results 
 
3.3.1 Establishment of safe MP-plasmid doses and magnetic field conditions 
OPC cultures used in these experiments were of high purity as judged by staining 
for the OPC marker A2B5 (94.3 ± 2.3%; n = 5). In preliminary experiments, a 1.0x 
Neuromag:plasmid dose resulted in transfection of OPCs, with apparently normal bipolar 
morphologies, but also the obvious loss of processes by many cells, detachment of cells 
from the substrate, and the presence of cellular debris (Figure 3).  
 
Figure 3: High doses of MP-plasmid complexes mediate gene delivery to OPCs, but 
with toxic effects on many cells. (a) Fluorescence micrograph illustrating GFP
+
 
transfected OPCs (1.0x dose, F = 4 Hz, 24 h post-transfection). (b) Counterpart phase 
contrast micrograph to (a), illustrating rounded cells (arrow) and large quantities of 
debris, indicative of toxicity. 
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With a 0.1x Neuromag:plasmid dose, phase-contrast microscopic observation 
showed phase-bright morphologically typical OPCs at 48 h post-transfection (Figure 4), 
but particle-plasmid cytotoxicity was apparent at a 0.5x dose, as judged by the presence of 
rounded non-adherent cells (Figure 4, inset), pyknotic nuclei, and a reduction in the 
number of A2B5
+
 cells per microscopic field (Figure 5). By these same criteria, no 
significant effects were apparent at a particle-plasmid dose of 0.1x, and no magnetic field-
related effects were apparent in either control or treated cultures (Figure 5). 
 
 
 Figure 4: An MP-plasmid dose that does not affect OPC morphology has been 
established. Representative phase-contrast micrograph of OPCs, 48 h post-transfection 
with 0.1x Neuromag-plasmid complexes. Note phase-bright cells with mostly bipolar 
morphologies. Inset shows OPCs 48 h post-transfection with 0.5x Neuromag-plasmid 
complexes. Note reduced density of cells and lack of processes. 
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Figure 5: Establishment of safe particle dose and magnetic field conditions for OPC 
magnetofection. Bar chart showing average number of cells stained for the OPC marker 
A2B5 per microscopic field, 48 h post-transfection with Neuromag-plasmid complexes. 
There was a concentration-dependent effect on the number of A2B5
+
 cells (F2,72 = 28.1; p 
< 0.001), but no effect due to the application of a magnetic field (F3,72 = 0.913; ns; two-
way ANOVA; n = 5). For all magnetic field conditions tested and the no field condition, 
the number of A2B5
+
 cells per field was markedly reduced at 0.5x complex concentration, 
but not at 0.1x, compared to control cultures exposed to plasmid alone (0.5x equivalent 
dose). *p < 0.05 versus control, no field; Bonferroni’s post-tests. 
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3.3.2 Static and oscillating magnetofection strategies enhance MP-mediated 
transfection efficiency in OPCs 
Having established a safe transfection protocol (0.1x complexes, 48 h incubation), 
including a lack of magnetic field-related toxicity, the transfection efficiency of these 
complexes was evaluated in the presence of static and oscillating magnetic field 
conditions. Expression of GFP was not observed in any control cultures (plasmid only). 
Basal GFP expression was observed (no magnetic field; mean transfection efficiency: 6.1 ± 
1.0%; range: 3.1 – 8.1%; Figure 6a). Application of a static magnetic field resulted in 
significantly enhanced GFP expression, approximately two-fold greater than basal levels 
(F = 0 Hz; 12.5 ± 1.2%; range: 10.8 – 17%). Application of an oscillating magnetic field 
also produced enhanced GFP expression, with levels approximately 2.5-fold (F = 1 Hz; 
15.5 ± 1.9%; range: 9.3 – 19.9%) and 3.5-fold (F = 4 Hz; 20.6 ± 2.2%; range: 15.9 – 
26.3%) greater than basal levels. Importantly, application of a 4 Hz oscillating field 
resulted in a significantly greater proportion of GFP
+
 OPCs than the static field condition 
(Figure 6a). Under all field conditions, transgene-expressing OPCs were phase bright, 
adherent and exhibited bipolar morphologies typical of OPCs, with GFP-expression 
throughout the cells (Figure 6b; Figure 7a). Transfected cells also displayed normal 
A2B5 staining profiles and DAPI-labelled nuclei were without evidence of increased 
chromatin condensation or pyknosis (Figure 7b). 
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Figure 6: Application of static or oscillating magnetic field conditions 
(magnetofection) enhances MP-mediated gene delivery to OPCs. (a) Bar graph 
indicating transfection efficiencies achieved in OPC cultures 48 h post-transfection using 
Neuromag-plasmid complexes encoding GFP (0.1x complex concentration), as judged by 
the percentage of A2B5
+
 cells expressing GFP. All magnetic field conditions significantly 
enhanced transfection efficiency compared to the basal (no field) condition (F3,16 = 16.1; p 
< 0.001; one-way ANOVA; n = 5). Importantly, a 4 Hz oscillating field significantly 
enhanced transfection efficiency over the static field condition (*p < 0.05, **p < 0.01, 
***p < 0.001; Bonferroni’s post-tests; n = 5). (b) Representative fluorescence micrograph 
of transfected OPCs (0.1x, F = 4 Hz) with bipolar morphologies, expressing GFP 
throughout the cell body and processes. 
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Figure 7: Magnetofection does not affect OPC morphologies or staining profiles. (a) 
Representative fluorescence micrograph of transfected OPCs. Note co-localisation of GFP 
expression with A2B5 staining. (b) Magnified section of (a), indicated by white box, 
showing morphologically normal DAPI-stained nuclei. Arrows indicate the same 
transfected cells in (a) and (b). 
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3.3.3 Magnetofection does not affect the proliferation or differentiation potential of 
OPCs 
The developed transfection protocols (0.1x Neuromag-plasmid dose) did not affect 
OPC proliferation under any magnetic field condition, as assessed by comparing OPC 
densities with controls at 48 h (Figure 5). In addition, when transfected OPC cultures were 
maintained in Sato differentiation medium to generate oligodendrocytes, the progeny could 
be observed with closely-apposed daughter nuclei, indicative of recent mitosis (Figure 8a). 
Furthermore, when monitoring live transfected cultures, the striking observation was made 
that transfected cells were often in pairs, suggestive of a recent cell division, and providing 
further evidence that transfection does not adversely affect OPC proliferation potential 
(Figure 8b). Transfected OPCs produced GFP
+
/MBP
+
 oligodendrocytes with mature, 
highly branched morphologies comparable to those observed in control cultures (Figure 
9a). No significant difference was observed in the proportion of MBP
+
 cells in control 
cultures compared to transfected cultures (F = 4 Hz; 12 days post-magnetofection; Figure 
9b). No differences were apparent in the range of oligodendroglial phenotypes present in 
control and treated cultures, from bipolar OPCs to multipolar, highly branched 
oligodendrocytes with extensive membrane elaboration (see Figure 9 for a highly-
processed example), providing further evidence that this protocol does not affect the 
differentiation potential of OPCs. Longer term monitoring of cultures showed persistence 
of GFP expression for up to 22 days post-transfection (the latest time-point examined), 
although expression had declined to approximately 5% of peak levels by this time.  
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Figure 8: Magnetofection does not affect OPC proliferation potential. (a) Multipolar 
morphologies typical of early-stage oligodendrocytes were present in cultures at 48 h post-
magnetofection (arrows indicate two nuclei, suggestive of a recent cell division, and 
therefore normal proliferative activity). (b) In magnetofected cultures (culture shown: 
0.1x, F = 4 Hz, 40 h post-transfection), GFP
+
 cells were frequently observed in pairs 
(arrows), indicative of a recent cell division, further suggesting normal proliferative 
activity. Note that indicated pairs are frequently without processes, which is indicative of 
recent mitosis.  
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Figure 9: Magnetofection does not affect OPC differentiation potential. (a) Following 
culture in Sato differentiation medium, magnetofected OPCs developed morphologies 
typical of mature oligodendrocytes, with GFP expressed throughout their processes, which 
stained for MBP (a late-stage oligodendrocyte marker). Arrow indicates a MBP
+
/GFP
-
 
cell. (b) Bar graph showing percentage of MBP
+
 cells, 12 days post-transfection. The 
percentage of MBP
+
 cells in magnetofected cultures (0.1x complex concentration; F = 4 
Hz) was not significantly different from controls (plasmid only, no magnetic field; n = 4).  
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3.3.4 MPs can mediate delivery of multiple genes to OPCs (co-transfection) 
The potential to deliver two genes to an OPC population was assessed, and 
expression of both transgenes was apparent (Figure 10), with ~75% of transfected cells 
expressing both GFP and RFP (Figure 11a). In co-transfected cultures the proportion of 
magnetofected cells expressing RFP only was significantly lower than that expressing GFP 
only (Figure 11b), and transfection levels in cultures treated with pDsRed only tended to 
be lower than with pmaxGFP only (with or without application of a magnetic field), 
although this was not shown to be significant (Figure 11a). These data suggest that 
transfection using pDsRed is less efficient than with pmaxGFP. For both field conditions, 
co-transfection with pDsRed and pmaxGFP tended towards greater transfection than with 
either plasmid alone, although this was only shown to be significant compared to pDsRed 
in the presence of a 4 Hz oscillating field (Figure 11a). 
 
Figure 10: Multiple genes can be delivered to OPCs using MPs. (a & b) Counterpart 
representative fluorescence micrographs of an OPC culture 48 h following simultaneous 
magnetofection (F = 4 Hz) with both GFP and RFP encoding plasmids (0.1x Neuromag, 
0.05x pmaxGFP, 0.05x pDsRed). Cells are clearly expressing both GFP (a) and RFP (b), 
and the majority of cells are both GFP
+
 and RFP
+
, appearing yellow in the merged image 
(c). Arrows in (a-c) indicate the same GFP
+
/RFP
-
 cell.  
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Figure 11: Combinatorial gene delivery typically results in co-expression of both 
transgenes. (a) Bar chart indicating the total percentage of transfected OPCs (identified 
morphologically) 48 h post-transfection (either no field or F = 4 Hz). 0.05x RFP and 0.05x 
GFP indicate that a culture was treated with half the established 0.1x dose of pDsRed or 
pmaxGFP plasmid, respectively. 0.05x GFP + 0.05x RFP indicates a culture 
simultaneously treated with a half-dose of each plasmid, amounting to the established 0.1x 
dose. Both plasmid- (F2,18 = 9.21; p < 0.01) and field-dependent effects were detected 
(F1,18 = 91.6; p < 0.001; two-way ANOVA; n = 4). For both field conditions, co-
transfection resulted in greater transfection than with either plasmid alone, although this 
was only shown to be significant compared to pDsRed at 4 Hz; the application of a 4 Hz 
oscillating magnetic field resulted in a significantly enhanced transfection efficiency for 
each plasmid alone and in combination (**p < 0.01, ***p < 0.001; Bonferroni’s post-
tests). (b) Bar graph indicating the proportions of all transfected cells (F = 4 Hz, 0.05x 
pmaxGFP plus 0.05x pDsRed) which express only RFP, only GFP, or both RFP and GFP. 
The majority of transfected cells express both transgenes, and significantly more cells were 
GFP
+
/RFP
-
 than were RFP
+
/GFP
-
 (F2,9 = 173; p < 0.001; one-way ANOVA; *p < 0.05, 
***p < 0.001; Bonferroni’s post-tests; n = 4). 
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3.3.5 MPs can mediate delivery of a therapeutic gene to OPCs 
Transfected OPCs, identified by staining for the OPC markers A2B5 and NG2, 
were observed under all magnetic field conditions and for both the pFGF2-GFP and pAN-
GFP plasmids. Cultures transfected with pFGF2-GFP were comparable to both pAN-GFP 
and plasmid-only controls in terms of the numbers of adherent phase-bright cells, and did 
not exhibit other signs of toxicity, consistent with pmaxGFP experiments (data not shown). 
Cells transfected with pAN-GFP exhibited GFP expression throughout the cell body and 
processes (Figure 10), as was observed for pmaxGFP and pDsRed. However, cells 
transfected with pFGF2-GFP exhibited GFP expression localised to the nucleus (Figure 
12b-d; <1% of cells exhibited GFP expression throughout the cell). This is consistent with 
reports that some FGF2 isoforms are localised to the nucleus, including in astrocytes,
301,302
 
and demonstrates normal subcellular localisation of the fusion protein by OPCs. For both 
pFGF2-GFP and pAN-GFP transfected cultures [as was observed for pmaxGFP (Figure 
8b) and pDsRed transfection (data not shown)], transfected cells were frequently observed 
in pairs, indicative of a recent cell division (Figure 13a-b). Furthermore, GFP expression 
in these pairs of cells was typically of comparable intensity, as would be expected 
following symmetric division of a transfected cell. Such regular appearance of cells with 
similar intensity of protein expression with a small spatial separation would not be 
anticipated to result from separate transfection events in neighbouring cells. 
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Figure 12: MP-mediated delivery of a therapeutic gene to OPCs. (a) Fluorescence 
micrograph of cells transfected with a control plasmid (pAN-GFP; F = 4 Hz). The cells 
display bipolar morphologies typical of OPCs and exhibit GFP expression throughout the 
cell body and processes. Inset shows the same cells stained for A2B5 and DAPI. (b) 
Merged phase and fluorescence micrographs of live cells transfected with a plasmid 
encoding a therapeutic gene [pFGF2-GFP; encodes fibroblast growth factor 2 (FGF2) 
tagged with GFP, producing a FGF2-GFP fusion protein], at 24 h post-transfection (F = 
4 Hz). The cells display bipolar morphologies typical of OPCs, with GFP expression 
prominently localised to the nucleus. (c) Fluorescence micrograph of NG2
+
 cells 48 h 
post-transfection with pFGF2-GFP (F = 4 Hz). Arrows indicate OPCs with GFP
+
 nuclei. 
(d) Fluorescence micrograph of a proliferating OPC transfected with pFGF2-GFP and 
stained for A2B5. Both daughter cells have GFP
+
 nuclei (arrows indicate daughter nuclei).  
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Figure 13: Transgene expressing cells are often observed in pairs, indicative of recent 
mitosis. Representative fluorescence micrographs of a live OPC culture magnetofected (F 
= 4 Hz) with pFGF2-GFP plasmid. Images taken at 12 h (a) and 48 h (b) post-transfection 
(not the same field). GFP
+
 cells are apparent from ~6 h post-transfection and the number 
of GFP
+
 cells increases until peaking at approximately 48 h. Arrows indicate pairs of 
GFP
+
 cells, suggestive of recent proliferation. Note that intensity of GFP expression varies 
across the field, but is typically similar for each indicated pair. 
 
Expression of the FGF2-GFP fusion protein was confirmed using an FGF2 
antibody. Untreated OPC cultures stained for FGF2 throughout the cell body and 
processes, but with a marked reduction in signal intensity in the nuclear region (Figure 
14a, c, e). This is to be expected, as OPCs show endogenous expression of some isoforms 
of FGF2,
63
 and FGF2 is an essential component of chemically-defined OPC culture 
medium. In pFGF2-GFP treated cultures, successfully transfected OPCs (with nuclear-
localised GFP expression) also exhibited FGF2 staining throughout the cell body and 
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processes, but with uniform intensity of staining in the nuclear region, indicating a greater 
presence of nuclear-localised FGF2 than in untransfected cells (Figure 14b, d, f). 
Untransfected OPCs in these treated cultures stained with identical profiles to OPCs in 
control cultures, i.e. noticeably lower FGF2 staining intensity in the nucleus. 
As has been shown for pmaxGFP and pDsRed, the application of both static and 
oscillating magnetic fields enhanced transfection efficiencies compared to basal levels for 
pAN-GFP and pFGF2-GFP (Figure 15). An oscillation frequency of 4 Hz produced the 
greatest transfection efficiencies for both plasmids, significantly enhancing transfection 
levels compared to a static field, with F = 4 Hz also significantly enhancing efficiency over 
the F = 1 Hz condition for pFGF2-GFP (Figure 15). Analysis by two-way ANOVA of the 
transfection efficiency achieved with pmaxGFP, pAN-GFP and pFGF2-GFP (no field 
versus F = 4 Hz), indicated effects of field (F1,22 = 90.1; p < 0.001) and plasmid (F2,22 = 
54.3; p < 0.001). With or without a magnetic field, transfection efficiencies for both pAN-
GFP and pFGF2-GFP were significantly lower than those achieved using pmaxGFP (p < 
0.001 for each of the following comparisons: pAN-GFP versus pmaxGFP, no field; 
pFGF2-GFP versus pmaxGFP, no field; pAN-GFP versus pmaxGFP, F = 4 Hz; pFGF2-
GFP versus pmaxGFP, F = 4 Hz; Bonferroni’s post-tests). A regression analysis indicated 
that increasing plasmid size led to a systematic reduction in transfection efficiency (Figure 
16). The equations of the slopes show the x axis intercepts to be approximately 8.9 and 8.7 
kb (for the no field and F = 4 Hz conditions respectively), indicating that the percentage of 
cells transfected tends to zero as plasmid size approaches 9 kb. 
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Figure 14: Expression of a therapeutic fusion protein in transfected OPCs. 
Fluorescence micrographs of OPC cultures. (a) Untransfected OPCs stained for FGF2 
throughout the cell body and processes, but with lower levels of expression in the nucleus. 
Arrows indicate less intensely-stained regions. DAPI-stained nuclei are shown in 
counterpart image (c), and (e) shows a merged image. (b) OPCs transfected with pFGF2-
GFP (0.1x, F = 4) stained for FGF2 evenly throughout the cell body and processes, 
including strong staining within the nucleus (arrows). (d) Counterpart image to (b) 
showing nuclear FGF2-GFP expression. (f) Merged image of (b) and (d), including DAPI-
stained nuclei. Arrows indicate the nuclei in (b), (d) and (f). 
 127 
 
 
Figure 15: Static and oscillating magnetofection enhances therapeutic gene 
transfection efficiency in OPCs. Bar graph illustrating transfection efficiency achieved 
with and without application of static and oscillating magnetic fields when Neuromag was 
complexed with either pAN-GFP or pFGF2-GFP. There was a field-dependent effect for 
pAN-GFP (F3,12 = 17.7; p < 0.001; one-way ANOVA; n = 4) and pFGF2-GFP (F3,13 = 
50.5; p < 0.001; one-way ANOVA; n = 4). For both plasmids, all magnetic field conditions 
significantly enhanced transfection efficiency over basal (no field) levels, with F = 4 Hz 
also significantly enhancing efficiency compared to the static field condition. For pFGF2-
GFP, F = 4 Hz also significantly enhanced transfection efficiency over the F = 1 Hz 
condition. *p < 0.05, **p < 0.01, ***p < 0.001; Bonferroni’s post-tests.  
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Figure 16: MP-mediated transfection/magnetofection efficiency is inversely related to 
plasmid size. Regression analysis using the data provided in Figures 6 and 15, showing 
that transfection efficiency achieved in OPCs using Neuromag conjugated to different 
plasmids (0.1x) is inversely related to plasmid size, in the absence of a magnetic field (no 
field; r
2
 = 0.750; p < 0.01), and also when an oscillating magnetic field is applied (F = 4 
Hz; r
2
 = 0.872; p < 0.01). Both basal and magnetofection transfection levels show a 
systematic reduction along with increasing plasmid size. The equations describing the 
slopes for the no field and F = 4 Hz conditions are, respectively, (y = 9.987 – 1.116x) and 
(y = 34.28 – 3.928x). The respective x axis intercepts are 8.949 and 8.726. n ≥ 3. 
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3.3.6 Characterisation of organotypic cerebellar slice cultures 
In initial experiments, cerebellar slices were prepared at either 350 or 400 µm 
thickness then cultured for 10 days. Slices at 350 µm were observed to become thinner 
over a course of 3 – 5 DIV, whereas 400 µm slices frequently remained at their initial 
thickness. These thicker slices were of low viability, potentially due to poor penetration of 
oxygen and nutrients. Therefore, slices were routinely prepared at 350 µm thickness. Slices 
typically exhibited good cytoarchitectural preservation, with cerebellar folia and axonal 
tracts being readily identifiable under light microscopy (Figure 17a). After 8 – 10 days in 
culture, staining for MBP revealed distinct WM tracts (Figure 17b), and live/dead assays 
revealed that slices were of high viability (>90% live cells; Figure 18). After 8 DIV, 
typically 10 – 12 cerebellar slices per animal were observed to thin sufficiently for use, 
with clear preservation of WM tracts. 
Calbindin staining of slices during these studies demonstrated the presence of 
Purkinje cells, with soma aligned in the Purkinje cell layer (Figure 19a-b). Slices were 
also stained for the astrocyte marker GFAP (Figure 19c-d) and the OPC marker NG2 
(Figure 20a-c), demonstrating the presence of each of these cell types within the slices. 
These slice cultures remained viable for up to 74 DIV, as demonstrated by live/dead assay 
(Figure 20d). After this period of time in culture, slices still stained for GFAP, NG2, MBP 
and calbindin, and WM tracts and cerebellar folia were still identifiable, although less 
distinct than at earlier time-points.   
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Figure 17: Organotypic cerebellar slices retain cytoarchitectural features of the 
cerebellum. (a) Light micrograph of a cerebellar slice culture at 5 days in vitro (DIV), 
showing preservation of cerebellar features. Arrows indicate white matter (WM) tracts 
which branch into the cerebellar folia and converge on the deep cerebellar nuclei (DCN). 
In some of the folia, the molecular and granular layers are apparent. (b) Fluorescence 
micrograph of a cerebellar slice at 10 DIV stained for the oligodendrocyte marker MBP. 
WM tracts are apparent (arrows), converging on the DCN from each of the cerebellar 
folia.  
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Figure 18: Organotypic cerebellar slices exhibit high viability. Fluorescence 
micrograph of a cerebellar slice at 10 DIV, following a viability assay; dead/dying cells 
are labelled with ethidium bromide, live cells are labelled with calcein. Inset, magnified 
region (white box) of the same slice. Arrows indicate ethidium-labelled cells. 
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Figure 19: Cerebellar slices retain populations of Purkinje cells and astrocytes. 
Fluorescence micrographs of slices stained at 10 DIV for the Purkinje cell marker 
calbindin (a, b) and the astrocyte marker GFAP (c, d). (b & d) are merged images of (a & 
c) respectively,including DAPI-labelled nuclei. (a, b) Purkinje cell bodies are present in a 
thin line, suggesting good preservation of the narrow Purkinje cell layer found in the 
cerebellum in vivo. 
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Figure 20: Cerebellar slices retain a population of OPCs, and remain viable for up to 
74 days. (a-c) Fluorescence micrographs of slices stained at 10 DIV for OPC marker 
NG2. NG2
+
 cells are present in a syncytium, representative of their arrangement in vivo. 
(b) Counterpart image to (a), merged with DAPI-labelled nuclei. (c) Higher magnification 
image of a slice stained for NG2, showing a prominent cell with multiple processes. (d) 
Fluorescence micrograph of a live/dead-stained cerebellar slice at 74 DIV, demonstrating 
high viability, although with more dead cells apparent than in slices stained at 10 DIV. 
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3.3.7 Magnetofected OPC populations transplanted onto cerebellar slice cultures 
survived, migrated, proliferated and differentiated 
Magnetofected (GFP
+
) OPCs could be delivered focally to slices by pipette and 
were readily visualised by fluorescence microscopy (Figure 21a-b). At 24 and 48 h 
following transplantation, GFP
+
 cells could be observed with bipolar morphologies that are 
characteristic of migratory OPCs (Figure 21c) and were frequently observed in pairs, 
suggestive of proliferation (Figure 21d). Further, transplanted cells were present with 
multipolar morphologies indicating differentiation (Figure 21d, inset). Confocal 
microscopy revealed that transplanted cells could be visualised at depth within the slices, 
rather than being entirely superficial. Transplanted cells also demonstrated co-expression 
of the OPC marker NG2 with GFP (Figure 22a), and co-expression of the oligodendrocyte 
marker MBP with GFP (Figure 22b). Transplant populations re-plated into chamber slides 
with Sato differentiation medium also retained GFP expression, stained for NG2 or MBP, 
and exhibited normal oligodendroglial morphologies, demonstrating that factors inherent to 
the slice cultures or slice culture medium (e.g. serum) were not necessary to promote 
survival of the modified cells. 
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Figure 21. Magnetofected OPCs survive, migrate, proliferate and differentiate 
following transplantation onto organotypic cerebellar slice cultures. (a) Magnetofected 
OPCs were focally delivered to slices, as evidenced by fluorescence microscopy 
immediately post-transplantation. GFP
+
 transplanted cells exhibited the rounded 
morphology typical of enzymatically detached cells. (b) Counterpart phase image to (a), 
illustrating slice margin (arrows). Post-transplantation, GFP
+
 cells were observed with 
bipolar morphologies typical of migrating OPCs [24 h; (c)], in pairs, suggestive of 
proliferation [48 h; (d)], and with multipolar morphologies, indicative of normal 
differentiation (d, inset).  
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Figure 22. Magnetofected OPCs express OPC and oligodendrocyte markers following 
transplantation onto organotypic cerebellar slice cultures. (a) When slices were stained 
for the OPC marker NG2, 48 h post-transplantation, confocal microscopy revealed 
GFP
+
/NG2
+
 transplanted OPCs (yellow arrow) against a background of red NG2
+
 host 
OPCs (red arrow). Some GFP
+
 cells were NG2
-
 (green arrow). (b) Confocal image of 
GFP
+
 cells stained for the oligodendrocyte marker MBP (yellow arrows) 48 h post-
transplantation, indicating OPC differentiation within the slice. Red arrow indicates a 
MBP
+
 host oligodendrocyte; green arrow indicates a GFP
+
/MBP
-
 transplanted cell. 
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3.4 Discussion 
A number of proof-of-principle studies have been performed: MP-mediated gene 
delivery to OPCs has been demonstrated for the first time, with transfection efficiency 
enhanced by employing static and state-of-the-art oscillating magnetofection techniques; 
these techniques appear to be safe as evidenced by normal proliferation and differentiation 
profiles of the transfected cells. Both combinatorial gene delivery and therapeutic gene 
delivery have also been safely demonstrated in OPCs using MP vectors. Further, this is the 
first use of organotypic neural slices as a safety assay for nanomaterial-modified transplant 
cells (by studying key regenerative properties of the transfected OPCs following their 
transplantation onto slices). Use of this assay supports the concept that the transfection 
protocols developed under this study have a good safety profile and that slice models 
represent a valuable tool in neural tissue engineering studies.  
 
3.4.1 Magnetofection enhances MP-mediated gene delivery to OPCs 
The safety and efficiency of the magnetofection protocol used here show that it 
could serve as an inexpensive, technically simple alternative to the viral transduction 
methods which are widely used with OPCs. Table 1 provides transfection efficiencies 
achieved in rodent OPCs derived from primary sources using a variety of viral and 
nonviral methods, showing these to be highly variable. All alternative nonviral vectors 
tested with OPCs have resulted in significant reductions in cell viability, with most also 
demonstrating lower levels of transfection than those demonstrated here with MPs. 
Although some viral methods have produced greater levels of transfection (up to 90%)
50
 
than reported here, results can vary greatly, with another retroviral study transfecting less 
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than 0.5% of OPCs.
108
 Crucially, toxicity data have rarely been published for viral 
transduction of OPCs, an omission also common to nonviral techniques, and the lack of 
detailed data in this regard prevents assessment of the potential for clinical translation of 
these techniques. 
Use of MPs and magnetofection techniques compare favourably with the 
transfection efficiencies achieved using other nonviral methods, with the critical advantage 
of high cell viability post-transfection. Techniques such as electroporation and 
nucleofection produce transient pores in the cell membrane, through which transfection 
vectors gain cell entry.
303
 However, this membrane disruption can result in extensive cell 
death, and surviving cells are often damaged.
207
 An advantage of MPs as vectors is that 
they exploit the natural endocytotic mechanisms of cells, and avoid membrane disruption. 
From a translational perspective, it is highly desirable that a cell transplant population 
demonstrates high viability, as introducing dead/dying cells into a patient may lead to 
detrimental effects, such as secondary pathology due to necrotic release of the cell 
contents, and possibly inflammatory responses.
304
 Furthermore, in terms of large scale 
culture of cells for clinical translational applications, a high rate of cell attrition can be 
predicted to add to the cost of production, especially where limited primary tissue sources 
are available. MPs additionally offer unique advantages for the development of 
‘theragnostic’ applications, as their multimodality enables therapeutic effects to be 
combined with diagnostic functionality (e.g. non-invasive imaging of MP-labelled cells).
146
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Table 1: Comparative in vitro transfection efficiencies in rodent OPCs (derived from 
primary sources) for viral and nonviral techniques. 
Transfection method Transgene/protein 
Transfection 
efficiency 
Viability Ref 
Viral methods 
Lentivirus GFP ~90% 
‘Viability not affected’; numerical data 
not reported 
50 
Retrovirus LacZ ~90% 
‘Viability not affected’; numerical data 
not reported 
50 
Retrovirus (LZRS) CNTF/EGFP 60 – 70% Data not reported 60 
Retrovirus (LZRS) D15A/EGFP ~60% Data not reported 64 
Retrovirus (MoMuLV) LacZ <0.5% Data not reported 108 
Retrovirus EGFP/p27/p18 Data not reported Data not reported 305 
Adenovirus EGFP ~70% Data not reported 290 
Adenovirus LacZ >50% Data not reported 306 
Adenovirus p27 Data not reported ~75% (MTT assay) 307 
Nonviral methods 
Magnetic particles GFP 21% 
No significant toxicity (established 
dose) 
† 
Lipofection (GenePORTER 
2) 
CASK-EGFP 2 – 5% Data not reported 290 
Lipofection (Lipofectamine, 
Lipofectin, Cellfectin) 
LacZ 1 – 3% 
Data not reported; toxic at even low 
doses (<2 µg) 
110 
Lipofection (Effectene) NT3 Data not reported Data not reported 267 
Calcium phosphate 
precipitation 
LacZ 3 – 5% ~10% 108 
Calcium phosphate 
precipitation 
LacZ <2% 
Data not reported; induced 
morphological changes 
110 
Electroporation EGFP ~49% ~78% 288* 
Electroporation EGFP ~43% 60% 289* 
Electroporation LacZ ~15% 20 – 25% 110 
Electroporation GFP-KLHL1/MRP2 Data not reported Data not reported 113 
GFP = green fluorescent protein; β-Gal = β-galactosidase; D15A = multineurotrophin, with brain-derived neurotrophic 
factor (BDNF) and neurotrophin 3 (NT3) activity; EGFP = enhance green fluorescent protein; CNTF = ciliary neurotrophic 
factor; MTT = 2-(4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-2H-tetrazolium bromide; CASK = calcium/calmodulin-dependent 
serine kinase; KLHL1/MRP2 = Kelch-like 1 protein/Mayven-related protein 2, actin binding protein. *Company website. 
†Reported here. 
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3.4.2 OPCs are potentially more amenable to transfection during mitosis 
Proliferating cells such as OPCs undergo breakdown of the nuclear envelope during 
mitosis, potentially permitting access of exogenous DNA into the nucleus. It is also 
reported that proliferating cells have larger nuclear channels and exhibit higher rates of 
nuclear transport.
176
 For all plasmids, transfected cells in OPC cultures were frequently 
observed in pairs. Presuming that each of these pairs does represent two daughter cells, it is 
not clear from this evidence whether (i) each is the result of a GFP
+
 cell that has divided, 
with approximately equal inheritance of GFP molecules and/or plasmids by each daughter 
cell, or (ii) a GFP
-
 cell (with intracellular Neuromag-plasmid complexes) has divided, and 
the process of nuclear membrane breakdown during mitosis has permitted approximately 
equal plasmid entry into the nucleus of both daughter cells. Possibility (ii) implies rapid 
GFP expression post-mitosis, particularly for cells with intense GFP expression, and 
therefore seems less likely than (i), which is further supported by the observation that these 
pairs of cells typically exhibit equal levels of GFP or RFP expression. 
 
3.4.3 Optimising MP-based engineering of OPCs for delivery of therapeutic factors  
In addition to delivery of reporter genes, it has been shown here that a therapeutic 
gene can be delivered to OPCs using MPs as vectors. The therapeutic factor FGF2 was 
chosen as it is a mitogen for OPCs (and other cell types) and promotes angiogenesis, which 
are both potentially valuable for promoting CNS regeneration. These experiments 
demonstrated that transfection efficiency declined as plasmid size increased. As the 
Neuromag:plasmid ratio was kept constant for all experiments, a possible explanation for 
this finding is that each Neuromag-pmaxGFP complex (3.5 kb) consists of a higher number 
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of individual plasmids than each Neuromag-pFGF2-GFP complex (7.4 kb), resulting in 
OPCs with higher plasmid copy numbers when transfected with smaller plasmids. 
However, it may be the case that individual plasmids associate with multiple particles, and 
larger plasmids may result in larger complexes, with potential implications for cellular 
uptake of these complexes. This is speculative, and it must be considered that plasmids are 
typically supercoiled, making them highly compacted, as evidenced by the dynamic light 
scattering (DLS) measurements of Neuromag:pmaxGFP complexes showing only a 35% 
increase in hydrodynamic diameter over Neuromag alone.
164
 Ultrastructural analyses of 
MP-plasmid complexes [e.g. EM, atomic force microscopy (AFM)] and analyses such as 
DLS (with different sizes of plasmid) would greatly aid the development of these 
transfection techniques by providing insights into the nature of physico-chemical 
interactions at the particle-plasmid interface and hence factors that govern effective 
plasmid delivery. A further factor pertinent to transfection efficiency is likely to be that 
smaller plasmids may more readily traverse the nuclear membrane and be expressed.
176
  
The inverse relationship between transfection efficiency and plasmid size indicates 
that plasmids should be engineered without unnecessary elements in order to minimise 
their size. For example, the pFGF2-GFP plasmid used here contains a neomycin resistance 
sequence, which is unnecessary for transient expression and could be removed. Similarly, 
for therapeutic effects without fluorescent tagging, the GFP encoding sequence could be 
removed. If the pmaxGFP plasmid were to be re-engineered, with the gfp sequence (~710 
bp) replaced by the FGF2 sequence (867 bp) from the pFGF2-GFP plasmid, the resulting 
plasmid would be approximately 3.7 kb. From the relationships between plasmid size and 
transfection efficiency determined here, it can be predicted that this plasmid would result 
in transfection levels approaching those seen with pmaxGFP (~21%). Most 
neurotherapeutic growth factor genes have open reading frames of <1.2 kb (e.g. NT3: 774 
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bp, National Centre for Biotechnology Information database, www.ncbi.nlm.nih.gov) and 
could therefore be incorporated into plasmids of similar size to the pmaxGFP plasmid with 
the aim of achieving comparable transfection efficiency. Regression analysis predicts that 
Neuromag particles will not be able to achieve transfection with plasmids larger than 
approximately 9 kb, but the delivery of large plasmids is desirable in order that multiple 
therapeutic genes can be delivered simultaneously, with the potential inclusion of complex 
regulatory elements for region-specific or inducible transgene expression.
63,117
 These data 
highlight the biomedical need for particles capable of delivering plasmids of this size or 
larger, which may depend upon producing larger particles, or by devising alternative 
coatings or morphologies in order to increase binding capacity/DNA compaction. Any 
such particle modifications would require further toxicity testing using procedures similar 
to those outlined here. Importantly for the development of combinatorial CNS therapies, 
the delivery of multiple genes to an OPC population has been demonstrated here, with 
many cells showing expression of both genes. This raises the possibility of producing an 
OPC transplant population engineered to express two or more therapeutic factors. 
 
3.4.4 Translational considerations for repair of demyelinating lesions 
Plasmid-based transfection typically results in transient transgene expression, as 
observed here. Such transient expression is desirable for promoting CNS remyelination in, 
for example, MS or SCI lesions. Successful remyelination follows a specific sequence of 
cellular events, and each phase of the repair process is temporally controlled by precisely 
regulated expression of repair-promoting signals. This process involves the recruitment of 
OPCs into lesions sites with subsequent proliferation followed by the differentiation phase 
and formation of functional myelin sheaths around axons. Notably, maintaining expression 
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of OPC proliferation- or differentiation-promoting factors for an inappropriate length of 
time is likely to be detrimental to effective regeneration.
1,6,9,14,29,308
 For example, PDGF-
AA and FGF2 both have mitogenic and migration promoting effects on OPCs, but also 
inhibit the late-stages of differentiation into mature oligodendrocytes, and therefore their 
upregulation should not be prolonged beyond the ‘recruitment’ phase of regeneration.63,309 
Given this limitation, if multiple therapeutic genes are to be delivered to a transplant 
population it will be important to select compatible, complementary molecules, such as 
PDGF-AA and FGF2. However, if sufficient advances are made in particle and plasmid 
engineering, it may be possible to transfect OPCs with inducible transgenes. For example, 
the OPC cell line CG4 has been successfully transfected (by calcium phosphate 
precipitation) with a plasmid encoding FGF2 controlled by the Tet-on system and stably 
transfected clones isolated by antibiotic selection.
63
 By exposing these cells to a 
tetracycline (e.g. Doxycycline), FGF2 expression is activated. In theory, multiple genes 
could be delivered to OPC transplant populations, using distinct induction signals but the 
translation of such an approach to the clinical setting would require further research, taking 
into account critical factors such as the ability of the relevant inducing molecules to cross 
the BBB.
310
  
 
3.4.5 The underlying mechanisms of oscillating magnetic field enhancement of 
transfection are not known 
If the mechanisms underlying the enhanced transfection efficiency achieved 
through oscillating magnetofection can be elucidated, it may be possible to further improve 
these effects, either by modifying the current protocols or potentially modifying the 
magnetofection device. It is suggested that static magnetofection does not alter the 
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mechanisms of vector uptake by cells, but merely reduces the time taken for particles to 
come into contact with adherent cells, and possibly prolongs contact time;
161,185
 
endocytotic mechanisms remain the proposed method of cellular uptake leading to gene 
delivery.
186
 Based on this, there are a number of theories which could possibly explain the 
enhanced transfection efficiency observed in the case of oscillating magnetofection: (i) An 
oscillating field may simply move the MPs laterally (in these experiments, with an 
amplitude of 200 nm), such that particles in a cell-free area are brought into contact with 
cells, increasing the likelihood of each particle coming into contact with a cell within a 
given time. A static magnetic field model predicts that magnetic particles (>10 nm 
diameter) will accumulate at the centre of a culture well (due to the radial component), 
potentially with an annulus of slightly greater acuumulation surrounding it (due to the axial 
component). Therefore, incorporating an oscillating magnetic field may be predicted to 
overcome these accumulation biases, resulting in a more uniform dispersion of particles.
298
 
(ii) An oscillating field may cause MPs to distort or stimulate the cell membrane such that 
endocytosis is more likely to occur.
173,311
 It is not clear whether this effect would require 
that particles be bound (specifically or non-specifically) to the membrane, or whether 
unbound MPs pulled onto the cell surface by the magnetic field and subsequently 
manipulated by an oscillating field can have a stimulatory effect.
172
 (iii) It may be the case 
that an oscillating field alters intracellular processing of MPs, for example disrupting 
endosomal processing and facilitating endosomal escape.
172
 
Kamau et al. have experimented with a pulsating electromagnetic field approach, 
showing greatly enhanced MP-mediated transfection of the HeLa cell line.
312
 They report 
that pre-sedimentation using a static magnet followed by the application of a pulsating 
magnetic field produced optimal results, significantly enhancing efficiency compared to a 
static field alone, whereas application of a pulsed field followed by a static field 
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significantly underperformed compared to a static field alone, although still producing 
greater transfection than seen in the absence of a field. Application of the pulsed field is 
thought to produce both horizontal (0.75 Hz, 1.5 cm amplitude) and vertical oscillations 
(50 Hz) of the MPs. The particle movements induced by these oscillations presumably 
underpin the mechanism by which transfection efficiency is increased by the pulsed field, 
and these effects are observed after a 10 min exposure to magnetic fields, lending support 
to the idea that membrane stimulation by MPs in a dynamic magnetic field leads to 
enhanced cellular uptake, rather than a post-uptake intracellular event. It should be noted 
that a 5 min exposure to the magnetic field raised the temperature at the surface of the 
device from 37°C to 42.5°C, which is potentially damaging to cells, but the authors do not 
report any toxicity data. Similar heating effects have not been observed using the protocols 
reported here. 
The ultimate measure of gene therapy and cell transplantation therapies will be 
based on functional recovery, or at least inhibition of disease progression, but it remains 
vital to investigate all possible indications of toxicity or abnormality due to MP and 
magnetofection applications. With respect to the use of magnetofection, the application of 
a magnetic field has been reported to affect cells, for example by causing alignment of the 
cytoskeletal protein F-actin in human fibroblasts exposed to 350 mT for 30 min.
135
 
However, a review by Smith et al. reports that the majority of studies showing these effects 
have investigated prolonged field exposures (up to 60 h) and often greater field strengths 
(up to 8 T, compared to 421 mT used here).
313
 No obvious effects of magnetic fields on 
OPCs were observed here, but as microarray analyses of cells exposed to MPs (Fe3O4 core 
of 6 nm diameter, gold coated) demonstrated significant changes in gene expression in the 
presence of a magnetic field versus absence of a field,
313
 it will be of interest to perform 
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similar microarray analyses of magnetofected OPCs, and also OPCs exposed to MPs with a 
variety of physico-chemical characteristics.  
 
3.4.6 Safety profiles of nanoengineered OPC transplant populations can be assayed 
using cerebellar slices: potential refinements of the approach using injury 
models 
Having shown that the magnetofection protocol developed here is safe for OPCs on 
culture plastic, a more rigorous analysis of cellular behaviour was performed by 
transplanting modified OPCs onto organotypic neural slices, as a bridge between in vitro 
isolated cell culture and in vivo transplantation studies. It should be noted that confocal 
microscopy demonstrated that transplanted cells were not merely using the slices as a 
substrate, but could migrate into the slices and integrate into the tissue, shown by the 
presence of GFP
+
 cells beneath the surface layer of cells. The normal behaviour of the 
modified cells demonstrates the safety of the magnetofection protocols developed in this 
study and highlights both the potential of the MP platform for clinical translational 
applications, and the utility of organotypic neural slice cultures to function as ‘host’ tissue 
to evaluate cell therapies when used in conjunction with nanotechnology platforms. 
The data presented here demonstrate the potential for cerebellar slice cultures in 
particular, and organotypic CNS slice cultures in general, to serve as a high-throughput 
screening technique for assessing cell transplant populations. The clinical relevance of this 
approach can be greatly improved by developing injury/disease models in these slices. 
Remyelination strategies can be tested by inducing demyelinating lesions in slices, for 
example by focal injection of ethidium bromide or by adding demyelinating agents to the 
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culture media (e.g. lysolecithin).
314
 Furthermore, a number of severely debilitating in vivo 
neurological injury/disease models use animals with severely restricted life expectancy. 
The slice model technique provides the possibility of establishing organotypic cultures 
from such animals at an early age, minimising suffering and prolonging the time course 
over which the relevant pathology can be studied. 
Having established that OPCs derived from a primary source can be labelled and 
transfected using MPs, in the following chapter the capacity for oligodendrocytes to be 
labelled and transfected using Sphero MPs and Neuromag MPs, respectively, will be 
assessed. These data will be compared with the OPC data in this chapter and Chapter 2, to 
provide the first systematic intra-lineage comparison of MP-handling. 
 
3.4.7 Conclusions and future directions 
The MP platform has significant potential for the genetic engineering of OPCs 
derived for cell therapies. Further, the slice model approach can offer a simple, high 
throughput assay to evaluate the survival and regenerative properties of nano-engineered 
transplant populations. A number of questions have been raised during the course of this 
study, and further work to enhance MP-based gene delivery methods will need to address a 
number of issues: (i) To optimise delivery of therapeutic gene sequences, the plasmids will 
need to be engineered to produce constructs that contain only therapeutic gene sequences 
and the elements necessary for transcription, thereby minimising their overall size, with the 
aim of enhancing transfection efficiency. Additionally, the development of alternative 
transfection-grade MPs (including those with a range of surface coatings and geometries) 
warrant further investigation, in order to identify physico-chemical parameters that may 
allow for the attachment and the delivery of larger plasmids and/or greater copy numbers. 
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Such work will be critically dependent on multidisciplinary collaborations between 
materials scientists and biologists, and need to be informed by a detailed understanding of 
the chemical interactions at the organic-inorganic hybrid interface of magnetic particles 
and biomolecules (for example the associations of large versus small plasmids with the 
particle surface and their implications for DNA attachment and intracellular release), an 
area where little information currently exists. (ii) In terms of the magnetofection conditions 
used, further work will need to test various permutations of oscillation frequencies and 
amplitudes. The feasibility of combining a repeat transfection ('multifection') approach in 
conjunction with magnetofection (i.e. a 'magneto-multifection' approach)
163
 has also not 
been tested with OPCs to date. As this would involve multiple manipulations, rigorous 
toxicity testing must be employed to evaluate their potential in the translational context. 
(iii) To evaluate the remyelinating potential of OPCs genetically modified using MPs, the 
modelling of demyelinating disease models warrant investigation in cerebellar slice 
cultures warrants investigation, as this approach can offer a powerful alternative to in vivo 
models. As an example, brief exposure of rat cerebellar slices to the gliotoxin lysolecithin 
in slice medium at 7 DIV results in extensive myelin damage/loss in slices, but spares 
Purkinje cell nerve fibres.
314
 Limited subsequent remyelination occurs, mimicking many 
aspects of MS lesions,
4,38,78,315
 providing a valuable system in which to study various 
therapeutic interventions, including transplantation of engineered cell populations, with 
assessment of the extent of remyelination. Slice cultures can be processed for 
ultrastructural analyses of WM tracts utilising techniques such as serial sectioning,
316
 
stereology and 3-D reconstruction.
259,317
 Further, by assembling an upright time-lapse 
microscope, with a temperature- and CO2-controlled incubation chamber, it will be 
possible to monitor cells transplanted onto slices in real time and obtain far more accurate 
data regarding the migratory capacity of the engineered cells, for example, than can be 
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obtained from fixed tissue. Electrophysiological recordings can be performed in neural 
slices, including with cerebellar slices, although they are more readily achieved in slices of 
spinal cord, which can be prepared with long, laminar sections, preserving extensive 
axonal tracts
73
 within which transecting or crush lesions can be induced to simulate SCI.
318
 
Recordings can be made pre- and post-lesioning, and used to evaluate functional 
improvement following experimental treatments, including transplantation of modified 
OPCs, highlighting the versatility of the slice approach for use in neural tissue engineering 
studies.
b
  
 
 
  
                                                 
b
 Most of the data in sections 3.3.1 – 3.3.3 and 3.3.5 – 3.3.7 have been published. The article is reproduced 
here as appendix 4. 
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Chapter 4: Labelling and gene delivery 
applications of MPs in oligodendrocytes: 
An intralineage comparison with OPCs 
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4.1 Introduction 
Oligodendrocytes are key targets of disease processes in a range of pathologies 
such as demyelination conditions and traumatic/hypoxic injury,
7,319
 both during adulthood 
and in a range of neurodevelopmental disorders. Understanding the biology of these cells 
(for example, elucidating the factors/genes that participate in oligodendrocyte 
development, their associations with axons and the genesis of myelin) along with the 
development of effective neuroprotective strategies to promote oligodendrocyte survival, 
are key goals for regenerative medicine.
290
  
Such research into the biology of oligodendrocytes is heavily reliant on the ability 
to effectively deliver genes to oligodendrocyte populations. In this context, and as with 
OPCs, viral transduction techniques are commonly employed for gene delivery to 
oligodendrocytes (both in vivo and in vitro). As discussed in section 1.7.3, these methods 
are associated with significant drawbacks, and the direct cytopathic effects associated with 
viral transduction of oligodendrocytes represent a significant obstacle to progress in 
understanding oligodendrocyte biology.
108,111,114
 Further, the few reported attempts to 
mediate gene delivery to oligodendrocytes in vitro typically report low efficiency, 
including for example, retroviral transduction.
108,111
 Indeed, one in vivo study comparing 
adeno-, retro- and lenti-viral systems found no evidence of oligodendrocyte transduction 
even at high viral titres.
320
 By contrast, another report found evidence that 
oligodendrocytes can be transduced in vivo using adenoviruses, but that gene delivery is 
complicated by cytopathic effects.
114
  
Such findings have added to the demand for the development of nonviral gene 
delivery techniques, and several such methods have been tested in recent years to 
genetically modify oligodendrocytes. However, commonly used nonviral transfection 
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methods such as calcium phosphate precipitation and electroporation yield no/low 
transfection in oligodendrocytes and are associated with high levels of cell loss.
108,111
 
Delivery methods such as the gene gun approach and lipofection have yielded the greatest 
transfection levels in the literature (approximately 20% and 10%, respectively) and appear 
to be relatively safe, although detailed toxicity data were not provided.
111
 However, these 
transfection levels can still be considered to be relatively low from the point of view of 
basic research and translational applications. Therefore, the development of an alternative 
nonviral technique for safe and effective gene delivery to oligodendrocytes is a desirable 
goal.  
While the previous chapters have shown that OPCs (i.e. the parent cells of 
oligodendrocytes) can be labelled and transfected using MPs, it is not clear whether the 
MP-handling characteristics displayed by the precursor populations will be representative 
of MP-handling by their daughter cells, owing to the substantial biological differences 
between these cell types. Cellular morphology alters extensively as OPCs progress through 
the individual stages of the oligodendroglial lineage, changing from a bipolar cell with 
very limited membrane, to a highly branched oligodendrocyte, with a complex highly 
branched morphology, producing extensive quantities of myelin membrane.
9,321,322
 
Progression through the oligodendroglial lineage, from the highly migratory, mitotic 
precursor form to the fully differentiated post-mitotic, non-migratory mature 
oligodendrocyte, is also associated with a series of antigenic shifts, with characteristic 
patterns of marker expression being associated with each phase of maturation (section 
1.2).
7,9,29
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4.1.1 Knowledge gap: Do intralineage differences exist in MP handling between 
OPCs and oligodendrocytes? 
 Many of the differences described above between OPCs and oligodendrocytes in 
relation to their developmental status, have the potential to affect their handling of MPs 
and indeed synthetic materials in general. For example, the extent of myelin production by 
oligodendrocytes has been estimated to peak at three times the cell’s own weight per day, 
and to reach a total of one hundred times the weight of the cell body.
7
 As a consequence, 
the production and exocytosis of myelin constituents dominates the metabolic activity and 
intracellular trafficking mechanisms of these cells.
7
 It not clear what effect, if any, this will 
have on MP-based uptake and transfection in these cells, processes that are critically 
dependent on endocytotic uptake. There are few studies available in the literature in 
relation to such issues. One study reports that limited MP-labelling of GalC
+
 
oligodendrocytes was achieved in an undefined mixed neural culture,
222
 but MP handling 
has not been studied in a purified/enriched oligodendrocyte population. Further, it might be 
expected that oligodendrocytes would exhibit lower MP-mediated transfection efficiency 
than OPCs, as post-mitotic cells are typically considered intransigent to gene delivery,
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but few systematic comparisons of this nature exist in the context of nonviral gene delivery 
in oligodendroglial lineage cells. A critical point to note here is that it is currently unknown 
if differentiated oligodendrocytes are amenable to MP-mediated transfection, and therefore 
the effectiveness of the magnetofection methodologies that enhanced transfection 
efficiency in OPCs (section 3.3.2) is also unknown.  
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4.1.2 Objectives 
The first part of this chapter will address the following questions using the ‘test’ 
(Sphero) MP characterised in sections 2.2 and 2.3.2:  
(i) Do oligodendrocytes exhibit uptake of MPs? 
(ii) Is the rate and extent of MP uptake by oligodendrocytes time- and 
concentration-dependent? 
(iii) Does exposure to these MPs result in acute cytotoxicity in 
oligodendrocytes? 
(iv) Do MP uptake dynamics in oligodendrocytes differ from those in OPCs? 
The second part of this chapter will assess the feasibility of MP-mediated gene 
delivery to oligodendrocytes, using the transfection grade MPs described in section 3.2 
(Neuromag) to address the following questions: 
(i) Do MP-plasmid complexes, with and without applied magnetic fields, have 
acute toxic effects on oligodendrocytes? 
(ii) Can MPs mediate gene delivery to oligodendrocytes?  
(iii) Does static/oscillating magnetofection result in enhanced MP-mediated 
transfection efficiency in oligodendrocytes? 
(iv) Does the amenability of oligodendrocytes to MP-mediated transfection 
differ from that of OPCs?  
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4.2 Methods and materials 
Oligodendrocyte cultures: Please see section 2.2 for details of the derivation of 
OPCs from mixed glial cultures. Cultures intended for Sphero uptake studies and 
transfection studies were plated in parallel to OPC cultures described in sections 2.2 and 
3.2, respectively. By plating these OPC and oligodendrocyte cultures in parallel: (i) the 
purity of the OPC cultures corresponds to the initial purity of the oligodendrocyte cultures, 
and (ii) confounding biological variability is minimised for the purposes of drawing 
intralineage comparisons. OPCs were plated on coverslips (0.3 ml/well, at 3 x 10
4
 
cells/cm
2
) in Sato differentiation medium (see section 2.2) and maintained for 7 days 
(before uptake experiments) or 12 days (before transfection experiments) to generate 
oligodendrocyte cultures (50% medium changes every 2 – 3 days). After the uptake 
experiments were performed, the culture time for transfection experiments was extended in 
an attempt to produce cultures with a greater percentage of MBP
+
 cells. Oligodendrocyte 
differentiation has been reported to be largely complete within 7 – 9 days (in vitro), as 
assessed by the limited changes in gene expression from this point onwards.
323
 
Sphero uptake experiments: Oligodendrocytes were treated identically to OPCs, as 
described in section 2.2, but incubations were conducted in Sato medium.  
Transfection experiments: These were performed as described for OPCs in section 
3.2, but using Sato medium. Preliminary experiments tested transfection with a 1.0x dose 
which resulted in obvious toxicity. Therefore the 0.1x dose developed for use with OPCs 
was used for all data presented here. 
 156 
 
Culture purity analysis: The purity of each culture was determined by scoring at 
least 200 DAPI-stained nuclei for coincidence with MBP staining in fluorescence 
micrographs.  
Assessment of MP-labelling and extent of uptake: These data were obtained in 
identical fashion to that described for OPCs (section 2.2), except that MBP replaces A2B5. 
Cells were scored as exhibiting ‘low’, ‘medium’ or ‘high’ levels of MP accumulation by 
comparing the extent of MP fluorescence with the average area of an oligodendrocyte 
nucleus, in an identical manner to that described in section 2.2 (OPC and oligodendrocyte 
nuclei are of comparable size). A minimum of 100 nuclei and three microscopic fields 
were assessed per treatment group. 
Assessment of transfection efficiency: These data were obtained in identical fashion 
to that described for OPCs (section 3.2), except that MBP replaces A2B5. A minimum of 
100 nuclei and three microscopic fields were assessed per treatment group. 
Toxicity assessment (uptake and transfection): Fluorescence microscopy was used 
to count the pyknotic and total (healthy plus pyknotic) nuclei per microscopic field, as 
measures of MP-related toxicity in both uptake and transfection experiments. For 
transfection experiments, the percentage of cells expressing MBP was also determined, in 
order to assess whether there was any MP-related alteration in the expression of this 
protein, which is a major constituent of myelin. A minimum of 200 nuclei and five fields 
were assessed for every condition. 
Statistical analysis: Data were analysed using GraphPad Prism statistical analysis 
software. Data are expressed as mean ± SEM. The number of experiments (n) refers to the 
number of mixed glial cultures from which the initial OPC cultures were derived, with 
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each primary culture being established from a different rat litter. To determine time- and 
concentration-dependence of the percentage of oligodendrocytes with (i) MP-labelling, (ii) 
perinuclear MPs, (iii) ‘low’ levels of MP accumulation or (iv) ‘medium’ levels of MP 
accumulation, a two-way ANOVA was performed with Bonferroni’s post-tests comparing 
each concentration with 2 µg/ml at the same time-point and comparing each 4 and 24 h 
data-point with the same concentration at 1 h. For toxicity analyses, two-way ANOVA was 
performed at each timepoint to compare (i) the nuclei per field and (ii) percentage of 
pyknotic nuclei across all MP concentrations. For comparison of (i) the transfection 
efficiency, (ii) the percentage of MBP
+
 cells, (iii) the number of nuclei, and (iv) the 
percentage of pyknotic nuclei, a one-way ANOVA was performed including each field 
condition, with Bonferroni’s post tests performed for (i). For intralineage comparisons, 
uptake data for oligodendrocytes were collated with data for OPCs (section 2.3.4; identical 
Sphero concentrations and incubation times). Transfection data for oligodendrocytes were 
collated with data for OPCs (section 3.3.2; identical Neuromag-plasmid dose, incubation 
time and oscillating field protocols). A two-way ANOVA was performed at each time-
point to compare the percentage of MP-labelled OPCs with the percentage of MP-labelled 
oligodendrocytes across all concentrations, with Bonferroni’s post tests to compare OPC 
versus oligodendrocyte data at each concentration. Two-way ANOVA was also used at 
each time-point to compare the percentage of OPCs exhibiting ‘medium’-to-‘high’ levels 
of MP accumulation with the percentage of oligodendrocytes exhibiting the same 
accumulations, for all concentrations. A two-way ANOVA was performed to compare the 
effects of different field conditions and cell type on transfection efficiency, with 
Bonferroni’s post-tests to compare OPC v oligodendrocyte data for each field condition. 
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4.3 Results 
 
4.3.1 Oligodendrocyte culture characterisation 
Oligodendrocytes were derived from high purity parent OPC cultures, and the 
majority of cells stained positive for MBP (Figure 1). For Sphero uptake studies, 70.3 ± 
1.3% of cells were MBP
+
 (n = 4); for transfection studies, 75.9 ± 5.4% of cells were MBP
+
 
(n = 3). Reports typically show that multiple antigenically-distinct stages of the 
oligodendroglial lineage are typically present in such cultures,
324
 and phase contrast 
microscopy showed that ~80% of MBP
-
 cells exhibited multi-processed morphologies 
typical of early oligodendrocytes (see Figure 1 for examples). Approximately 5% of cells 
were identified by phase contrast microscopy as microglial contamination, consistent with 
observations in OPC cultures. Oligodendroglia were phase-bright, with multipolar 
morphologies, including the complex highly-branched, membrane elaborating 
morphologies typical of mature oligodendrocytes (Figure 1). 
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Figure 1: Characterisation of oligodendrocyte cultures. (a) Representative phase-
contrast micrograph of an oligodendrocyte culture, showing multipolar cells with 
branching processes. (b) Counterpart fluorescence micrograph to (a), showing 
oligodendrocytes stained for the late-stage oligodendrocyte marker MBP. Arrows indicate 
the same MBP
-
 cells in each image, with morphologies typical of early oligodendrocytes. 
Note the presence of multiple processes under phase microscopy. 
 
4.3.2 MP uptake in oligodendrocytes is time- and concentration-dependent 
Fluorescence microscopy, including z-stack and confocal analyses, confirmed the 
presence of intracellular Sphero MPs within oligodendrocytes, including perinuclear 
accumulations (Figure 2; confocal images not shown). The percentage of labelled 
oligodendrocytes was time- and concentration-dependent, with the greatest dose and 
exposure tested resulting in MP-labelling of ca. 45% of MBP
+
 cells (Figure 3a). MP 
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concentrations of 20 and 50 µg/ml resulted in the labelling of a significantly greater 
percentage of MBP
+
 cells than 2 µg/ml, at all time-points. Heterogeneity in the extent of 
MP-uptake by individual cells was apparent, and this was assessed semi-quantitatively 
using the same criteria employed for OPCs (Table 1; criteria detailed in section 2.2). 
Under all conditions, the majority of MP-labelled cells were judged to exhibit a ‘low’ level 
of particle accumulation. At 4 and 24 h, oligodendrocytes with ‘medium’ levels of MP 
accumulation were observed, but ‘high’ levels were observed only at the greatest MP 
concentration and incubation time (Table 1). Analysis by two-way ANOVA demonstrated 
a time-dependent effect on the percentage of labelled cells exhibiting perinuclear MPs 
(Figure 3b). 
 
Figure 2: Uptake of Sphero MPs by oligodendrocytes. Z-stack fluorescence analysis of 
a Sphero-labelled MBP
+
 oligodendrocyte (5 µg/ml, 4 h). Nile red fluorescence indicates 
the presence of MPs in cytoplasmic and perinuclear (crosshairs) accumulations. White 
arrow indicates extracellular MPs amongst processes. 
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Figure 3: Uptake of Sphero MPs by oligodendrocytes is time- and concentration-
dependent, and perinuclear localisation is time-dependent. (a) Bar chart showing the 
time- and concentration-dependent labelling of oligodendrocytes with MPs. The 
percentage of labelled cells is related to both particle concentration (F3,36 = 92.8; p < 
0.001) and incubation time (F2,36 = 52.7; p < 0.001; two-way ANOVA; n = 4). (b) Bar 
chart showing that the percentage of oligodendrocytes with perinuclear particles is related 
to incubation time (F2,36 = 9.95; p < 0.001) but not MP concentration (F3,36 = 1.08; p = 
0.161; two-way ANOVA; n = 4). For (a) and (b): *p < 0.05 versus 2 µg/ml at the same 
time-point; 
+
p < 0.05 versus the same concentration at 1 h (Bonferroni’s post-tests). 
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Table 1. Semi-quantitative analysis of the extent of Sphero MP uptake by 
oligodendrocytes. 
Incubation 
time (h) 
MP concentration 
(µg Sphero/ml) 
Level of particle accumulation in MP-labelled 
oligodendrocytes (%) 
‘Low’ ‘Medium’ ‘High’ 
1 2 100.0 0.0 0.0 
5 100.0 0.0 0.0 
20 100.0 0.0 0.0 
50 100.0 0.0 0.0 
4 2 100.0 0.0 0.0 
5 96.2 ± 4.4 3.8 ± 4.4  0.0 
20 93.5 ± 0.4 6.5 ± 0.4 0.0 
50 85.1 ± 3.6
†
 14.9 ± 3.6
**
 0.0 
24 2 98.2 ± 2.1 1.8 ± 2.1 0.0 
5 95.0 ± 5.8 5.0 ± 5.8 0.0 
20 91.6 ± 5.6 8.4 ± 5.6 0.0 
50 86.0 ± 5.4 12.8 ± 5.5
*
 1.2 ± 1.0 
*
p < 0.05, 
**
p < 0.01, versus same concentration at 1 h; 
†
p < 0.05, versus 2 µg/ml at the 
same time-point (Bonferroni’s post-tests); n = 4. 
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4.3.3 Sphero MPs are not acutely toxic to oligodendrocytes 
At all concentrations and incubation times tested, no significant effects of Sphero 
MPs were observed in oligodendrocyte cultures with respect to (a) cell adherence, as 
judged by the number of DAPI-labelled nuclei (either healthy or pyknotic) per microscopic 
field (concentration: F4,45 = 0.913, ns; time: F4,45 = 0.569, ns; two-way ANOVA; n = 4; 
Figure 4a), and (b) cell death, as judged by the percentage of cells exhibiting pyknotic 
nuclei (i.e. shrunken or fragmenting morphologies; concentration: F4,45 = 0.598, ns; time: 
F4,45 = 0.751, ns; two-way ANOVA; n = 4; Figure 4b). For all concentrations and 
incubation times, oligodendrocyte cultures appeared morphologically similar to controls at 
24 h.  
 
Figure 4: Incubation of oligodendrocytes with Sphero MPs at a range of 
concentrations does not result in acute cytotoxicity. Bar graphs of oligodendrocyte time 
course experiments showing (a) total (healthy plus pyknotic) nuclei per microscopic field, 
and (b) percentage of nuclei with pyknotic features. No significant differences were found 
in these parameters either in relation to particle incubation time or particle concentration 
(n = 4). 
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4.3.4 OPCs are more readily labelled with MPs and show larger MP accumulations 
than oligodendrocytes 
A comparison (two-way ANOVA) of the percentage of MP-labelled OPCs with 
MP-labelled oligodendrocytes showed a cell type-dependent effect at 4 h (F1,24 = 23.5; p < 
0.001) and 24 h (F1,24 = 7.6; p < 0.05), and a concentration-dependent effect at 1 h (F3,24 = 
64.7; p < 0.001), 4 h (F3,24 = 31.8; p < 0.001) and 24 h (F3,24 = 26.9; p < 0.001; n = 4 
cultures; Figure 5a shows 4 h data). Similar statistical comparisons of the percentage of 
OPCs and oligodendrocytes exhibiting ‘medium’-to-‘high’ levels of MP accumulation 
showed both cell type-dependent (1 h: F1,24 = 28.8, p < 0.001; 4 h: F1,24 = 4.30, p < 0.05) 
and concentration-dependent (1 h: F3,24 = 28.8, p < 0.001; 4 h: F3,24 = 12.4, p < 0.001; 24 h: 
F3,24 = 8.72, p < 0.001) effects (n = 4; Figure 5b shows 4 h data). Also, for cells scored as 
demonstrating ‘low’ levels of uptake, MP accumulations were typically larger in OPCs 
than in oligodendrocytes (compare Figure 2 in this chapter with Figure 6b in section 2.3.4, 
which both show typical levels of MP accumulation, and also see the direct fluorescence 
and electron microscopy comparisons in sections 5.1 and 5.3.6). Furthermore, in both OPC 
and oligodendrocyte cultures, cells at more advanced stages of oligodendrocyte 
differentiation (as judged by number and complexity of processes), contained smaller 
accumulations of particles than cells with relatively immature and less branched 
morphologies. This suggests an inverse relationship between the extent of differentiation 
and capacity for MP uptake in oligodendroglial lineage cells.  
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Figure 5: OPCs exhibit a greater percentage of labelled cells than oligodendrocytes. 
Bar graphs illustrating (a) the percentage of MP-labelled OPCs and oligodendrocytes and 
(b) the percentage of OPCs and oligodendrocytes exhibiting ‘medium’-to-‘high’ MP 
accumulations following 4 h incubation with various concentrations of Sphero particles. 
Note that a greater percentage of OPCs are labelled than oligodendrocytes at all data-
points (*p < 0.05, **p < 0.01; Bonferroni’s post tests; n = 4). 
4.3.5 MP-mediated transfection of oligodendrocytes: A safe magnetofection protocol 
has been developed 
No toxicity was apparent with a 0.1x Neuromag-plasmid dose, under any magnetic 
field condition, as the percentage of cells which were MBP
+
 (MPs: F1,14 = 1.76, ns; field: 
F3,14 = 0.297, ns; two-way ANOVA; n = 4; Figure 6a), the total healthy nuclei per 
microscopic field (MPs: F1,16 = 0.116, ns; field: F3,16 = 0.149, ns; two-way ANOVA; n = 4; 
Figure 6b) and the percentage of nuclei exhibiting pyknosis did not significantly differ 
from control cultures (MPs: F1,16 = 0.0331, ns; field: F3,16 = 0.431, ns; two-way ANOVA; 
n = 4; Figure 6c). 
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Figure 6: The magnetofection protocols developed for OPCs are also safe for 
oligodendrocytes. OPC cultures were maintained in Sato medium for 12 days to produce 
oligodendrocyte cultures, then transfected (0.1x) and fixed at 48 h post-transfection. (a) 
Bar graph indicating the percentage of cells staining for the late-stage oligodendrocyte 
marker MBP for all field conditions tested. (b) Bar graph showing average healthy plus 
pyknotic nuclei per microscopic field in oligodendrocyte cultures for all fields tested. (c) 
Bar graph illustrating the percentage of all nuclei that were pyknotic, as judged by DAPI 
staining. Note that all treatment conditions are similar to controls for all parameters. n =3 
for all graphs. 
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4.3.6 Oligodendrocytes are amenable to MP-mediated gene delivery, which is 
enhanced by magnetofection 
Transfected oligodendrocytes (GFP
+
/MBP
+
) were observed in oligodendrocyte 
cultures (Figure 7a). The extent of MBP expression in GFP
+
 cells ranged from strong 
expression that matched the extent of GFP expression throughout the cell, to faint 
expression limited to patches of the cell (Figure 7b-d). Some GFP
+
/MBP
-
 cells were 
observed and these cells showed morphologies typical of earlier stages of the 
oligodendroglial lineage. All stages of the oligodendrocyte lineage were observed to have 
been transfected, including those with a small number of branches and those with highly 
branched complex morphologies (Figure 7a-d). Compared with basal conditions (no 
magnetic field; transfection efficiency = 1.9 ± 0.1%), application of a static or 4 Hz 
oscillating magnetic field increased transfection efficiency between two- and three-fold to 
4.9 ± 1.1% (F = 0 Hz) and 6.3 ± 0.6% (F = 4 Hz; Figure 8). Although there was a trend 
towards higher transfection levels at F = 4 Hz, this was not statistically significantly 
compared with the F = 0 or 1 Hz conditions. 
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Figure 7: MP-mediated gene delivery to oligodendrocytes. Fluorescence micrographs 
of oligodendrocyte cultures 48 h post-magnetofection (0.1x; F = 4 Hz). (a) 
Oligodendrocyte culture containing cells with various oligodendroglial morphologies, 
including the highly branched morphology typical of oligodendrocytes (arrow), with most 
cells staining for MBP. Note that GFP expression is present throughout the cell body and 
processes of magnetofected cells. (b) Several GFP
+
 cells are shown in an oligodendrocyte 
culture, at various stages of differentiation as judged by bipolar/multipolar status and 
number of processes. (c) Counterpart fluorescence micrograph to (b) showing MBP 
expression. (d) Merged image of (b) and (c) showing one GFP
+
 cell with clear MBP 
expression throughout the cell (red arrow), two GFP
+
 cells with faint MBP expression 
(white arrows indicate regions of MBP expression), and a GFP
+
/MBP
-
 cell. Note also two 
MBP
+
/GFP
-
 cells.  
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Figure 8: Static and oscillating magnetofection enhances MP-mediated gene delivery 
to oligodendrocytes. Bar graph illustrating transfection efficiencies achieved in 
oligodendrocyte cultures, for all field conditions tested, as judged by the percentage of 
MBP
+
 cells expressing GFP. Analysis by one-way ANOVA indicated a field-dependent 
effect (F3,8 = 10.7; p < 0.01; n = 3). The F = 0 and 4 Hz magnetic field conditions 
significantly enhanced transfection levels compared to the no field condition (*p < 0.05, 
**p < 0.01; Bonferroni’s post-tests).  
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4.3.7 Oligodendrocytes are less amenable than OPCs to MP-mediated transfection 
For all field conditions tested, oligodendrocytes exhibited lower transfection 
efficiency than OPCs, although this was not shown to be significant for the no field 
condition (Figure 9). For each field condition, OPC transfection efficiency was typically 
three-fold greater than oligodendrocyte transfection efficiency (Figure 9). 
 
 
Figure 9: Oligodendrocytes are less amenable than OPCs to magnetofection. Bar 
graph illustrating comparative MP-mediated transfection efficiencies achieved in OPCs 
and oligodendrocytes, under all magnetic field conditions tested. Analysis by two-way 
ANOVA indicated a cell type- (F1,24 = 82.0; p < 0.001) and a field-dependent effect (F3,24 = 
14.5; p < 0.001). **p < 0.01, ***p < 0.001; Bonferroni’s post tests; n ≥ 3. 
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4.4 Discussion 
This is the first comparative analysis of MP-mediated cell labelling and transfection 
between OPCs and mature oligodendrocytes, and, indeed, the first to address intralineage 
differences in MP-cell interactions in any cell type. Sphero MPs were taken up by 
oligodendrocytes in a time- and concentration-dependent manner, without acute toxicity 
(in agreement with OPC data), but the rate and extent of uptake was more limited than that 
found in OPCs. It has also been shown for the first time that Neuromag:plasmid complexes 
successfully transfected oligodendrocytes, with efficiency enhanced by both static and 
oscillating magnetofection techniques, in broad agreement with findings in OPCs. 
However, transfection levels achieved were significantly lower than those in OPCs.  
The fundamental biological question of how alterations in biological properties of 
cells during differentiation may influence their interactions with synthetic materials, has 
never previously been addressed. By exploiting the simple technique of plating sister 
cultures in different media to promote either proliferation or differentiation of OPCs, two 
different cell types from the same lineage can be derived. Although from the same lineage, 
OPCs and oligodendrocytes are recognised as distinct cell types due to the dramatic 
alterations that take place during the maturation process.
9
 The elegant culture model 
employed here therefore allows the robust dissection of the influence of biological 
parameters such as proliferation/differentiation status that may govern neural cell-
nanomaterial interactions (and consequently, successful nanomaterial uptake/transfection 
in neural cells), whilst excluding differences in cell behaviour which may be inherent to 
the different lineages of the cell types in question (e.g. comparing astrocyte behaviour with 
microglial behaviour).  
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4.4.1 MP-based transfection and effects of magnetofection strategies in 
oligodendrocytes 
Use of a range of magnetofection conditions showed that the application of 
magnetic fields (F = 0 and 4 Hz) could enhance transfection efficiency over the no field 
condition. However transfection levels achieved using these protocols were considerably 
lower than that obtained using some other nonviral methods (Table 2). This comparison 
shows that, so far, the gene gun has demonstrated the greatest transfection efficiency in 
oligodendrocytes in vitro. This method may therefore remain the technique of choice for 
oligodendrocyte transfection. However, the safety and simplicity of the magnetofection 
protocol developed here highlights the need for detailed investigation into strategies to 
further enhance MP-based transfection and magnetofection approaches in oligodendrocytes 
(for example, by testing a range of transfection grade MPs, varying magnetofection 
conditions such as different oscillating frequencies applied at a range of amplitudes, or by 
utilising different magnetofection protocols such as the 'magneto-multifection' protocol as 
described by Pickard et al.,
163
 which employs repeated magnetofection procedures).  
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Table 2: Comparative in vitro transfection efficiencies in rat oligodendrocytes 
(derived from primary sources) for viral and nonviral vectors.  
Method  Transgene Source of cells Efficiency Toxicity Ref 
Viral methods 
Retrovirus  lacZ P15 – 20 <0.1% Data not reported 
111
 
Retrovirus (MoMuLV)  lacZ P28 – 42 0% Data not reported 
108
 
Nonviral methods 
Gene gun (gold 
particles) 
lacZ P15 – 20 20% Data not reported 
111
 
Lipofection  lacZ P15 – 20 10% Data not reported 
111
 
Lipofection  lacZ P28 – 42 0% Data not reported 
108
 
Magnetofection 
(magnetic particles)  
gfp P1 – 3 6% 
Not significant at 
established dose 
* 
Calcium phosphate 
precipitation  
lacZ P28 – 42 <3% 90% cell death 
108
 
Calcium phosphate 
precipitation  
lacZ P15 – 20 <2% “Most cells died” 
111
 
Electroporation  lacZ P28 – 42 
Data not 
reported 
“Drastic” cell death 
108
 
MoMuLV = Moloney murine leukaemia virus; lacZ = β-Galactosidase; P# = postnatal day #; gfp = green 
fluorescent protein; *Reported here.  
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4.4.2 Intercellular differences in MP uptake and MP-mediated transfection 
The observation that it was possible to label a greater percentage of OPCs than 
oligodendrocytes, with marked differences between the cell types with respect to MP 
accumulation, suggests that as OPCs differentiate into oligodendrocytes the rate of MP 
uptake may diminish. It is not clear whether the larger accumulations of MPs seen in OPCs 
were taken up in a single endocytotic event, or formed inside the cell following uptake of 
MPs in several events. Oligodendrocytes typically display small MP accumulations, often 
potentially a single particle (as judged by measurements in fluorescence and electron 
micrographs; data to be shown in section 5.3.6), suggesting that these cells may not be able 
to endocytose several MPs in a single endocytotic event. Detailed comparisons of the 
surface interactions of OPCs and oligodendrocytes with synthetic particles (for example 
using the OTOTO methodology described in section 2.3.9) would be useful in elucidating 
such issues.  
Mature MBP
+
 oligodendrocytes proved to be far less amenable to MP-mediated 
transfection than A2B5
+
 OPCs, even under a variety of magnetofection conditions. This 
reduction in transfection efficiency is consistent with studies using various protocols that 
suggest that post-mitotic cells are typically less readily transfected than mitotic 
populations.
178,179
 Indeed, for other gene delivery techniques, both viral and nonviral, 
OPCs are typically more amenable than oligodendrocytes, demonstrating that there are 
cell-intrinsic differences with respect to the capacity for transfection/transduction. In this 
context, it should be noted that the task of determining the underlying causes for 
differences in transfection capability is complicated by the diversity of approaches 
employed with oligodendroglial cells (Table 2), which exploit different mechanisms of 
gene delivery. Data derived from cell lines are of little value for discerning differences 
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between OPCs and oligodendrocytes, as the ‘true’ differentiation status of such cells is at 
best difficult to ascertain, and it may not be possible to categorise such cells as either OPCs 
or oligodendrocytes due to their contradictory morphological, behavioural or antigenic 
profiles. For example, the OLN-93 cell line is proliferative and described as 
morphologically resembling bipolar OPCs, yet these cells stain A2B5
-
/MBP
+
.
244
 It is not 
clear how such cell lines should be categorised within the oligodendroglial lineage, and 
therefore transfection data obtained using cell lines will be excluded from the following 
discussion. 
 
4.4.3 Underlying reasons for differences in MP uptake and MP-mediated 
transfection efficiency 
A number of speculations can be made as to the underlying reasons for the 
differences in MP-handling observed between OPCs and oligodendrocytes, and these have 
been summarised in Figure 10. First, it is not clear which regions of membrane (i.e. what 
proportion/which regions of the cell body and/or cellular processes) are capable of 
endocytosis. For both OPCs and oligodendrocytes, Sphero particle uptake appears to be 
restricted to the cell body, as although particles were sometimes observed in association 
with cellular processes, particularly the extensive oligodendrocyte processes, these MPs 
were never deemed to be intracellular under either confocal or TEM analysis. This 
suggests that the total membrane elaborated by the cell is not necessarily reflective of the 
capacity for particle uptake, as more limited particle uptake was observed in 
oligodendrocytes than in OPCs, suggesting that a only a small proportion of the 
oligodendrocyte membrane is capable of endocytosis. 
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Figure 10: Schematic summary of the potential factors underlying the differences in 
MP uptake and amenability to transfection in OPCs versus oligodendrocytes. 
Representative fluorescence micrographs are included of GFP
+
 OPCs and a GFP
+
 
oligodendrocyte, in order to highlight the morphological differences between the two cell 
types. The OPCs display typical morphologies with few processes and a nucleus occupying 
a large proportion of the small oval cell body. GFP
+
 OPCs were frequently observed in 
pairs, indicative of recent mitosis (inset). Note that the oligodendrocyte has a similar sized 
nucleus to OPCs, but a larger cell body and substantially more membrane elaborations. 
Although less amenable to transfection than OPCs, even mature oligodendrocytes could be 
transfected, as indicated by the complex highly-branched morphology of the transfected 
cell shown here. 
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A second parameter is the particular combination of endocytotic mechanisms 
employed by each cell type. During differentiation, the capacity to use an individual 
endocytotic mechanism may be lost or gained, and such a change in endocytotic profile 
could significantly affect MP uptake dynamics. Even if both cell types exhibit the same 
endocytotic processes, the basal rates of each endocytotic process may differ between 
OPCs and oligodendrocytes. For example, based on the observation that neuronal signals 
can up-regulate oligodendrocyte endocytosis of PLP,
325
 Kippert et al. cultured the 
oligodendroglial cell line Oli-neu with and without neuronal conditioned medium and 
assessed endocytotic activity.
322
 The authors demonstrated a reduction in the rate of 
macropinocytosis in Oli-neu cells in neuronal conditioned medium, but reductions in other 
endocytotic mechanisms were not detected. This suggests that in vivo, as cells commit to 
oligodendrocyte differentiation and interact with neurons, they will experience a reduction 
in macropinocytotic activity, in line with reports from other physiological systems of the 
downregulation of endocytotic activity during differentiation.
22
 Such a reduction in 
macropinocytosis could potentially explain the smaller MP accumulations observed in 
oligodendrocytes compared to OPCs reported here.  
However, the reduction in transfection efficiency observed in oligodendrocytes 
(typically a three-fold difference) is more dramatic than might be predicted by a simple 
comparison of the percentage of MP-labelled cells (typically less than a two-fold 
difference) and may be further related to the smaller accumulations of Sphero MPs 
(particularly that of perinuclear MPs) in oligodendrocytes compared to OPCs. This 
suggests that a greater plasmid copy number may be present in OPCs, although other 
contributory factors may include differing tendencies between the cell types for vacuolar 
localisation of MP:plasmid complexes, potential degradation of the complexes, or damage 
to the nucleic acid cargo (e.g. by nucleases). One indication that developmental changes 
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occurring during the maturation of oligodendroglial cells may impact on their intrinsic 
amenability to plasmid based transfection is provided by a microarray comparison of gene 
expression between immature and mature oligodendrocytes. Findings from this study 
showed that of the genes exhibiting two-fold or greater differences between the cell types 
in levels of expression, 5% of 341 genes in immature oligodendrocytes and <0.5% of 368 
genes in mature oligodendrocytes, were related to nuclear trafficking.
326
 If such difference 
in gene expression manifest as a reduction in nuclear transport activity, then this in turn 
could limit nuclear delivery of plasmids in oligodendrocytes, limiting transfection 
efficiency.  
The lower transfection efficiency observed in oligodendrocytes compared to OPCs 
may also be speculated to be related, at least in part, to their mitotic status. Proliferating 
cells such as OPCs have larger nuclear channels and undergo breakdown of the nuclear 
envelope during mitosis, readily permitting access of exogenous (but intracellular) DNA 
into the nucleus.
176
 By comparison, the oligodendrocytes (a major post-mitotic population) 
may therefore be relatively refractory to transfection. In support of the nuclear breakdown 
hypothesis, GFP expression is consistently found in cells that appear to have recently 
undergone mitosis. However, an earlier study in primary human fibroblasts has suggested 
that for virus-independent transfection methods, a round of cell division (with dissolution 
of the nuclear membrane) is not a pre-requisite for DNA to enter the nucleus.
327
 Indeed, it 
has been shown here that complex, highly processed, post-mitotic cells can be transfected 
using MPs. Therefore the relationship between cell proliferation, nuclear breakdown and 
the extent of transfection in oligodendroglial cells is currently unresolved.  
Finally, the size of MPs used here may affect both uptake and intracellular 
processing. For example, the smaller MP accumulations observed in oligodendrocytes 
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compared to OPCs may suggest that the endocytotic size limit is lower in 
oligodendrocytes, possibly restricting uptake to single Sphero particles, whereas small 
clusters of MPs were frequently observed associated with OPC membrane and 
intracellularly, suggesting that these cells may be able to endocytose larger numbers of 
particles per endocytotic event than oligodendrocytes. In turn, this may be related to the 
specific uptake mechanism used. For example, OPCs may use both macro- and micro-
pinocytosis, but oligodendrocytes may only employ micropinocytosis. It should be noted 
that macropinocytosis is more likely to result in transfection than is clathrin-mediated 
endocytosis.
240
 Systematic analyses of oligodendrocyte handling of different MPs and the 
related uptake mechanisms will be required to determine whether the differences between 
OPCs and oligodednrocytes are indeed due to differences in macropinocytotic activity. 
This, in turn, will inform the development of MPs suitable for engineering oligodendroglial 
lineage cells. 
 
4.4.4 Conclusions and future directions 
Within the oligodendroglial lineage, the differentiation status of the cells influences 
both the capacity for MP uptake and the amenability to MP-mediated transfection. These 
findings have broader implications for the translation of OPC transplantation therapies as 
they suggest the major need to maintain transplant populations at an early, precursor form 
of the oligodendroglial lineage in order to effectively label or transfect cells using MPs. 
The presence of 'contaminants' in the form of more differentiated phenotypes can be 
predicted to reduce the overall efficiency of MP-based applications. Whilst a number of 
potential causative factors have been suggested here in order to explain the differences 
between precursor and differentiated cell forms, our knowledge of the reasons governing 
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such findings is currently limited and warrants detailed investigation. Such information 
will allow for the identification of key parameters that support or limit MP applications in 
neural cells, providing possibilities for the enhancement of such applications for neural 
tissue engineering. Ideally such research will employ particles possessing a wide range of 
physico-chemical properties in combination with cell biology and ultrastructural methods 
and genomic/proteomic analysis, to evaluate interactions at the particle-cell interface, and 
to elucidate intracellular trafficking mechanisms, including the fate of internalised particles 
and plasmids.  
This is the first report to study intralineage differences in particle uptake and gene 
delivery potential, and the next chapter will build on this comparative analysis by 
performing a global, cross-cellular comparison of MP-handling across the four major CNS 
glial cell types.
c
 
  
                                                 
c
 The data relating to oligodendrocyte transfection, and the comparative analysis of OPC and oligodendrocyte 
transfection have been published. The article is reproduced here as appendix 5. 
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Chapter 5: Differences in MP-handling by 
CNS glial subclasses: Competitive MP 
uptake in glial co-cultures 
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5.1 Introductiond 
The preceding chapters have studied MP interactions with cells derived from a 
single neural (oligodendroglial) cell lineage, viz. the OPCs and their progeny the 
oligodendrocytes. These studies revealed differences between these cell types in terms of 
MP handling, including differences in the accumulation of intracellular MPs (section 4.3.4) 
and marked differences in amenability to transfection (section 4.3.7). Having shown that 
intralineage differences exist, it is important to address the wider issue regarding the 
differences in MP-handling between oligodendroglia and the other major glial lineages of 
the CNS, namely the microglia and astrocytes. Each of these cell types has unique 
structural, functional and molecular properties related to their specific roles, and can 
therefore be predicted to show important differences in their uptake and handling of 
synthetic materials. For example, microglia have a haematopoietic origin, arising from 
uncommitted myeloid progenitors that infiltrate the CNS during development.
328
 Microglia 
are located throughout the CNS parenchyma, and they are the primary CNS phagocytes.
328
 
Even in a ‘resting’ ramified state, microglia constantly monitor their environment with 
                                                 
d
 Note: In this chapter, data on MP uptake and toxicity in OPCs and oligodendrocytes 
(from Chapters 2 and 4) have been collated with previously published data derived from 
astrocyte
240
 (article reproduced as appendix 6) and microglial
241
 cultures that were 
obtained using the same MP formulation (Sphero) and identical treatment conditions 
(methodology detailed in Appendix 2, section 2.2 and section 5.2). Pooling of the data in 
this manner has allowed, here, for a systematic cross-cellular comparison of MP uptake by 
the four major neuroglial subpopulations of the CNS. Based on this cross-cellular analysis, 
a hypothesis has been developed regarding particle handling in mixed glial populations; 
testing of this hypothesis is the main focus of this chapter. 
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highly motile processes, phagocytosing or endocytosing nutrients, debris and 
damaged/dying cells; microglia exhibit all endocytotic mechanisms.
241,329
 Following CNS 
insults, these cells become activated, proliferate, migrate to lesion sites, and secrete several 
cytokines/immunomodulatory factors.
330
  
Astrocytes perform a variety of functions in the CNS, chiefly the maintenance of 
homeostasis.
331,332
 They are a major constituent of the BBB, regulate ionic fluxes in the 
extracellular milieu, recycle neurotransmitters, and are involved in the function of virtually 
all synapses.
328
 Astrocytes also supply metabolites to neurons and are highly active in the 
secretion of various signalling molecules, including trophic factors.
328
 Given these 
functions, astrocytes are highly endocytotically active, and exhibit all of the main 
mechanisms, including phagocytosis.
191,333
 The roles of OPCs and oligodendrocytes in 
myelin genesis have been discussed in detail in sections 1.2 and 1.3. No information is 
available regarding endocytotic mechanisms in primary OPCs, and most oligodendrocyte 
studies focus on the role of endocytosis in the cycling of membrane/myelin proteins, rather 
than uptake of extracellular molecules.
322,325
 
Together, these neuroglial populations form an extensive cellular network in the 
CNS and outnumber neurons by a factor of approximately ten,
334,335
 consequently it can be 
predicted that elucidating the mechanisms of particle handling by this major class of cells 
will be a critical component in understanding interactions between biomaterials and the 
CNS as a whole. Such knowledge will be vital for the development of MP-based neural 
engineering tools for use in vivo and in vitro. Despite this, there are few reports in the 
literature of MP handling by glial cells, and many of these relate to either cell lines, which 
may not be representative of in vivo behaviour (see section 1.10), or poorly characterised 
co-cultures,
222
 in which case it can be difficult to delineate the intrinsic behaviours of 
individual cell types. 
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This laboratory has reported Sphero MP uptake dynamics in astrocytes
240
 and 
microglia.
241
 By collating these published data with similar analyses for OPCs and 
oligodendrocytes, reported for the first time in this thesis, information relating to Sphero 
MP uptake are now available for all four major CNS glial cell types, allowing for 
comparative MP uptake dynamics and MP-related toxicity in these cells to be described 
(statistical methods detailed in Appendix 2). Major findings from these analyses are: (i) In 
time-course experiments, cultures fixed and stained after 1 h incubation (20 µg/ml) showed 
rapid labelling of microglia (96.9 ± 1.0%), and markedly fewer labelled cells in astrocyte 
(30.4 ± 10.1%), OPC (16.6 ± 1.2%) and oligodendrocyte (16.8 ± 0.8%) cultures. (ii) The 
extent of accumulation also differed greatly between the glial cell types at 1 h, with 79.5 ± 
4.4% of all microglia exhibiting ‘medium’-to-‘high’ levels of MP accumulation, compared 
to 10.3 ± 4.4% of all astrocytes, while no OPCs or oligodendrocytes exhibited ‘medium’ or 
‘high’ levels of uptake at this time-point. Marked differences in particle accumulation were 
also evident at 24 h, with heterogeneity evident in the extent of MP accumulation within 
individual, non-microglial cells (Figure 1a-d shows typical examples of MP accumulation 
by the different glial subtypes). (iii) Comparing the extent of MP uptake at 4 h highlights 
the rapid labelling of >88% of microglia, even with the lowest MP concentrations tested, 
compared to the gradual time- and concentration-dependent uptake observed in the other 
cell types (Figure 2a). Within this time frame and with the maximum MP concentration 
used, 85 – 100% of microglia and astrocytes could be labelled with MPs, but in contrast, 
an average of 40% of OPCs and 27% of oligodendrocytes could be labelled (Figure 2a). 
(iv) Following 24 h MP exposure, toxicity was not observed in OPCs, oligodendrocytes, or 
astrocytes but was marked in microglial cultures at an identical applied MP concentration 
(Figure 2b). (v) Perinuclear localization of particles was observed in all the cell types, but 
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with marked differences in the proportions of cells containing MPs in the perinuclear 
region (Figure 2c). 
 
Figure 1: Characteristic MP uptake profiles of glial cell types. Fluorescence 
micrographs of glia (high purity microglial, astrocyte and OPC cultures, and an enriched 
oligodendrocyte culture) following incubation with Sphero MPs (20 µg/ml, 24 h). (a) 
Microglia stain for the marker lectin and exhibit high levels of MP uptake, with large 
perinuclear accumulations. (b) Astrocytes stain for the marker GFAP and exhibit 
heterogeneity in the extent of MP uptake. Note flattened cells, large quantities of 
membrane relative to nucleus in cross-section, and greater extent of uptake compared to 
(c) and (d). (c) OPCs stain positive for the marker A2B5, and exhibit typically small 
clusters of MPs compared to (a) and (b). Note bipolar forms and potentially limited 
quantity of membrane available to undertake endocytosis. (d) Oligodendrocyte stained 
with MBP, and exhibiting a highly branched, mature morphology. Very small 
accumulations of MPs are present (white arrows, and enlarged in inset). Despite extensive 
membrane elaboration, MPs are mainly extracellular.  
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Figure 2: The extent and rate of glial MP uptake are cell type-specific. (a) Bar graph 
comparing Sphero-labelling of each glial cell type (4 h). Note the rapid microglial uptake 
compared to the other cell types. The percentage of cells labelled was cell type- (F3,40 = 310; p < 
0.001) and concentration-dependent (F3,40 = 44.8; p < 0.001; two-way ANOVA with Bonferroni’s 
post-tests; lines on graph indicate p < 0.05). (b) Bar graph comparing MP-related toxicity in 
neuroglial cells (24 h, 20 µg/ml; *p < 0.05). (c) Bar graph showing the percentage of all cells 
exhibiting perinuclear MPs (50 µg/ml). Note the rapid perinuclear accumulation in virtually all 
microglia, compared to the gradual accumulation in the other glial cell types. The percentage of 
cells with perinuclear MPs was cell type- (F3,30 = 171; p < 0.001) and time-dependent (F2,30 = 
32.8; p < 0.001; two-way ANOVA with Bonferroni’s post-tests; lines on graph indicate p < 0.05). 
ODC = MBP
+
 cells in enriched oligodendrocyte cultures; OPC = A2B5
+
 cells in high purity OPC 
cultures; Astro = GFAP
+
 cells in high purity astrocyte cultures; Micro = OX42
+
 cells in high 
purity microglial cultures. For all graphs, n = 4 for OPCs and oligodendrocytes; for astrocytes 
and microglia, n = 3 for (a) and (c), n = 5 for (b). 
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5.1.1 Knowledge gap: Do microglial cells exhibit competitive uptake dynamics in 
relation to other neuroglial subtypes? 
The cross-cellular comparison of MP uptake above reveals clear differences 
between individual glial classes in the rate and extent of MP accumulation, with the 
relationship with respect to these parameters being: microglia > astrocytes > OPCs > 
oligodendrocytes. The rapidity and avidity of particle accumulation by microglia suggests 
that these cells could exhibit competitive uptake in the presence of other glial cells thereby 
constituting an ‘extracellular barrier’ to MP uptake in the other cell types, a phenomenon 
that will have major implications for the use of the MP platform within mixed neural cell 
populations for neuroengineering applications. Therefore, a mixed glial system will be 
developed here to test the prediction that microglia will outcompete other glial cell types in 
terms of particle uptake when these cells are co-cultured. The basic premise of this system 
is that the presence of substantial numbers of microglia will limit MP uptake by a second 
cell type, in a two-glial-cell-type co-culture. 
Current mixed cell type culture models have significant drawbacks, notably high 
variability in the cell source (for example combined use of cell lines with primary cells, or 
CNS with peripheral nervous system cells) limiting the utility of these studies, and 
therefore an appropriate co-culture technique is required, in order to test these competitive 
uptake predictions. A defined glial co-culture system, with all cells being derived in 
parallel from a single primary cell source, will reduce such variability, yielding more 
reliable data in relation to intrinsic differences in MP uptake by neuroglial subpopulations. 
While such an approach could also be attempted in organotypic slice cultures, less control 
can be brought to bear on the precise stoichiometry of cells present and this will therefore 
limit a robust quantification of relative MP uptake by individual cell types.  
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A further observation made from the cross cellular comparison is that incubation 
with MPs at 20 µg/ml for 24 h resulted in significant toxicity in microglial cultures but not 
in the other cell types (Figure 2b). The underlying basis for this difference is unknown, 
and, in general, the mechanisms of intracellular processing of MPs across neuroglial 
subtypes are unclear. These considerations have therefore prompted a cross cellular TEM 
analysis of MP uptake and stability in individual neuroglial subpopulations, with the aim of 
taking the first step towards elucidating particle fate within these cells, to provide a 
mechanistic basis for the observed toxicity.  
 
5.1.2 Objectives 
i. To develop a glial co-culture system to test the hypothesis that microglia act as 
an 'extracellular barrier' to MP uptake in other neuroglial subtypes. The model 
will be used to specifically test whether co-culture with microglia limits the 
extent of MP uptake by OPCs and astrocytes. 
 
ii. To conduct a cross-cellular transmission electron microscopical analysis of MP 
stability and fate within neuroglial subpopulations, to attempt to discern the 
underlying reasons for inter-cellular differences in particle-related toxicity.   
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5.2 Materials and Methods 
Reagents and equipment: Trypsin, biotin-conjugated lectin (from Lycopersicon 
esculentum, tomato), monoclonal anti-biotin FITC-conjugated secondary antibody (clone 
BN-34) were from Sigma (Poole, Dorset, UK). 
Sphero and Neuromag particles: These are described in sections 2.2 and 3.2, 
respectively. 
Dynamic light scattering (DLS) and zeta-potential of Sphero MPs: In order to 
prove that differences in MP uptake are due to cell intrinsic biological differences in 
neuroglia, it is important to rule out the effects on cellular MP uptake of different culture 
media,and the potential for particle aggregation with time. To evaluate the effects of the 
culture medium on particle size and charge, measurements of hydrodynamic diameter and 
zeta potential were made using a Malvern Zetasizer Nano ZS. Particles were added to 
various biological media: deionised water, D10, OPC-MM and Sato. Media were incubated 
(37°C, 5% CO2/95% humidified air) before analysis, to ensure measurements were made at 
the same pH as that at which cells were cultured. 
OPC cultures: OPC cultures were derived from primary mixed glial cultures as 
described in section 2.2. 
Development of the co-culture models: The development of the co-culture system 
requires that different cell types are cultured in the same medium. OPCs are usually 
cultured in a chemically-defined medium (OPC-MM), but in pilot experiments microglia 
and astrocytes did not tolerate this medium. When OPCs were cultured in the D10 medium 
used for microglia and astrocytes, most cells began to differentiate within 24 h, including 
differentiation into type 2 astrocytes, which stain for GFAP and are considered an artefact 
of in vitro culture.
336
 All three cell types can be cultured together in D10 in the primary 
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mixed glial cultures from which they are derived, with astrocyte-derived factors preventing 
OPC differentiation. Therefore, a co-culture medium was developed consisting of D10 
medium supplemented with 20% conditioned medium from primary mixed glial cultures, 
which was sterile filtered (D10-CM). Under these conditions, OPCs largely retained their 
bipolar morphologies and few type 2 astrocytes were observed (~1%). 
Furthermore, it was important to ensure that each of the cell types required for a co-
culture was ready for plating within a short period of time, to ensure that the highly 
proliferative astrocytes did not significantly alter their plating density and/or reach 
confluence, at which point their behavior might be altered. Therefore, mixed glial cultures 
were prepared as described in section 2.2, but flasks were plated at differing densities, such 
that they would reach confluence at different rates (Figure 3). OPCs were plated on PDL-
coated coverslips in 24-well culture plates (0.3 ml D10-CM; 4 x 10
5
 cells/ml for OPC 
cultures, 2 x 10
5
 cells/ml for co-cultures) and cultured for 24 h to allow the cells to attach 
and recover their processes. At this point, astrocyte cultures were trypsinized and plated on 
PDL-coated coverslips in 24-well culture plates (0.3 ml D10-CM; 4 x 10
5
 cells/ml for 
astrocyte cultures, 2 x 10
5
 cells/ml for co-cultures). Microglia were plated on PDL-coated 
coverslips in the same 24-well culture plates in high purity cultures (0.3 ml D10-CM; 4 x 
10
5
 cells/ml) and onto previously prepared OPC and astrocyte cultures to form co-cultures 
(0.3 ml D10-CM, replacing the medium already present; 2 x 10
5
 cells/ml). Microglia attach 
to coverslips rapidly (typically <1 h), at which point uptake or transfection experiments 
could be performed. High purity cultures of OPCs, astrocytes and microglia were studied 
in parallel with the co-cultures.  
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Figure 3: Schematic indicating procedure to produce different glial cell types for co-
cultures. Mixed glial cultures were established at differing initial plating densities such 
that they became confluent at different rates. Astrocytes (Astro), OPCs and microglia 
(Micro) were then derived from these cultures and plated as high purity cultures (100%) 
and at half density for co-cultures (50:50). 
 
Competitive Sphero uptake experiments: Once microglia had adhered to coverslips, 
all cultures were incubated with Sphero particles (20 µg/ml). At 24 h after MP treatment, 
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cultures were washed with PBS, fixed with 4% PFA and immunostained as described in 
section 2.2, using FITC secondary antibodies. Identically treated coverslips were stained 
with A2B5 or lectin for pure OPC and microglial cultures, as well as OPC:microglia 
cocultures. Lectin was found to stain astrocytes, and so for pure astrocyte cultures and for 
astrocyte:microglia cocultures one coverslip was stained for GFAP, and the other was 
unstained. For pure microglial cultures, one coverslip was stained for GFAP, and the 
identically treated counterpart was stained for lectin. 
Fluorescence microscopy and uptake analysis: Stained co-cultures were imaged 
and analysed in identical fashion to that described in section 2.2.  
TEM sample preparation: Cells were plated on polyornithine-coated aclar (0.3 
ml/well, at 6 x 10
4
 cells/cm
2
; OPCs in OPC-MM for 24 h; for oligodendrocytes, OPCs 
were plated in Sato and maintained for 8 d; microglia in D10 for 24 h) then incubated with 
20 µg/ml Sphero MPs for 24 h and processed and imaged in an identical manner to that 
described in section 2.2. Sphero MPs were also processed on polyornithine-coated aclar in 
D10 without cells to study the shape and size of particles alone. 
Statistical analysis: Data were analysed using GraphPad Prism statistical analysis 
software, with statistical tests as detailed in the text. Data are expressed as mean ± SEM. 
The number of experiments (n) refers to the number of mixed glial cultures from which 
OPC cultures were derived, with each primary culture being established from a different 
rat litter. For analysis of MP uptake in co-cultures, unpaired two-tailed t-tests were 
performed for each cell type to compare the following in pure versus co-cultures: (i) the 
percentage of MP-labelled cells, (ii) the percentage of cells showing ‘medium’ levels of 
uptake, and (iii) the percentage of cells showing ‘high’ levels of MP uptake. 
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5.3 Results 
 
5.3.1 Sphero MPs exhibit similar characteristics in different culture media 
The Sphero particles used in all the uptake studies compared here have been 
characterised in sections 2.2 and 2.3. However, the astrocyte and microglial experiments 
involved culturing cells in different media than was used in the isolated 
OPC/oligodendrocyte cultures, therefore further characterisation was performed to address 
the possibility that the particles may adopt different properties once added to these 
different media. Limited differences in hydrodynamic diameter were observed in the three 
culture media used to propagate each of the cell types, suggesting limited aggregation of 
particles immediately after addition to media (Table 1). Comparison of 5 min and 24 h 
measurements in Sato medium showed that a small amount of particle aggregation 
occurred, as the particle size increased by a factor of ca. 2. The mean diameter of these 
particles was shown to be ~360 nm (range 200 – 390 nm) by SEM analysis (section 2.2), 
but the mean hydrodynamic diameter was in the range 843 – 961 nm. These values were 
determined by DLS, a technique that measures the hydrodynamic diameter of the particle 
surrounded by the solvation layers. Measurements by DLS are more accurate for soft 
materials, such as proteins, with the size of more dense materials commonly being 
overestimated.
280,337
 These observations are consistent with the literature relating to 
magnetic particles, where different methods of size-determination can produce conflicting 
data.
139,280
 The zeta potential measurements showed that these particles carry a negative 
charge in all media, attributable to the carboxylic surface groups, with small differences 
observed across the media. As the charge on a particle is pH-dependent, the zeta potential 
would not be expected to vary across these culture media, as all are of similar pH values. 
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Together, these results suggest that MP characteristics do not substantially vary across 
culture conditions, and are not the reason for the observed differences in MP uptake 
between neuroglial subtypes. 
 
 
5.3.2 Characteristics of glial co-cultures: Competitive uptake assays 
High purity OPC cultures were produced, as judged by A2B5 staining (98.3 ± 0.7% 
A2B5
+
; n = 4). Astrocyte cultures largely consisted of cells with the flattened, polygonal 
morphologies typical of type 1 astrocytes, with <1% exhibiting the complex, branching 
morphologies of type 2 astrocytes. These cultures were of high purity, as judged by 
staining for GFAP (98.7 ± 0.8%; n = 3). Microglial cultures were of high purity, as judged 
by staining for the microglial marker lectin (97.9 ± 0.9%; n = 4). Characterisation of co-
cultures of OPCs with microglia by staining duplicate coverslips revealed that both cell 
types were present and in proportions approximating the target 50:50 ratio (A2B5
+
 cells: 
Table 1. Physical characteristics of Sphero MPs in various biological media. 
 Medium  Relevant cell type(s) 
ζ-potential (mV)a dDLS (nm)
a
 
Incubation time: 5 min 5 min 24 h 
H2O - - 843 - 
OPC-MM OPCs -14.6 867 - 
Sato Oligodendrocytes -14.3 850 1650 
D10 Astrocytes; Microglia -13.7 961 - 
dDLS = Hydrodynamic diameter, determined by dynamic light scattering (DLS). 
a
Average 
values of three measurements. 
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55.6 ± 4.5%; lectin
+
 cells: 44.8 ± 5.6%; n = 4 cultures). Characterisation of co-cultures of 
astrocytes with microglia by staining duplicate coverslips revealed that 56.1 ± 2.9% of 
cells were GFAP
+
; n = 3 cultures. However, lectin staining was found to be a non-specific 
microglial marker as it also stained astrocytes. Therefore quantification of microglial 
proportions in the co-cultures was not feasible using immunohistochemical staining, and 
this marker was excluded from further astrocyte-microglia co-culture experiments. 
However, the microglial phenotype could be inferred from (i) a GFAP
-
 staining profile 
associated with the DAPI-stained nuclei, and (ii) the distinct rounded morphologies of 
microglia under phase microscopy, compared with the flattened morphologies of 
astrocytes, enabling a clear distinction to be made between the two cell types for 
quantification of cell-specific MP uptake. 
 
5.3.3 Microglial uptake of MPs is rapid and extensive compared to astrocytes and 
OPCs 
After 90 min incubation, astrocyte and OPC cultures demonstrated an even 
distribution of particles across the culture wells, with few cell-associated aggregations 
(MPs identified by nile red fluorescence, Figure 4a-b & d-e; extracellular MPs were 
identified by agitating the culture plate, causing the particles to move). In stark contrast, 
microglial cultures rapidly showed large accumulations of nile red fluorescence, within 
~100% of cells, readily judged to be within cells by the characteristic perinuclear 
aggregations, which remained static during agitation of the culture plate (Figure 4c-f). 
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Figure 4: Microglial uptake of MPs is far more rapid than OPC or astrocyte uptake. 
Representative phase-contrast images of high purity live OPC (a), astrocyte (b) and 
microglial (c) cultures after 90 min incubation with MPs (Sphero, 20 µg/ml), with 
counterpart fluorescence micrographs, respectively (d), (e) and (f). Astrocytes (flattened 
morphologies) and microglia are indicated with arrows. Sphero MPs, identified by 
fluorescence, are distributed evenly across the OPC and astrocyte culture wells, with few 
labelled cells, but microglia exhibit extensive MP uptake with clear perinuclear 
localisation. As these are live cultures, many particles are suspended in the medium, rather 
than being attached to the substrate/cells, and could be determined as such by gently 
agitating the plate.  
 197 
 
5.3.4 MP uptake by OPCs is dramatically reduced when co-cultured with microglia 
Co-culture of OPCs with microglia resulted in a dramatic reduction in the 
proportion of MP-labelled OPCs, and in the extent of MP accumulation in OPCs, 
compared to high purity OPC cultures (Figure 5). Approximately 75% of OPCs in pure 
cultures were MP-labelled, and over 50% of OPCs demonstrated ‘medium’-to-‘high’ levels 
of MP accumulation (Figure 6). In stark contrast, when co-cultured with microglia there 
was a significant reduction in the percentage of MP-labelled OPCs (to an average of 
approximately 35%), with many regions of the cultures showing no uptake in OPCs 
(Figure 5b-d). Less than 4% of OPCs exhibited ‘medium’ levels of particle accumulation, 
and no OPCs were observed with ‘high’ levels of uptake (Figure 6). In pure microglial 
cultures, ~100% of microglia were MP-labelled, with ~54% showing ‘high’ levels of 
particle accumulation. Approximately 100% of microglia in co-cultures with OPCs were 
also MP-labelled, but with a significant increase in the percentage showing ‘medium’–to-
‘high’ levels of MP accumulation.  
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Figure 5: Reduction in MP uptake by OPCs in the presence of microglia. (a) 
Fluorescence micrograph of a high purity OPC culture (stained for A2B5; <2% microglia) 
demonstrating a high proportion of MP-labelled cells. Arrows indicate OPCs scored as 
having a ‘high’ level of MP accumulation. (b) Fluorescence micrograph of an 
OPC:microglia co-culture (~50% microglia) showing extensive accumulation of MPs in 
DAPI-labelled A2B5
-
 cells (some indicated by arrows), identified as microglia by phase 
contrast microscopy (not shown). Note the almost complete lack of MP-labelling of A2B5
+
 
OPCs. (c) Fluorescence micrograph of an OPC:microglia co-culture (~50% microglia) 
showing extensive accumulation of MPs in cells identified as microglia by lectin staining. 
Note the lack of MP-labelling in DAPI-labelled lectin
-
 cells, identified by phase contrast 
microscopy as OPCs. (d) Phase contrast counterpart to (c). Arrows indicate the same 
OPCs in (c) and (d). All cultures incubated for 24 h at 20 µg Sphero/ml. 
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Figure 6: The proportion of MP-labelled OPCs and the extent of MP accumulation by 
OPCs is markedly reduced in the presence of microglia. Bar graph illustrating the 
percentage of MP-labelled cells and the extent of MP accumulation by OPCs and 
microglia in high purity isolated cultures (left and right hand bars, respectively) and in 
50:50 co-cultures (central bars, OPCs to the left and microglia to the right). When co-
cultured with microglia, the percentage of MP-labelled OPCs was significantly reduced 
(
+++
p < 0.001; n = 4). A greater percentage of OPCs exhibited ‘medium’ (***p < 0.001; n 
= 4) accumulations of MPs in high purity OPC cultures than in co-cultures. A greater 
percentage of microglia exhibited ‘medium’ levels of uptake in high purity microglial 
cultures than in co-cultures (***p < 0.001; n = 4), and a greater percentage of microglia 
exhibited ‘high’ levels of uptake in co-culture than in high purity culture (***p < 0.001; n 
= 4). ~100% OPCs = high purity OPC culture (>98% A2B5
+
); 50:50 co-culture = OPCs 
and microglia in a 50:50 co-culture; ~100% Micro = microglia in a high purity culture 
(~98% lectin
+
). 
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5.3.5 MP uptake by astrocytes is dramatically reduced when co-cultured with 
microglia 
Co-culture of microglia with astrocytes resulted in a marked reduction in the 
proportion of MP-labelled astrocytes, and in the extent of MP accumulation in astrocytes, 
compared to high purity astrocyte cultures (Figure 7). Approximately 100% of cells were 
labelled in pure astrocyte cultures, with ~94% of astrocytes showing ‘medium’ or ‘high’ 
levels of MP accumulation (Figure 8). This is in stark contrast to the restricted astrocyte 
uptake observed in the presence of microglia, where MP-labelling was reduced to ~70% of 
astrocytes, with some regions of the cultures showing near complete abolition of MP 
uptake in astrocytes (illustrative examples are shown in Figure 7b). Less than 30% of 
astrocytes accumulated ‘medium’-to-‘high’ levels of particles; Figure 8). The presence of 
astrocytes did not significantly affect microglial uptake of MPs, with 100% of microglia in 
these co-cultures showing MP-labelling, and ~65% of microglia exhibiting ‘high’ levels of 
MP accumulation. This was comparable to microglial uptake in high purity microglial 
cultures, where ~100% of microglia were MP-labelled, with ~54% of microglia showing 
‘high’ levels of MP uptake (Figure 8).  
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Figure 7: Reduction in MP uptake by astrocytes in the presence of microglia. (a) 
Fluorescence micrograph of a high purity astrocyte culture (stained for GFAP; <2% 
microglia) demonstrating a high proportion of MP-labelled cells. Arrows indicate 
astrocytes scored as having a ‘high’ level of MP accumulation. (b) Fluorescence 
micrograph of an astrocyte:microglia co-culture (~50% microglia) showing extensive 
accumulation of MPs in DAPI-labelled GFAP
-
 cells (some indicated by white arrows), 
identified as microglia by phase contrast microscopy (not shown). Note the reduction in 
MP-labelling of GFAP
+
 astrocytes (unlabelled astrocytes indicated by yellow arrows). (c) 
Fluorescence micrograph of a high purity microglial culture (~98% lectin
+
; data not 
shown) exhibiting extensive accumulation of MPs in cells identified as microglia by phase 
contrast microscopy and by a lack of GFAP staining. (d) Phase contrast counterpart to (c). 
Arrows indicate the same microglia in (c) and (d). All cultures incubated for 24 h at 20 µg 
Sphero/ml. 
 202 
 
 
Figure 8: The proportion of MP-labelled astrocytes and the extent of MP 
accumulation by astrocytes is markedly reduced in the presence of microglia. Bar 
graph illustrating the percentage of MP-labelled cells and the extent of MP accumulation 
by astrocytes and microglia in high purity isolated cultures (left and right hand bars, 
respectively) and in 50:50 co-cultures (central bars, astrocytes to the left and microglia to 
the right). A greater percentage of astrocytes exhibited ‘medium’ (*p < 0.05; n = 3) or 
‘high’ (*p < 0.05; n = 3) accumulations of MPs, and significantly fewer exhibited ‘low’ 
uptake (***p < 0.001; n = 3), in high purity astrocyte cultures than in co-cultures. No 
differences were shown between pure microglial and co-cultures in terms of the percentage 
of MP-labelled microglia, or the extent of MP uptake. ~100% Astro = high purity astrocyte 
culture (>98% GFAP
+
); 50:50 co-culture = astrocytes and microglia in a 50:50 co-
culture; ~100% Micro = microglia in a high purity culture (~98% lectin
+
).   
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5.3.6 The intracellular processing of Sphero MPs, and associated toxicity, is glial 
cell type-specific 
TEM analyses of glia incubated with Sphero MPs were compared. Electron dense 
MPs were readily identifiable in electron micrographs of astrocytes (unpublished image 
shown from a previous study by this lab),
240
 OPCs and oligodendrocytes, and were 
observed to be free in the cytosol, including the perinuclear accumulations (Figure 9a-c). 
The intracellular particles exhibited the same characteristic ring of iron oxide around the 
polystyrene core as was seen when particles were processed for TEM in D10 medium 
without cells (Figure 9a, inset), suggesting that they were morphologically intact within 
these cell types. Particle clusters were typically smaller in oligodendrocytes than in OPCs, 
and strikingly smaller in OPCs and oligodendrocytes compared with astrocytes, supporting 
the observations made using fluorescence microscopy (compare Figure 1b-d and Figure 
9a-c). TEM analyses of microglia revealed extensive particle accumulations which were 
often associated with multilamellar bodies (Figure 9d & 10a). In contrast to astrocytes, 
OPCs and oligodendrocytes, MPs within microglia appeared to be undergoing extensive 
sequestration and degradation, likely within lysosomes (Figure 10b).  
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Figure 9: Intracellular fate of MPs is cell type-dependent. TEM analyses of glial cells 
following 24 h incubation with 20 µg Sphero/ml. (a) An astrocyte with intact intracellular 
MPs, as evidenced by the presence of electron dense rings of iron surrounding the 
polystyrene cores (*). Inset, intact MPs in D10 medium without cells (24 h), for 
comparison of particle shape and structure. (b) An OPC showing intact MPs in a small 
cluster in the cell cytosol (arrow). (c) An oligodendrocyte showing a single MP in the 
cytosol (arrow). Inset shows magnified image of the MP. Note the relative size of the MP 
accumulations in (a), (b) and (c), which are typical of astrocytes, OPCs and 
oligodendrocytes. (d) A microglial cell showing large intracellular accumulations of MPs. 
Note that particles appear to be undergoing degradation, as evidenced by comparison with 
intact MPs [see (a), inset]. * indicates polystyrene core of MPs; Nu indicates nucleus; 
Scale bars indicate 0.5 µm, except (c, inset) where scale bar indicates 200 nm. 
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Figure 10: Microglia sequester and degrade MPs. A microglial cell, showing particles 
associated with an electron dense multilamellar body. Note that the electron dense iron 
particles are not accumulated in rings, but appear to be condensing into clusters, 
suggesting that particles are undergoing degradation. Inset shows extensive MP 
degradation within a lysosome, as evidenced by dispersion of iron deposits. 
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5.4 Discussion 
This is the first reported systematic comparison of MP handling by the major 
classes of CNS glia (using purified or enriched cultures, derived from the same primary 
source, viz. neonatal rat cortex). For Sphero particles, the glial cell types exhibit key 
differences in the rate and extent of MP uptake, and subsequent intracellular processing of 
particles, as well as their susceptibility to MP-related toxicity. There are also differences 
between the glial subtypes in their amenability to MP-mediated gene delivery as shown in 
chapters 3 and 4 for OPCs and oligodendrocytes, and by comparison with previously 
published astrocyte
164
 and microglial
241
 data.  
Based on these observations, it can be predicted that these variations will exert 
important influences on the biological utility of MP platforms for neural engineering 
applications. These findings have broad implications for the design of novel 
neurocompatible materials, and the development of protocols for their use, especially in the 
presence of mixed neural populations. A schematic summary of these cell type-specific 
MP-handling characteristics is shown below (Figure 11), and this discussion will now 
address the significance of each of these findings in turn. 
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Figure 11: Schematic overview of intercellular differences in MP-processing by glia 
and relevance to neural tissue engineering applications. Diagrams illustrate typical cell 
morphologies, relative levels of MP-accumulation, extent of perinuclear localisation and 
degradation of MPs. MPs are indicated by yellow circles. Tables summarise MP-handling 
characteristics for each cell type, relating to cell labelling efficiency, cytotoxicity and 
transfection levels achievable. ODC = oligodendrocyte. References: †241, ‡240, ¥164. 
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5.4.1 Microglial MP uptake is rapid and extensive compared to other glial cell types 
Microglial uptake of Sphero MPs is far more rapid and extensive than is seen in 
astrocytes, OPCs or oligodendrocytes. Various MP-based applications may depend upon 
loading cells with a sufficient quantity of particles, for example non-invasive detection of 
transplanted cells will require cells with sufficient label for effective detection by MRI. 
Astrocytes and microglia are likely to be readily labelled with sufficient particles for such 
an application, with potentially 100% of cells detectable by MRI and histological 
techniques. However, for the concentrations and incubation times tested, it was not 
possible to label 100% of an OPC or oligodendrocyte culture, and as discussed in section 
2.4.1, it remains possible that one or more subpopulations exist in primary oligodendroglial 
cultures which are not amenable to MP-labelling, at least with the Sphero particle. These 
suppositions would need to be assessed empirically, and MRI contrast capability of the 
labelled cells would also depend upon particle properties. For example, employing a high-
contrast particle (e.g. the Fe3O4-PEI-RITC particles studied in Chapter 2) may facilitate 
adequate accumulation of MRI-compatible contrast agent in cells which exhibit typically 
‘low’ levels of MP accumulation per cell. 
 
5.4.2 Unlike other glial cell types, microglia sequester and degrade MPs, and exhibit 
MP-related toxicity 
Intracellular Sphero MPs were observed in all glial cell types, but important 
differences were noted in their subsequent intracellular processing. For astrocytes, OPCs 
and oligodendrocytes, TEM analyses indicate that the particles are intact and commonly 
free in the cell cytosol, rather than being within endosomes/vesicles or associated with 
structures such as the nuclear membrane, Golgi apparatus or endoplasmic reticulum (in 
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agreement with the previously published astrocyte data).
240
 However, TEM analyses of 
microglia suggest that these cells sequester MPs in vesicles, including multilamellar 
bodies, and also undergo degradation within lysosomes, with iron leaching from the 
particles. These findings could provide a mechanistic basis for the differences in MP 
toxicity observed in the different glial subtypes, information that is vital to assessing the 
potential for translation of MP-based engineering techniques.  
Differences in intracellular processing of MPs can determine whether toxic effects 
are produced, as illustrated by Chen et al.
338
 The authors exposed a human glioma cell line 
(U251) to two different DMSA-coated iron oxide MPs and assessed whether ROS were 
produced.
338
 In a neutral environment (pH 7.4, typical of cytosol) no toxic effects were 
observed. However, in an acidic environment (pH 4.8; pH 4.5 – 5.0 is typical of a 
lysosome)
198
 MPs catalysed the production of ROS (hydroxyl radicals) from H2O2, with 
concomitant MP-dose-dependent cytotoxicity. TEM analyses of these cells revealed the 
presence of MPs within lysosomes, and the authors offer this intracellular localisation as an 
explanation for the toxicity observed with these MPs, potentially explaining why MP-
related toxicity was observed in microglia in the current study (i.e. in the only cell type 
where intralysosomal MPs were observed). 
In contrast to these findings, Hohnholt et al. (this report is also discussed in section 
2.4.3) assessed the toxicity of DMSA-coated iron oxide MPs in the OLN-93 
oligodendroglial cell line and did not find evidence of increased ROS levels or acute 
cytotoxicity.
273
 Their findings indicate that OLN-93 cells metabolise iron from these 
particles, although it is not clear by what mechanism the iron is released from the MPs. No 
evidence was seen of Sphero MPs undergoing breakdown in OPCs or oligodendrocytes, in 
contrast to Hohnholt et al.,
273
 but future work should attempt to study this issue further by 
measuring particle breakdown products and associated toxic by-products, such as ROS, 
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using particles with a range of physico-chemical properties. Such studies may indicate 
which formulations are the most stable within cells.  
Direct in vivo delivery of MPs as contrast agents exploits microglia/macrophage 
activity allowing for the mapping of CNS lesions. The data presented here in relation to 
toxic effects of MPs in microglia raise the possibility of secondary toxic effects, as 
microglia may take up large quantities of MPs and succumb to cell death within lesion 
sites, potentially exacerbating immune responses. The potential for such an outcome 
highlights the need for detailed toxicity assessments of synthetic materials intended for 
biomedical applications.  
 
5.4.3 Amenability to MP-mediated transfection, and optimal magnetofection 
conditions, differ between glial cell types 
A further point to note here is that all glial cell types demonstrated perinuclear 
accumulation of Sphero MPs, suggesting the feasibility of MP-mediated gene delivery. 
This has previously been shown to be possible with astrocytes,
164
 and gene delivery to 
OPCs and oligodendrocytes has now been demonstrated here (section 3.3.1 and 4.3.6, 
respectively). The most effective magnetofection condition for astrocytes was the 
application of a 1 Hz oscillating field. However, for OPCs, a 4 Hz oscillating field proved 
most effective. The reasons for these intercellular differences are unknown, but as recent 
data from this laboratory (submitted for publication) shows that NSCs are also optimally 
transfected at 4 Hz, it may be speculated that these differences may be related to cellular 
morphology. Both OPCs and NSCs have small spherical or oval cell bodies, with few 
processes, whereas astrocytes adopt broad flat morphologies. For broad, flat cells (e.g. 
astrocytes), membrane associated MPs are likely to be on top of the cell, oriented such that 
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an oscillating field would move/agitate them approximately parallel to the membrane, 
whereas for small, spherical cells (e.g. OPCs, NSCs), there may be an approximately equal 
chance that cell membrane associated particles are attached to the side of the cell, in which 
case an oscillating field would move/agitate them perpendicular to the membrane. If the 
direction of particle agitation relative to the membrane affects uptake then this could 
explain the frequency-dependent differences in transfection efficiency observed. 
Oscillating magnetofection of other cell types with broad flat morphologies (similar to 
astrocytes, e.g. fibrocytes) should be investigated, to determine whether they are also more 
effectively transfected at low frequencies. The efficiency of magnetofection of 
oligodendrocytes differed little between F = 0, 1 and 4 Hz, and therefore no conclusions 
can be drawn with respect to cell morphology influencing the effectiveness of the field 
conditions. Overall, these data indicate that effective MP-mediated gene delivery requires 
that a protocol be tailored for each specific cell type. 
Initial attempts to transfect microglia (with the same Neuromag MPs as used in 
chapters 3 and 4, and with static but not oscillating magnetofection) resulted in very low 
transfection efficiency (<1%).
241
 Based on the TEM analyses of Sphero MPs in microglia, 
it seems likely that Neuromag-plasmid complexes may also be sequestered or degraded by 
microglia, without gene delivery to the nucleus, providing a reason for the limited 
transfection observed in these cells. In recent preliminary competitive transfection 
experiments, oscillating magnetofection techniques (0.1x dose, F = 4 Hz) have been tested 
with OPC and microglial co-cultures, and although some GFP expression was observed in 
cells identified as microglia, the pattern of expression differed greatly from that seen in all 
other cell types. Whereas transfected OPCs in the same cultures exhibited uniform green 
fluorescence throughout the cell body and processes, GFP expression in microglia was 
punctate, in numerous round structures with variable intensity (Figure 12), suggesting that 
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GFP had been expressed by the cell, but that it was subsequently sequestered within 
vesicles. It is not clear from the analyses performed so far whether this ‘abnormal’ GFP 
expression is cytotoxic to microglia, but some microglia which had undergone these 
‘aborted transfection’ events showed evidence of pyknotic nuclei. 
 
 
Figure 12: Microglia demonstrate ‘abnormal’ GFP expression following oscillating 
magnetofection. Fluorescence micrographs of an OPC:microglial co-culture 48 h 
following magnetofection (Neuromag MPs, pmaxGFP plasmid, 0.1x dose, F = 4 Hz). (a) 
Lectin
+
 microglia. Arrow indicates a microglial cell with a rounded morphology and 
shrunken, potentially pyknotic nucleus. (b) Counterpart image to (a) showing abnormal 
GFP expression in a microglial cell (arrow). Note that GFP appears to be sequestered in 
multiple intracellular regions, rather than evenly expressed throughout the cell. Scale bar 
= 20 µm. 
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5.4.4 Microglia represent an ‘extracellular barrier’ to MP-based engineering of 
other glial subtypes 
To the best of my knowledge, this is the first report of a stoichiometrically-defined 
neural co-culture system being developed with cells derived from a common primary 
origin. The method of co-culture of individual glial subtypes that I have developed here 
has allowed for the co-propagation of cells that usually require different media. The 
success of the method is evidenced by microscopic observations which revealed that cells 
within the co-cultures demonstrated their characteristic morphological and antigenic 
staining profiles. The observation that near 50:50 glial mixtures could be achieved, 
suggests that the cell plating densities and relative timings of cellular additions can 
potentially be refined further to result in varying cell to cell ratios, as required (for example 
90:10 or 70:30). 
In this context, it is noteworthy that whilst other studies have compared cellular 
responses to a single particle across a variety of cell types (in purified/enriched cultures), 
these studies have frequently employed cell lines
220
 (see section 1.10 for details of the 
drawbacks of cell line-derived data), and rarely attempted to include multiple cell types 
from a single tissue source. Some studies have attempted to evaluate particle uptake in 
undefined mixed cell cultures established from dissociated neural tissue. For example, 
Pinkernelle et al. established mixed cultures from P5 – 8 rat cerebellum.222 Commercially 
available MPs (magnetite core, 185 – 190 nm diameter) were added to these cultures and 
the authors conclude that “...most MNPs [magnetic nanoparticles] were phagocytosed by 
the microglial cells in the mixed cultures which presumably reduce the amount of MNPs 
for uptake by other cells”.222 Without demonstrating greater MP uptake in isolated high 
purity cultures of these non-microglial cell types (as has been reported in this thesis) than 
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was shown in the mixed cultures, it is clear that this conclusion cannot be reached from 
this single study. Furthermore, there are significant limitations to this culture system as a 
model to compare uptake between neural cells. These mixed neural cultures were not well 
characterised, were highly variable in composition, and underwent significant 
stoichiometric changes during culture, presumably due to cell proliferation, differentiation 
or death. While the authors provided a percentage composition of several cell types, actual 
cell counts were not reported. Also, the oligodendroglial lineage is assessed in limited 
detail, with the use of a single oligodendrocyte marker, which suggested the presence of a 
low proportion of oligodendroglial cells in these cultures, questioning the validity of the 
interpretations with respect to competitive uptake dynamics between microglia and 
oligodendrocytes. 
Using the co-culture approach developed here to perform competitive uptake assays 
has confirmed the hypothesis that microglia act as a significant ‘extracellular barrier’ to 
MP-based engineering of other glial cell types. Both astrocytes and OPCs exhibited a 
dramatic reduction in the percentage of cells labelled, and a reduction in the extent of MP 
accumulation when co-cultured with microglia. On average, individual microglia exhibited 
a greater extent of particle accumulation when co-cultured with OPCs. This was 
presumably due to the fact that, in these co-cultures, each microglial cell is ‘competing’ for 
particles with a reduced number of neighbouring microglia, which have been replaced with 
another, less avid, cell type (the OPC). This effect was not noted for microglial co-culture 
with astrocytes, which is consistent with the greater levels of uptake seen in astrocytes than 
in OPCs, suggesting that astrocytes will compete with microglia more effectively than will 
OPCs. Despite the greater ‘competitive’ uptake shown by astrocytes, it should be noted 
that the microglial ‘barrier’ significantly limited the extent of MP accumulation by 
astrocytes in co-cultures. 
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5.4.5 Glial co-cultures as complex models to mimic the interactions of mixed CNS 
cell populations with synthetic materials 
In agreement with findings from the co-culture model developed here, competitive 
uptake dynamics in glial cell populations have been previously reported following MP 
delivery to the CNS in vivo, with uptake dominated by microglia, highlighting the 
predictive value of the approach utilised here. For example, Fleige et al. tested uptake of 
MPs in three glioma cell lines, showing that incubation with MPs for 30 minutes (at three 
different concentrations) resulted in all cell lines demonstrating similar concentration-
dependent accumulation of particles.
339
 In a separate experiment, in vivo injections of a 
GFP-expressing tumour cell line (F98) were made in the rat putamen in order to produce 
GFP
+
 gliomas at this site.
339
 Acute forebrain slices from these animals were incubated with 
MPs for 30 minutes and the authors report “massive” particle uptake by activated ameboid 
microglia and invading macrophages, but “almost no” uptake by glioma cells, suggesting 
that the presence of microglia and blood macrophages can act as an ‘extracellular barrier’ 
to MP uptake by glioma cells. The authors further tested the capacity of glia in co-cultures 
to take up MPs by culturing microglia over a monolayer of primary astrocytes (undefined 
ratio). Following incubation of these co-cultures with particles for 30 min, they report that 
microglial uptake is “evident” but that there is “almost no detectable” labelling of 
astrocytes,
339
 further supporting the concept that competitive uptake mechanisms exist 
between microglia and other glial cell types. 
 
  
 216 
 
5.4.6 Conclusions and future directions 
Microglia are one of the most abundant cell types in the CNS and demonstrate 
rapid and efficient uptake of MPs. Therefore, any MP-based applications intended for use 
in the CNS in vivo must give consideration to their presence, especially in the context of 
CNS lesions where microglia will be more numerous and more active than in healthy 
tissue. As such the microglia can be considered a substantial barrier to MP-mediated gene 
or drug delivery, as they are likely to sequester and probably digest such functionalised 
particles, reducing the likelihood of a successful functional outcome. Further, the MP-
associated toxicity in microglia, as reported here, could potentially become a cause of 
significant secondary pathology in CNS lesions. Despite the lack of success with gene 
delivery, transfection of microglial cells remains a significant goal in regenerative 
medicine. As a neural population that readily migrates to CNS lesions and releases a wide 
variety of cytokines, microglia are a major target for gene therapy, whether by the 
introduction of exogenous genes or by the regulation of endogenous genes.  
If it is intended that MPs are to be delivered to a specific CNS cell type other than 
the microglia, it will be necessary to design a particle that evades microglial uptake. Such 
‘stealth’ particles are currently being investigated by numerous laboratories.340–342 If 
microglial uptake is successfully limited, astrocytes seem the next most likely cell type to 
exhibit uptake of MPs in the CNS, due to their abundance and the greater accumulation of 
MPs seen here compared to oligodendroglial cells, and the low level of particle uptake 
reported in primary neurons.
222
 If a MP is intended to reach an oligodendroglial 
population, it may be necessary to employ a specific targeting strategy, such as the 
incorporation of a ligand or antibody directed towards an oligodendroglial-specific 
receptor,
133,261,343
 owing to the inherently low levels of uptake in these cells compared to 
other glia. 
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Lastly, the co-culture system developed here could be expanded to include 
additional neural cell types (e.g. oligodendrocytes, neurons or NSCs), in defined ratios, and 
with the desired extent of differentiation/activation [e.g. mature oligodendrocytes, 
activation of microglia by granulocyte-macrophage colony-stimulating factor (GM-CSF)] 
to match particular CNS regions or disease states. Introducing these additional levels of 
refinement can potentially provide superior models with enhanced cellular complexity for 
the testing of interactions of synthetic materials with the CNS. 
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Chapter 6: Conclusions and general 
discussion 
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6.1 Summary of thesis findings 
It has been shown in this thesis that OPCs and oligodendrocytes are amenable to 
MP-based cell labelling and transfection (including magnetofection strategies), albeit with 
notable cell type-dependent differences. Through intercellular comparisons of particle 
uptake and handling by the major neuroglial subtypes, it has become apparent that 
substantial differences exist between individual cell subclasses. 
 The findings presented in this thesis can be summarised as follows: 
 OPCs derived from a primary source were safely labelled with MPs (up to 60% of 
cells) of two physico-chemically different (and well-characterised) formulations, 
without the need for specific cell targeting strategies. MP-labelled OPCs displayed 
normal differentiation profiles and could retain their label for up to 30 days. 
 The OTOTO SEM protocol enabled the ultrastructural visualisation of OPC-MP 
interactions, including the identification of endocytotic events. 
 OPCs were safely transfected using MPs, with transfection efficiency enhanced by 
magnetofection techniques. An oscillating magnetic field (4 Hz) has proved optimal 
with the protocols tested so far. Genetically modified OPCs transplanted onto 
organotypic cerebellar slice cultures survived and displayed normal migration, 
proliferation and differentiation profiles. 
 Combinatorial and therapeutic gene delivery to OPCs was safely achieved using 
MPs, but MP-mediated transfection efficiency is inversely proportional to plasmid 
size. 
 Oligodendrocytes were safely labelled with MPs (up to 45% of cells), without the 
need for cell-targeting strategies, albeit with smaller MP accumulations than 
observed in OPCs. 
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 Oligodendrocytes were safely transfected using MPs, with transfection efficiency 
enhanced by static and oscillating magnetofection techniques. Transfection levels 
under all magnetofection conditions were significantly lower than those obtained in 
OPCs.  
 A cross-cellular comparison of data from this thesis with data previously published 
by this laboratory, shows that astrocytes are more amenable to MP-mediated gene 
delivery than OPCs, which are more amenable than oligodendrocytes. The most 
effective oscillating field condition for transfection varies between cell types. 
 The same cross-cellular comparison of MP uptake and handling shows that 
microglial MP uptake is far more rapid and extensive than the other glial cell types, 
and a glial MP uptake hierarchy is apparent: microglia > astrocytes > OPCs > 
oligodendrocytes. 
 MP-based toxicity (associated with lysosomal MP degradation) was observed in 
microglia, but not in astrocytes, OPCs or oligodendrocytes, all of which contained 
intact cytosolic MPs, at identical MP concentrations and incubation times. 
 A protocol has been developed for the co-culture of different glial subtypes with 
defined stoichiometry. Using this model, the hypothesis that microglia constitute an 
‘extracellular barrier’ to MP-based engineering of other cell types has been 
confirmed in defined co-cultures with astrocytes, and with OPCs. 
The immediate implications of these findings have been discussed in detail within 
each chapter, and the discussion here will consider broader implications for the use of the 
MP platform in conjunction with neural tissue engineering. Here, I propose further 
directions for developments in the fields of MP design/analysis, genetic engineering of 
transplant populations, and in vitro transplant modelling. 
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6.2 Implications of findings and future directions 
The design of neurocompatible MPs will require systematic analyses of MP 
interactions with neural cells on a cell-by-cell basis, including OPCs, which is a vast 
undertaking. The development of automated analytical systems would be of benefit in this 
regard for high-throughput MP screening. The most detailed information about cell-
particle interactions, including uptake, comes from ultrastructural studies, but these are 
typically low throughput. The OTOTO SEM technique developed here begins to address 
the need to gather quantifiable data across large numbers of cells, but the process could be 
further developed by introducing automation of both the sample processing and 
imaging/analysis stages. The processing of coverslips for OTOTO SEM consists of a 
simple procedure of adding and removing solutions, which could easily be automated, 
followed by the packaging of coverslips in filter paper for critical point drying. Although 
this packaging step may prove difficult to automate, the critical point drying would not. 
Having prepared the samples, the imaging and analysis could be amenable to software-
based automation for detection and quantification of particles
344
 and endocytotic events. 
The development of such technologies represents commercial opportunities for industry, 
with the equipment and software likely being translatable to various other purposes (e.g. 
studying membrane interactions and uptake mechanisms for viral vectors, or quantifying 
the effects of stimulatory/inhibitory molecules on the extent of endocytotic membrane 
ruffling or pit formation). 
The successful labelling and transfection of OPCs shown in this thesis illustrates 
the considerable potential for the development of multimodal MPs for use with neural 
transplant populations. The prototype Fe3O4-PEI-RITC particles tested here were designed 
to deliver such multifunctionality, providing MRI contrast, histological detection by 
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fluorescence or iron staining, and incorporating PEI as a transfection agent. However, low 
transfection levels (<1%) were achieved in astrocytes using these particles, even with static 
field magnetofection techniques.
102
 The reasons for this low efficiency are unclear, but are 
apparently not due to limited MP uptake, as ~100% of astrocytes were successfully 
labelled with MP:plasmid complexes, even without magnetofection.
102
 The high iron 
content of these particles, and hence high density, may lead to rapid sedimentation of these 
MPs, such that magnetofection does not significantly enhance vector-cell contact.
102
 
Therefore the limited gene delivery observed may be related to MP-plasmid interactions, 
or intracellular processing of the complexes, and further particle development will seek to 
address these issues.
102
 For example, the quantity and conformation of DNA bound by the 
particles should be investigated, and the rate of release of the plasmid from the complex, 
necessary for nuclear import, should be assessed. Such information will inform the 
modification of the current prototype, and the design of novel particles. The prototype 
particle tested here may prove to be amenable to magnetic cell targeting approaches (aided 
by the high iron content), but yet further functionality could also be incorporated into 
multimodal MPs, producing so-called ‘smart nanostructures’. This concept refers to 
particles that react to intracellular physiological changes, or external stimuli (e.g. heat, 
light), with this reaction often being proposed to result in a conformational change in the 
particle, releasing a drug payload from an internal compartment.
345
 However, the 
interesting possibility has also been raised that a structural change in the particle could be 
detectable non-invasively in real-time, signalling an event such as a change in pH (e.g. 
reporting lysosomal localisation of the particle).
99
  
This research interface between materials chemistry and cell transplant biology is 
an area of high scientific interest, and the development of MPs as cellular engineering tools 
would be aided by standardised reporting of at least some particle characteristics, such as 
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the size, shape and charge of particles. The lack of routine characterisation of synthetic 
materials (which are frequently novel, and even when not, may exhibit significant batch-to-
batch variability), in conjunction with the fact that the choice of model cell type(s) is not 
standardised, hampers progress in the field of tissue engineering as findings cannot readily 
be compared and contrasted between studies. Therefore, sound conclusions cannot be 
drawn in respect of which particle properties influence their utility for cellular engineering 
(e.g. it is not clear how particle charge affects the extent of cellular uptake; see section 
1.9). Agreement also needs to be reached regarding which particle characteristics should be 
reported, and which analyses are most appropriate to determine each of these properties 
(e.g. the limitations of hydrodynamic diameter as a measure of MP size have been 
discussed in section 5.3.1; and although determining zeta potential in a physiological 
medium rather than water may be more biologically relevant, there may not be a medium 
upon which standardisation could be agreed). 
The proofs-of-principle of MP-mediated delivery of multiple reporter genes and a 
therapeutic gene to OPCs indicate that multiple therapeutic genes could be delivered to an 
OPC transplant population, allowing a combination of goals to be targeted. However, 
further to this, the combinatorial therapies likely required for CNS regeneration would be 
more effectively delivered with temporal control of transgene expression. Through further 
vector and plasmid engineering it may be possible to deliver multiple therapeutic genes to 
a transplant population, each under the control of a different promoter. A number of 
inducible promoter systems have been developed, whereby transgene expression can be 
triggered by drugs (e.g. tetracycline, rapamycin, or tamoxifen).
117
 To provide more clinical 
control of the process, the promoters could be designed to be manipulable through external 
signalling, potentially in real-time. For example, the technology developed to perform 
hyperthermia therapy in tumours can be adapted for use with thermoinducible 
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promoters.
346
 An oscillating magnetic field can be used to raise the temperature in the 
vicinity of MPs (this technology is based on the fact that tumour cells are more sensitive to 
this heating than normal cells) activating this thermoinducible promoter and hence 
triggering expression of the associated transgene.
347
 
With reference to the translational relevance of these findings, clinical transplant 
populations are likely to be derived either from primary foetal tissue or from in vitro 
differentiation of human ESCs or NSCs.
34
 In the first instance, the cell source will likely be 
heterogeneous (consisting of OPCs at various stages of differentiation, and potentially 
including different subtypes), and of indeterminate age (human conception can only be 
estimated to within 1 – 2 weeks),348,349 and furthermore it will be difficult to predict what 
approximate age and quantity of cells will become available for a treatment. This scenario 
will be more accurately modelled by studies using cells from primary sources, than by 
studies employing cell lines (see section 1.10), and the heterogeneous uptake dynamics 
noted in the cross-cellular comparison of astrocyte, OPC and oligodendrocyte populations 
from primary sources is likely to be representative of human foetal tissue, although this 
will need to be established empirically. The fact that oligodendrocytes display lower 
amenability to manipulation than OPCs should be investigated further, with MP handling 
by defined oligodendroglial stages being studied. These stages can be derived by 
immunopanning,
305,323
 and evaluated in isolation, and by determining the amenability to 
engineering of each stage/subtype, it may be possible to predict the amenability to 
labelling/transfection of a donor cell population based on that population’s antigenic 
profile. Such data may allow the determination of developmental windows within which 
donor populations are most/least amenable to MP-based engineering. It will be of interest 
to determine whether MP uptake and transfection efficiency decreases continuously as the 
cells differentiate and mature. Furthermore, it will be of interest to test MP handling and 
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transfection efficiency in cell types that precede OPCs in development (e.g. NSCs, ESCs) 
to determine whether there is a step-wise decrease in amenability to MP 
uptake/transfection throughout development. If this is found to be the case, it raises 
interesting questions about whether it may be more effective in general to manipulate cells 
at a precursor/antecedent stage and then induce differentiation, rather than attempting to 
manipulate the desired cell type directly. For cell transplant populations derived from 
ESCs or NSCs, an industrial opportunity is available, as these cells are likely to be 
expanded and differentiated in vitro using automated cell culture machines. As the 
oscillating magnetofection protocol developed here is technically simple, it could be 
incorporated into such machinery, automating the process of transfection, and limiting the 
risks of pathogenic contamination by confining these manipulations within a single device. 
Two models consisting of multiple cell types have been utilised in this thesis: slice 
cultures and defined co-cultures. The organotypic cerebellar slice culture system employed 
here has already been adapted to serve as an injury model of both focal and diffuse 
demyelination, including traumatic injury (see section 1.6), but it has only begun to be 
exploited as ‘host’ tissue for genetically modified neural cell transplantation strategies, 
with one report of the transplantation of GFP-expressing OPCs,
4
 in addition to the report in 
this thesis, and has not yet been used to test therapeutically-modified OPC transplant 
populations. The clinical relevance of this organotypic model can be improved by seeking 
to establish slice cultures from human tissue,
37,350
 and potentially from patients with 
myelin-related disease (e.g. MS). This will involve collaboration with hospitals/tissue 
banks, application(s) for ethical clearance, and regulation by the Human Tissue Authority 
(HTA), but given the lack of translation of treatments developed in many animal 
models,
67,68
 such an approach could yield data of far greater predictive value for the clinic. 
This model could be combined with the transplantation of neural cells derived from human 
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ESCs and NSCs, and also primary human neural cells (although these are less readily 
available), to further enhance the translational relevance of the studies. Furthermore, these 
models provide an opportunity to test MP-based engineering of human cells/tissue, 
including transplantation modelling. In this context, there are no reports of MP-mediated 
gene delivery to non-tumourigenic primary human neural cells (there is one report of static 
magnetofection of primary glioblastoma cells),
351
 representing a significant knowledge 
gap. It is unknown whether inter-species differences exist in the amenability of neural cells 
to MP-based engineering in general, or to magnetofection techniques in particular, either 
static or oscillating. Furthermore, it is not known whether species-specific differences in 
MP-based toxicity exist, and it is unknown whether the human oligodendroglial lineage 
will exhibit a similar reduction in amenability to MP-labelling/transfection as is shown by 
rat OPCs/oligodendrocytes; the prolonged developmental period for humans
348,349
 may 
provide a longer developmental window in which OPCs can be effectively engineered, 
compared to rats. The defined co-culture system developed during this thesis can be 
expanded to include additional cell types (subject to the development of suitable media), at 
defined ratios, and the stages of differentiation/activation of each cell type can be 
influenced. Stoichiometrically-representative models can potentially be produced of 
various CNS regions and/or disease states, including the production of models with pre-
immunosuppressed microglia, of relevance to the modelling of corticosteroid-treated 
patients, for example some MS patients.
352,353
 
The demonstration that microglia constitute an ‘extracellular barrier’ limiting MP 
delivery to other glial cell types has implications for in vivo usage of MPs, which can be 
predicted to typically result in extensive accumulation by microglia, limiting their delivery 
to other neural cell types, with oligodendrocytes anticipated to demonstrate the lowest 
levels of uptake of the neuroglia. It will be of interest to perform comparable MP studies 
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with neurons, including competitive uptake studies in co-cultures, to determine how 
neurons fit into the ‘uptake hierarchy’ determined in this thesis for the neuroglia. By 
obtaining a sufficient number of data-points at various times and concentrations, it should 
be possible to develop a mathematical model of the rate and extent of uptake by each cell 
type, and these models could be used to make predictions of competitive uptake outcomes, 
which could then be tested in co-cultures, including co-cultures of three or more cell types. 
If these models demonstrate that the hierarchy of MP uptake suggested by comparing pure 
glial cultures also describes MP uptake in cultures with all glial cell types, then it can be 
anticipated that in vivo delivery of MPs to the CNS will typically be an ineffective method 
for engineering OPCs, and especially for engineering oligodendrocytes. Such applications 
would likely require specific cell targeting strategies, possibly combined with methods to 
evade microglial uptake, sequestration and breakdown.  
In terms of approval for clinical translation, synthetic materials, including magnetic 
particles, are regulated by the FDA in identical manner to other diagnostic and therapeutic 
agents, requiring studies of systemic clearance, biodistribution and toxicology;
218,354,355
 
regulations in the EU are similar. Although extensive work is required to gain FDA or EU 
approval, several iron oxide-based particles have been approved for use as contrast 
agents,
143,183
 for the treatment for iron-deficiency anaemia,
356,357
 or for hyperthermic 
tumour therapy.
347
 Therefore, by rigorously testing MPs in primary cells and relevant 
models that mimic the complexity of the CNS, to ensure neurocompatibility, followed by 
pre-clinical animal testing, it is feasible that an iron oxide-based MP designed for neural 
engineering could enter clinical trials. 
This thesis has demonstrated the utility of MPs for labelling and transfecting OPC 
transplant populations, and highlighted a number of ways in which the effectiveness of 
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these applications could be enhanced, through further research. Additionally, intercellular 
differences in glial MP handling have been described, and their implications discussed, 
particularly with reference to the role of microglia as an ‘extracellular barrier’ to particle 
uptake by other cell types. By developing effective tools for the engineering of neural cell 
transplant populations, and employing well-designed combinatorial strategies, it is hoped 
that such work will enable a step-change in the treatment of debilitating CNS 
injury/disease, from palliative approaches, to regenerative therapies. 
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Appendix 1: Particle calculations (Sphero and Fe3O4-PEI-RITC) 
This calculation for Fe3O4-PEI-RITC particles was kindly provided by Dr H H P Yiu 
(Heriot-Watt University, Edinburgh, UK). 
The unfunctionalised iron oxide core is ~25 nm in diameter, and has a density of 5 g/cm
3
. 
The volume (4/3 πr3) of one particle is 8181 nm3. 
The mass (density x volume) of one particle is 4.1 x 10
-17
 g. 
Therefore, 1 µg contains approximately 24 billion particles. 
Once functionalised with PEI and RITC, the organic content has been determined to be 
~20%. 
Correcting for this organic component, there are estimated to be 19.2 billion particles/µg. 
 
 
 
To compare the concentration of Fe3O4-PEI-RITC particles with Sphero particles: Sphero 
particles are supplied at 1% w/v (10 mg/ml) and reported by the manufacturer to contain 
2.59 x 10
11
 microspheres (particles) per ml. 
Therefore, 1 mg contains 2.59 x 10
10
 particles, and 1 µg contains 2.59 x 10
7
 particles. 
At 50 µg/ml, this equates to 1.295 billion Sphero particles/ml (2.59 x 10
7
 x 50). 
For Fe3O4-PEI-RITC particles at 5 µg/ml, there are 96 billion particles/ml (19.2 x 5). 
This gives a ratio of 1:74, Sphero:Fe3O4-PEI-RITC. 
For equal w/v concentrations (e.g. 20 µg/ml), the particle number ratio is 1:741. 
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Appendix 2: Statistical analyses for the cross-cellular comparison of MP uptake 
To compare the rate and extent of MP uptake by different glial cell types (section 
5.1), published data relating to astrocytes and microglia were collated with novel data 
reported in this thesis for OPCs and oligodendrocytes. All astrocyte, microglial and OPC 
cultures (section 2.4) were of high purity, and oligodendrocyte cultures were enriched 
(section 4.3). The phrase ‘each cell type’ refers to: all GFAP+ cells in pure astrocyte 
cultures (n = 3 cultures for uptake; n = 5 for toxicity), all OX42
+
 cells in pure microglial 
cultures (n = 3 cultures for uptake; n = 5 for toxicity), all A2B5
+
 cells in pure OPC 
cultures, and all MBP
+
 cells in enriched oligodendrocyte cultures. All of the data was 
obtained using Sphero MPs, which are characterised in section 2.2, and all experiments 
were performed with identical ranges of concentrations and incubation times. 
Rate of MP labelling: data-points were compared at (a) 1 h, 20 µg/ml, (b) 4 h, 2 
µg/ml, and (c) 4 h, 50 µg/ml for the percentage of each cell type exhibiting MP labelling. 
Extent of MP accumulation: data-points were compared at 1 h, 20 µg/ml for the 
percentage of each cell type that exhibited either ‘medium’ or ‘high’ levels of MP 
accumulation (‘medium’ and ‘high’ data were summated). 
Figure 1e, Rate of MP labelling: data-points were compared at 4 h for all 
concentrations (2, 5, 20 and 50 µg/ml) for the percentage of each cell type exhibiting MP 
labelling. 
Figure 1f, Toxicity: Data-points were compared following 24 h incubation with 
particles at 20 µg/ml. For oligodendrocytes, the number of MBP
+
 cells in MP-treated 
cultures was expressed as a percentage of the number of MBP
+
 cells in control cultures, 
giving a percentage viability assessment. For OPCs, the same procedure was performed for 
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A2B5
+
 cells. For astrocytes and microglia, MTS assays were performed, and absorbance 
readings from MP-treated cultures were expressed as a percentage of absorbance readings 
from controls, giving a percentage viability assessment. Unpaired two-tailed t tests were 
then performed comparing each viability assessment with controls (100%). 
Figure 1g, Perinuclear localisation: data-points were compared at (a) 1 h, 50 µg/ml, 
(b) 4 h, 50 µg/ml, and (c) 24 h, 50 µg/ml for the percentage of each cell type exhibiting any 
perinuclear MPs. 
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Appendix 3: Article published by Nanomedicine (London). 
Much of the data included in chapters 2, 4 and 5 has now been accepted for publication by Nanomedicine. 
This appendix consists of the unformatted article, accepted for publication on 30/08/2012. 
Adapted from Nanomedicine 2012 (Ahead of Print) with permission of Future Medicine Ltd (08/10/2012).. 
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Abstract 
Aims: To analyze magnetic particle (MP) uptake and intracellular processing by the four main non-neuronal 
subclasses of the central nervous system (CNS) [viz. oligodendrocyte precursor cells (OPCs), 
oligodendrocytes, astrocytes and microglia]. 
Materials and Methods: MP uptake and processing were studied in rat OPCs and oligodendrocytes, using 
fluorescence and transmission electron microscopy, and results collated with previous data from microglia 
and astrocytes. 
Results: Significant intercellular differences were observed between glial subtypes, with microglia 
demonstrating the most rapid/extensive particle uptake, followed by astrocytes, with OPCs and 
oligodendrocytes showing significantly lower uptake. Ultrastructural analyses suggest that MPs are 
extensively degraded in microglia but are relatively stable in other cells.  
Conclusions: Intercellular differences in particle uptake and handling exist which will have important 
implications for the utility of the MP platform for biological applications involving neuroglial cells, including 
their genetic modification, transplant cell labeling and direct biomolecule delivery to mixed CNS cell 
populations in vivo. 
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Introduction 
Magnetic particles (MPs) have emerged in recent years as an important platform for advanced 
biomedical technology, due to innovations in their large-scale synthesis and complex surface 
functionalization [1,2]. These advanced materials are used in key applications such as drug/gene delivery, 
magnetic drug targeting, thermotherapies, stem cell targeting, and in diagnostic imaging (as contrast agents) 
[2–6]. The size and surface chemistry of MPs can be tailored for molecules with which they are to be 
‘functionalized’, enabling the construction of multimodal particles that can mediate combinations of cellular 
applications, whilst retaining nanoscale dimensions [7]. The unique versatility achievable with their structural 
design therefore confers on MPs the ability to serve as a ‘theragnostic platform’ to integrate therapeutic 
strategies with diagnostic methods such as MRI [8].  
Despite their proven therapeutic potential, the use of MPs for central nervous system or CNS (ie. 
brain and spinal cord) applications has been a relatively underexploited area to date [2]. Their utility is being 
increasingly demonstrated for a range of regenerative applications including neural progenitor/stem cell 
transplant imaging [9,10], gene delivery deploying novel 'magnetofection' methods [11–15] and diagnostic 
imaging in neurological injury [16]. However, there are critical gaps in our knowledge of fundamental 
biological parameters governing the utility of this emergent technology for CNS applications, especially the 
factors that determine MP uptake and intracellular processing in neural cells. The influence of parameters 
such as MP size, coating and charge on particle uptake have been studied in non-neural cell types [17-20] but 
the influence of neural cell subtype on particle uptake has never been assessed. This is especially pertinent 
when considering MP applications in CNS tissue; the latter is uniquely complex and contains several, 
specialist, interacting cell types meaning that data obtained from other physiological systems cannot be 
extrapolated to the CNS. The neurons mediate electrical conduction but a diverse population of non-neuronal 
cells, collectively termed the 'neuroglia' undertake distinct and critical functions such as immune 
surveillance, blood-brain barrier maintenance, genesis of myelin (the insulating sheath around neurons) and 
regulation of electrochemical signalling [21-23]. Neuroglial subclasses consist of the oligodendrocytes [that 
co-exist with their parent population- the oligodendrocyte precursor cells (OPCs)], microglia, and astrocytes. 
These subclasses have unique structural, functional and molecular properties and can therefore be predicted 
to show important differences in their uptake and handling of synthetic materials. Indeed, our recent studies 
point to significant intercellular differences in toxicity and transfection levels between neuroglia, the reasons 
for which are unknown [12,14,24]. The neuroglia form an extensive cellular network and outnumber neurons 
by a factor of approximately ten, consequently, understanding particle handling by this major class of cells 
will be a critical component in understanding interactions between biomaterials and the CNS as a whole.  
A small number of studies have reported MP uptake by neuroglial cells [25,26] but whether 
differences in particle uptake and handling exist between different neuroglial subtypes in CNS tissue, is 
unknown. To address this issue, we have assessed the uptake and intracellular processing of a single type of 
MP (of specific size and formulation) by oligodendrocyte lineage cells ie. oligodendrocytes and OPCs 
derived from primary cell cultures. These findings were collated with data from our previous studies in 
astrocytes [27] and microglia [24] (also derived from primary cultures) to provide, for the first time, 
comparative data on the uptake characteristics and particle handling by these major subclasses of CNS cells.  
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Materials and Methods 
Reagents and equipment: Tissue culture-grade plastics, media, and media supplements were from Fisher 
Scientific (Loughborough, UK) and Sigma-Aldrich (Poole, UK). Recombinant human platelet-derived 
growth factor (PDGF-AA) and basic fibroblast growth factor (FGF2) were from Peprotech (London, UK). 
Monoclonal rat anti-MBP was from Serotech (Kidlington, UK), monoclonal mouse anti-A2B5 was from 
Sigma-Aldrich (Poole, UK), and secondary antibodies (FITC-conjugated) were from Jackson 
ImmunoResearch Laboratories Inc. (West Grove, PA, USA). Mounting medium with DAPI (4’,6-diamidino-
2-phenylindole) was from Vector Laboratories (Peterborough, UK). Paramagnetic, carboxyl-modified 
Sphero
TM
 nile red fluorescent MPs (diameter 0.20 – 0.39 µm, iron content 15 – 20% w/v) were obtained from 
Spherotech Inc. (Lake Forest, Illinois, USA). We have observed that their fluorophore does not leach, and 
their emission spectra remain stable following long periods of storage, making these an optimal choice for 
this study.  
 
Particle characterization: FTIR (Fourier transform infrared) spectroscopic analysis was carried out using a 
Perkin Elmer Spectrum 100 spectrometer fitted with an ATR (attenuated total reflection) sampling unit. For 
the sample measurement, 32 scans in the region from 650 to 4000 cm
-1
 were accumulated with a resolution of 
4 cm
-1
. Powder XRD (X-ray diffraction) analysis on the iron oxide component of the particles was carried out 
using a Bruker D8 Advance diffractometer with Cu Kα1 radiation (λ = 1.542 Å). The diffraction pattern was 
collected from 2θ = 5° to 80°, at a step size of 0.009° and a step time of 120 s. The particle size of iron oxide 
was estimated using Scherrer analysis on the most intense peak (311). Assessments of hydrodynamic size and 
zeta-potential of particles in various medium were made using a Malvern Zetasizer Nano ZS. To evaluate the 
effects of time on particle aggregation, size measurements were made at 5 min and 24 h after particle 
addition to Sato medium (37ºC). To evaluate the effects of different culture media on particle size and zeta 
potential, measurements were made after particle addition to all three media used for the maintenance of the 
individual cell types used in these studies and compared with particle size in deionized water. All media were 
incubated (37ºC, 5% CO2/95% humidified air) before analysis, to ensure measurements were made at the 
same pH as that at which cells were cultured. 
 
OPC and oligodendrocyte cultures for uptake experiments: The care and use of animals was in accordance 
with the Animals (Scientific Procedures) Act of 1986 (United Kingdom) with approval by the local ethics 
committee. Primary mixed neuroglial cultures were prepared from cerebral cortices of Sprague-Dawley rats 
at postnatal day 1 – 3, based on an established protocol [28]. Cultures were maintained in D10 medium 
(DMEM supplemented with 10% fetal bovine serum, 2 mM glutaMAX-I, 1 mM sodium pyruvate, 50 U mL
-1
 
penicillin, and 50 µg mL
-1
 streptomycin) at 37°C in 5% CO2/95% humidified air for 8 – 10 days, then shaken 
for 2 h on a rotary shaker at 200 rpm. This medium, containing largely microglia was discarded, fresh D10 
medium added, and flasks shaken overnight at 200 rpm. The resulting medium, containing largely OPCs, was 
transferred to non-tissue-culture grade petri dishes, to reduce residual microglial contamination. After 30 
min, unattached cells were resuspended in either OPC maintenance medium (OPC-MM: DMEM 
supplemented with 2 mM glutaMAX-I, 1 mM sodium pyruvate, 10 nM biotin, 10 nM hydrocortisone, 30 nM 
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sodium selenite, 50 µg mL
-1
 transferrin, 5 µg mL
-1
 insulin, 0.1% bovine serum albumin, 50 U mL
-1
 penicillin, 
50 µg mL
-1
 streptomycin, 10 ng mL
-1
 PDGF-AA, and 10 ng mL
-1
 FGF2) for OPC cultures, or in Sato 
medium (DMEM supplemented with 2 mM glutaMAX-I, 1 mM sodium pyruvate, 1X N2 supplement, 30 nM 
thyroxine, 30 nM triiodothyronine, 50 U mL
-1
 penicillin, and 50 µg mL
-1
 streptomycin) to generate 
oligodendrocyte cultures. Cells were plated onto poly-D-lysine (PDL) coated glass coverslips in 24-well 
plates (0.3 mL/well, at 3 x 10
4
 cells/cm
2
). OPC cultures were maintained for 24 h before incubation with 
MPs, to allow cell adherence and re-growth of processes. Oligodendrocyte cultures were maintained for 7 
days (50% medium changes every 2 – 3 days) to allow cell differentiation, before incubation with MPs. Cells 
were then incubated with 2 – 50 µg mL-1 MPs for 1 – 24 h. For long-term studies, OPCs were pulse-labeled 
with MPs for 24 h, then switched to Sato medium and maintained for 1 month. Control cultures were treated 
with equal volumes of fresh medium, without MPs. Samples were washed with phosphate buffered saline 
(PBS), then fixed and either immunostained, or processed for Perl's Prussian blue histochemical staining. 
OPC and oligodendrocyte cultures are not as strongly adherent to PDL-coated coverslips as microglial and 
astrocyte cultures. This presented a methodological problem for particle uptake experiments with regard to 
the removal of extracellular particles when terminating incubations. In previous work, extensive washing 
with PBS was necessary to reduce non-specific binding of MPs to minimal levels, and this was well tolerated 
by microglial and astrocyte cultures, resulting in minimal cell detachment. In the present study a similar 
washing protocol resulted in the loss of many OPCs and oligodendrocytes, even without the prior addition of 
MPs. Consequently, to minimize the loss of cells, several washes were performed by gently applying PBS to 
the walls of culture wells. 
 
Toxicity assessment: Initial experiments used a 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium 
bromide (MTS) assay to assess MP toxicity in OPCs and oligodendrocytes, as described earlier, for 
comparison with astrocyte and microglia data [24,27]. However, in these cell types, typically low levels of 
MTS reduction to formazan were consistently found in both control and MP-treated cultures, which was not 
deemed sufficiently sensitive to accurately assess toxicity. Therefore, epifluorescence microscopy was used 
to count the pyknotic and total (healthy plus pyknotic) nuclei per microscopic field, as measures of MP-
related toxicity. A minimum of five fields were counted for every condition. 
 
Immunocytochemistry: Washed cells were fixed with 4% paraformaldehyde [PFA; room temperature (RT); 
25 min] then washed again. For staining, cells were incubated with blocking solution [5% serum in PBS, 
with 0.3% Triton X-100 for MBP (myelin basic protein); RT; 30 min], then with primary antibody in 
blocking solution (A2B5 1:200; MBP 1:200; 4°C; overnight). A2B5 and MBP are widely-used markers of 
the oligodendroglial lineage: the A2B5 antibody recognizes cell surface ganglioside epitopes; MBP is one of 
the major protein constituents of myelin, and is used to label late-stage oligodendrocytes. Cells were then 
washed with PBS, incubated with blocking solution (RT; 30 min), and incubated with the appropriate FITC-
conjugated secondary antibody in blocking solution (1:200; RT; 2 h). Finally, coverslips were washed with 
PBS and mounted with the nuclear stain DAPI.  
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Fluorescence microscopy & image analysis: Samples were imaged using fixed exposure settings on an Axio 
Scope A1 fluorescence microscope (Carl Zeiss MicroImaging GmbH, Goettingen, Germany), and the images 
merged using Adobe Photoshop CS3 (version 10.0.1). The purity of each culture was determined by scoring 
at least 100 DAPI-stained nuclei for coincidence with A2B5 or MBP staining. Z-stack fluorescence images of 
samples were created using fixed exposure settings on a Nikon Eclipse 80i microscope fitted with a CA742-
95 camera (Hamamatsu Photonics, Hamamatsu, Japan), with manual focus stepping at 0.5 or 1.0 µm, and the 
image manipulations performed using Nikon NIS Elements (version 3.00). The proportion of A2B5
+
 OPCs or 
MBP
+
 oligodendrocytes with coincident nile red fluorescence was assessed (minimum 100 DAPI-stained 
nuclei for each concentration and time point), with the proportion of MP-labeled cells exhibiting any 
perinuclear MPs also being recorded. Some samples were also imaged using a BioRad MRC1024 confocal 
laser scanning microscope. 
 
Semi-quantitative assessment of MP uptake: It was deemed unsuitable to assess levels of uptake by means of 
a fluorescence plate reader, or in terms of incorporated iron per cell, as these techniques quantify the total 
fluorescence or iron present in a culture, and therefore assume an even distribution between cells. Such 
techniques would not enable the determination of uptake heterogeneity within the cell population, as 
observed in our cultures. A flow cytometry approach was also considered and rejected, as it is likely that 
extracellular MPs adherent to the plasma membrane would lead to a number of ‘false positives' and this 
technique cannot distinguish cytoplasmic versus nuclear accumulations of particles within cells. Microscopic 
cell counting analysis was therefore considered the most appropriate method to assess whether MPs were 
intracellular, or merely extracellularly attached to plasma membrane. To ensure that cellular uptake was 
judged correctly, z-stack analyses were performed for both OPC and oligodendrocyte cultures to confirm that 
MPs were intracellular, rather than adherent to the plasma membrane (minimum of 100 cells analyzed for all 
concentrations and timepoints). Analysis of oligodendrocyte cultures proved particularly problematic, as MPs 
were often observed amongst their extensive, lipid-rich processes. However, from the z-stack analyses it was 
apparent that MPs were external to the oligodendrocyte processes. Therefore, for these analyses, only MPs 
that were clearly within the oligodendrocyte soma, the main cell body, were considered to be intracellular, 
and all other particles were deemed to be extracellular. The level of MP uptake in individual cells was 
assessed in a semi-quantitative manner by comparison with the average cross-sectional area of an 
OPC/oligodendrocyte nucleus, and scored as either ‘low’ (<10% of the area of an average nucleus), 
‘medium’ (10 – 50%), or ‘high’ (>50%). We consider that such detailed microscopic assessment of MP 
uptake more accurately reflects the heterogeneity that is typically found in primary cell cultures. 
 
Cross cellular comparison of MP uptake across neuroglial subpopulations: Selected datapoints from OPC 
and oligodendrocyte uptake experiments were combined with equivalent datapoints obtained from rat 
astrocytes [27] and microglia [24] using identical particle concentrations and timings of exposure. In both 
cases, the cells were derived from mixed glial cultures (as used for derivation of OPCs and oligodendrocytes) 
however these two cells were maintained in D10 medium (which is detailed above) for uptake analyses. The 
relative plating densities used in these experiments were 3 x 10
4
 cells/cm
2
 (OPCs and oligodendrocytes), 4 x 
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10
4
 cells/cm
2
 (astrocytes) and 6 x 10
4
 cells/cm
2
 (microglia). Toxicity data (MTS assays) for astrocytes and 
microglia were obtained from references [27] and [24], respectively.  
Perls’ Prussian blue staining: Washed samples were fixed with 4% PFA (RT; 25 min), then washed again. 
Samples were incubated with 2% potassium ferricyanide in 2% HCl for 30 min, then washed three times with 
distilled water and mounted without DAPI. Images were then taken using light microscopy, to visualize 
intracellular iron, and fluorescence microscopy, to visualize nile red particle fluorescence. Images were 
merged to assess colocalization of iron deposits with fluorescence. 
 
Scanning electron microscopy (SEM): MPs in OPC-MM were air-dried onto aluminium stubs and visualized 
uncoated using a high resolution field emission scanning electron microscope (Hitachi S4500) operated at an 
accelerating voltage of 5 kV. 
 
Transmission electron microscopy (TEM): Microglial, oligodendrocyte, astrocyte and OPC cultures were 
established on PDL- or polyornithine-coated aclar sheet (microglial [24] and astrocyte [27] cultures were 
prepared as described previously), cut to fit a 24-well plate (0.3 mL/well, at 6 x 10
4
 cells/cm
2
), then incubated 
with 20 µg mL
-1
 MPs for 4 or 24 h. Samples were fixed with 2.5% glutaraldehyde [in sodium cacodylate 
buffer (SCB); RT; 2 h], then washed with SCB. Samples were postfixed with 1% osmium tetroxide in SCB 
for 1 h, washed with SCB, dehydrated in a graded series of ethanol, then infiltrated with Spurr resin, before 
polymerization at 60°C for 16 h. To obtain sections, the block was trimmed to expose the aclar sheet which 
was peeled off, leaving the cells in the resin. Ultrathin sections were then cut parallel to the original plane of 
the sheet on a Reichert Ultracut E ultramicrotome, mounted on 200 mesh thin bar copper grids, and stained 
with 2% uranyl acetate in 70% ethanol (RT; 20 min) and 2% Reynolds lead citrate (RT; <5 min). A 
minimum of three sections were examined for each cell type using a JEOL 100-CX transmission electron 
microscope operated at 100 kV. Images were acquired using a SIS systems Megaview III digital camera 
(Olympus). 
 
Statistical analysis: Data were analyzed using GraphPad Prism statistical analysis software. Data are 
expressed as mean ± SEM. The number of experiments (n) refers to the number of mixed glial cultures from 
which OPC or oligodendrocyte cultures were derived, with each primary culture being established from a 
different rat litter. Data were analyzed by two-way analysis of variance (ANOVA), with Bonferroni’s 
multiple comparison post-tests for post hoc analysis 
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Results 
Characterization of MPs 
The MPs used here have a multilayered design (Figure 1a), comprising a polystyrene core (stained 
with the fluorophore nile red), coated with a polystyrene/iron oxide composite layer; thus the fluorophore is 
encapsulated within the particle structure and we have found that these are stable in physiological media and 
consistently perform robustly under our experimental conditions, justifying their use in this study. These 'test' 
MPs are relatively large (200 – 390 nm diameter; mean = 360 nm); we have previously justified the use of 
particles of this diameter for in vivo biological applications [24]. Indeed, particles of up to 1 µm diameter 
have been used to image cells transplanted into the CNS without demonstrable effects on even complex 
biological functions such as myelination [29] and other particles, including functionalized transfection grade 
ones are of comparable diameter [29–32].  
 
Batch-to-batch variability can occur during MP synthesis, and particle size is an important factor in 
cellular uptake and processing [19]. Therefore, MPs were analyzed by SEM for size and shape assessments; 
our data were consistent with our previous findings, showing that the particles used here were regular in 
shape, and within the size range reported by the manufacturer (Figure 1b). Perls’ Prussian blue staining of 
cells which had been pulse-labeled with these MPs for 24 h revealed the presence of iron coincident with nile 
red fluorescence at 24 h (Figures 1c & d), and at 30 days post-treatment (data not shown). This demonstrates 
the reliability of fluorescence as an indicator of MP presence, and suggests the stability of MPs in the culture 
media and the cells. No blue staining was observed after Perls’ staining of control cultures. The particles 
carry ca. 1.63 × 106 carboxyl groups per particle (data provided by supplier, Spherotech Inc.). The 
hydrodynamic size of the particles was similar in Sato or OPC-MM, with a slight increase in D10 medium, 
therefore no differences in aggregation were observed in the three types of media used (Table 1). 
Comparison of 5 min and 24 h measurements in Sato medium showed that a small amount of particle 
aggregation occurred, as the particle size increased by a factor of ca. 2. The mean diameter of these particles 
was shown to be 360 nm by SEM analysis, but the hydrodynamic diameter was in the range 843 – 961 nm. 
These values were determined by dynamic light scattering (DLS), a technique that measures the 
hydrodynamic diameter of the particle surrounded by the solvation layers. Measurements by DLS are more 
accurate for soft materials, such as proteins, with the size of more dense materials commonly being 
overestimated [33]. These observations are consistent with the literature relating to magnetic nanoparticles 
[34]. 
  
The zeta potential measurements showed that the particles carried negative charge in all media, 
which can be attributed to the carboxylic acid groups (Table 1). The difference in zeta potential among 
particles in different media was found to be small (indeed, as the charge on a particle is pH dependent, the 
zeta potential of the particles would not be expected to vary significantly as the media used for the cell 
culture experiments are all of similar pH values). 
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Figure 1: Multi-layered MP structure with particle visualization by fluorescence and histochemical 
staining. (a) Schematic diagram of an idealized particle, illustrating the polystyrene core stained with nile 
red fluorophore, surrounded by a magnetite layer (Fe3O4), with a carboxyl-modified coating (layers not 
drawn to scale). (b) Scanning electron micrograph of an individual particle, showing typical size and shape. 
(c) Phase-contrast micrograph, showing Perls’ Prussian blue staining of iron within an OPC (24 h 
incubation with 20 µg
 
mL
-1
 MPs). (d) Counterpart fluorescence micrograph image to (c), showing nile red 
fluorescence is coincident with iron accumulations. Scale bar = 20 µm in (c) and (d). (e) FTIR spectroscopic 
analysis of MP shows a major polystyrene component characterized by peaks between the region 3083 – 
3025 cm
-1
 (C-H stretch, aliphatic) and 2923 – 2851 cm-1 (C-H stretch, aromatic ring). The peaks within the 
fingerprint region 1601, 1492 and 1452 cm
-1
 correspond to the C=C stretch in an aromatic system. The 
strong peaks at 755 and 696 cm
-1
 correspond to the C-H bending mode of the benzene ring. A small number 
of carboxylic acid groups were detected at 1707 cm
-1
 (C=O stretching), indicated by an arrow. (f) Powder 
XRD pattern of particles showing an inverse spinel structure of iron oxide crystallites in particles (a.u. = 
arbitrary units). 
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The FTIR spectrum of these Spherotech particles was dominated by the polystyrene component 
(Figure 1e) with a small number of carboxylic groups, shown as νC=O (C=O stretching) at 1707 cm
-1
. The 
powder XRD pattern (Figure 1f) revealed that the iron oxide crystallites in the particles are of an inverse 
spinel structure, eg. Fe3O4 (magnetite) or gamma-Fe2O3 (maghemite). However, due to the small crystal size 
or low crystallinity of the iron oxide, the diffraction peaks are broad and of low intensity. This is also partly 
due to the predominant amount of polystyrene (ca. 80%) present in the particles. The average crystal size was 
estimated to be around 18.5 nm in diameter using Scherrer analysis on the diffraction peak (311).  
 
 
Table 1. Physical characteristics of Sphero MPs in various biological media 
    ζ-potential [mV]a   dDLS [nm]
a
 
Medium Relevant cell type(s) Incubation time: 5 min   5 min 24 h 
H2O - -  
 
843 - 
Sato Oligodendrocytes -14.3  
 
850 1650 
D10 Astrocytes; Microglia -13.7  
 
961 - 
OPC-MM OPCs -14.6    867 - 
dDLS = Hydrodynamic diameter, determined by dynamic light scattering (DLS). 
a
Average values of three 
measurements 
 
 
OPC Culture Characteristics 
Phase contrast microscopy of untreated and MP-treated cultures revealed phase-bright cells with 
bipolar morphologies characteristic of OPCs (Figure 2a). High purity OPC cultures were routinely derived, 
as assessed by immunostaining for the OPC marker A2B5 (95.4 ± 0.9%; n = 4), and DAPI-staining showed 
typical round or oval nuclei (Figure 2a, inset). 
 
Concentration- and Time-Dependence of MP Uptake and Perinuclear Localization in OPCs 
Fluorescence microscopy, including z-stack and confocal analyses, confirmed the intracellular 
localization of MPs in OPCs (Figure 2b; confocal data not shown) with particles typically observed in small 
clusters. MP uptake was time- and concentration-dependent, with the highest dose and longest exposure 
tested resulting in labeling of ca. 60% of A2B5
+
 cells (Figure 2c). Concentrations of 20 and 50 µg mL
-1
 
labeled a significantly greater percentage of cells than 2 µg mL
-1
, at all time points. The extent of MP-uptake 
by individual cells was heterogeneous, therefore a semi-quantitative approach was employed to classify 
categories of uptake as described previously [24,27]. Under all conditions, the majority of MP-labeled OPCs 
exhibited a ‘low’ level of particle accumulation. At 4 and 24 h, a small percentage of MP-labeled cells 
exhibited ‘medium’ levels of uptake at all concentrations with ‘high’ levels of uptake rarely observed (Table 
2). The percentage of labeled OPCs with MPs in a perinuclear localization was time- and concentration-
dependent (Figure 2d). Intranuclear particles were not observed using confocal or z-stack analyses. 
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Figure 2: Uptake and perinuclear localization of MPs by OPCs is time- and concentration-dependent. 
(a) Typical phase-contrast micrograph of OPCs, with counterpart fluorescence micrograph, inset, showing 
A2B5 staining. (b) Z-stack fluorescence analysis of cells incubated with 5 µg
 
mL
-1
 MPs for 4 h. Nile red 
fluorescence reveals MPs in cytoplasmic accumulations (blue arrow), perinuclear accumulations 
(crosshairs), and attached to the substratum (white arrow). (c) Bar chart showing the time- and 
concentration-dependent labeling of OPCs with MPs. The proportion of labeled cells is related to particle 
concentration and incubation time (p<0.001 for each factor; two-way ANOVA; n = 4). (d) Bar chart showing 
the time- and concentration-dependence of perinuclear particle localization in MP-labeled OPCs. 
Perinuclear localisation was related to both particle concentration and incubation time (p<0.001 for each 
factor; two-way ANOVA; n = 4). For (c) and (d): [*p<0.05 versus 2 µg
 
mL
-1
 at the same timepoint; 
+
p<0.05 
versus the same concentration at 1 h (Bonferroni’s post-tests)]. Scale bar = 50 µm in (a), 20 µm in (b). 
 
Oligodendrocyte Culture Characteristics 
Oligodendrocytes were derived from high purity parent OPC cultures (Figure 3a), with 70.3 ± 1.3% 
of cells staining positive for the late-stage oligodendrocyte marker myelin basic protein (MBP; Figure 3a, 
inset). All stages of the oligodendroglial lineage are typically present in such cultures [35], and our own 
analyses show that a further ~25% stain for earlier markers such as NG2 and O4, with the remainder (<5%) 
being microglial contamination (data not shown). Cells were phase-bright, with multipolar morphologies, 
including the complex highly-branched, membrane elaborating morphologies typical of mature 
oligodendrocytes. 
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Table 2. Semi-quantitative analysis of extent of MP uptake by OPCs 
  
Proportion of labeled OPCs (%) 
Incubation 
time [h] 
MP concentration  
[µg
 
mL
-1
] 
‘Low’ ‘Medium’ ‘High’ 
1 2 100.0% 0.0% 0.0% 
5 100.0% 0.0% 0.0% 
20 100.0% 0.0% 0.0% 
50 95.0 ± 1.0% 5.0 ± 1.0% 0.0% 
4 2 99.6 ± 0.5% 0.4 ± 0.5% 0.0% 
5 96.7 ± 2.6% 3.3 ± 2.6% 0.0% 
20 88.2 ± 4.1% 11.8 ± 4.1% 0.0% 
50 87.0 ± 3.1% 12.1 ± 2.2% 0.9 ± 1.0% 
24 2 97.3 ± 1.9% 2.7 ± 1.9% 0.0% 
5 95.9 ± 2.2% 4.1 ± 2.2% 0.0% 
20 86.8 ± 4.3% 12.2 ± 3.6% 1.1 ± 0.7% 
50 85.1 ± 4.3% 13.3 ± 3.0% 1.6 ± 1.5% 
 
 
Figure 3: Uptake of MPs by oligodendrocytes is time- and concentration-dependent, and perinuclear 
localization is time-dependent. (a) Representative phase-contrast and fluorescence (inset) micrographs of 
oligodendrocytes. (b) Z-stack fluorescence analysis of an MBP
+
 oligodendrocyte, incubated with 5 µg
 
mL
-1
 
MPs for 4 h. Nile red fluorescence indicates the presence of MPs in cytoplasmic and perinuclear (crosshairs) 
accumulations. White arrow indicates extracellular MPs amongst processes. (c) Bar chart showing the time- 
and concentration-dependent labeling of oligodendrocytes with MPs. The percentage of labeled cells is 
significantly related to both particle concentration and incubation time (p<0.001 for each factor; two-way 
ANOVA; n = 4). (d) Bar chart showing that the percentage of oligodendrocytes with perinuclear particles is 
significantly related to incubation time but not MP concentration (p<0.001 and p = 0.161 respectively; two-
way ANOVA; n = 4). For (c) and (d): [*p<0.05 versus 2 µg
 
mL
-1
 at the same timepoint; 
+
p<0.05 versus the 
same concentration at 1 h (Bonferroni’s post-tests)]. Scale bar = 50 µm in (a), 10 µm in (b). 
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Concentration- and Time-Dependence of MP Uptake and Perinuclear Localization in 
Oligodendrocytes 
Z-stack and confocal fluorescence analyses, confirmed the presence of intracellular MPs in 
oligodendrocytes, including perinuclear accumulations (Figure 3b; confocal data not shown). The percentage 
of labeled oligodendrocytes was time- and concentration-dependent, with the greatest dose and exposure 
tested resulting in MP-labeling of ca. 45% of MBP
+
 cells (Figure 3c). MP concentrations of 20 and 50 µg 
mL
-1
 labeled a significantly greater percentage of MBP
+
 cells than 2 µg mL
-1
, at all timepoints. Heterogeneity 
in uptake was apparent and this was assessed semi-quantitatively using the same criteria used for scoring 
OPCs (Table 3). Under all conditions, the majority of MP-labeled cells exhibited a ‘low’ level of particle 
accumulation. At 4 and 24 h, oligodendrocytes with ‘medium’ levels of MP accumulation were observed 
with ‘high’ levels of accumulation rarely observed (only at the greatest MP concentration and incubation 
time; Table 3). By 24 h, cultures exposed to 2 and 5 µg mL
-1
 MPs exhibited a time-dependent increase in the 
percentage of MP-labeled MBP
+
 oligodendrocytes with perinuclear particles (Figure 3d). 
 
Table 3. Semi-quantitative analysis of extent of MP uptake by oligodendrocytes 
  Proportion of labeled oligodendrocytes (%) 
Incubation 
time [h] 
MP concentration  
[µg
 
mL
-1
] 
‘Low’ ‘Medium’ ‘High’ 
1 
2 100% 0.0% 0.0% 
5 100% 0.0% 0.0% 
20 100% 0.0% 0.0% 
50 100% 0.0% 0.0% 
4 
2 100% 0.0% 0.0% 
5 96.2 ± 4.4% 3.8 ± 4.4 % 0.0% 
20 93.5 ± 0.4% 6.5 ± 0.4% 0.0% 
50 85.1 ± 3.6% 14.9 ± 3.6% 0.0% 
24 
2 98.2 ± 2.1% 1.8 ± 2.1% 0.0% 
5 95.0 ± 5.8% 5.0 ± 5.8% 0.0% 
20 91.6 ± 5.6% 8.4 ± 5.6% 0.0% 
50 86.0 ± 5.4% 12.8 ± 5.5% 1.2 ± 1.0% 
 
Comparison of MP Uptake in OPCs and Oligodendrocytes 
When data for OPCs and oligodendrocytes were compared, the proportions of labeled cells were 
similar at 1 h post-MP addition (Figures 2c & 3c). At subsequent time points, a greater percentage of OPCs 
than oligodendrocytes were MP-labeled with the exception of the 24 h incubation with 20 µg mL
-1
 MP 
(Tables 2 and 3). With respect to cells scored as having ‘low’ levels of uptake, the accumulations of MPs 
present within OPCs were typically larger than those within oligodendrocytes (compare Figures 2b and 3b, 
which show representative levels of MP accumulation). Further, cells at more advanced stages of 
oligodendrocyte differentiation (judged by number/complexity of processes), contained smaller particle 
accumulations than cells with relatively immature and less branching morphologies (data not shown). This 
suggests an inverse relationship between cellular maturity and capacity for MP uptake. For both cell types, 
the percentage of cells with ‘medium-high’ levels of MP uptake was time- (p<0.001; two-way ANOVA; n = 
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4) and concentration-dependent (p<0.001; two-way ANOVA; n = 4), suggesting that the uptake mechanism 
is non-saturable in the time-frame examined.  
 
Assessment of MP Toxicity in OPCs and Oligodendrocytes  
No significant effects of MPs were observed in OPC or oligodendrocyte cultures with respect to (a) 
cell adherence, judged by number of DAPI-labeled nuclei (either healthy or pyknotic) per microscopic field 
(Figures 4a & b), and (b) cell death, judged by the percentage of nuclei exhibiting pyknotic features (ie. 
shrunken or fragmenting morphologies; Figures 4c & d). OPC and oligodendrocyte cultures appeared 
morphologically similar to controls at 24 h, and this was also true for oligodendrocytes at one month post-
pulse labeling with MPs (data not shown). No effects of MPs were noted on the time taken to reach 
confluence or extent of membrane elaboration in OPC or oligodendrocyte cultures. 
 
 
Figure 4: Incubation with MPs at a range of concentrations does not result in acute cytotoxicity in 
OPCs or oligodendrocytes. Bar graphs of time course experiments showing total (healthy plus pyknotic) 
nuclei per microscopic field for (a) OPC and (b) oligodendrocyte cultures, and percentage of nuclei with 
pyknotic features for (c) OPC and (d) oligodendrocyte cultures. No significant differences were found in 
these parameters either in relation to particle incubation time or particle concentration (p>0.05; two-way 
ANOVA; n = 4 for all graphs). 
 
Intercellular Differences in Extent of MP Uptake 
Data from OPCs and oligodendrocytes were combined with data obtained from rat astrocytes [27] 
and microglia [24] using identical particle concentrations and timings of exposure. From these analyses, there 
are clear differences between individual neuroglial classes in the rate and extent of MP accumulation, with 
the relationship with respect of these parameters being: microglia > astrocytes > OPCs > oligodendrocytes 
(Figures 5a-d). Comparing the extent of MP-uptake at 4 h, highlights the rapid labeling of >90% of 
microglia, even with low MP concentrations, compared to the gradual time- and concentration-dependent 
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uptake observed in the other cell types (Figure 5e), using an identical MP dose. Intercellular differences in 
perinuclear particle localization were also apparent with a representative dose of 50 µg mL
-1
, with microglia 
showing the most rapid and extensive accumulation (Figure 5f).  
 
Figure 5: The extent and rate of MP uptake by neuroglia are cell-type specific. Fluorescence 
micrographs of neuroglia, following incubation with MPs (20 µg mL
-1
, 24 h). (a) Microglia are stained with 
the marker OX42, in characteristic punctate fashion, and exhibit high levels of MP uptake, including large 
particle clusters and perinuclear accumulations. (b) Astrocytes stain for the marker GFAP, and exhibit 
heterogeneity in the extent of MP uptake. Note flattened cells, large quantities of cytoplasm relative to 
nucleus in cross-section, and greater extent of uptake compared to (c) and (d). (c) OPCs stain positive for the 
marker A2B5, and exhibit typically small clusters of MPs compared to (b). Note bipolar forms and 
potentially limited quantity of membrane available to undertake endocytosis. (d) Oligodendrocyte stained 
with the late-stage oligodendrocyte marker MBP, and exhibiting a highly branched, mature morphology. 
Very small accumulations of MPs are present (white arrows, and enlarged in inset). Despite extensive 
membrane elaboration, MPs are mainly extracellular. (e) Bar graph illustrating comparative MP-labeling in 
enriched/purified cultures of each neuroglial cell type after 4 h exposure to MPs. (f) Bar graph showing the 
percentage of all cells having perinuclear MPs in enriched/purified cultures of each neuroglial cell type (50 
µg
 
mL
-1
). For (e) and (f), data for astrocytes and microglia were obtained from references [27] and [24], 
respectively; ODC = MBP
+
 cells in oligodendrocyte cultures; OPC = A2B5
+
 cells in OPC cultures; Astro = 
GFAP
+
 cells in astrocyte cultures; Micro = OX42
+
 cells in microglial cultures. All scale bars are 10 µm. 
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Intercellular Differences in MP Processing in Cells 
TEM analyses were used to study the intracellular disposition of MPs. This is a time consuming and 
technically demanding method compared with other histological approaches, but we consider that this is the 
most robust ultrastructural approach to obtain morphological data on modes of particle uptake, evidence of 
vacuolar internalization, perinuclear trafficking, and lysosomal degradation/end products of MP breakdown, 
with high resolution. Electron dense MPs were easily identified within cells using TEM. Astrocytes, OPCs 
and oligodendrocytes contained intact MPs (Figures 6a-c), morphologically similar to particles incubated in 
medium alone (Figure 6a, inset), that were generally observed to be free in the cytosol including the 
perinuclear accumulations [27]. MP clusters were smaller in oligodendrocytes compared with OPCs, and 
strikingly smaller in OPCs and oligodendrocytes compared with astrocytes (Figures 6a-c), supporting our 
observations using fluorescence microscopy. By contrast, microglia revealed extensive MP accumulations 
which were often associated with multilamellar bodies (Figure 6d & e). In contrast to astrocytes and OPCs, 
MPs appeared to be undergoing extensive degradation in microglia, likely within lysosomes (Figure 6e, 
inset). Following 24 h MP exposure, toxicity was not observed in OPCs, oligodendrocytes, or astrocytes [27], 
but was marked in microglial cultures at an identical applied MP concentration (Figure 6f) [24].  
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Figure 6: Intracellular fate of MPs is cell-type dependent. (a-e) TEM analyses of glial cells following 24 h 
incubation with 20 µg
 
mL
-1
 MPs. (a) An astrocyte where MPs appear to be intact, as evidenced by the 
presence of electron dense rings of iron surrounding the polystyrene cores (*). Inset, intact MPs in D10 
medium without cells (24 h incubation), for comparison of particle shape and structure. (b) An OPC showing 
intact MPs in a small cluster in the cell cytosol (arrow). (c) An oligodendrocyte showing a single MP in the 
cytosol (arrow). Inset shows increased magnification image of the MP. Note the relative size of the MP 
accumulations in (a), (b) and (c), which are typical of astrocytes, OPCs and oligodendrocytes. (d) A 
microglial cell showing large intracellular accumulations of MPs. Note that these particles appear to be 
undergoing degradation, as evidenced by comparison with intact MPs [see (a), inset]. (e) A microglial cell, 
showing particles associated with an electron dense multilamellar body. Note that the electron dense iron 
particles are not accumulated in rings, but appear to be condensing into clusters, suggesting that particles 
are undergoing degradation. Inset, extensive MP degradation within a lysosome, as evidenced by dispersion 
of iron deposits. (f) Bar graph comparing MP-related toxicity in neuroglial cells following 24 h incubation 
with 20 µg
 
mL
-1
 MPs. Toxicity in OPC and oligodendrocyte (ODC) cultures is assessed by cell number per 
field (left y-axis) while toxicity to astrocytes (Astro) and microglia (Micro) is assessed by MTS assay (right y-
axis); data for astrocytes and microglia were obtained from references [27] and [24], respectively. Nu 
indicates nucleus. Scale bars indicate 0.5 µm, except (c, inset) where scale bar indicates 200 nm. 
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Discussion 
To the best of our knowledge, this is the first investigation into intercellular differences in MP 
uptake and handling by the major neuroglial subtypes. Our data reveal that these subpopulations exhibit key 
differences in the uptake and intracellular processing of MPs, which reflect cell intrinsic differences and 
cannot be attributed to differences in experimental conditions used to propagate the individual cell types. For 
example, astrocytes and microglia are cultured in the same medium (D10) in isolated culture experiments, 
but show significant differences with respect of particle uptake and accumulation. Indeed, in recent 
experiments, where microglia and astrocytes were co-cultured in a 1:1 ratio in D10 medium (ie. identical cell 
densities and medium), we found dramatic differences in the extent of MP uptake between these cells, with 
particles localized almost exclusively to microglial cells. Few differences were noted in particle size and 
charge in the different media, and all cell types were derived from primary mixed glial cultures, eliminating 
variability in the cell source seen in previous work evaluating intercellular differences in particle handling by 
neural cells [36]. This lends further support to the notion that the variations observed represent true cell 
specific properties. We consider that such variations could have important implications for the biological 
utility of MP platforms for neural tissue engineering applications. As such, we consider that the findings have 
broader implications for the design and development of novel neurocompatible materials for regenerative 
medicine, and associated protocols for their use. 
 
Most work to date evaluating cellular MP uptake and handling has utilized cell lines [37-41]. This 
has yielded valuable data but warnings about cell line identity have been made since the 1950s, with many 
instances of published work carried out in misidentified cell lines [42-44]. Cell lines possess an altered 
physiology compared with the corresponding primary cells and behave in a relatively homogenous clonal 
manner. Consequently, their properties may not represent biological variations that exist in vivo that reflect 
cell proliferation, differentiation and varying states of biological activation (particularly relevant in 
neurological injury), all of which will influence the outcomes of MP use. Cell lines show relatively high 
survival/proliferation rates and resistance to adverse stimuli such as cell death signals. Continuous passage of 
cells without robust quality control also risks chronic contamination by mycoplasma - such ‘cryptic’ 
contamination can alter cell structure, metabolism and growth, all of which can impact the interpretation of 
data [45]. These considerations, combined with the risk of cellular aneuploidy, can make cell lines a 
relatively poor model for toxicity testing [45,46]. This is an issue of high relevance to nanotechnology, where 
the neurotoxicity of nano- and micro-sized particles is currently an issue of major public and scientific 
concern. As such, we contend that cells derived from primary cultures, as used here, are of higher biological 
relevance than cell lines, particularly when developing protocols for translational applications.  
 
MP uptake is dependent on endocytosis (macropinocytosis, clathrin-, and caveolin-mediated uptake) 
in mammalian cells [2,19,47] but limited data exist on MP uptake mechanisms in primary neuroglia. The 
cells studied here display a range of endocytotic mechanisms overall, and differences in MP accumulation 
likely relate to variations in basal levels of endocytosis. We can predict that the specific endocytotic 
pathways utilized by each cell type, and their levels of activity, closely correlate with the functional role for 
each cell type. For example, microglia are phagocytic cells and continuously survey their microenvironment 
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using highly motile processes, removing debris and foreign materials; they utilize all endocytotic 
mechanisms, including receptor-mediated endocytosis, macropinocytosis and phagocytosis [24,48]. The 
astrocytes, in turn, have a major role in uptake of extracellular biomolecules and possess well-developed 
endocytotic machinery; we recently showed that astrocytes take up the MPs studied here by 
macropinocytosis and coated pit mechanisms [27]. In line with their broad regulatory and defence roles, 
microglia and astrocytes showed extensive and rapid particle uptake. By contrast, cells of the 
oligodendrocyte lineage have specialist roles in generating oligodendrocytes and the myelin sheath [23]. As 
such, we can predict that endocytotic cycling in these cells is lower, an expectation strikingly reflected in the 
finding that percentages of labeled oligodendroglial cells are about half that observed in astrocytes and 
microglia, along with substantially lower levels of MP accumulation. We are not aware of studies quantifying 
endocytotic mechanisms across neuroglial cells, and such a comparison will be a pre-requisite to providing 
formal proof of this idea.  
 
A further factor influencing uptake could be the relative extent of cell membrane available to 
undertake endocytosis. Astrocytes display characteristically flattened morphologies and large amounts of 
membrane. By contrast, OPCs and oligodendrocytes have small oval or round cell bodies, and, as far as we 
are aware, their processes are not involved in particle uptake - observations supported by our histological 
analyses. Differences in cell surface area may account for the differences in particle uptake, and it is not clear 
whether using particles of altered dimensions or geometry may result in greater MP accumulation [19,49].  
 
In line with their phagocytic role, microglial cells appear to inactivate particles by sequestration 
within vesicles and active lysosomal degradation. Extensive particle accumulation in conjunction with iron 
toxicity post-degradation is the likely pathological correlate of MP toxicity in these cells [50]. By contrast, in 
the other cell types, particles appeared to be relatively stable morphologically with negligible associated 
toxicity.  
 
We consider that the overall profiles of MP uptake and handling exhibited by neuroglia, as reported 
here, have broader predictive value with biological implications regarding MP use in neural tissue 
engineering (see Figure 7 for a schematic overview). First, if using MPs for cell labeling and imaging of 
neural transplant populations, then protocols will need to be individually tailored by cell type, with OPCs 
requiring higher particle concentrations and incubation times, to achieve high efficiency labeling. A previous 
study in an OPC cell line suggests that sub-10 nm magnetic nanoparticles show extensive accumulation in 
these cells [9] indicating that MP physicochemical properties (such as size, shape, coating, geometry and 
charge) may need to be tailored to achieve optimal labeling [8].  
 250 
 
 
Figure 7: Schematic overview of intercellular differences in MP-processing by neuroglia and relevance 
to neural tissue engineering applications. Diagrams illustrate typical cell morphologies, relative levels of 
MP-accumulation, extent of perinuclear localization and degradation of MPs. Tables summarize related 
effects on labeling and transfection levels achievable in individual cell types, and associated cytotoxicity. 
ODC = oligodendrocyte. 
 
Second, while MPs are effective transfection agents, the specific mode of intracellular trafficking of 
particles will exert an important influence on transfection levels achieved. Efficient perinuclear accumulation 
of MPs (a pre-requisite for DNA delivery [51]) in microglia, suggests that MPs could act as effective 
transfection agents in these cells, but we recently reported that microglial transfection was rarely achieved 
using transfection grade MPs [24]; particle sequestration and breakdown provides a reasonable explanation 
for our observations and indeed, there are few reports of non-viral, plasmid based transfection of microglia. 
Microglial transfection is a desirable goal, allowing immunomodulation in neurological injury, but our results 
indicate that there are significant 'intracellular barriers' to MP-mediated transfection in microglia that will 
need to be overcome, using strategies such as MP targeting to particular intracellular compartments to evade 
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degradation mechanisms. By contrast, the relative stability and non-sequestration of MPs in astrocytes and 
OPCs is in line with our findings that both cell types can be transfected (with the same transfection grade 
MPs tested in microglia), albeit with major differences in maximal transfection levels achieved (ca. 55% for 
astrocytes [12] versus ca. 23% for OPCs [14]). This trend correlates with the relative extent of basal MP 
uptake in astrocytes versus OPCs. There is a sharp drop in MP mediated transfection of oligodendrocytes (up 
to 4%; unpublished observations) despite perinuclear MP accumulation. This could be related to lower 
particle uptake but successful transfection may also depend on other factors. For example, nuclear breakdown 
during mitosis may facilitate entry of nucleic acids, so proliferative populations such as astrocytes/OPCs may 
be relatively amenable to MP-mediated transfection compared to non-dividing cells such as oligodendrocytes 
[17,51].  
 
Third, robust microglial uptake of MPs is beneficial for imaging sites of CNS injury/disease [52]. 
However, rapid and extensive particle uptake by endogenous microglia may limit particle uptake by other 
cell types where mixed populations of neural cells exist, for example, neurological injury sites [24]. Such 
considerations suggest that microglial MP uptake is a significant ‘extracellular barrier' when considering 
applications such as direct MP mediated drug/gene delivery to the CNS, that may potentially require 
strategies such as immunosuppression, cell targeting approaches or variations in particle physiochemical 
properties, to reduce microglial uptake. Further, MP related toxicity in microglia could become a cause of 
secondary CNS pathology, therefore particle doses and formulations must be selected with caution. 
 
 
Conclusions 
CNS neuroglial subclasses show considerable variability in MP uptake and intracellular handling. 
Such variations are likely related to differences in (a) their functional roles; (b) basal endocytotic activity; 
and (c) extent of membrane elaboration. We predict that the differences have implications for use of the MP 
platform in neural tissue engineering and translational applications such as imaging, cell labeling and 
gene/drug delivery. It is therefore essential for future work to take account of the complexity of neuroglial 
responses to synthetic materials, in order to optimize and refine the use of MPs for neural regeneration. Such 
work will need to be informed by a detailed understanding of the relationship between the physicochemical 
properties of MPs and neuroglial uptake, processing and toxicity - parameters that are poorly documented at 
present.  
 
Future Perspective 
 There is a critical knowledge gap in nanotechnology and neurotoxicology, regarding the influence 
of the chemistry of materials platforms on the biology of CNS cells [53]. Such information is vital to robustly 
evaluate the utility of novel materials for the development and optimization of new therapeutics. Further 
studies will need to characterize neuroglial cell interactions with MPs of a range of physicochemical 
properties to identify those with optimal features for specific biomedical applications. For each cell type, 
such investigations should include ultrastructural analyses of particle fate; endocytotic blocker studies to 
establish specific uptake mechanisms; microarray analyses for detailed toxicity analysis; evaluation of 
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vesicular trafficking of MPs, to develop particles with the potential for endosomal escape or to suggest the 
specific endocytotic mechanisms to which MPs should be preferentially targeted. 
 
Summary points 
 Non-neuronal cells of the CNS, termed the neuroglia, derived from primary cultures, show 
significant intrinsic differences in MP uptake. 
 Microglia show the most rapid and extensive MP uptake followed by astrocytes; oligodendrocyte 
precursor cells and oligodendrocytes show comparatively less uptake.  
 MPs undergo extensive degradation in microglia whereas particles appear relatively intact in the 
other cell types. Significant microglial toxicity was observed at concentrations that were non-toxic 
in the other cell types. 
 The differences in the extent of MP uptake and processing in the neuroglia could have significant 
implications for MP use in neural tissue engineering applications. 
 Rapid uptake and degradation of MPs in microglia could represent a significant 'extracellular barrier' 
for direct MP use (in gene/drug delivery) in the CNS. Such degradation is also a major 'intracellular 
barrier' in applications such as transfection. 
 MP stability in astrocytes and oligodendroglial cells indicates that MPs are compatible with these 
cells, but the relative levels of cellular uptake will determine the efficacy of MP use. 
 Utilising cells derived from primary cultures, as in the current study, offers several advantages over 
cell lines that are widely employed in bio-nanotechnology research.  
 Future studies will need to characterize relationships between MP physicochemical properties and 
cellular uptake, processing and toxicity in CNS cells, to identify optimal neurocompatible materials. 
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Appendix 4: Article published by ACS Nano. 
This appendix contains an article published in ACS Nano, containing a subset of the data 
from chapter 3. 
 
Reprinted with permission from ACS Nano vol. 5, no. 8, 6527-6538, 2011. Copyright 2011 
American Chemical Society. 
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O
ligodendrocyteprecursor cells (OPCs)
are a major transplant population
to promote repair followingmyelin
damage (as occurs in neurological diseases
such asmultiple sclerosis) and in spinal cord
injury (SCI).15 The beneﬁcial eﬀects of OPCs
are primarily due to the production of new
myelin by oligodendrocytes, the daughter
cells of OPCs.6 Myelin is the lipid-based
insulating sheath covering nerve ﬁbers that
aids in the eﬃcient conduction of electrical
signals and exerts neuroprotective eﬀects
on axons.7,8 Cell replacement studies have
noted a down-regulation of genes asso-
ciated with tissue damage and inﬂamma-
tion followingOPC transplantation, indicating
additional mechanisms by which OPCs may
exert tissue-sparing eﬀects.9 These cells are
abundant in fetal and adult brain, and rela-
tively pure OPC populations can be obtained
from CNS tissue using FACS/antibody selec-
tion; protocols have also been established
to derive OPCs from rodent/human embryo-
nic stemcells (hESCs), highlighting their trans-
lational potential for clinical cell transplan-
tation therapies.911 The major therapeutic
and translational potential of OPCs is evi-
denced by the commencement of human
clinical trials in regenerative medicine, for
example that by Geron Corporation (CA,
USA) of their product GRNOPC1, consisting
of hESC-derived OPCs for repair of SCI.12
While cell transplantation therapies have
major potential to mediate neural repair,
successful therapeutic interventions are like-
ly to require so-called “combinatorial” ap-
proaches (e.g., delivery of cells plus thera-
peutic factors to injury foci), as neural repair
is acomplexprocess requiringmultiplegoals to
be achieved for successful regeneration.1317
Consequently, engineering the repair prop-
erties of transplanted OPCs, for example by
introducing genes encoding therapeutic fac-
tors, constitutes a key strategy to improve
neural repair. OPCs can bemodiﬁed to deliver
therapeuticproteins suchasﬁbroblast growth
factor 2 (FGF2), ciliary neurotrophic factor
* Address correspondence to
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Received for review May 22, 2011
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ABSTRACT This study has tested the feasibility of using physical delivery methods, employing
static and oscillating ﬁeld “magnetofection” techniques, to enhance magnetic nanoparticle-
mediated gene transfer to rat oligodendrocyte precursor cells derived for transplantation therapies.
These cells are a major transplant population to mediate repair of damage as occurs in spinal cord
injury and neurological diseases such as multiple sclerosis. We show for the ﬁrst time that magnetic
nanoparticles mediate eﬀective transfer of reporter and therapeutic genes to oligodendrocyte
precursors; transfection eﬃcacy was signiﬁcantly enhanced by applied static or oscillating magnetic
ﬁelds, the latter using an oscillating array employing high-gradient NdFeB magnets. The eﬀects of
oscillating ﬁelds were frequency-dependent, with 4 Hz yielding optimal results. Transfection
eﬃcacies obtained using magnetofection methods were highly competitive with or better than
current widely used nonviral transfection methods (e.g., electroporation and lipofection) with the
additional critical advantage of high cell viability. No adverse eﬀects were found on the cells' ability
to divide or give rise to their daughter cells, the oligodendrocytes;key properties that underpin
their regeneration-promoting eﬀects. The transplantation potential of transfected cells was tested
in three-dimensional tissue engineering models utilizing brain slices as the host tissue; modiﬁed
transplanted cells were found to migrate, divide, give rise to daughter cells, and integrate within
host tissue, further evidencing the safety of the protocols used. Our ﬁndings strongly support the
concept that magnetic nanoparticle vectors in conjunction with state-of-the-art magnetofection
strategies provide a technically simple and eﬀective alternative to current methods for gene transfer
to oligodendrocyte precursor cells.
KEYWORDS: oligodendrocyte precursor cells . magnetic nanoparticles .
magnetofection . transplantation . organotypic slice culture . gene therapy .
transfection
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(CNTF), and neurotrophin 3 (NT3) following trans-
plantation.14,15,18,19 Such interventions make lesion
environments more conducive to repair, enhance both
graft-mediated and endogenous cellular repair, encou-
rage axonal outgrowth in lesions, and promote angio-
genesis.2024
From a technical perspective, it is important to note
that previous studies have reliedheavily on viralmethods
to achieve gene transfer to OPCs.14,15,25,26 Viral meth-
ods are eﬃcient and have yielded valuable information
in experimental studies on neural repair. However,
despite recent technological advances, there are still
signiﬁcant risks and disadvantages associated with viral-
mediated gene transfer, primarily safety issues such as
toxicity, nonspeciﬁc cellular uptake, inﬂammatory re-
sponses, and oncogenic eﬀects leading to abnormal
cellular growth.25,2732 Concerns have been raised that
viral vectors may themselves cause alterations in OPC
proliferation and diﬀerentiation, oligodendrocyte death,
and myelin damage.27 There are also major limitations
with viral delivery in terms of limited plasmid insert size
and achieving large-scale production for clinical appli-
cations, leading to a major international drive for the
development and evaluation of nonviral transfection
methods.31,32 Despite this, many of the nonviral meth-
ods used for neural gene transfer also have major as-
sociated disadvantages. For example, nonviral vectors
have lower transfection eﬃcacies than their viral coun-
terparts, leading to theadoptionof physical genedelivery
methods, such as biolistic transfection and electro-
poration, which can be associated with adverse eﬀects
such as membrane damage, abnormal cell physiology,
and substantial cell death (up to 80% cell loss).30,33
In this context, magnetic nanoparticle (MNP)-based
vector platforms have emerged as an essential tool for
advanced biomedical technology, due to progress in
recent years in both the large-scale synthesis and com-
plex surface functionalization of such particles.29,34 These
next-generation nanomaterials are used in major areas
of biological research and medicine, including drug/
gene therapy, magnetic targeting (e.g., cancer therapies),
and diagnostic imaging (as contrast enhancers).3540
The particles consist of a superparamagnetic core, within
a biocompatible surface coating, allowing attachment
of speciﬁc functional groups to the surface coating
(Figure 1). MNP size and surface chemistry can be
adapted to suit the “functionalizing” molecule, and a
tailored combination of surface functionalizations can
potentially be achieved to construct complex particles
that can mediate multiple applications (e.g., real-time
imaging of neural transplant populations plus drug/gene
therapy) while retainingnanoscale dimensions.34,40,41 For
example, MNP platforms have been shown to have key
applications for noninvasive MR imaging of a range of
transplant cells, notably, for tracking of myelin-generat-
ing cell populations: MNP-labeled primary Schwann and
olfactory ensheathing cells (OECs),42 as well as CG4 cells
(anOPCcell line),43 couldall bedetectedbyMRI following
transplantation into areas of brain and spinal cord
pathology, without adverse eﬀects on transplant cell
migration, cell fate, or repair potential.
In terms of MNP-based transfection, a key feature of
MNP vectors is their compatibility with novel magne-
tofection techniques, viz., the application of magnetic
ﬁelds to assist gene transfer.4447 These methods have
the major safety advantage that they exploit the natural
uptake pathways (endocytotic mechanisms) of cells
during the transfection process, without disrupting the
cell membrane, resulting in high cell viabilities post-
transfection.4852 We have recently demonstrated the
signiﬁcant potential of MNPs to mediate gene transfer
to key neural transplant cell populations [such as
astrocytes53 and neural stem cells (NSCs)].54We proved
that transfection eﬃcacies could be dramatically im-
proved using magnetofection approaches, the latter
including use of an oscillating array system utilizing
high-gradient NdFeB magnets applied at a range of
frequencies.53 To date, however, the use of MNPs to
mediate safe gene transfer to the major transplant
population of OPCs has not been assessed. The current
study aims to address this issue by employing OPCs
derived from primary rat mixed glial cell cultures to
assess (i) whether OPCs can be transfected using MNP
vectors, (ii) if novel static and oscillating ﬁeld magne-
tofection techniques can enhance transfection eﬃcien-
cies, (iii) whether these transfection protocols aﬀect the
survival or diﬀerentiation potential of OPCs, and (iv) the
transplantation potential of MNP-transfected OPCs
using organotypic cerebellar slice cultures as host tissue.
RESULTS AND DISCUSSION
Cell Cultures. These experiments were performed
using untransformed OPCs, derived from primary rat
mixed glial cultures, to eliminate the potential pro-
blems commonly encountered with the use of cell lines,
which include transformation-induced abnormalities
Figure 1. Schematic diagram depicting the multilayered
design of magnetic nanoparticles, illustrating the magnetic
iron oxide (magnetite) core and biocompatible coating,
with examples of potential functionalization for biomedical
applications.
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in cell physiology, microbial contamination, karyotyp-
ing necessitated by the risk of cellular aneuploidy, and
genetic instability. Highly pure cultures of OPCs were
consistently obtained, as judged by cellular morphol-
ogy and A2B5 (OPC marker) staining (94.3 ( 2.3%;
n = 5). Light microscopic observations showed that
cells displayed an elongated bipolar morphology with
oval cell bodies characteristic of OPCs.
Choice of Particles and Particle Concentrations. Neuromag
particles are transfection-grade MNPs that were origin-
ally designed for use with primary neurons and in which
they have a history of “safe” usage. We have utilized
these particles to demonstrate MNP-mediated trans-
fection and the efficacy of magnetofection approaches,
in a range of neural cell types [astrocytes,53 NSCs,54
OECs, and oligodendrocytes (unpublished data)], mak-
ing them the nanoparticle of choice in our laboratory.
In terms of incubation times required to achieve optimal
transfection, removal of particleplasmid complexes
after 1 h incubation (as per the protocol developed by
ourselves for transfection of astrocytes)53 resulted in
negligible transfection (typically <1%) over a 48hmonitor-
ing period, for all field conditions. By contrast, increasing
the length of OPC exposure to complexes to 48 h resulted
in a dramatic increase in reporter protein expression over a
similar monitoring period. This exposure time was not
associated with toxicity, and qualitative microscopic ob-
servations on the extent of green fluorescent protein (GFP)
expression in OPCs over a three-week observation period
revealed that protein expression peaks at 48 h, consistent
with the timing of peak expression reported earlier for
plasmid-based transfection.19,53 Therefore, in all experi-
ments, toxicity and transfection efficiency were routinely
assessed by fluorescence microscopy at 48 h.
Establishment of Safe ParticlePlasmid Concentrations and
Field Conditions. As cell survival and phenotypic stability
are key considerations in cell replacement strategies, a
battery of assays was used to assess the toxicity of
Neuromaggfp (pmaxGFP plasmid) complexes and
magnetofection techniques on OPCs. At every concen-
tration and applied magnetic field condition, plasmid
alone controls were found to be without any effect on
OPC morphology or survival and never resulted in GFP
expression (Figure 2A). The particle concentration routi-
nely used to safely transfect neurons (1.0) as recom-
mended by the manufacturer resulted in the obvious
presence of rounded, detaching cell profiles and dra-
matic loss of OPCs. Therefore, lower concentrations
(0.5 and 0.1) of Neuromaggfp were evaluated;
irrespective of the applied magnetic field, treatment
with 0.5 Neuromaggfpwas also found to result in a
decrease in cell number per field, the presence of non-
adherent cells, and an increase in pyknotic nuclei
(Figure 2A and B). In contrast, 0.1 Neuromaggfp
had no statistically significant effects on any of these
parameters under all magnetic field conditions used
(Figures 2A). It was deemed unnecessary to test for
toxicity of the particles alone, as Neuromag MNPs have
been specifically developed as transfection grade par-
ticles and, as such, have no intended usage without
conjugation of nucleic acids. However, in pilot experi-
ments, 0.1 Neuromag particles alone were not found
to be associated with any adverse effects on OPC
viability or proliferative/differentiation potential. Addi-
tionally, OPCs could be incubated with 0.1 Neuro-
maggfp complexes for up to 48 h without induction
of significant toxic effects, and no alterations were
observed in the morphology or A2B5 staining profiles
of OPCs at this concentration. Thiswas therefore deemed
the “safe” dose for transfection applications.
These data highlight the need for rigorous dose-
optimization prior to MNP use. When considering the
development of optimal magnetofection methodolo-
gies for cells of neural origin, it is of note that experi-
mental protocols required to prevent toxicity vary
between individual neural cell types. This underscores
Figure 2. Establishment of safe particle dose and magnetic
ﬁeld conditions for OPC magnetofection. (A) Bar chart
showing average number of cells stained for the OPC
marker A2B5 per microscopic ﬁeld, 48 h post-transfection
with Neuromagplasmid complexes. For all magnetic ﬁeld
conditions tested and the no ﬁeld condition, the number of
A2B5þ cells perﬁeldwasmarkedly reducedat 0.5 complex
concentration, but not at 0.1, compared to control cultures
exposed to plasmid alone. *p < 0.05 versus control, no ﬁeld;
n = 5 cultures. (B) Representative phase-contrast micrograph
ofOPCs, 48hpost-transfectionwith0.1Neuromagplasmid
complexes. Note phase-bright cells with mostly bipolar
morphologies. Inset shows OPCs 48 h post-transfection with
0.5Neuromagplasmid complexes. Note reduceddensity
of cells and lack of processes.
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the critical importance of tailoring particle dosing regi-
mens on a cell-by-cell basis with respect to (i) particle
concentration and (ii) incubation time, in order to
develop safe protocols for biomedical applications. First,
the particle concentration routinely used to safely trans-
fect neurons is toxic not only to OPCs, as shown here,
but also to astrocytes53 and NSCs,54,55 necessitating
the use of lower MNP concentrations for these non-
neuronal cell types. Second, at a given particle con-
centration, the duration of particle exposure that can
be considered “safe” also varies between cell types. For
example, in a previous study, it was necessary to limit
astrocyte incubation time with 0.1 Neuromaggfp
complexes to 1 h to prevent toxicity,53 whereas in the
present study, OPCs could be safely incubated with the
same particleplasmid complex concentration for a
prolonged period of time (48 h).
It is not clear what speciﬁc cellular mechanisms
account for these intercellular diﬀerences. As uptake of
MNPs is known to occur via endocytotic mechanisms
such as macropinocytosis and receptor-mediated up-
take (for example clathrin- and caveolin-mediated), we
can speculate that diﬀerences in the mechanisms and/
or activity of endocytosis between astrocytes andOPCs
account for diﬀerences in the extent of particle uptake
and toxicity.48,50,52 This may in turn be related to the
speciﬁc neurophysiological functions performed by
the cell type in question (e.g., homeostasis, immune
surveillance).
Assessment of Magnetofection Techniques for Transfection of
OPCs. OPC Transfection Studies and Effects of Applied
Magnetic Fields (Magnetofection). Transfection efficacy
was assessed at 0.1 Neuromaggfp concentrations,
with and without application of static and oscillating
magnetic fields. Basal GFP expression was observed, i.e.,
in the absence of a magnetic field (mean transfection ef-
ficiency: 6.1 ( 1.0%; range: 3.18.1%; Figure 3A). All
magnetofection conditions produced transfection effi-
ciencies significantly higher than basal levels (Figure 3A).
Specifically, the application of a static magnetic field
resulted in a transfection efficiency that was approxi-
mately 2-fold that in the absence of a field (F = 0 Hz:
12.5 ( 1.2%; range 10.817.0%). The oscillating mag-
netic field conditions resulted in transfection efficiencies
that were approximately 2.5-fold (F = 1 Hz: 15.5 ( 1.9%;
range 9.319.9%) and 3.5-fold (F = 4 Hz: 20.6 ( 2.2%;
range 15.926.3%) that in the absence of a field. Im-
portantly, the 4 Hz oscillating magnetic field condition
produced significantly greater transfection efficiency than
the static magnetic field condition (Figure 3A). However,
no significant difference was found between the 1 Hz
oscillating field condition and either the static or 4 Hz
oscillating field conditions. In all experiments, transfected
OPCs were observed to be phase bright and exhibited
normal cell adherence. Cells expressed GFP throughout
the cell body and processes (Figure 3B). Transfected
cells retained their characteristic bipolar phenotypes and
exhibited normal staining profiles for the OPC marker
A2B5, and DAPI-stained nuclei appeared healthy with no
evidence of increased chromatin condensation or pykno-
sis (Figure 3C).
Figure 3. Applicationof static or oscillatingmagnetic arrays
(magnetofection) enhances MNP-based OPC transfection
without aﬀecting cellular morphology or staining proﬁles.
(A) Bar chart showing transfection eﬃciencies achieved in
OPCs 48 h post-transfection using Neuromaggfp complexes
(0.1 complex concentration), as judged by the percentage
of A2B5þ cells expressing GFP (A2B5 is an OPC marker). Static
andoscillatingmagneticﬁeld conditions signiﬁcantly enhanced
transfection eﬃciency compared to the basal level (no ﬁeld).
Importantly, application of the 4 Hz oscillating magnetic ﬁeld
signiﬁcantly enhanced transfection eﬃciency compared to
the staticmagneticﬁeld condition. *p<0.05, **p<0.01, ***p
< 0.001; n = 5 cultures. (B) Representative image of trans-
fected OPCs with bipolar morphologies, expressing GFP
throughout the cell body and processes. (C) Representative
image of transfected OPCs. Note co-localization of GFP
expression with A2B5 staining, and (inset) morphologically
normal DAPI-stained nuclei. Arrows indicate same transfected
cells in main image and inset.
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A range of nonviral methods have been tested
previously for OPC transfection (Table 1). Our data
show that magnetofection strategies compare favor-
ably with such methods, in terms of both transfection
eﬃciency and cell viability. There is considerable varia-
bility in transfection eﬃciencies reported previously for
OPCs, and all nonviral alternatives have resulted in
reduced cell viability. For example, calcium phosphate-
based transfection of OPCs produced <5% transfection
eﬃciency and resulted in abnormal morphological
changes in cells.56 The lipofection agents Lipofecta-
mine, Lipofectin, and Cellfectin were found to be toxic
to OPCs, even at low concentrations, and resulted in
<3% of cells being transfected,30 while electroporation
has been reported to result in eﬃciencies ranging from
10% to 15% (2025% cell viability)30 to approximately
43% (60% viability).57 In terms of virus-mediated gene
delivery, although retroviral transduction has been
reported to yield a gene transfer eﬃciency of up to
70% in OPCs,15 results can vary greatly, with another
study reporting only 0.0050.5% transfection using
retroviral methods56 (OPC viability not reported in
either study). Irrespective of the eﬃciencies of other
techniques, it must be stressed that MNPs oﬀer a
combination of advantages for neural cell transplanta-
tion therapies (comparedwith existing vector platforms),
owing to their unique multifunctionality for “therag-
nostic” applications, i.e., the fusion of therapeutic ap-
proaches, such as gene/drug delivery, with imaging
methods such as MRI.29,3436,38,41
In keepingwith our previous ﬁndings,53,54 the eﬃcacy
of oscillating ﬁelds was found to be frequency-depen-
dent (optimal frequency = 4 Hz for OPCs). We have
described previously the eﬃcacy of magnetofection
strategies in NSCs54 and astrocytes53 and discussed the
basis for their eﬀects; this ﬁnding is in contrast to the
optimal oscillation frequency for astrocyte transfection
(F = 1 Hz) but identical to that for NSC monolayers. It is
not clear whatmechanisms are responsible for the cell-
to-cell variation in optimal transfection-promoting
frequencies. The oscillating movements may serve to
reduce biases in magnetic ﬁeld strength across the cel-
lular monolayer, thereby improving cellular access to
particles and hence transfection levels. The lateral
motion imparted by oscillating magnetic ﬁelds may
also increase the likelihood of particlecell contact
and stimulate endocytosis; we cannot rule out the
induction of pro-transfection uptakemechanisms such
as macropinocytosis by the oscillating ﬁelds.38,53,59 If
this is the case, diﬀerences in cell size/plating density
and extent of membrane elaboration by cells may ac-
count for such frequency-dependent eﬀects. Combined
with the signiﬁcant variations in the timing of particle
exposure and extent of transfection between cells,
these results highlight further the need to tailor
MNP transfection protocols for individual cell types,
as protocols for one neural cell type cannot be extra-
polated to another. Further analyses using blockers of
speciﬁc endocytotic pathways and detailed TEManalyses
to systematically compare MNP uptake are necessary
to establish the basis of intercellular variability in the ef-
ﬁcacy of magnetofection methods.
Effects of Magnetofection on OPC Fate (Proliferation
and Differentiation). MNP-mediated transfection did
not alter the proliferative capacities of OPCs, as com-
parative counts of OPC densities per field between
cultures treated with particleplasmid complexes and
plasmid only controls revealed no significant differences
at 48 h (Figure 2A). Additionally, transfected progeny
(immature oligodendrocytes) with daughter nuclei in
close apposition and therefore appearing to result
from recent OPC divisions could be observed (Figure
4A), supporting the finding that MNP-based transfec-
tion does not alter the proliferative potential of OPCs.
Furthermore, transfected OPCs differentiated into GFPþ/
MBPþ oligodendrocytes (myelin basic protein, MBP, is a
late-stage oligodendrocyte marker) with mature, highly
branched morphologies, comparable to that observed
in control cultures (Figure 4B). Counts of MBPþ cells
from untreated cultures versus MNP transfected
TABLE 1. Comparative Transfection Efficiencies in Rat OPCs for Viral and Nonviral Vectorsa
transfection method gene transfection eﬃciency viability ref
Viral Methods
retrovirus (MoMuLV) β-Gal 0.0050.5% not reported 56
retrovirus (LZRS) D15A/EGFP 60% not reported 14
retrovirus (LZRS) CNTF/EGFP 6070%; adult OPCs not reported 15
adenovirus (AdLacZ) β-Gal >50%; did not distinguish OPCs and astrocytes not reported 38
Nonviral Methods
magnetic nanoparticles GFP 21% no signiﬁcant toxicity current study
lipofection β-Gal 13% not reported; toxic at even low doses (<2 μg) 30
calcium phosphate precipitation β-Gal 35% ∼10% 56
calcium phosphate precipitation β-Gal <2% not reported; induced morphological changes 30
electroporation EGFP ∼43% 60% 57b
electroporation β-Gal 1015% 2025% 30
a β-Gal = β-galactosidase; D15A = multineurotrophin, with brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT3) activity; EGFP = enhanced green ﬂuorescent
protein; CNTF = ciliary neurotrophic factor; GFP = green ﬂuorescent protein. b Company Web site.
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cultures (F = 4 Hz) (cultured in differentiation-promot-
ing medium) revealed no significant difference in the
percentage of MBPþ cells at 12 days post-transfection
(Figure 4C). Transfected OPCs and their progeny were
observed to display the full range of morphological
phenotypes observed as standard within differentiating
cultures of the oligodendroglial lineage, from bipolar
unbranched cells to multipolar, highly branched, com-
plex forms with extensive membrane elaboration, lend-
ing further support to the finding that the differentiation
potential of OPCs is unaffected by the transfection
protocols used in this study. Longer termmonitoring of
cultures revealed that expression of GFP persisted
within oligodendrocytes for up to 22 days (the latest
time point observed). However levels of expression
declinedwith time, and at 22 days approximately 5%of
peak levels of transfection were observed. Such tran-
sient expression is especially desirable in the context of
myelin repair, where regeneration-promoting molecules
are expressed in a temporally specific pattern, such
that each stage of the repair process occurs in the
appropriate sequence; maintaining pro-proliferation
or pro-differentiation environments for inappropriate
periods has been suggested to be detrimental to re-
pair.6,7,17,6062 For example, platelet-derived growth
factor (PDGF-AA) and FGF2 induce proliferation and
migration of OPCs, but also inhibit late-stage oligoden-
drocyte differentiation, and so their upregulation should
not be prolonged beyond the “recruitment” phase of
repair.18,63
Evaluation of Transplantation Potential of Transfected OPCs.
Organotypic Cerebellar Slice Cultures As Host Tissue.
The study has employed organotypic models for the
introduction and subsequent monitoring of OPC trans-
plant cells. Such three-dimensional, in vitromodels are
widely used in experimental neurology research, pro-
viding an excellent bridge between isolated cell cul-
tures (which lack tissue organization and environmental
cues that can influence transplant cell behavior) and
in vivo investigations that are typically expensive, time-
consuming, and difficult to monitor in real time.6467
Slice cultures demonstrated high viability, as judged by
Figure 4. Transfection of OPCs using magnetofection does
not aﬀect proliferation or diﬀerentiation potential. (A)
Following culture in Sato diﬀerentiation medium, transfected
OPCs developed multipolar morphologies typical of early-
stage oligodendrocytes. Arrows indicate two nuclei, sug-
gestive of a recent cell division, and therefore normal
proliferative activity. (B) Following culture in Sato diﬀeren-
tiationmedium, transfected OPCs developedmorphologies
typical of mature oligodendrocytes, expressed GFP throughout
their processes, and stained for myelin basic protein (a late-
stage oligodendrocyte marker). Arrow indicates MBPþ/GFP
cell. (C) Bar chart showingpercentageofMBPþ cells, 12 days
post-transfection. The percentage ofMBPþ cells in transfected
cultures (0.1 complex concentration; F = 4 Hz) was not
signiﬁcantly diﬀerent from controls (without complexes or
magnetic ﬁeld). n = 4 cultures.
Figure 5. Cerebellar slice cultures (10 days in culture) retain
structural and anatomical organization. (A) Representative
imageof slice culture,with clearly visiblewhitematter tracts
(arrows) branching from thebase. Inset illustrates that these
white matter tracts are distinctly revealed by MBP staining,
a marker for mature oligodendrocytes.
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live/dead staining (Viability kit, Invitrogen, UK; data not
shown).Well-preservedwhitematter (WM) tracts could
be clearly observed using phase contrast microscopy
(Figure 5). This was confirmed by fluorescence micro-
scopy following MBP immunostaining (Figure 5, inset),
andWM tracts showed similar anatomical organization
to that found in vivo.66
OPC Transplantation onto Cerebellar Slices. Trans-
plants were performed with 15 slices in total, from four
animals. Slices imaged immediately post-transplanta-
tion showed that focal delivery of OPCs could be
achieved. Delivery of the cells was by simply pipetting
onto the slices, rather than by invasive injection. From
an experimental perspective, this approach has the
major advantage of greatly reduced trauma to both
cells and slice host tissue. The transplantation procedure
produced passive spread with a radius of 700 μm
(Figure 6A and B), due to the force of the transplanta-
tion procedure alone. Immediately after transplanta-
tion, OPCs were clearly observed to express GFP and
displayed rounded morphologies characteristic of
enzymatically detached cells (Figure 6A). Post-trans-
plantation, cells were observed to recover their charac-
teristic cellular morphologies. At 2448 h post-
transplantation, GFPþ cells showed evidence of (1)
migration, as indicated by the presence of cells with
elongated bipolar morphologies that are characteristic
of migratory OPCs (Figure 6C), and (2) proliferation,
indicated by the striking occurrence of GFPþ cells in
pairs (Figure 6D). Slices were stained for either NG2, an
OPC marker, or MBP, a late-stage oligodendrocyte
marker, to establish the cellular identity of transplant
cells. Confocal microscopy revealed the presence of
GFPþ/NG2þ cells against a background of host NG2þ
cells, confirming the OPC identity of the transplanted
cells (Figure 6E). There was also clear evidence of OPC
differentiation in slices, as demonstrated by the pre-
sence of multipolar cells (Figure 6D, inset), and GFPþ/
MBPþ cells, detected in slices using confocal micro-
scopy (Figure 6E, inset). Transplant populations re-
plated into chamber slides with Sato differentiation
medium also retained GFP expression and exhibited
normal oligodendroglial morphologies, supporting
the observations that MNP transfection protocols do
not alter the differentiation capabilities of the trans-
fected, transplanted cells.
These results demonstrate the transplantation po-
tential of MNP-transfected OPCs. They further prove
Figure 6. Transfected OPCs survive, migrate, proliferate, and diﬀerentiate following transplantation into organotypic slice
cultures. (A) Transfected OPCs could be focally delivered to slices, as evidenced by ﬂuorescence microscopy immediately
post-transplantation. GFPþ transplanted cells exhibited the rounded morphology typical of enzymatically detached cells.
(B) Counterpart phase image to (A), illustrating slice margin (arrows). Post-transplantation, GFPþ cells were observed with
bipolar morphologies typical of migrating OPCs (24 h; C), in pairs, suggestive of proliferation (48 h; D), and with multipolar
morphologies, indicative of normal diﬀerentiation (D, inset). (E) When slices were stained for the OPCmarker NG2, 48 h post-
transplantation, confocal microscopy revealed GFPþ/NG2þ transplanted OPCs (yellow arrow) against a background of red
NG2þ host OPCs (red arrow). Some GFPþ cells were NG2 (green arrow). Inset shows confocal image of GFPþ cells stained for
the oligodendrocyte marker MBP 48 h post-transplantation (arrows), indicating OPC diﬀerentiation within the slice.
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that cellular properties of OPCs that are key to their
regenerative potential, such as the ability to divide,
migrate, and give rise to myelin-generating cells, are
unimpaired following the transfection protocols. These
ﬁndings emphasize the safety of the protocols devel-
oped and suggest that theMNP platform has consider-
able potential for clinical translational OPC applications
involving ex vivo CNS gene transfer. In terms of the
transplantationmethods used here, tissue engineering
approaches using brain and spinal cord slice cultures to
evaluate cell replacement therapies represent a key
recent advance in the reduction, replacement, and re-
ﬁnement (3Rs) of experimental animal usage in neu-
rological research. We have extensively documented
the suitability of organotypic model systems for asses-
sing the transplantation potential of key neural cells,
including NSCs and astrocytes, using high-throughput
analyses.50,53,55 Our current data lend support to our
previous work and further demonstrate that the slice
model can be successfully used to monitor the survival
and fate of transplanted OPC populations. It is impor-
tant to note that cerebellar slice models oﬀer unique
advantages as host tissue within which to evaluate
OPC transplantation approaches, as these retain large,
well-deﬁned, axonal (WM) tracts that undergo myeli-
nation in vitro.66,67 Additionally, slices can be prepared
from dysmyelinating mutants (including those with
limited postnatal survival), and focal/disseminated de-
myelinating lesions can be induced in normal slice WM
tracts, highlighting the translational potential of cere-
bellar slices for evaluating the regeneration-promoting
eﬀects of OPC transplantation therapies.6668
MNP-Mediated Delivery of Plasmid Encoding Therapeutic
Growth Factor. The preceding experiments were con-
ducted with the pmaxGFP plasmid, which encodes a
reporter gene only. To assess the potential of the opti-
mized magnetofection protocol for functional gene de-
livery,OPC cultures (n=4)were transfected usingMNPs
conjugated with a plasmid encoding the therapeutic
protein FGF2 taggedwith GFP (FGF2-GFP; 7.4 kb); FGF2
is a major growth factor that promotes neural regen-
eration due to its mitogenic properties (including for
OPCs) and angiogenesis-promoting effects. A recom-
mended plasmid (AN-GFP; 6.6 kb) lacking the FGF2
insert was used as a control. It should be noted that
both these plasmids are considerably larger than the
pmaxGFP plasmid (3.5 kb) used in earlier experiments.
Magnetofection of OPCswith these plasmids, using the
optimizedprotocol (oscillatingmagnetic field of F=4Hz),
revealed cellular GFP expression using both the ther-
apeutic and control plasmids (Figure 7AC). For the
FGF2-encoding plasmid, GFP expression was largely
restricted to the nucleus (Figure 7A andB). These findings
are consistent with several reports, demonstrating en-
dogenous expression of nuclear isoforms of FGF2 in
glia, notably astrocytes.69,70 Occasional rounded pro-
files consistent with dividing OPCs could be observed
Figure 7. MNP-mediated delivery of therapeutic genes to
OPCs. (A) Representative phase image of live cells trans-
fected using the FGF2-GFP plasmid, which encodes ﬁ-
broblast growth factor 2 (FGF2) tagged with green
ﬂuorescent protein (GFP) at 24 h post-transfection.
Transfected cells exhibit bipolar morphologies typical of
OPCs with GFP expression prominently localized to the
nucleus. (B) Fluorescence image of a proliferating OPC
transfected with the FGF2-GFP plasmid and stained for
the OPC marker A2B5; both daughter cells appear to
express GFP (arrows indicate daughter nuclei). (C) Re-
presentative ﬂuorescence image of cells transfected
using the AN-GFP control plasmid. Note that GFP ex-
pression is present throughout the cell body and pro-
cesses. (D) Bar chart illustrating transfection eﬃciencies
achieved in OPCs using Neuromag (0.1) conjugated to
various plasmids, as judged by percentage of A2B5þ cells
expressing GFP. Data are shown for transfection without
a magnetic ﬁeld and with applied oscillating ﬁeld (F = 4
Hz). For each plasmid, the 4 Hz oscillating ﬁeld signiﬁ-
cantly enhances transfection eﬃciency over the no ﬁeld
condition (***p < 0.001). Transfection eﬃciency for both
the AN-GFP and FGF2-GFP plasmids is signiﬁcantly lower
compared to pmaxGFP, for the corresponding ﬁeld con-
ditions (ap < 0.001 compared to pmaxGFP no ﬁeld con-
dition; bp < 0.001 compared to pmaxGFP F = 4 Hz). n = 5
cultures for pmaxGFP studies; n = 4 cultures for AN-GFP
and FGF2-GFP studies. Data in BD were at 48 h post-
transfection.
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with both daughter cells appearing to inherit the intro-
duced gene (Figure 7B). For the control plasmid, the
pattern of GFP expression (Figure 7C) was similar to
that seen in earlier experiments with the pmaxGFP plas-
mid (Figure 3B and C), i.e., with GFP expression evident
throughout the cell body and extending into the pro-
cesses of cells. In immunostaining studies, all trans-
fected cells were found to clearly express the OPC-
specific marker A2B5 (for example see Figure 7B). Deter-
mination of transfection efficiencies yielded values of
5.5( 0.4% for the FGF2-GFPplasmid and 8.1( 1.0% for
the AN-GFP control plasmid with applied oscillating
magnetic fields, both of which were significantly high-
er than the corresponding values determined in the
absence of a magnetic field (Figure 7D).
It is clear from these data that use of larger plasmids
results in a systematic decrease in MNP-mediated
transfection eﬃcacy. This strongly indicates that ex-
perimental protocols will need to be modiﬁed to ac-
count for variations in plasmid size. This issue could be
addressed using a range of strategies, including (i) re-
duction of overall plasmid size by removal of the re-
porter protein component and other elements of the
constructs; (ii) use of particles with diﬀerent polymer
coatings/sizes to further enhance the DNA binding
capacity of the particles; and (iii) testing of diﬀerent
oscillation frequencies to determine if the optimal fre-
quency diﬀers with plasmid size, with additional opti-
mization of the duration of ﬁeld application.
In terms of the translational applications of our ﬁnd-
ings to clinical cell transplantation therapies, a number
of studies have demonstrated that repair mechanisms
can be enhanced by genetic manipulation of OPC
transplant populations.14,15,18,19 The optimal transfec-
tion eﬃciency for neural repair following ex vivo gene
delivery will ultimately need to be determined by
evaluation of functional recovery post-transplantation
of transfected OPCs in a range of experimental pathol-
ogies; such eﬀects can be predicted to be dependent
on the nature of the pathology, the functional gene
under study, and extent of the neural injury. Cao et al.
(2010) retrovirally transfected adult rat primary OPCs
(transfection eﬃcacy approximately 70%) with CNTF,
then transplanted them into adult spinal cord, 9 days
post-contusion.15 At 7 weeks post-transplantation, rats
that received transplants of CNTF-OPCs demonstrated
4-fold greater survival of transplanted OPCs, a greater
number of myelinated axons, and a greater level of func-
tional recovery, compared to rats that received trans-
plants of unmodiﬁedOPCs. Previous studies suggest that
transfection of 2050%of a neural progenitor transplant
population can help to promote eﬀective functional
recovery (via angiogenesis and neuroprotection, for
example).22,23 In addition, theunmodiﬁedOPC transplant
populations per se have an intrinsic repair capability;9,13
therefore our results indicate that the OPC transfection
levels obtained here (with protocol optimization to ac-
count for plasmid size variations as described above)may
be suﬃcient to promote neural repair; thiswill need to be
tested using functional genes in neural injury models.
Further work is being carried out to measure the migra-
tory capacity and long-term integration of transfected
OPCs following transplantation into slice cultures.
In summary,MNPs can beused to transfectOPCs, with
transfectioneﬃciencyenhancedbyapplicationof a static/
oscillating magnetic ﬁeld. Transfected OPCs can be suc-
cessfully transplanted into cerebellar tissue slices, where
they survive, migrate, proliferate, and diﬀerentiate into
oligodendrocytes, highlighting the translational potential
of the MNP platform for OPC transplantation therapies.
EXPERIMENTAL SECTION
Reagents and Equipment. Tissue culture-grade plastics, media,
andmedia supplementswere fromFisherScientific (Loughborough,
UK) and Sigma-Aldrich (Poole, UK). Recombinant human plate-
let-derived growth factor (PDGF-AA) and basic fibroblast growth
factor (FGF2) were from Peprotech (London, UK). Polyclonal
rabbit anti-NG2, Omnipore membrane (JHWP01300), and Milli-
cell culture inserts were obtained from Millipore (Watford, UK).
Monoclonal rat antimyelin basic protein was from Serotech
(Kidlington, UK), monoclonal mouse anti-A2B5 was from Sigma-
Aldrich (Poole, UK), and secondary antibodies (Cy3-conjugated)
were from Jackson ImmunoResearch Laboratories Inc. (West
Grove, PA, USA). Mounting medium with DAPI (40 ,6-diamidino-
2-phenylindole) was from Vector Laboratories (Peterborough,
UK). The pmaxGFP plasmid (3.5 kb) was fromAmaxa Biosciences
(Cologne, Germany), and both the pCMV6-FGF2-GFP plasmid
(encodes the open reading frame of human FGF2 with a carboxy-
terminal turboGFP tag; 7.4 kb, FGF2-GFP) and the recommended
control plasmid, pCMV6-AN-GFP (6.6 kb, AN-GFP), were from
OriGene Technologies (Rockville, MD, USA).
Neuromag transfection-grade MNPs were purchased from
Oz Biosciences (Marseille, France). These positively charged par-
ticles have an average diameter of 160 nm (range 140200 nm).
DNA binding curves showed that these particles bind DNA
eﬀectively with DNA binding increasing particle size by 35%,
assessed using a Malvern Zetasizer 3000. The MAGNEFECT-
NANO oscillating magnetic array system was from NanoTherics
Ltd. (Stoke-on-Trent, UK). This system allows 24-well plates to be
placed over a horizontal array of 24 neodymium (NdFeB)
magnets, grade N42, which match the plate conﬁguration.
The magnetic array can be programmed to oscillate laterally
beneath the culture plate via a computerized motor; both the
frequency and the amplitude of oscillation can be varied. The
ﬁeld strength at the face of each magnet is 421 ( 20 mT
(NanoTherics Ltd., personal commun.).
Cell and Tissue Culture Procedures. The care and use of animals
was in accordance with the Animals (Scientific Procedures) Act
of 1986 (United Kingdom) with approval by the local ethics
committee.
OPC Cell Cultures. Primary mixed glial cell cultures were first
prepared from cerebral cortex of SpragueDawley rats at post-
natal day 13 (P13), using an established protocol.71 Medium
(D10) was DMEM supplemented with 10% fetal bovine serum,
2 mM glutaMAX-I, 1 mM sodium pyruvate, 50 U/mL penicillin,
and 50 μg/mL streptomycin. After 810 days culture at 37 C in
5% CO2/95% humidified air, flasks were shaken for 2 h on a
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rotary shaker at 200 rpm, and the medium, containing mainly
microglia, was discarded. Fresh D10 medium was then added,
and the flasks were shaken overnight at 200 rpm. This medium,
containing mainly OPCs, was transferred to nontissue culture
grade Petri dishes, to whichmicroglia (but not OPCs) will readily
attach in order to reduce microglial contamination. After 30 min,
unattached cells were resuspended at 2  105 cells/mL in OPC
maintenance medium (OPC-MM, comprising DMEM, 2 mM
glutaMAX-I, 1 mM sodium pyruvate, 10 nM biotin, 10 nM hydro-
cortisone, 30 nM sodium selenite, 50 μg/mL transferrin, 5 μg/mL
insulin, 0.1% BSA, 50 U/mL penicillin, 50 μg/mL streptomycin,
10 ng/mL PDGF-AA, 10 ng/mL FGF2). OPCs were plated
(0.3 mL/well of a 24-well plate) either on PDL-coated coverslips
for assessment of transfection efficiency or on PDL-coated
wells for transplantation experiments. This plating density
(3  104 cells/cm2) yields optimal cell survival, as lower OPC
densities can result in significant cell death, likely due to loss of
paracrine effects.
Organotypic Cerebellar Slice Cultures. Brains were extracted from
P914 rats into ice-cold slicing medium (EBSS buffered with
25 mMHEPES). Cerebella were dissected andmeninges removed;
then 350 μm parasagittal slices were prepared using a McIlwain
tissue chopper. Slices were incubated on ice for 30 min, then
transferred to pieces of Omnipore membrane on Millicell
culture inserts in six-well plates containing slice culturemedium
(50% MEM, 25% heat-inactivated horse serum, 25% EBSS,
supplemented with 36 mM D-glucose, 50 U/mL penicillin, and
50 μg/mL streptomycin). Slices were incubated at 37 C in 5%
CO2/95% humidified air for at least 8 days before transplanta-
tion, with medium changes every 23 days.
Toxicity Experiments. It was necessary to determine the max-
imum safe dose of Neuromagplasmid complexes for transfec-
tion and to determine whether magnetofection conditions af-
fected toxicity. NeuromagMNPs are recommended for use with
neurons at a final concentration of 7 μL/mL inmedium (referred
to here as 1.0), but lower concentrations have been required
for safe use with other neural cells (astrocytes, NSCs).5355 Control
cultures were treated with pmaxGFP plasmid alone, without
Neuromag. The DNA-binding capacity of Neuromag MNPs is
maximal at a ratio of 3.5 μL Neuromag to 1 μg DNA;53 this ratio
was therefore routinely used in thepresent study. Plasmid-based
transfection is often reported to result in peak expression at
48 h,19,53 and the results of preliminary experiments were con-
sistentwith this timing; therefore in all cases transfection efficiency
was assessed at 48 h. Accordingly, Neuromaggfp toxicity was
assessed by incubating OPCs with various concentrations of
complexes (1.0, 0.5, and 0.1), with andwithout exposure to
magnetic fields (no field, static field, 1 Hz oscillating field, and
4 Hz oscillating field). Exposure to a magnetic field was for
30 min, and total incubation time for all conditions was 48 h, at
which point cells were fixed. Several parameters of cytotoxicity
were assessed by microscopy, specifically (i) whether cells were
processed, phase bright, and adherent; (ii) the presence of
pyknotic nuclei, as judged by DAPI staining; (iii) expression of
the OPC marker A2B5; and (iv) cell counts per microscopic field,
which are indicative of proliferative capacity.
Transfection (Magnetofection) Experiments. Transfection proto-
cols were based on those supplied with the Neuromag MNPs;
however the specific protocols used in this study were tailored
for the OPC densities used (3  104 cells/cm2). In preliminary
experiments, Neuromaggfp concentrations at 0.1, 0.5,
1.0, 2.0, and 4.0 were tested rather than simply adopting
the 0.1 dose devised for use with astrocytes as reported by
ourselves previously.53 In terms of DNA quantity, we have pre-
viously generated DNA binding curves for Neuromag MNPs to
determine the particle:DNA ratio that results inmaximal binding;53
this ratio was maintained constant while varying particle con-
centrations. The combination of parameters resulting in optimal
OPC survival and maximal DNA binding that yielded transfec-
tion without cytotoxicity were used in this study. For the trans-
fection step, at 2 h after OPC plating, mediumwas replacedwith
0.225mL of fresh antibiotic-free OPC-MM. After a further 2448 h,
transfection complexes (per well, at 0.1) were prepared by
mixing 60 ng of pmaxGFP in 75 μL of DMEM basemedium, then
gently mixing this with 0.21 μL of Neuromag. For control wells,
pmaxGFP wasmixed in DMEM, but no Neuromag was included.
After 20 min incubation, the entire complex mix was added
dropwise to cells, while gently swirling the plate. For magneto-
fection, immediately following application of complexes to
cells, the 24-well plate was placed above a 24-magnet array
on the MAGNEFECT-NANO device, which had been prewarmed
in the incubator. The array either remained static or was pro-
grammed to oscillate with an amplitude of 0.2 mm and a
frequency (F) of 1 or 4 Hz. After 30 min, the plate was removed
from the magnetic array. For the no field condition, plates were
returned to the incubator without application of a magnetic
field. Cells were incubated with complexes for 48 h in total, then
fixed. Experiments to assess the delivery of the plasmid FGF2-
GFP (which encodes the functional gene FGF2 tagged with
turboGFP) and the appropriate control plasmid AN-GFP (which
encodes turboGFP alone) were conducted in an identical
manner. Transfections were performed either without applica-
tion of a magnetic field or with the initial application of an
oscillating magnetic field of F = 4 Hz.
Differentiation Potential of Transfected OPCs and Long-Term GFP-
Expression in Oligodendrocyte Progeny. At 48 h post-transfection,
cells were washed with PBS, then switched to Sato medium
(DMEM supplemented with 2 mM glutaMAX-I, 1 mM sodium
pyruvate, 30 nM triiodothyronine, 30 nM thyroxine, 1% N2 sup-
plement, 50 U/mL penicillin, and 50 μg/mL streptomycin) to
induce oligodendrocyte differentiation. Cellsweremonitored to
assess the extent of cellular expression of GFP and to evaluate
potential adverse effects on OPC differentiation for up to 3 weeks.
Medium was changed every 23 days.
Transplantation of Transfected OPCs onto Slice Cultures. At 24 h
post-magnetofection (F = 4 Hz), OPCs were washed with PBS,
then detached using accutase-DNase I. Cells were resuspended
at 2 107 cells/mL Sato medium, and 0.5 μL was pipetted onto
cerebellar slice cultures. Passive spread of cells due to the
pipetting procedure was assessed by transferring cerebellar
slices to a small quantity of PBS on a microscope slide, then
transplanting cells onto these slices and viewing immediately
using fluorescence microscopy. At the end of the transplant
procedure, remaining cells were also plated at 2 105 cells/mL
Sato medium directly on PDL-coated chamber slides. Samples
were fixed and stained 2448 h post-transplantation to assess
the survival and morphology of the transplanted and replated
cells.
Immunocytochemistry and Immunohistochemistry. Cells and slices
were washed with PBS, fixed with 4% paraformaldehyde [room
temperature (RT); 25 min], then washed again. For staining,
samples were incubated with blocking solution (5% serum in
PBS, with 0.3% Triton X-100 for NG2 and MBP; RT; 30 min), then
with primary antibody in blocking solution (A2B5 1:200, NG2
1:150, MBP 1:200; 4 C; overnight). The A2B5 antibody recog-
nizes cell surface ganglioside epitopes, while the NG2 antibody
recognizes a cell surface chondroitin sulfate proteoglycan; MBP
is a major protein constituent of myelin and is used to detect
late-stage oligodendrocytes. All the above markers are widely
used to label cells of the oligodendrocyte lineage. Sampleswere
then washed with PBS, incubated with blocking solution (RT; 30
min), and then incubated with the appropriate Cy3-conjugated
secondary antibody in blocking solution (1:200; RT; 2 h). Sam-
ples were then washed with PBS and mounted with DAPI.
Fluorescence Microscopy and Image Analysis. Sampleswere imaged
using fixed exposure settings on an Axio Scope A1 fluorescence
microscope (Carl Zeiss MicroImaging GmbH, Goettingen,
Germany), and the images merged using Adobe Photoshop
CS3 (version 10.0.1). For toxicity and transfection exper-
iments, a minimum of 200 nuclei per treatment per culture
were scored for association with A2B5 staining (for culture
purity) or for GFP expression (for transfection efficiency). For
OPC differentiation experiments, a minimum of 100 nuclei per
treatment per culture were scored for MBP expression. Slices
were imaged post-transplantation using the AxioScope and, in
some experiments, using a BioRad MRC1024 confocal laser
scanning microscope.
Statistical Analysis. Data were analyzed using GraphPad Prism
statistical analysis software. Data are expressed as mean( SEM.
The number of experiments (n) refers to the number of OPC
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culturesused, each fromadifferent rat litter. Todeterminewhether
transfection conditions affected toxicity or transfection
efficiency, data (the number of A2B5þ cells per field and the
percentage of A2B5þ cells expressing GFP, respectively) were
analyzed by one-way ANOVA, with Bonferroni's multiple com-
parison test for post hoc analysis. To determine whether trans-
fection conditions affected the differentiation of OPCs into
MBPþ oligodendrocytes, the percentage of MBPþ cells in cultures
without Neuromag and without application of a magnetic field
was compared to magnetofected cultures using a two-tailed
paired t-test. To compare the transfection efficiencies for the
pmaxGFP, FGF2-GFP, and AN-GFP plasmids, with and without
the application of an oscillating magnetic field, the percentage
of A2B5þ cells expressing GFP was analyzed by one-way ANOVA,
with Bonferroni's multiple comparison test for post hoc analysis.
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Magnetic nanoparticles (MNPs) have emerged as a major platform for the formulation of magnetic
vectors for nonviral gene delivery. Notably the application of \magnetofection" strategies (use of
magnetic ¯elds to increase MNPcell interactions) can signi¯cantly enhance MNPmediated gene
transfer. Despite the potential of this approach, the use of MNPs and magnetofection for gene
delivery to oligodendrocytes (the cells that make and maintain myelin, the insulating sheath
around nerve ¯bers in the central nervous system) has never been tested. Here, we prove the
feasibility of using MNPs in conjunction with applied static or oscillating gradient magnetic ¯elds
(the \magnetofection" method) to deliver genes to oligodendrocytes; all applied magnetic ¯eld
conditions resulted in greater transfection than the no ¯eld condition but overall transfection levels
obtained were typically low (ca: < 6%). Oligodendrocyte transfection levels under all magnetic
¯eld conditions were less than a third compared with their parent cell population, the oligoden-
drocyte precursor cells. We demonstrate for the ¯rst time that, within cells of a speci¯c neural
lineage, the amenability to transfection is dependent on the di®erentiation status of the cell.
Keywords: Oligodendrocytes; oligodendrocyte precursors; magnetic nanoparticles; gene delivery;
transfection.
1. Introduction
Oligodendrocytes are a major class of neuroglial
cells of the central nervous system (CNS), and arise
during development from migratory and mitotic
precursors called oligodendrocyte precursor cells
(OPCs). The oligodendrocytes are responsible for
the production and maintenance of myelin — the
fatty, insulating sheath around CNS nerve ¯bers—
which plays a major role in aiding rapid conduction
of electrical impulses and is increasingly believed
to have a neuroprotective function.13 Loss of
myelin (a process termed \demyelination") is a
major pathological ¯nding in a range of neurological
injuries/diseases, therefore genetic modi¯cation of
oligodendrocytes, in order to understand their bi-
ology and devise e®ective therapeutic approaches, is
a major goal in experimental neurology.
E®orts so far to achieve genetic modi¯cation of
oligodendrocytes have largely relied on the use of
viral transduction methods that can be associated
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with a range of drawbacks including oligodendro-
cyte death and demyelination, suggesting the need
to ¯nd alternative methods for gene transfer to
these cells.47 In this context, magnetic nano-
particles (MNPs) have recently emerged as a major
nanotechnology platform for the formulation of
magnetic vectors for gene transfer, that are addi-
tionally amenable to \magnetofection" strategies
(viz. the application of magnetic ¯elds to assist
transfection). MNP mediated gene transfer,
enhanceable by magnetofection, is feasible in a
range of neural cells including neurons,8 neural stem
cells,9 astrocytes10 and OPCs.11 Despite this po-
tential, the use of MNPs deployed with magneto-
fection methods to achieve gene delivery to
oligodendrocytes has never been attempted. The
aim of this study was twofold: (i) To assess the
feasibility of MNP based transfection in oligoden-
drocytes; and (ii) to determine whether transfection
e±ciency varies with the di®erentiation status of
oligodendroglial lineage cells, by comparing trans-
fection in oligodendrocytes versus OPCs, under
various magnetofection conditions.
2. Methods
2.1. Materials
Tissue culture-grade plastics, media and media
supplements were from Fisher Scienti¯c (Lough-
borough, UK) and Sigma-Aldrich (Poole, UK).
Recombinant human platelet-derived growth factor
(PDGF-AA) and basic ¯broblast growth factor
(FGF2) were from Peprotech (London, UK).
Monoclonal rat anti-myelin basic protein (MBP; a
late stage oligodendrocyte marker) was from Ser-
otech (Kidlington, UK), and secondary antibodies
(Cy3-conjugated) were from Jackson ImmunoR-
esearch Laboratories Inc. (West Grove, PA, USA).
Mounting medium with DAPI (4',6-diamidino-2-
phenylindole) was from Vector Laboratories
(Peterborough, UK). The pmaxGFP plasmid
(3.5 kb) was from Amaxa Biosciences (Cologne,
Germany). Neuromag transfection-grade MNPs
were purchased from Oz Biosciences (Marseille,
France); their physicochemical properties have
been previously described.9,10 The magnefect-
nanoTM oscillating magnetic array system was
from nanoTherics Ltd. (Stoke-on-Trent, UK) and
the details of this system have been previously
published.10
2.2. Cell culture procedures
The care and use of animals was in accordance with
the Animals (Scienti¯c Procedures) Act of 1986
(United Kingdom) with approval by the local ethics
committee. Primary mixed glial cell cultures were
prepared from cerebral cortex of Sprague-Dawley
rats at postnatal day 13 (P13), and puri¯ed
OPC cultures derived from these using an estab-
lished protocol.12 OPCs were plated on PDL-coated
glass coverslips in 24-well plates (0.3ml/well; 3
104 cells/cm2). To induce di®erentiation into oli-
godendrocytes, OPCs were cultured in Sato di®er-
entiation medium (DMEM supplemented with
2mM glutaMAX-I, 1mM sodium pyruvate, 30 nM
3,5,3 0-triiodothyronine, 30 nM thyroxine, 1% N2
supplement, 50U/ml penicillin and 50 g/ml
streptomycin) for 12 days. Before transfection,
culture medium was replaced with 225 l fresh
medium. Neuromag-plasmid complexes were formed
by mixing plasmid (60 ng per well) with DMEM (75
l/well), then gently mixing this with Neuromag
particles (0.21 l). Complexes were allowed to form
for 20min, then added dropwise to the culture wells.
Plates were then incubated either in the absence of
a magnetic ¯eld or magnetofected using a static
(frequency, F ¼ 0) or oscillating (F ¼ 1 or 4Hz)
magnetic ¯eld (30min incubation). The concentra-
tion of Neuromag used here, termed 0.1X, repre-
sents 10% of the dose recommended by the
manufacturers for use with neurons, and this pro-
tocol has been developed in our laboratory for safe
use with OPCs.11
Control cultures were incubated with plasmid
alone; in preliminary experiments, we found that
plasmid alone controls showed similar cell numbers,
morphologies and staining pro¯les to untreated
controls (data not shown), validating the control
group used here. Cells were ¯xed (4% paraformal-
dehyde) and stained for MBP at 48 h post-trans-
fection as described previously.11
2.3. Assessment of particle toxicity
in oligodendrocyte cultures
A battery of assays was used to assess particle
toxicity following 48 h exposure to complexes. Cell
adherence and survival were evaluated by quanti-
fying the percentage of MBPþ cells, average num-
ber of nuclei and percentage of pyknotic nuclei per
¯eld. It was deemed unnecessary to test for toxicity
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of the particles alone as Neuromag MNPs have been
speci¯cally developed as transfection grade particles
and, as such, have no intended usage without con-
jugation of nucleic acid.
2.4. Fluorescence microscopy
and image analysis
Samples were imaged using ¯xed exposure settings
on an Axio Scope A1 °uorescence microscope (Carl
Zeiss MicroImaging GmbH, Goettingen, Germany),
and the images merged using Adobe Photoshop CS3
(version 10.0.1). For toxicity and transfection
experiments, a minimum of 200 nuclei per treat-
ment per culture, selected from a minimum of ¯ve
random ¯elds, were scored for various parameters of
toxicity, association with MBP staining (to assess
oligodendrocyte culture purity) and for GFP
expression (to quantify transfection e±ciency).
2.5. Statistical analysis
Data were analyzed using GraphPad Prism statis-
tical analysis software. Numerical and graphical
data for transfection and toxicity experiments
are presented as mean SEM. All data were ana-
lyzed by one-way ANOVA with Bonferroni's mul-
tiple comparison test for post hoc analysis. The
number of experiments (n) refers to the number of
cultures used, each established from a di®erent rat
litter. Transfection data obtained for each ¯eld
condition were compared with previous transfection
data for OPCs obtained under identical treatment
conditions.11
3. Results
3.1. Oligodendrocyte culture purity
High purity OPC cultures (95.1% 1.4% of cells
stained for the OPC marker A2B5; n ¼ 3 cultures)
were used to produce oligodendrocytes; a high pro-
portion of the latter stained for MBP at seven days
post-di®erentiation (75.9% 5.4%; n ¼ 3 cultures)
[Fig. 1(a)]. An additional 20% of cells stain for
earlier markers of the lineage such as NG2 and O4,
with the remainder (5%) being microglial con-
tamination (data not shown). MBPþ cells were
phase-bright, with multipolar morphologies, in-
cluding the complex highly-branched, membrane
elaborating morphologies typical of mature oligo-
dendrocytes [Figs. 1(a) and 1(a), inset).
3.2. Assessment of MNP toxicity
in oligodendrocytes
Following incubation with MNPDNA complex-
esmagnetic ¯eld application, cells appeared phase
bright and showed normal adherence on micro-
scopic examination, with all stages of cell matura-
tion observed in terms of cell phenotype and process
elaboration. In the presence of particleplasmid
complexes, no toxicity was apparent under any
magnetic ¯eld condition, as the percentage of
MBPþ cells [Fig. 1(b)], the total nuclei per micro-
scopic ¯eld [Fig. 1(c)] and the percentage of nuclei
exhibiting pyknosis [Fig. 1(d)] did not signi¯cantly
di®er from control cultures.
3.3. MNP-mediated transfection
in oligodendrocytes and e®ects
of magnetofection
Under all ¯eld conditions, plasmid alone controls
never resulted in GFP expression. Following incu-
bation with NeuromagpmaxGFP complexes,
GFPþ/MBPþ cells were observed in oligodendro-
cyte cultures. From morphological evaluations, all
stages of the oligodendrocyte lineage were observed
to have been transfected, ranging from cells with a
small number of processes to those with complex
morphologies elaborating extensive myelin sheets
[Figs. 2(a)2(c)]. The extent of MBP expression in
GFPþ cells ranged from strong expression that
overlapped GFP expression throughout the cell in-
cluding processes, to faint expression limited to
patches of the cell [Figs. 2(a)2(c)].
The basal level of transfection with plasmid
conjugated MNPs (no ¯eld condition) was 1.9%
0.1% [Fig. 2(d)]. Application of a static or oscillat-
ing magnetic ¯eld increased transfection e±ciency
between two- and three-fold to 4.9% 1.1%
(F ¼ 0Hz), 4.4% 0.5% (F ¼ 1Hz) and 6.3%
0.6% (F ¼ 4Hz). The static and F ¼ 4Hz (but not
F ¼ 1Hz) conditions signi¯cantly enhanced e±-
ciency relative to the no ¯eld condition. Although
there was a trend towards higher transfection levels
at F ¼ 4Hz compared with the F ¼ 0Hz or 1Hz
conditions, this was not statistically signi¯cantly
[Fig. 2(d)].
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3.4. Comparison of MNP mediated
transfection in oligodendrocytes
versus OPCs
Comparison of the numbers of transfected oligo-
dendrocytes compared with our previously pub-
lished data for OPCs at each ¯eld condition11 shows
that the di®erentiated cells consistently exhibit
lower transfection e±ciencies than the precursor
cells, although this was not found to be signi¯cant
for the no ¯eld condition [Fig. 2(e)]. The di®erence
in transfection levels was most pronounced at the
F ¼ 4Hz condition, with OPC transfection levels
being almost four-fold higher than for oligoden-
drocytes [Fig. 2(e)].
4. Discussion
During neural development, the di®erentiation of
OPCs into mature oligodendrocytes is characterized
by dramatic alterations in the migratory and pro-
liferative features of these cells. This includes a
switch from the bipolar highly migratory and pro-
liferative phenotype characteristic of OPCs, to the
complex, highly branched, nonmigratory and non-
proliferative phenotype of the di®erentiated oligo-
dendrocyte; such changes are accompanied by a
major changes in antigenic expression by these
cells.2,13 Therefore, the use of oligodendroglial cell
cultures allows for the genesis of two cell types that
exhibit distinct biological properties but are derived
(a) (b)
(c) (d)
Fig. 1. Magnetofection protocols are not acutely toxic to oligodendrocytes. (a) Fluorescence micrograph of an oligodendrocyte
culture stained for the late-stage oligodendrocyte marker MBP, with cells displaying the highly branched morphology typical of
oligodendrocytes (also see phase-contrast micrograph, inset). (b) Bar graph indicating the average percentage of MBPþ cells, at all
¯eld conditions tested (p > 0:05 versus control, no ¯eld; one-way ANOVA with Bonferroni's post-test; n ¼ 3 cultures). (c) Bar
graph showing average number of healthy nuclei per microscopic ¯eld in oligodendrocyte cultures for all ¯eld conditions tested. No
di®erences were found between any treatment condition and the no particle, no ¯eld control (p > 0:05; one-way ANOVA with
Bonferroni's post-test; n ¼ 3 cultures). (d) Bar graph illustrating the percentage of all nuclei that were pyknotic, as judged by DAPI
staining (p > 0:05 versus control, no ¯eld; one-way ANOVA with Bonferroni's post-test; n ¼ 3 cultures).
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from the same neural cell lineage. This ability o®ers
a relatively simple experimental technique to
robustly dissect the in°uence of biological para-
meters such as proliferation/di®erentiation status
that may govern neural cell-nanomaterial interac-
tions (and consequently, successful transfection in
neural cells), whilst excluding neural lineage related
variations. As far as we are aware, this is the ¯rst
report to address the e®ect of cellular di®erentiation
state on such interactions in any cell type (either
neural or nonneural).
More speci¯cally, our report is the ¯rst to prove
that oligodendrocytes can be transfected using
MNP-plasmid complexes as vectors. Similar to
reports in other neural cell types, gene transfer
could be signi¯cantly enhanced using applied static
(a) (b) (c)
(d) (e)
Fig. 2. Application of a static or oscillating magnetic ¯eld (magnetofection) enhances MNP-mediated gene delivery to oligoden-
drocytes. (a) Fluorescence micrograph showing GFPþ cells in an oligodendrocyte culture magnetofected at F ¼ 4Hz. (b) Coun-
terpart °uorescence micrograph to (a) showing MBP expression. (c) Merged image of (a) and (b) showing one GFPþ cell with clear
expression of the late-stage oligodendrocyte marker MBP throughout the cell (red arrow), two GFPþ cells with faint MBP
expression (white arrows indicate regions of MBP expression), and a GFPþ/MBP cell. Note also two GFP/MBPþ cells. (d) Bar
graph illustrating transfection e±ciencies in oligodendrocyte cultures for all ¯eld conditions tested as judged by the percentage of
MBPþ cells expressing GFP. The F ¼ 0Hz and 4Hz magnetic ¯eld conditions signi¯cantly enhanced transfection levels compared
to the no ¯eld condition (*p < 0:05, **p < 0:01; one-way ANOVA with Bonferroni's post-test; n ¼ 3 cultures). (e) Bar graph
indicating comparative transfection e±ciencies in OPCs and oligodendrocytes under all ¯eld conditions tested (OPC data adapted
from Ref. 11). (**p < 0:01, ***p < 0:001; one-way ANOVA with Bonferroni's post-test; n ¼ 3 cultures). OL ¼ oligodendrocyte
(Color online).
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and oscillating magnetic ¯elds.8,10,11 Transfection
levels in oligodendrocytes were dramatically lower
than those achieved in OPCs and it is noteworthy
that transduction levels for oligodendrocytes using
viral systems, such as retroviruses, are also typically
low (Table 1). Indeed, one in vivo study comparing
adeno-, retro- and lentiviral systems found no evi-
dence of oligodendrocyte transduction even at high
viral titres.14 By contrast, another report found
evidence that oligodendrocytes can be transduced
in vivo using adenoviruses, but that gene delivery
is complicated by immunogenic and cytopathic
e®ects on oligodendrocytes, limiting the transla-
tional potential of the approach.6 Nonviral trans-
fection methods such as calcium phosphate
precipitation and electroporation yield no/low
transfection in oligodendrocytes and are associated
with high levels of cell loss.15,16 Delivery methods
such as the gene gun approach and lipofection yield
higher transfection levels than MNPs (up to 20%,
Table 1) and have been described to be relatively
safe, so these approaches should still represent the
methods of choice for oligodendrocyte transfection
applications.16
In every case, the methodologies above have
yielded signi¯cantly higher transfection in OPCs
than in oligodendrocytes. Together, these data
clearly indicate that di®erentiated oligodendrocytes
are intrinsically far less amenable to gene delivery
than are their precursor forms; the underlying
causes for this intercellular di®erence are not
clear. The issue is complicated by the diversity of
approaches used for genetic modi¯cation of cells of
the oligodendrocyte lineage, each of which utilizes
di®erent mechanisms to achieve gene trans-
fer.11,1519 This highlights a major current need to
systematically evaluate the biological and physico-
chemical parameters governing successful transfec-
tion of neural cells using nonviral vectors, an area
where little or no information currently exists.
Uptake of MNPDNA complexes by mammali-
an cells is widely accepted to be via endocytosis of
these complexes. Magnetofection approaches are
considered to enhance gene transfer by simple sed-
imentation of particle plasmid complexes over
cells,9,20,21 or potentially by stimulation of endocy-
tosis in the case of oscillating ¯eld strategies.10,11,22
Bearing this in mind, we can speculate that the
di®erences in OPC versus oligodendrocyte trans-
fection levels could be related to a number of
parameters (Fig. 3). The ¯rst is the extent of
membrane that participates in the endocytotic up-
take of MNPs into cells. Although oligodendrocytes
have a high branch order per cell and generate
elaborate sheets of myelin membrane, for both
OPCs and oligodendrocytes we observe that parti-
cle uptake is restricted to the cell body, and uptake
in cellular processes is never seen. This suggests that
the total amount of membrane elaborated by the
cell (and hence the total cell surface area) is not
necessarily re°ective of the capacity for particle
uptake. In general there is little information cur-
rently regarding which speci¯c modes of endocytosis
are utilized by OPCs versus oligodendrocytes, and
what the level of activity for each of these
mechanisms is. Such information will be a pre-req-
uisite to understanding the relationship between
particle uptake and transfection. In recent studies,
Table 1. Comparative in vitro transfection e±ciencies in rat oligodendrocytes for viral and nonviral vectors.
Method Gene Source of cells E±ciency Related toxicity Ref
Viral
Retrovirus -Gal P1520 < 0:1% No data supplied 15
Retrovirus (MoMuLV) -Gal P2842 0% No data supplied 16
Nonviral
Particle bombardment -Gal P1520 20% No data supplied 15
Lipofection -Gal P1520 10% No data supplied 15
Lipofection -Gal P2842 0% No data supplied 16
Magnetic nanoparticles GFP P13 6% Not signi¯cant 
Calcium phosphate precipitation -Gal P2842 < 3% 90% cell death 16
Calcium phosphate precipitation -Gal P1520 < 2% \most cells died" 15
Electroporation -Gal P2842 No data supplied \drastic" cell death 16
Note: MoMuLV ¼Moloney murine leukaemia virus; -Gal ¼ -Galactosidase; P ¼ postnatal day; GFP ¼ green
°uorescent protein; *current study.
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we applied a test magnetic particle [speci¯cally,
SpheroTM from Spherotech Inc, USA (particles with
a polystyrene core incorporating a Nile Red °uor-
ophore, surrounded by a polystyrene and magnetite
layer bound to carboxyl groups with ca:1:63 106
carboxyl groups per particle), 1520% iron content,
average diameter (SEM) ¼ 360 nm, average hy-
drodynamic diameter (dynamic light scattering) ¼
850 nm, zeta potential 14.3mV (in Sato medi-
um)], to cultures of OPCs and oligodendrocytes
(using identical cell densities, particle concentra-
tions and incubation times). Here, we have consis-
tently found that the proportion of OPCs
incorporating MNPs is signi¯cantly higher than
oligodendrocytes, with particle accumulations
within OPCs also being typically larger (Jenkins
et al., 2012, manuscript in preparation). Further,
cells at more advanced stages of oligodendrocyte
di®erentiation (judged by the number/complexity of
processes) contained smaller particle accumulations
than oligodendrocytes with relatively immature, less
branching morphologies. These observations suggest
an inverse relationship between cellular maturity
and the capacity for particle uptake, which could
provide a basis for the lower transfection levels
observed here.
The second parameter could be the proliferative
status of the target cell population and related nu-
clear breakdown, facilitating DNA entry into the
nucleus, a mechanism similar to that utilized by
some viral vectors,23,24 with the consequence that
oligodendrocytes, a major post-mitotic population,
Fig. 3. Schematic summary of the potential factors underlying the di®erence in amenability to transfection in OPCs versus
oligodendrocytes. Representative °uorescence micrographs are included of GFPþ OPCs and a GFPþ oligodendrocyte to highlight
the morphological di®erences between the two cell types. The OPCs typically display bipolar morphologies with limited branching
and a nucleus occupying a large proportion of the soma. GFPþ OPCs were frequently observed in pairs, indicative of recent mitosis
(inset). Although less amenable to transfection than OPCs, even mature oligodendrocytes could be transfected, as indicated by the
complex highly-branched morphology of the transfected cell shown here.
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may be relatively refractory to transfection. How-
ever, contradicting this idea, an earlier study in
primary human ¯broblasts has suggested that for
virus-independent transfection methods, a round of
cell division (with dissolution of the nuclear mem-
brane) is not a pre-requisite for DNA to enter the
nucleus.25 Our own experiments provide contradic-
tory data in this regard. In support of the nuclear
breakdown hypothesis, we observe consistently that
GFP expression is often found in cells that appear
to have recently undergone mitosis (see Ref. 11 and
Fig. 3 inset for an example). However, using cul-
tures of di®erentiated oligodendrocytes, we have
also shown that complex, highly processed, post-
mitotic cells can be transfected using MNPs (Figs. 2
and 3). Therefore the relationship between cell
proliferation, nuclear breakdown and the extent of
transfection in oligodendroglial cells, is currently
unresolved.
Third, it is not apparent whether there are dif-
ferences in the mechanisms of intracellular proces-
sing of MNPs and nucleic acids within OPCs versus
oligodendrocytes, in respect of rates of intracellular
particle tra±cking (especially to the nucleus), the
extent of vacuolar localization, potential breakdown
of particles and so on. Ideally, studies should use
particles with well characterized physicochemical
properties, in conjunction with high resolution
electron/time lapse microscopy and inhibitors of
various endocytotic pathways, to resolve these
issues. Such work will aid nanotechnology research
in the identi¯cation of MNPs with appropriate
properties for optimal use in a range of biological
applications involving oligodendroglial cells, a
major target population in regenerative medicine.
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Appendix 6: Article published by Tissue Engineering: Part C. 
The astrocyte uptake data (Sphero MPs) used for the cross-cellular comparison (Chapter 5) 
was published previously, and the article is included here as appendix 6. 
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Magnetic Nanoparticle Labeling of Astrocytes Derived
for Neural Transplantation
Mark R. Pickard, Ph.D.,1 Stuart I. Jenkins, B.Sc.,1 Chris J. Koller, M.Sc.,2
David N. Furness, Ph.D.,1 and Divya M. Chari, D.Phil.1
Astrocytes are a major transplant cell population to promote neural repair in a range of pathological condi-
tions. In this context, the development of robust methods to label neural transplant populations (for subse-
quent detection and cell tracking in vivo) is key for translational applications. Magnetic iron oxide
nanoparticles (MNP)-based vector systems offer a range of advantages for neural cell transplantation, notably,
as contrast agents for magnetic resonance imaging, which allows for MNP-labeled cells to be detected using
minimally invasive methods. Additionally, MNPs have other key features such as safety, the potential for
linking with genetic material/drugs, and magnetic cell targeting. Therefore, MNPs can potentially be devel-
oped as a multipurpose nanoplatform for neural cell transplantation. The feasibility of labeling astrocytes
derived for transplantation with MNPs has not been assessed to date. Here, we have established simple
protocols to safely label astrocytes with MNPs; the survival and differentiation of labeled cells was assessed in
three dimensional neural tissue arrays. Additionally, we have established the major mechanisms of MNP
uptake by astrocytes.
Introduction
Astrocytes are a major neuroglial subclass, ie., non-neuronal support cells of the central nervous system
(CNS), that outnumber neurons by about 10-fold.1 These cells
play key roles in the maintenance of normal CNS homeo-
static mechanisms, including synaptic glutamate uptake,
regulation of extracellular calcium, and provision of nutri-
ents for neurons1–4; indeed, a range of neuropathological
conditions are associated with astrocytic dysfunction.5–7
Importantly, these cells have been proven to be major
candidates for ex vivo gene delivery and neural tissue
engineering/transplantation strategies in several experi-
mental models of neural injury/disease, given the significant
capacity of these cells to migrate, survive, and integrate after
introduction into the normal or injured CNS parenchyma.8–11
When evaluating the translational potential of astrocyte
transplantation (to promote neural regeneration) into viable
clinical therapies, a major (but often overlooked) consider-
ation is the development of robust methodologies to non-
invasively detect transplant populations in host tissue to
monitor transplant cell survival and fate; this is critical to
evaluating the comparative benefits and limitations of var-
ious cell therapies to promote neural regeneration. Experi-
mental studies in transplantation neurobiology generally
employ a wide range of methods to label neural cell trans-
plant populations for identification in host tissue. Examples
of these are labeling with lipophilic carbocyanine dyes, Y
chromosome detection (after transplantation of male cells
into female hosts), and genetic labeling with subsequent
detection of enzymes or fluorescent protein (e.g., LacZ or
GFP) and chemical markers such as bisbenzamide.12–16
Many of these labeling methods have significant disadvan-
tages associated with them such as technical complexity,
toxicity, unreliability due to diffusion of label, and the lack of
ability to detect transplanted cells by noninvasive methods.
Recent advances in nanotechnology have highlighted the
significant potential offered by delivery systems employing
magnetic iron oxide nanoparticles (MNPs) for imaging
applications in tissue engineering. Such particles have
emerged as a major class of contrast agent for magnetic
resonance imaging (MRI) with advances in chemical
methods to control particle properties such as size, coatings,
biodegradability, and toxicity. The ability to label cells with
MNPs ex vivo therefore provides a technique to detect
transplant cell populations in vivo using MRI17 allowing for
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the noninvasive monitoring of the biodistribution, integra-
tion, and survival of transplanted cells. In this context, it has
been demonstrated that neural progenitor/stem cells, in-
cluding glial-restricted precursors, can be safely labeled
with magnetic particles and tracked using MRI after
transplantation into areas of pathology (with no demon-
strable loss of functional capacity and limited effects on cell
survival/differentiation).18–21 To date, however, the feasi-
bility of using MNPs for cell labeling in astrocyte trans-
plantation therapies has not been assessed. In addition to
cell tracking, MNPs have applications in magnetic targeting
(including magnetic cell targeting) and—because they can
be readily functionalized with drugs/genetic material—
they have the potential to serve as a multifunctional nano-
platform for cell transplantation applications.22 We recently
demonstrated, for the first time, that astrocytes derived
from primary cultures can be transfected using MNPs in the
presence of applied static/oscillating magnetic fields (the
so-called magnetofection approaches), achieving efficien-
cies close to that of some viral vector systems. We further
proved in this study that transfected cells could survive and
integrate into host neural circuitry after transplantation into
three-dimensional neural tissue arrays (organotypic cere-
bellar slice cultures).22 These findings taken in conjunction
with the multiple benefits of MNP vector systems led us to
suggest that MNPs could represent the multifunctional
vector system of choice for astrocyte transplantation ther-
apies.
Here, we have established protocols to safely label astro-
cyte transplant populations with MNPs ex vivo for cell
tracking applications. To achieve this, we have employed
fluorescently labeled MNPs and astrocyte cultures to exam-
ine a range of parameters related to particle uptake and
toxicity. We also demonstrate the survival and differentia-
tion potential of astrocytes post-MNP labeling after trans-
plantation into organotypic slice cultures derived from the
rat cerebellum.
Materials and Methods
Astrocyte cell culture
Mixed glial cultures were established from cerebral corti-
ces of neonatal Sprague-Dawley rats and astrocytes were
purified using a published procedure.23 The adherent astro-
cyte cell layer was trypsinized, and subcultured once in D-10
medium (Dulbecco’s modified Eagle’s medium plus 2 mM
glutaMAX-I, 1 mM sodium pyruvate, 50 U/mL penicillin,
50 mg/mL streptomycin, and 10% fetal bovine serum) in
poly-D-lysine (PDL)-coated T75 flasks. All cultures were in-
cubated at 378C in 5% CO2/95% air, with medium changes
every 2–3 days, unless otherwise specified. Subconfluent
astrocyte cultures were trypsinized, resuspended in D-10
medium, and used for MNP uptake, transplantation, and
toxicity studies, as described below.
Cerebellar slice cultures
Brains of Sprague-Dawley rat pups at 10 postnatal days
were collected into ice-cold slicing medium (Earle’s balanced
salts solution buffered with 25 mM HEPES). Cerebella were
dissected, meninges removed, and 400mm parasagittal slices
prepared using a McIlwain tissue chopper. Slices were
transferred to slicing medium at 48C for 30 min, and then
individual slices were transferred to pieces of Omnipore
membrane on Millicell culture inserts (Millipore) in six-well
plates containing the culture medium (50% minimum es-
sential medium, 25% Earle’s balanced salts solution, and 25%
horse serum; supplemented with 1 mM glutaMAX-I, 36 mM
D-glucose, 50 U/mL penicillin, and 50 mg/mL streptomycin).
Slices were cultured at 378C in 5% CO2/95% air, with me-
dium changes every 2–3 days. All experiments involving
animals were conducted in strict accordance with United
Kingdom Home Office guidelines.
Uptake experiments
Paramagnetic, carboxyl-modified SPHERO Nile Red
fluorescent magnetic particles (0.20–0.39 mm diameter, iron
content 15%–20%) were obtained from Spherotech, Inc.
These comprise a polystyrene core, stained with the fluor-
ophore Nile Red, coated with a magnetite layer, and then
overcoated with a functionalized monomer. For all incuba-
tions, unless specified otherwise, astrocytes were seeded into
PDL-coated chamber slides (0.4105 cells/cm2) and allowed
to attach for 24 h before MNP addition in fresh D-10 me-
dium. (A) For time course experiments, cells were incubated
with 2–50 mg/mL MNPs for 1–24 h. (B) To determine the
temperature dependence of uptake, cells were incubated
with 20 mg/mL MNPs for 1 h at 48C or 378C (in 100% air);
uptake at 378C under these conditions was similar to that in
incubations conducted in 5% CO2/95% air. (C) To determine
mechanisms of MNP uptake, selective endocytosis inhibi-
tors24 (Sigma) were used at concentrations routinely em-
ployed for other cell types.24–26 Inhibitors comprised
dynasore (80mM) and tyrphostin 23 (350 mM) (inhibitors of
clathrin-dependent endocytosis); filipin III (5 mg/mL) (in-
hibitor of caveolin-dependent endocytosis); and amiloride
(1 mM) and 5-(N-ethyl-N-isopropyl) amiloride (EIPA;
100 mM) (macropinocytosis inhibitors); all stock solutions
(1000) were dissolved in dimethyl sulfoxide (DMSO) vehi-
cle. Cells were preincubated for 20 min with inhibitor, and
then with the same inhibitor plus MNPs (20mg/mL) for 1 h.
Controls included cells incubated with vehicle or medium
alone (‘‘no addition’’ control). The latter was included to
verify that the vehicle (DMSO) was without effect on cells.
(D) To determine the intracellular fate of MNPs by trans-
mission electron microscopy (TEM), cells were seeded onto
PDL-coated Aclar sheeting (0.6105 cells/cm2). After 24 h,
cells were incubated with 20 mg/mL MNPs for 24 h. (E) To
determine the long-term disposition of particles (up to 3
weeks), cells were seeded onto PDL-coated glass coverslips
or 12-well plates (0.1105 cells/cm2). After 24 h, cells were
incubated with either 0 or 20 mg/mL Spherofluor MNPs for
24 h. The medium was replaced with fresh D-10 minus
MNPs and cells were cultured for up to a further 21 days.
Cells were split (1 in 3) by trypsinization at weekly intervals.
To terminate incubations, cells were washed three times with
phosphate-buffered saline (PBS) then fixed, as described
below.
Transplantation of labeled astrocytes into slice cultures
Astrocytes were seeded into PDL-coated plates (0.2105
cells/cm2) and, after 24 h, incubated with fresh D-10 medium
containing 20 mg/mL MNPs for 4 h. Medium was then
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replaced with fresh D-10 medium alone for 20 h. Nuclei were
labeled by subsequent incubation of cells in medium con-
taining 50mg/mL 4,6-diamidino-2-phenylindole (DAPI) for
30 min, and then washed with PBS; this dual labeling pro-
cedure was used to robustly differentiate the transplant
population from host astrocytes. Cells were trypsinized and
resuspended at 4107 cells/mL D-10 medium. Then, 0.25 mL
of medium containing 10,000 cells was pipetted onto cere-
bellar slices that had been cultured for 9 days in vitro. To
observe the passive spread of transplanted astrocytes due to
the force of injection, immediately after application of cells
(t¼ 0 h), slices were transferred to a slide, cells applied, and
live slices observed using fluorescence microscopy. To
monitor the survival and morphology of the trypsinized cells
after transplantation and to confirm intracellular MNP lo-
calization, astrocyte transplant populations were addition-
ally plated onto PDL-coated chamber slides. A total of 12
slices were examined.
Immunocytochemistry and histochemistry
Samples were fixed with 4% (w/v) paraformaldehyde (in
PBS) for 20 min and then washed three times with PBS. For
identification of astrocytes, polyclonal rabbit anti-glial fi-
brillary acidic protein (GFAP) antibody (DakoCytomation)
was used. Fixed samples were incubated with blocking so-
lution (5% normal donkey serum in PBS–0.3% Triton X-100)
(room temperature [RT], 30 min), and then with primary
antibody to GFAP (1:500 dilution in blocking solution; 48C,
overnight). After washing, samples were incubated with
blocking solution (RT, 30 min), and then with fluorescein
isothiocyanate-labeled donkey anti-rabbit IgG ( Jackson Im-
munoResearch Laboratoratories, Inc.; diluted 1:200 in
blocking solution; RT for 2 h). Samples were then washed
and usually mounted with Vectashield mounting medium
containing DAPI (Vector Laboratories); for the slice cultures
experiments, mounting medium without DAPI was used for
cells and slices. For Perl’s Prussian Blue staining to observe
intracellular iron, fixed cells were incubated with 2% potas-
sium ferricyanide in 2% HCl for 30 min, washed three times
with distilled water, and mounted without DAPI.
Fluorescence microscopy and image analysis
Fluorescence microscopy was performed using an Axio
Scope A1 microscope equipped with an Axio Cam ICc1
digital camera and AxioVision software (release 4.7.1; Carl
Zeiss MicroImaging GmbH). Images were merged in Adobe
Photoshop CS3 (version 10.0.1), and used for semiquantita-
tive analysis, as described previously.27 Purity of astrocyte
cultures was assessed from merged images of GFAP and
DAPI-stained cells (100 cells were scored per culture). To
assess the effects of particles or endocytosis inhibitors on cell
viability, counts of DAPI-positive nuclei were compared
between control and treated wells with assessment of nuclear
morphology; a minimum of three microscopic fields at400
magnification (100 nuclei in total) were assessed. Particle
uptake by astrocytes (including endocytosis inhibitor ex-
periments) was assessed from triple merges (400 magnifi-
cation) of DAPI, Nile Red, and GFAP fluorescent images,
and the proportion of astrocytes (GFAP-positive cells) dem-
onstrating particle uptake (termed % labeled cells) was cal-
culated. To determine the extent of particle accumulation,
labeled astrocytes were categorized based on the area of the
cell occupied by the accumulated nanoparticles relative to
the area of the cell nucleus; categories were low (10%),
moderate (11%–50%), and high (51%). Labeled astrocytes
were also classified with respect to the subcellular localiza-
tion of nanoparticles; the proportion of labeled cells with a
perinuclear particle localization either exclusively or com-
bined with a cytoplasmic particle distribution is reported
here. For all uptake calculations, a minimum of 100 GFAP-
positive cells per treatment were evaluated. Confocal laser
scanning microscopy, using a BioRad MRC1024 confocal
microscope, was employed to determine if cell-associated
particles had been internalized rather than simply adsorbed
onto the cell surface.
Electron microscopy (scanning and transmission)
To assess particle size and shape, Spherofluor particles
were placed in pure water, air-dried onto aluminum stubs,
and observed uncoated using a high-resolution field emis-
sion scanning electron microscope (Hitachi S4500) operated
at an accelerating voltage of 5 kV. To assess the intracellular
localization of MNPs, samples were fixed with 2.5% (w/v)
glutaraldehyde (in 0.1 M sodium cacodylate buffer contain-
ing 2 mM CaCl2; SCB) for 2 h, and then washed three times
with SCB. Samples were postfixed with 1% osmium tetroxide
in SCB for 1 h, washed, and then dehydrated in a graded
series of ethanol, before infiltration in Spurr resin. After po-
lymerization of the resin at 608C for 16 h, ultrathin sections
were cut on a Reichert Ultracut E microtome, and placed on
200 mesh thin bar copper grids and stained with 2% uranyl
acetate in 70% ethanol and 2% Reynold’s lead citrate. Sec-
tions were examined in a JEOL 1230 TEM operated at 100 kV.
MRI of agar-embedded MNPs
An initial proof of principle study was undertaken using
a 1.5 T Philips Intera-Achivea MRI Scanner (Best) and a
medium sense flex coil, to provide an assessment of the
clinical feasibility of detecting MNP labeled astrocytes using
clinical scanning methods. Spherofluor particle concentra-
tions of 5, 20, and 50mg/mL were embedded in agar gel; a
test transfection-grade MNP with low iron content (0.5%,
Neuromag; Oz Biosciences) was also included and a gradient
echo sequence undertaken to qualitatively assess visibility.
Toxicity assays
Astrocytes were plated into PDL-coated 96-well plates
(1104 cells/cm2; 0.2 mL medium/well). After 24 h, the me-
dium was replaced with fresh D-10 containing 0–50mg/mL
concentrations of Spherofluor MNPs, and cells were incu-
bated at 378C in a humidified atmosphere of 5% CO2/95%
air for 24 h. The medium was then replaced with fresh D-10
alone, and the medium was changed every 2–3 days. MTS
assays (CellTiter 96 AQueous One Solution Cell Proliferation
Assay; Promega) were performed at 0–96 h postmedium
change according to the supplier’s instructions. Blank incu-
bations, comprising medium plus MNPs but no cells, were
run with each assay and the corresponding absorbance
readings at 490 nm (A490) were subtracted from the appro-
priate test readings. Values were expressed as percentage
cellular viability relative to control incubations minus MNPs.
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Statistical analysis
Data are expressed as mean standard error of the mean.
To assess the effects of MNP concentration and time of ex-
posure on proportion of cells showing particle uptake, extent
of particle accumulation, and degree of perinuclear lo-
calization, data were analyzed by a two-way analysis of
variance followed by Bonferroni’s post-tests; for clarity,
comparisons versus the 2 mg/mL MNP group at a given time
point (in the case of concentration dependence) and com-
parisons versus the same MNP concentration at 1 h (in the
case of time dependence) only are displayed on bar charts.
For temperature dependence of uptake, data were analyzed
by Student’s t-test (two-tailed). One-way analysis of vari-
ance, with either Bonferroni’s multiple comparison test or
Dunnett’s multiple comparison test, was used to analyze
data for the endocytosis inhibitor and cytotoxicity experi-
ments, respectively. GraphPad Prism 4 for Windows soft-
ware (version 4.03) was used for statistical analyses.
Results
Culture characteristics
Astrocyte cultures were of consistently high purity, as
judged by GFAP immunostaining (97.8% 0.3%; n¼ 8 cul-
tures). The majority of cells exhibited a flattened, polygonal
appearance, characteristic of type 1 astrocytes, while cells
with the complex, branching morphology of type 2 astro-
cytes accounted for <1% of the astrocyte population.
MNP uptake by astrocytes
Cell-associated fluorescent MNPs were clearly visible
within both type 1 and type 2 astrocytes. Confocal micros-
copy revealed that fluorescence associated with MNPs and
cytoskeletal GFAP was coincident; the former was only
clearly visible in internal slices of cells (Fig. 1A and Supple-
mentary Fig. S1, available online at www.liebertonline.com/
ten); therefore, cell-associated fluorescence was inferred to
represent internalized MNPs. Importantly, Perl’s staining of
cells prelabeled with MNPs for 24 h revealed colocalization
of iron-containing material (Fig. 1B) and Nile Red fluores-
cence (Fig. 1C), indicating that ingested MNPs remained
chemically stable. Blue deposits, characteristic of precipitated
iron, were not seen in control cells (data not shown). Scan-
ning electron microscopy analyses revealed that particles
were of regular shape and size (Fig. 1D), consistent with the
size range (200–390 nm diameter; mean¼ 360 nm) reported
by the manufacturer.
Astrocytes demonstrated clear heterogeneity in particle up-
take (Fig. 1E); both the proportions of cells exhibiting MNP
uptake and the extent of particle accumulation within cells
showed time and concentration dependence (Fig. 1 F, G). Im-
portantly, near-complete labeling of cells (>95%) was observed
in incubations with 20mg/mL MNPs for 24 h (Fig. 1F).
MRI of agar-embedded MNPs
Spherofluor particles embedded in agar gel at the higher
concentrations studied (20 and 50 mg/mL) were readily ob-
served using MRI. The lowest particle concentration and
particles with low iron content yielded limited contrast.
Preliminary findings indicate that the different concentra-
tions resulted in *25%–75% reduction in T2* relaxation
times compared with agar gel alone.
Perinuclear targeting of MNPs
Perinuclear clustering was a prominent feature after in-
cubation of astrocytes with MNPs (Fig. 1E); presence of cy-
toplasmic and perinuclear collections of MNPs were
confirmed by TEM (Fig. 2A). Perinuclear particles were
never observed fusing with the nuclear membrane, localized
within membrane bound structures or in obvious association
with the endoplasmic reticulum or Golgi apparatus.
Analysis of the subcellular location of MNPs revealed
that in incubations with 2 mg/mL MNPs for 1 h, ingested
particles were localized to the cytoplasm in most cells with
a minor proportion showing perinuclear/nuclear distribu-
tion. The proportion of labeled cells containing particles
with a perinuclear localization showed both time and con-
centration dependence (Fig. 2B). Astrocytes prelabeled with
MNPs for 24 h, then cultured for a further 6 days retained
large collections of particles (Fig. 2C). There was clear evi-
dence of cellular heterogeneity of astrocytes with respect
to the subcellular localization of MNPs at this time. Thus,
although the majority (*85%) of labeled cells contained
particles in close proximity to the nucleus; the remainder
contained MNPs with a predominantly cytoplasmic locali-
zation (Fig. 2C). Particles showed progressive dilution of
label with time, with *82% of cells labeled at 14 days and
63% at 21 days.
Mechanism of MNP uptake and intracellular trafficking
MNP uptake was temperature dependant, as reducing the
incubation temperature to 48C markedly inhibited (by 84%)
the proportion of cells showing uptake (Fig. 3A), indicating
the energy dependence of uptake mechanisms. In endocy-
tosis blocker studies, the proportions of astrocytes that ac-
cumulated MNPs were similar to that under both control
conditions (Fig. 3B). Macropinocytosis inhibitors markedly
inhibited MNP uptake by astrocytes (Fig. 3B) compared with
DMSO alone (reduced by 66% [amiloride] and 70% [EIPA]).
Inhibitors of clathrin-dependent endocytosis reduced the
proportion of astrocytes displaying particle uptake to a lesser
extent than macropinocytosis blockers (Fig. 3B); (reduced
by 31% [tyrphostin 23] and 28% [dynasore]). A blocker of
caveolin-mediated uptake (filipin) did not inhibit particle
uptake (data not shown). In experiments where both inhib-
itors of clathrin mediated uptake and macropinocytosis were
applied to cultures, significant cellular toxicity was observed;
therefore, it was difficult to draw conclusions from these
experiments. Cell densities, as judged by counts of DAPI-
stained nuclei per field, were similar for astrocytes treated
with and without inhibitors (Table 1), indicating the absence
of associated short-term toxic effects of inhibitors alone.
TEM analyses supported findings from the inhibitor
studies. Cells displayed extensive projections of the plasma
membrane that appeared to be engulfing collections of
MNPs (Fig. 3C), consistent with a role for macropinocytosis
in particle uptake. Further, coated pit-like structures in the
astrocytic plasma membrane were also observed (Fig. 3D;
inset) and, occasionally, particles were seen externally, in
close apposition to such structures (Fig. 3D), consistent with
a role for clathrin-mediated endocytosis.
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Toxicity
Incubation of astrocytes with 2–50 mg/mL MNPs for 24 h
had no statistically significant cytotoxic effects as judged by a
MTS assay, immediately after incubation with particles or
after a further 24–96 h in medium alone (Table 2). Indeed, in
the experiment to determine the time course and concen-
tration dependence of MNP uptake, visual examination
revealed that incubation of astrocytes with increasing con-
centrations of MNPs had no effect on counts of DAPI-stained
nuclei per microscopic field, nuclear morphology (Supple-
mentary Fig. S2, available online at www.liebertonline
.com/ten), and cell morphology (data not shown).
Transplantation of labeled astrocytes into slice cultures
To assess if MNP-labeled astrocytes could survive and
integrate within host tissue after transplantation, experi-
ments were conducted using organotypic cerebellar slice
cultures as the recipient tissue. Immediately after delivery of
trypsinized cells, colocalization of DAPI and Nile Red
(MNP) fluorescence could be observed (Fig. 4) in a highly
localized focus within the slice (Fig. 4A; inset); cells typically
FIG. 1. Uptake of magnetic iron oxide nanoparticles
(MNPs) by rat astrocytes varies with particle concentration
and length of incubation. (A) Confocal image through the
center of an astrocyte incubated with MNPs (50 mg/mL,
24 h). MNP-linked fluorescence and glial fibrillary acidic
protein (GFAP) staining is coincident, demonstrating an in-
tracellular localization for MNPs. Please see Supplemental
Figure S1 for the full montage of images taken through the
cell. (B) Iron (Perl’s stain) of astrocytes at 7 days postlabeling
with MNPs. (C) Nile Red fluorescence in the same field
shown in (B). Note the colocalization of iron and Nile Red
fluorescence in these cells. (D) Scanning electron microscopy
image of Spherofluor MNPs demonstrating uniformity of
size of particles. (E) Example triple-merged image of cells
demonstrating classification of cells showing low (L), mod-
erate (M), and high (H) levels of particle accumulation. (F)
Bar graph demonstrating variation in proportions of cells
showing particle uptake with length of incubation and MNP
concentration. The proportion of labeled cells is significantly
related to each factor ( p< 0.001; n¼ 3 cultures; two-way
analysis of variance [ANOVA]); *p< 0.05, **p< 0.01, and
***p< 0.001 versus the same MNP concentration at 1 h;
þp< 0.05, þþp< 0.01, and þþþp< 0.001 versus 2mg/mL
MNPs at the same time point (Bonferroni’s post-tests). (G) Bar
graph showing variations in extent of MNP accumulation in
cells with length of incubation and MNP concentration. The
proportion of labeled cells classified as having low, moderate,
or high levels of particle accumulation varies with length of
incubation and MNP concentration ( p< 0.001 for each factor
for each category; n¼ 3 cultures; two-way ANOVA); *p< 0.05,
**p< 0.01, and ***p< 0.001 versus the same MNP concentra-
tion at 1 h; þp< 0.05, þþp< 0.01, and þþþp< 0.001 versus
2mg/mL MNPs at the same time point (Bonferroni’s post-
tests). (H) Magnetic resonance imaging (1.5 T clinical scanner)
image of MNP embedded in agar gel showing contrast is
proportional to MNP concentration: well 1, 0mg/mL; well 2,
5mg/mL; well 3, 20mg/mL; and well 4, 50mg/mL Spherofluor
MNPs. Commercial transfection-grade MNPs with low iron
content were embedded in well 5. Scale bar¼ 50mm in (A),
100mm in (C), 250 nm in (D), and 25mm in (E). Color images
available online at www.liebertonline.com/ten.
‰
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display a rounded morphology at this stage with withdrawal
of cellular processes, consequent upon trypsinization. At 10
days post-transplantation, a restricted area of DAPI fluores-
cence was detected within the slice (Fig. 4A); robust GFAP
labeling was present throughout the slice that can be attrib-
uted to both host and transplanted astrocytes (Fig. 4B). A
focus of Nile Red fluorescence associated with the injection
site could also still be clearly observed (Fig. 4C) with colo-
calization of DAPI and red fluorescence detected against a
background of host tissue (Fig. 4D). Importantly, Nile Red
and DAPI-labeled cells appeared to be radiating outward
from the central application point, suggesting cell migration;
the majority of cells appeared to remain at the application
site. Further, high-power images of slices revealed the pres-
ence of multiple, well-differentiated DAPI/Nile Red/GFAP
triple-positive cells (Fig. 4E), indicating that MNP label was
retained by astrocytes and did not impair the ability of as-
trocytes to re-acquire their normal cellular morphologies af-
ter transplantation. When labeled astrocyte transplant
populations were replated in culture wells, retention of
particles was apparent (Fig. 4F), although a slight decline in
the proportion of labeled cells with time observed (from
*93% at 72 h to 70% at 10 days; this suggests that the ma-
jority of fluorescent signal detected in transplanted slices at
10 days is due to the transplant population). This was as-
sociated with a gradual decrease in the proportion of labeled
cells showing MNPs in a perinuclear localization (from
*80% at 72 h to 50% at 10 days), with particles showing a
tendency to progressively accumulate near the cell mem-
brane. Importantly, labeled cells were able to reacquire their
normal morphological characteristics after trypsinization
and transplantation (Fig. 4F), and cultures exhibited similar
confluence and cell morphology to cultures that had been
treated in a similar manner but incubated without either
MNPs or DAPI (data not shown). The dominant morphology
observed in both transplanted and plated astrocytes was that
of type 1 cells (similar to the distributions observed before
cell labeling), indicating that MNP labeling did not alter the
phenotypic distributions of astrocytes.
Discussion
Here, we provide proof of principle (using cells obtained
from primary cultures) that astrocytes derived for neural
tissue engineering applications can be rapidly and efficiently
labeled with MNPs. We employed relatively large (0.20–
0.39 mm) particles for cell labeling in these studies; we have
considered elsewhere the advantages of using particles with
these dimensions.27 We consider that the combination of
methods used in this study is valid for several reasons. Ex-
periments using cell lines have provided valuable informa-
tion on the cellular dynamics of nanoparticle uptake;
FIG. 2. Perinuclear localization of MNPs in astrocytes. (A)
Electron micrograph of an astrocyte showing perinuclear
accumulation of MNPs (small arrow). Other particles show a
more distal cytoplasmic localization (large arrow). Nu, nu-
cleus. (B) Bar graph showing proportions of cells with a
perinuclear/nuclear particle localization (either exclusively or
with a cytoplasmic distribution) after incubation with MNPs
for up to 24 h. This parameter is significantly related to MNP
concentration and length of MNP exposure ( p< 0.001 for each
factor; n¼ 3 cultures; two-way ANOVA); *p< 0.05 and
**p< 0.01 versus the same MNP concentration at 1 h; þp< 0.05
versus 2mg/mL MNPs at the same time point (Bonferroni’s
post-tests). (C) Triple-merged fluorescent images of astrocytes
prelabeled with MNPs taken at 7 days. Labeled cells show
heterogeneity with respect to the subcellular localization of
MNPs; most show perinuclear accumulations, whereas a mi-
nor proportion (arrows) show cytoplasmic accumulations.
Scale bar¼ 1mm in (A) and 50mm in (C). Color images
available online at www.liebertonline.com/ten.
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however, the use of untransformed cells can overcome a
range of disadvantages that are inherent to the use of cell
lines (such as microbial contamination, aneuploidy, the need
for cellular karyotyping to establish cell identity, and altered
cell physiology secondary to transformation). In cells that
had been pulse-labeled with MNPs, close overlap was found
between particle-associated fluorescence and iron-containing
material, excluding possible experimental artifacts due to
chemical instability of the particles or their intracellular
Table 1. Short-Term Exposure of Astrocytes
to Endocytosis Inhibitors Has No Effect
on Cell Density as Estimated from Counts
of 4,6-Diamidino-2-Phenylindole-Stained Nuclei
Inhibitor DAPI counts
None 54.0 11.3
DMSO 50.1 10.4
Tyrphostin A23 44.8 6.6
Dynasore 52.2 11.3
Amiloride 51.2 15.1
EIPA 50.3 2.7
Data are from three different cultures.
DAPI, 4,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide;
EIPA, 5-(N-ethyl-N-isopropyl) amiloride.
FIG. 3. Mechanism of MNP uptake in rat primary astrocytes. (A) Bar chart showing temperature dependence of particle
uptake. The proportions of cells demonstrating particle uptake is reduced at 48C versus 378C incubation (*p< 0.05; Student’s
t-test). (B) Bar chart showing effects of endocytosis inhibitors on particle uptake (*p< 0.05 and **p< 0.01 vs. dimethyl
sulfoxide [DMSO] control; Bonferroni’s multiple comparison test). (C) Electron micrograph showing extensive projections of
the plasma membrane (arrows) enveloping collections of MNPs suggestive of macropinocytosis-mediated uptake. (D)
Electron micrograph showing MNPs in association with a coated pit-like structure (arrows); inset shows the presence of a
coated pit at the cell surface (arrow), suggesting clathrin-mediated uptake. Scale bar¼ 1mm in (C) and 500 nm in (D). Color
images available online at www.liebertonline.com/ten.
Table 2. Exposure of Astrocytes to a Range of Particle
Concentrations Does Not Result in Significant
Cytotoxicity at 24–120h Postincubation
Concentration
(mg/mL)
Viability (% control)
24 h 48 h 120 h
0 100.0 15.6 100.0 14.9 100.0 7.8
2 90.1 15.6 101.5 14.7 92.7 12.0
5 93.2 15.8 95.7 12.8 93.9 11.7
20 88.2 14.1 83.8 13.5 82.5 13.9
50 81.9 12.1 68.8 14.5 75.1 14.4
Data are from five different cultures.
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degradation; this stability was further confirmed in electron
microscopy analyses and may account for the limited particle
toxicity observed for astrocytes. Confocal microscopy con-
firmed that cells had internalized particles rather than the
latter adhering to the astrocyte surface. This observation, in
conjunction with the marked reduction in MNP uptake at
48C or in the presence of endocytosis inhibitors, suggests that
the contribution of particles adherent to the astrocyte surface
(to cell counts) was negligible and that cellular labeling is a
true reflection of intracellular particle localization, which will
be important for imaging applications involving trans-
planted astrocytes.
The extent and time course of particle uptake was found to
be dependant on both extracellular MNP concentrations and
the length of exposure to particles. These observations sug-
gest that MNP loading of astrocyte transplant populations
can be varied to suit the required downstream application by
simply manipulating particle concentrations at the initial
incubation step. Combined with the ease of detection of the
particles using standard fluorescence techniques, these ob-
servations make the particles employed a desirable choice for
studies related to cell tracking and intracellular MNP pro-
cessing in astrocytes. Notably, we found that after embed-
ding in gels, the particles can be readily observed using a 1.5
T MRI scanner that is used routinely in human clinical test-
ing. Particle detection in vitro does not necessarily indicate
that cells containing MNPs can be detected in vivo (as the
sample itself will impact on image signal to noise ratio and
contrast to noise ratio particularly in neural injury sites).
However, our preliminary findings do suggest that MNP
labeling of transplant populations may have considerable
translational potential for clinical tracking of transplanted
astrocytes in vivo, an issue that that warrants further inves-
tigation.
In pulse-labeling experiments, particles were retained in
high numbers in astrocytes for up to 21 days. Indeed, recent
FIG. 4. Survival and differentiation of astrocytes prelabeled with MNPs and 4,6-diamidino-2-phenylindole (DAPI) after
transplantation into organotypic slice cultures of cerebellum. (A) DAPI image of slice at 10 days after transplantation with
DAPI/Spherofluor-labeled astrocytes; inset shows a Nile Red (MNP) and DAPI double-merged image of a live slice im-
mediately after transplantation of cells. (B) GFAP image of the same slice shown in (A). (C) Nile Red (MNP) image of the
same slice shown in (A). (D) Triple-merged image of the transplanted slice; arrows indicate central application point of the
labeled astrocyte population. (E) High-magnification image of slice demonstrating the presence of DAPI/Nile Red/GFAP
triple-positive cells. (F) Image of the transplant population after plating on tissue culture plastic also demonstrating the
presence of DAPI/Nile Red/GFAP triple-positive cells at 10 days. Scale bar¼ 400mm in (A–D), 200 mm in (A, inset), 10 mm in
(E), and 50mm in (F). Color images available online at www.liebertonline.com/ten.
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preliminary data from our laboratory indicate significant
particle retention for up to 28 days (the latest time point
examined so far) although we observed a gradual dilution of
MNP label with time. We can predict that such dilution
may be due to cell division and/or cellular excretion (likely
via exocytosis); the gradual reduction in perinuclear MNPs
with time, in conjunction with progressive accumulation
of particles near the cell membrane, would be consistent
with a process of cellular excretion. During this period, cul-
tures became confluent and exhibited normal morpholo-
gies, suggesting limited MNP effects on cell survival and
differentiation—observations that were further supported by
the MTS assays. Others have reported significant short-term
toxicity of MNPs (of undisclosed formulation and size) on
primary rat astrocytes, as evidenced by markedly reduced
cell adherence, when nanoparticles were added to cells be-
fore attachment to the substratum.28 We noted no effects
on astrocyte adherence, possibly because cells were allowed
to attach and mature before MNP addition. Our findings
agree with a recent report that MNP addition (10 nm diam-
eter particles) to astrocytes results in no acute loss of cell
viability.29
Importantly, astrocytes prelabeled with MNPs could sur-
vive and differentiate after transplantation into organotypic
slice cultures of the rat cerebellum; the latter model provides
a three-dimensional network of neural cells and has been
widely employed in studies on neural regeneration, pro-
viding an ideal bridge between experiments on isolated cells
and the intact CNS in vivo, while allowing for high-
throughput assays. Although we cannot rule out that ex-
creted particles and/or particles that are released from dying
transplanted astrocytes are taken up by cells such as micro-
glia and host astrocytes, the majority of the astrocyte trans-
plant population (*70%) was noted to be both MNP and
DAPI positive at 10 days after plating on tissue culture
plastic, suggesting that the majority of signal in host tissue is
due to the transplant population. Our findings therefore in-
dicate that this major neural cell population is highly ame-
nable to labeling with MNPs and can provide the basis for
the development of a technically simple and efficient method
to safely label astrocytes derived for transplantation (which
can be further adapted for long-term tracking of transplanted
cells in host tissue). This method would be adaptable for
either noninvasive imaging of transplant populations by
MRI or for simple histological staining of tissue (to detect
iron in transplant populations), and fluorescence/electron
microscopy, making this a highly versatile labeling ap-
proach.
Findings from various mammalian cell types indicate that
the intracellular accumulation of iron oxide-particles is me-
diated by endocytosis.30,31 With regard to the specific en-
docytotic pathways that mediate MNP uptake, there is
FIG. 5. Schematic diagram illustrating the primary modes of MNP uptake by astrocytes, subsequent intracellular processing
and implications for gene delivery. Macropinocytosis, the major mechanism of astrocytic MNP uptake, can be considered a
protransfection mechanism of uptake, as macropinosomes fuse with lysosomes at a low rate. Consequently, successful gene
delivery to the nucleus is likely by this route. In contrast, clathrin-mediated endocytosis, a minor mechanism of astrocytic MNP
uptake, can be considered a prodegradative mechanism of uptake, since clathrin-coated vesicles fuse with lysosomes at a high
rate, resulting in degradation of cargo and particles. Color images available online at www.liebertonline.com/ten.
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limited information in relation to primary neural cells and no
information with regard to primary astrocytes. In our ex-
periments, the dramatic decrease in particle uptake by as-
trocytes after incubation at 48C strongly suggests that the
process is mediated by active transport; MNP uptake by
primary astrocytes has been recently reported to exhibit a
similar temperature dependence, although the actual uptake
mechanisms were not addressed further.29 Our endocytosis
blocker analyses reveal that MNP uptake is mediated by two
primary mechanisms: macropinocytosis (*70%) and clathrin
mediated uptake (*30%); these findings are supported by
our TEM analyses. Caveolin-dependent endocytosis, by
contrast, does not appear to contribute to MNP uptake. In
support of our findings, macropinocytosis is suggested to
play a major role in the uptake of a range of nanoparticles (of
a similar size to the MNPs employed in our study) in various
cell types.32–35
We consider our observations on the mechanisms of MNP
uptake to be significant from the point of view of developing
high efficiency vectors to transfect astrocytes. The rapid
perinuclear targeting of MNPs in astrocytes can clearly
provide the basis for rapid delivery of genetic material to the
nucleus for transfection applications (rapid trafficking of
nanoparticles resulting in perinuclear accumulation has been
reported previously for other cell types)36–38 but not, as far as
we are aware, for astrocytes. However, a further point to
consider with regard to transfection is the mode of particle
uptake by astrocytes. Some studies argue that particle uptake
via clathrin-dependent mechanisms is not advantageous for
transfection, as endolyososomal trafficking is a predictable
consequence of clathrin-mediated endocytosis representing a
critical rate-limiting step.39 By contrast, cellular uptake me-
diated by macropinocytosis may confer significant advan-
tages for drug/gene delivery, since macropinosomes fuse
with lysosomes at lower rates than clathrin-coated vesicles,39
thereby minimizing lysosomal degradation of nanoparticles
and/or their cargo (Fig. 5).32–34 As macropinocytosis ac-
counts for 70% of MNP uptake in astrocytes, we can predict
that without further manipulation, it will only be possible to
transfect an upper limit of *70% of astrocytes. This is
strongly supported by our recent report that particles (of
similar dimensions to those used in this study and with
perinuclear targeting properties) can be used to transfect
between 43% and 75% of rat astrocytes.
Our findings that MNPs can be used effectively for la-
beling/imaging of astrocytes derived for transplantation
(coupled with earlier findings that MNPs can be used for
astrocyte transfection applications) lend support to the idea
that MNPs are a versatile platform that can be employed for
cell tracking and magnetic cell targeting, transfection, and
noninvasive imaging applications for neural cell transplan-
tation therapies. To develop the clinical translational poten-
tial of this approach, future challenges will involve
collaboration between materials scientists and transplanta-
tion neurobiologists to develop multimodal iron oxide na-
noparticles that can safely mediate the above combinatorial
functions in neural cell transplant populations.
Acknowledgments
This work is supported by research grants from the British
Biotechnology and Biological Sciences Research Council
(New Investigator Award) and the Royal Society, UK. We
would like to thank Ms. Karen Walker for expert assistance
with TEM.
Disclosure Statement
No competing financial interests exist.
References
1. Magistretti, P.J., and Ransom, B.R. Astrocytes. In: Davis,
K.L., Charney, D., Coyle, J.T., and Nemeroff, C., eds.
Neuropharmacology: The Fifth Generation of Progress.
Philadelphia: Lippincott Williams and Wilkins, 2002, pp.
181–208.
2. Anderson, C.M., and Swanson, R.A. Astrocyte glutamate
transport: review of properties, regulation, and physiologi-
cal functions. Glia 32, 1, 2000.
3. Pekny, M., and Nilsson, M. Astrocyte activation and reactive
gliosis. Glia 50, 427, 2005.
4. Abbott, N.J., Ronnback, L., and Hansson, E. Astrocyte-
endothelial interactions at the blood-brain barrier. Nat Rev
Neurosci 7, 41, 2006.
5. Liedtke, W., Edelmann, W., Bieri, P.L., Chiu, F.C., Cowan,
N.J., and Kucherlapati, R. GFAP is necessary for the integrity
of CNS white matter architecture and long-term mainte-
nance of myelination. Neuron 17, 607, 1996.
6. Quinlan, R.A., Brenner, M., Goldman, J.E., and Messing, A.
GFAP and its role in Alexander disease. Exp Cell Res 313,
2077, 2007.
7. Maragakis, N.J., and Rothstein, J.D. Mechanisms of disease:
astrocytes in neurodegenerative disease. Nat Clin Pract
Neurol 2, 679, 2006.
8. Lepore, A.C., Rauck, B., Dejea, C., Pardo, A.C., Rao, M.S.,
Rothstein, J.D., and Maragakis, N.J. Focal transplantation-
based astrocyte replacement is neuroprotective in a model of
motor neuron disease. Nat Neurosci 11, 1294, 2008.
9. White, R.E., and Jakeman, L.B. Don’t fence me in: harnessing
the beneficial roles of astrocytes for spinal cord repair. Re-
stor Neurol Neurosci 26, 197, 2008.
10. Ericson, C., Georgievska, B., and Lundberg, C. Ex vivo gene
delivery of GDNF using primary astrocytes transduced with
a lentiviral vector provides neuroprotection in a rat model of
Parkinson’s disease. Eur J Neurosci 22, 2755, 2005.
11. Lin, Q., Cunningham, L.A., Epstein, L.G., Pechan, P.A.,
Short, M.P., Fleet, C., and Bohn, M.C. Human fetal astro-
cytes as an ex vivo gene therapy vehicle for delivering bio-
logically active nerve growth factor. Hum Gene Ther 8, 331,
1997.
12. Sechrist, J., Coulombe, J.N., and Bronner-Fraser, M. Com-
bined vital dye labeling and catecholamine histofluorescence
of transplanted ciliary ganglion cells. J Neural Transplant 1,
113, 1989.
13. O’Leary, M.T., and Blakemore, W.F. Use of a rat Y chro-
mosome probe to determine the long-term survival of glial
cells transplanted into areas of CNS demyelination. J Neu-
rocytol 26, 191, 1997.
14. Othman, M.M., Klueber, K.M., and Roisen, F.J. Identification
and culture of olfactory neural progenitors from GFP mice.
Biotech Histochem 78, 57, 2003.
15. Lee, J.P., McKercher, S., Muller, F.J., and Snyder, E.Y. Neural
stem cell transplantation in mouse brain. Curr Protoc Neu-
rosci Chapter 3, Unit 3.10, 2008.
16. Aleksandrova, M.A., Poltavtseva, R.A., Revishchin, A.V.,
Korochkin, L.I., and Sukhikh, G.T. Development of neural
stem/progenitor cells from human brain by transplantation
98 PICKARD ET AL.
into the brains of adult rats. Neurosci Behav Physiol 34,
659, 2004.
17. Bulte, J.W., and Kraitchman, D.L. Monitoring cell therapy
using iron oxide MR contrast agents. Curr Pharm Biotechnol
5, 567, 2004.
18. Song, M., Kim, Y., Kim, Y., Ryu, S., Song, I., Kim, S.U., and
Yoon, B.W. MRI tracking of intravenously transplanted
human neural stem cells in rat focal ischemia model. Neu-
rosci Res 64, 235, 2009.
19. Guzman, R., Uchida, N., Bliss, T.M., He, D., Christopherson,
K.K., Stellwagen, D., Capela, A., Greve, J., Malenka, R.C.,
Moseley, M.E., Palmer, T.D., and Steinberg, G.K. Long-term
monitoring of transplanted human neural stem cells in de-
velopmental and pathological contexts with MRI. Proc Natl
Acad Sci USA 104, 10211, 2007.
20. Dunning, M.D., Lakatos, A., Loizou, L., Kettunen, M.,
ffrench-Constant, C., Brindle, K.M., and Franklin, R.J. Su-
perparamagnetic iron oxide-labeled Schwann cells and ol-
factory ensheathing cells can be traced in vivo by magnetic
resonance imaging and retain functional properties after
transplantation into the CNS. J Neurosci 24, 9799, 2004.
21. Lepore, A.C., Walczak, P., Rao, M.S., Fischer, I., and Bulte,
J.W. MR imaging of lineage-restricted neural precursors
following transplantation into the adult spinal cord. Exp
Neurol 201, 49, 2006.
22. Pickard M., and Chari, D. Enhancement of magnetic
nanoparticle-mediated gene transfer to astrocytes by ‘‘mag-
netofection’’: effects of static and oscillating fields. Nano-
medicine (Lond) 5, 217, 2010.
23. Cole, R., and de Vellis, J. Preparation of astrocyte, oligo-
dendrocyte, and microglia cultures from primary rat cere-
bral cultures. In: Fedoroff, S., and Richardson, A., eds.
Protocols for Neural Cell Culture. Totowa, NJ: Humana
Press, 2001, pp. 117–127.
24. Ivanov, A.I. Pharmacological inhibition of endocytic path-
ways: is it specific enough to be useful? Methods Mol Biol
440, 15, 2008.
25. Macia, E., Ehrlich, M., Massol, R., Boucrot, E., Brunner, C.,
and Kirkhausen, T. Dynasore, a cell-permeable inhibitor of
dynamin. Dev Cell 10, 839, 2006.
26. Banbury, D.N., Oakley, J.D., Sessions, R.B., and Banting, G.
Tyrphostin A23 inhibits internalization of the transferring
receptor by perturbing the interaction between tyrosine
motifs and the medium chain subunit of the AP-2 adaptor
complex. J Biol Chem 278, 12022, 2003.
27. Pickard, M.R., and Chari, D.M. Robust uptake of magnetic
nanoparticles (MNPs) by central nervous system (CNS)
microglia: implications for particle uptake in mixed neural
cell populations. Int J Mol Sci 11, 967, 2010.
28. Au, C., Mutkus, L., Dobson, A., Riffle, J., Lalli, J., and
Aschner, M. Effects of nanoparticles on the adhesion and cell
viability on astrocytes. Biol Trace Elem Res 120, 248, 2007.
29. Geppert, M., Hohnholt, M., Gaetjen, L., Grunwald, I., Ba¨u-
mer, M., and Dringen, R. Accumulation of iron oxide na-
noparticles by cultured brain astrocytes. J Biomed
Nanotechnol 5, 285, 2009.
30. Bulte, J.W.M., Duncan, I.D., and Frank, J.A. In vivo magnetic
resonance tracking of magnetically labeled cells after trans-
plantation. J Cereb Blood Flow Metab 22, 899, 2002.
31. Rogers, W.J., Meyer, C.H., and Kramer, C.M. Technology
insight: in vivo cell tracking by use of MRI. Nat Clin Pract
Cardiovasc Med 3, 554, 2006.
32. Walsh, M., Tangney, M., O’Neill, M.J., Larkin, J.O., Soden,
D.M., McKenna, S.L., Darcy, R., O’Sullivan, G.C., and
O’Driscoll, C.M. Evaluation of cellular uptake and gene
transfer efficiency of pegylated poly-L-lysine compacted
DNA: implications for cancer gene therapy. Mol Pharm 3,
644, 2006.
33. Khalil, I.A., Kogure, K., Futaki, S., and Harashima, H. High
density of octaarginine stimulates macropinocytosis leading
to efficient intracellular trafficking for gene expression. J Biol
Chem 281, 3544, 2006.
34. Khalil, I.A., Kogure, K., Futaki, S., Hama, S., Akita, H., Ueno,
M., Kishida, H., Kudoh, M., Mishina, Y., Kataoka, K., Ya-
mada, M., and Harashima, H. Octaarginine-modified mul-
tifunctional envelope-type nanoparticles for gene delivery.
Gene Ther 14, 682, 2007.
35. Nam, H.Y., Kwon, S.M., Chung, H., Lee, S.Y., Kwon, S.H.,
Jeon, H., Kim, Y., Park, J.H., Kim, J., Her, S., Oh, Y.K., Kwon,
I.C., Kim, K., and Jeong, S.Y. Cellular uptake mechanism
and intracellular fate of hydrophobically modified glycol
chitosan nanoparticles. J Control Release 135, 259, 2009.
36. Lai, S.K., Hida, K., Chen, C., and Hanes, J. Characterization
of the intracellular dynamics of a non-degradative pathway
accessed by polymer nanoparticles. J Control Release 125,
107, 2008.
37. Shenoy, D., Little, S., Langer, R., and Amiji, M. Poly (eth-
ylene oxide)-modified poly(beta-amino ester) nanoparticles
as a pH-sensitive system for tumor-targeted delivery of
hydrophobic drugs: part 2. In vivo distribution and tumor
localization studies. Pharm Res 22, 2107, 2005.
38. Suh, J., Wirtz, D., and Hanes, J. Efficient active transport of
gene nanocarriers to the cell nucleus. Proc Natl Acad Sci
USA 100, 3878, 2003.
39. Khalil, I.A., Kogure, K., Akita, H., and Harashima, H. Up-
take pathways and subsequent intracellular trafficking in
nonviral gene delivery. Pharmacol Rev 58, 32, 2006.
Address correspondence to:
Mark R. Pickard, Ph.D.
Cellular and Neural Engineering Group
Institute for Science and Technology in Medicine
Keele University
Staffordshire ST5 5BG
United Kingdom
E-mail: m.r.pickard@biol.keele.ac.uk
Received: March 19, 2010
Accepted: July 19, 2010
Online Publication Date: September 21, 2010
MNP LABELING OF ASTROCYTES 99

 289 
 
References 
1. Chari, D. M. Remyelination in Multiple Sclerosis. Int. Rev. Neurobiol. 79, 589–620 (2007). 
2. Keegan, B. M. & Noseworthy, J. H. Multiple Sclerosis. Annu. Rev. Med. 53, 285–302 (2002). 
3. Waxman, S. G. Demyelination in spinal cord injury and multiple sclerosis: what can we do to 
enhance functional recovery? J. Neurotrauma 9 Suppl 1, S105–S117 (1992). 
4. Zhang, H., Jarjour, A. A., Boyd, A. & Williams, A. Central nervous system remyelination in culture - 
A tool for multiple sclerosis research. Exp. Neurol. 230, 138–148 (2011). 
5. Kim, B. G., Hwang, D. H., Lee, S. I., Kim, E. J. & Kim, S. U. Stem cell-based cell therapy for spinal 
cord injury. Cell Transplant. 16, 355–364 (2007). 
6. Franklin, R. J. M. & ffrench-Constant, C. Remyelination in the CNS: from biology to therapy. Nat. 
Rev. Neurosci. 9, 839–855 (2008). 
7. Bradl, M. & Lassmann, H. Oligodendrocytes: biology and pathology. Acta Neuropath. 119, 37–53 
(2010). 
8. Hartline, D. K. What is myelin? Neuron Glia Biol. 4, 153–163 (2008). 
9. Baumann, N. & Pham-Dinh, D. Biology of oligodendrocyte and myelin in the mammalian central 
nervous system. Physiol. Rev. 81, 871–927 (2001). 
10. Potter, G. B., Rowitch, D. H. & Petryniak, M. A. Myelin restoration: progress and prospects for 
human cell replacement therapies. Arch. Immunol. Ther. Exp. (Warsz) 59, 179–193 (2011). 
11. Chandran, S. & Compston, A. Neural stem cells as a potential source of oligodendrocytes for myelin 
repair. J. Neurol. Sci. 233, 179 – 181 (2005). 
12. Felts, P. A., Baker, T. A. & Smith, K. J. Conduction in segmentally demyelinated mammalian central 
axons. J. Neurosci. 17, 7267–77 (1997). 
13. Constantinou, S. & Fern, R. Conduction block and glial injury induced in developing central white 
matter by glycine, GABA, noradrenalin, or nicotine, studied in isolated neonatal rat optic nerve. Glia 
57, 1168–1177 (2009). 
14. Rodriguez, M. A function of myelin is to protect axons from subsequent injury: implications for 
deficits in multiple sclerosis. Brain 126, 751–752 (2003). 
15. Nave, K.-A. Myelination and the trophic support of long axons. Nat. Rev. Neurosci. 11, 275–283 
(2010). 
16. Griffiths, I. et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. 
Science 280, 1610–1613 (1998). 
17. Lappe-Siefke, C. et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support 
and myelination. Nat. Genet. 33, 366–374 (2003). 
18. Lee, Y. et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. 
Nature 487, 443–448 (2012). 
19. Bunge, M. B., Bunge, R. P. & Ris, H. Ultrastructural study of remyelination in an experimental 
lesion in adult cat spinal cord. J. Biophys. Biochem. Cytol. 10, 67–94 (1961). 
 290 
 
20. Bunge, R. P., Bunge, M. B. & Ris, H. Electron microscopic study of demyelination in an 
experimentally induced lesion in adult cat spinal cord. J. Biophys. Biochem. Cytol. 7, 685–696 
(1960). 
21. Blakemore, W. F. Pattern of remyelination in the CNS. Nature 249, 577–578 (1974). 
22. Gledhill, R. F., Harrison, B. M. & McDonald, W. I. Pattern of remyelination in the CNS. Nature 244, 
443–444 (1973). 
23. Smith, K. J., Blakemore, W. F. & McDonald, W. I. Central remyelination restores secure conduction. 
Nature 280, 395–396 (1979). 
24. Smith, K. J., Blakemore, W. F. & McDonald, W. I. The restoration of conduction by central 
remyelination. Brain 104, 383–404 (1981). 
25. Mekhail, M., Almazan, G. & Tabrizian, M. Oligodendrocyte-protection and remyelination post-
spinal cord injuries: a review. Prog. Neurobiol. 96, 322–339 (2012). 
26. Richardson, W. D., Kessaris, N. & Pringle, N. Oligodendrocyte wars. Nat. Rev. Neurosci. 7, 11–18 
(2006). 
27. Kessaris, N. et al. Competing waves of oligodendrocytes in the forebrain and postnatal elimination of 
an embryonic lineage. Nat. Neurosci. 9, 173–179 (2006). 
28. Chari, D. M. & Blakemore, W. New insights into remyelination failure in multiple sclerosis: 
implications for glial cell transplantation. Mult. Scler. 8, 271–277 (2002). 
29. De Castro, F. & Bribián, A. The molecular orchestra of the migration of oligodendrocyte precursors 
during development. Brain Res. Brain Res. Rev. 49, 227–241 (2005). 
30. Watkins, T. A., Emery, B., Mulinyawe, S. & Barres, B. A. Distinct stages of myelination regulated 
by gamma-secretase and astrocytes in a rapidly myelinating CNS coculture system. Neuron 60, 555–
569 (2008). 
31. Huang, J. K. et al. Glial membranes at the node of Ranvier prevent neurite outgrowth. Science 310, 
1813–1817 (2005). 
32. LeBaron, F. N., Sanyal, S. & Jungalwala, F. B. Turnover rate of molecular species of sphingomyelin 
in rat brain. Neurochem. Res. 6, 1081–1089 (1981). 
33. Lajtha, A., Toth, J., Fujimoto, K. & Agrawal, H. C. Turnover of myelin proteins in mouse brain in 
vivo. Biochem. J. 164, 323–329 (1977). 
34. Buchet, D. & Baron-Van Evercooren, A. In search of human oligodendroglia for myelin repair. 
Neurosci. Lett. 456, 112–119 (2009). 
35. Butts, B. D., Houde, C. & Mehmet, H. Maturation-dependent sensitivity of oligodendrocyte lineage 
cells to apoptosis: implications for normal development and disease. Cell Death Differ. 15, 1178–
1186 (2008). 
36. Yakovlev, A. Y., Boucher, K., Mayer-Pröschel, M. & Noble, M. Quantitative insight into 
proliferation and differentiation of oligodendrocyte type 2 astrocyte progenitor cells in vitro. Proc. 
Natl. Acad. Sci. USA 95, 14164–14167 (1998). 
37. Jakovcevski, I., Filipovic, R., Mo, Z., Rakic, S. & Zecevic, N. Oligodendrocyte development and the 
onset of myelination in the human fetal brain. Front. Neuroanat. 3, 1–15 (2009). 
 291 
 
38. Miron, V. E. et al. Fingolimod (FTY720) enhances remyelination following demyelination of 
organotypic cerebellar slices. Am. J. Pathol. 176, 2682–2694 (2010). 
39. Zawadzka, M. et al. CNS-resident glial progenitor/stem cells produce Schwann cells as well as 
oligodendrocytes during repair of CNS demyelination. Cell Stem Cell 6, 578–90 (2010). 
40. Franklin, R. J. M. & Hinks, G. L. Understanding CNS remyelination : clues from developmental and 
regeneration biology. J. Neurosci. Res. 58, 207–213 (1999). 
41. Hinks, G. L. & Franklin, R. J. Distinctive patterns of PDGF-A, FGF-2, IGF-I, and TGF-beta1 gene 
expression during remyelination of experimentally-induced spinal cord demyelination. Mol. Cell 
Neurosci. 14, 153–168 (1999). 
42. Miron, V., Cuo, Q., Wegner, C., Antel, J. & Brück, W. Differentiation block of oligodendroglial 
progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131, 1749–
1758 (2008). 
43. Stangel, M. & Trebst, C. Remyelination strategies: new advancements toward a regenerative 
treatment in multiple sclerosis. Curr. Neurol. Neurosci. Rep. 6, 229–235 (2006). 
44. Webber, D. J., Compston, A. & Chandran, S. Minimally manipulated oligodendrocyte precursor cells 
retain exclusive commitment to the oligodendrocyte lineage following transplantation into intact and 
injured hippocampus. Eur. J. Neurosci. 26, 1791–1800 (2007). 
45. Franklin, R. J. M. Remyelination of the demyelinated CNS: the case for and against transplantation 
of central, peripheral and olfactory glia. Brain Res. Bull. 57, 827–832 (2002). 
46. Groves, A. K. et al. Repair of demyelinated lesions by transplantation of purified 0-2A progenitor 
cells. Nature 362, 453–455 (1993). 
47. Gumpel, M. et al. Transplantation of human embryonic oligodendrocytes into shiverer brain. Ann. N. 
Y. Acad. Sci. 495, 71–85 (1987). 
48. Windrem, M. S. et al. Neonatal chimerization with human glial progenitor cells can both remyelinate 
and rescue the otherwise lethally hypomyelinated shiverer mouse. Cell Stem Cell 2, 553–565 (2008). 
49. Vignais, L. et al. Transplantation of oligodendrocyte precursors in the adult demyelinated spinal 
cord: migration and remyelination. Int. J. Dev. Neurosci. 11, 603–612 (1993). 
50. Givogri, M. I. et al. Oligodendroglial progenitor cell therapy limits central neurological deficits in 
mice with metachromatic leukodystrophy. J. Neurosci. 26, 3109 –3119 (2006). 
51. Keirstead, H. S. et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell 
transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci. 25, 4694–705 
(2005). 
52. Hinks, G. L. et al. Depletion of endogenous oligodendrocyte progenitors rather than increased 
availability of survival factors is a likely explanation for enhanced survival of transplanted 
oligodendrocyte progenitors in X-irradiated compared to normal CNS. Neuropathol. Appl. Neurobiol. 
27, 59–67 (2001). 
53. Franklin, R. J. M., Bayley, S. A. & Blakemore, W. F. Transplanted CG4 cells (an oligodendrocyte 
progenitor cell line) survive, migrate, and contribute to repair of areas of demyelination in X-
irradiated and damaged spinal cord but not in normal spinal cord. Exp. Neurol. 137, 263–276 (1996). 
54. Brüstle, O. et al. Embryonic stem cell-derived glial precursors: a source of myelinating transplants. 
Science 285, 754–756 (1999). 
 292 
 
55. Sypecka, J. Searching for oligodendrocyte precursors for cell replacement therapies. Acta Neurobiol. 
Exp. (Wars) 71, 94–102 (2011). 
56. Watson, R. A. & Yeung, T. M. What is the potential of oligodendrocyte progenitor cells to 
successfully treat human spinal cord injury? BMC Neurol. 11, 113 (2011). 
57. Lebkowski, J. GRNOPC1: the world’s first embryonic stem cell-derived therapy. Interview with Jane 
Lebkowski. Regen. Med. 6, 11–13 (2011). 
58. Frantz, S. Embryonic stem cell pioneer Geron exits field, cuts losses. Nat. Biotechnol. 30, 12–13 
(2012). 
59. Karimi-Abdolrezaee, S., Eftekharpour, E., Wang, J., Schut, D. & Fehlings, M. G. Synergistic effects 
of transplanted adult neural stem/progenitor cells, chondroitinase, and growth factors promote 
functional repair and plasticity of the chronically injured spinal cord. J. Neurosci. 30, 1657–1676 
(2010). 
60. Cao, Q. et al. Transplantation of ciliary neurotrophic factor-expressing adult oligodendrocyte 
precursor cells promotes remyelination and functional recovery after spinal cord injury. J. Neurosci. 
30, 2989–3001 (2010). 
61. Milward, E. A. et al. Enhanced proliferation and directed migration of oligodendroglial progenitors 
co-grafted with growth factor-secreting cells. Glia 32, 264–270 (2000). 
62. Rose, L. C., Kucharski, C. & Uludağ, H. Protein expression following non-viral delivery of plasmid 
DNA coding for basic FGF and BMP-2 in a rat ectopic model. Biomaterials 33, 3363–3674 (2012). 
63. Magy, L. et al. Inducible expression of FGF2 by a rat oligodendrocyte precursor cell line promotes 
CNS myelination in vitro. Exp. Neurol. 184, 912 – 922 (2003). 
64. Cao, Q. et al. Functional recovery in traumatic spinal cord injury after transplantation of 
multineurotrophin-expressing glial-restricted precursor cells. J. Neurosci. 25, 6947– 6957 (2005). 
65. Russell, W. M. S. & Burch, R. L. The principles of humane experimental technique. xiv + 238 pp. 
(Methuen & Co. Ltd., London: 1959). 
66. Liebsch, M. et al. Alternatives to animal testing: current status and future perspectives. Arch. Toxicol. 
85, 841–858 (2011). 
67. Baker, D. & Jackson, S. J. Models of Multiple Sclerosis. ACNR 6, 10–12 (2007). 
68. Baker, D., Gerritsen, W., Rundle, J. & Amor, S. Critical appraisal of animal models of multiple 
sclerosis. Mult. Scler. 17, 647–657 (2011). 
69. Stoppini, L., Buchs, P. A. & Muller, D. A simple method for organotypic cultures of nervous tissue. 
J. Neurosci. Methods 37, 173–182 (1991). 
70. Gähwiler, B. H., Capogna, M., Debanne, D., McKinney, R. A. & Thompson, S. M. Organotypic slice 
cultures: a technique has come of age. Trends Neurosci. 20, 471–477 (1997). 
71. Kessler, M., Kiliman, B., Humes, C. & Arai, A. C. Spontaneous activity in Purkinje cells: multi-
electrode recording from organotypic cerebellar slice cultures. Brain Res. 1218, 54–69 (2008). 
72. De Simoni, A. & Yu, L. M. Y. Preparation of organotypic hippocampal slice cultures: interface 
method. Nat. Protoc. 1, 1439–1445 (2006). 
 293 
 
73. Sundstrom, L., Morrison, B. 3rd, Bradley, M. & Pringle, A. Organotypic cultures as tools for 
functional screening in the CNS. Drug Discov. Today 10, 993–1000 (2005). 
74. Morrison, B. 3rd, Saatman, K. E., Meaney, D. F. & McIntosh, T. K. In vitro central nervous system 
models of mechanically induced trauma: a review. J Neurotrauma 15, 911–928 (1998). 
75. Gähwiler, B. H. Organotypic monolayer cultures of nervous tissue. J. Neurosci. Methods 4, 329–342 
(1981). 
76. Xiang, Z. et al. Long-term maintenance of mature hippocampal slices in vitro. J. Neurosci. Methods 
98, 145–154 (2000). 
77. Adamchik, Y. & Frantseva, M. Methods to induce primary and secondary traumatic damage in 
organotypic hippocampal slice cultures. Brain Res. Brain Res. Protoc. 5, 153–158 (2000). 
78. Dean, J. M. et al. An organotypic slice culture model of chronic white matter injury with maturation 
arrest of oligodendrocyte progenitors. Mol. Neurodegener. 5, 46 (2011). 
79. Cho, S., Wood, A. & Bowlby, M. R. Brain slices as models for neurodegenerative disease and 
screening platforms to identify novel therapeutics. Curr. Neuropharmacol. 5, 19–33 (2007). 
80. Lu, H.-X., Levis, H., Liu, Y. & Parker, T. Organotypic slices culture model for cerebellar ataxia: 
potential use to study Purkinje cell induction from neural stem cells. Brain Res. Bull. 84, 169–173 
(2011). 
81. Berger, T. & Frotscher, M. Distribution and morphological characteristics of oligodendrocytes in the 
rat hippocampus in situ and in vitro: an immunocytochemical study with the monoclonal Rip 
antibody. J. Neurocytol. 23, 61–74 (1994). 
82. Bahr, B. A. Long-term hippocampal slices: a model system for investigating synaptic mechanisms 
and pathologic processes. J. Neurosci. Res. 42, 294–305 (1995). 
83. Jaeger, C., Kapoor, R. & Llinás, R. Cytology and organization of rat cerebellar organ cultures. 
Neuroscience 26, 509–538 (1988). 
84. Reeves, S. A. & Xiang, Z. Simvastatin induces cell death in a mouse cerebellar slice culture (CSC) 
model of developmental myelination. Exp. Neurol. 215, 41–47 (2009). 
85. Kapfhammer, J. P. Cellular and molecular control of dendritic growth and development of cerebellar 
Purkinje cells. Prog. Histochem. Cytochem. 39, 131–182 (2004). 
86. Davids, E. et al. Organotypic rat cerebellar slice culture as a model to analyze the molecular 
pharmacology of GABAA receptors. Eur. Neuropsychopharmacol. 12, 201–208 (2002). 
87. Ohnishi, T., Matsumura, H., Izumoto, S., Hiraga, S. & Hayakawa, T. A novel model of glioma cell 
invasion using organotypic brain slice culture. Cancer Res. 58, 2935–2940 (1998). 
88. Harrer, M. D. et al. Live imaging of remyelination after antibody-mediated demyelination in an ex-
vivo model for immune mediated CNS damage. Exp. Neurol. 216, 431–438 (2009). 
89. Seil, F. J. & Blank, N. K. Myelination of central nervous system axons in tissue culture by 
transplanted oligodendrocytes. Science 212, 1407–1408 (1981). 
90. Nishimura, R. N., Blank, N. K., Tiekotter, K. L., Cole, R. & De Vellis, J. Myelination of mouse 
cerebellar explants by rat cultured oligodendrocytes. Brain Res. 337, 159–162 (1985). 
 294 
 
91. Franklin, R. J. M. & Blakemore, W. F. Transplanting myelin-forming cells into the central nervous 
system: principles and practice. Methods 16, 311–9 (1998). 
92. Muja, N. & Bulte, J. W. M. M. Magnetic resonance imaging of cells in experimental disease models. 
Prog. Nucl. Magn. Reson. Spectrosc. 55, 61–77 (2009). 
93. Bulte, J. W. M. et al. Magnetic labeling and tracking of cells using magnetodendrimers as MR 
contrast agent. Eur. Cells Mater. 3, 7–8 (2002). 
94. Franklin, R. J. M. et al. Magnetic resonance imaging of transplanted oligodendrocyte precursors in 
the rat brain. Neuroreport 10, 3961–3965 (1999). 
95. Lepore, A. C., Walczak, P., Rao, M. S., Fischer, I. & Bulte, J. W. M. MR imaging of lineage-
restricted neural precursors following transplantation into the adult spinal cord. Exp. Neurol. 201, 
49–59 (2006). 
96. Bulte, J. W. et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of 
stem cells. Nat. Biotechnol. 19, 1141–1147 (2001). 
97. Bulte, J. W. M., Duncan, I. D. & Frank, J. A. In vivo magnetic resonance tracking of magnetically 
labeled cells after transplantation. J. Cereb. Blood Flow Metab. 22, 899–907 (2002). 
98. Dunning, M. D. et al. Superparamagnetic iron oxide-labeled Schwann cells and olfactory ensheathing 
cells can be traced in vivo by magnetic resonance imaging and retain functional properties after 
transplantation into the CNS. J. Neurosci. 24, 9799–9810 (2004). 
99. Taylor, A., Wilson, K. M., Murray, P., Fernig, D. G. & Lévy, R. Long-term tracking of cells using 
inorganic nanoparticles as contrast agents: are we there yet? Chem. Soc. Rev. 41, 2707–2717 (2012). 
100. Hinds, K. A. et al. Highly efficient endosomal labeling of progenitor and stem cells with large 
magnetic particles allows magnetic resonance imaging of single cells. Blood 102, 867–872 (2003). 
101. Stroh, A. et al. In vivo detection limits of magnetically labeled embryonic stem cells in the rat brain 
using high-field (17.6 T) magnetic resonance imaging. Neuroimage 24, 635–645 (2005). 
102. Yiu, H. H. P. et al. Fe3O4-PEI-RITC magnetic nanoparticles with imaging and gene transfer 
capability: development of a tool for neural cell transplantation therapies. Pharm. Res. 29, 1328–
1343 (2012). 
103. Kulbatski, I. et al. Glial precursor cell transplantation therapy for neurotrauma and multiple sclerosis. 
Prog. Histochem. Cytochem. 43, 123–176 (2008). 
104. Mothe, A. J. & Tator, C. H. Transplanted neural stem/progenitor cells generate myelinating 
oligodendrocytes and Schwann cells in spinal cord demyelination and dysmyelination. Exp. Neurol. 
213, 176–190 (2008). 
105. Willerth, S. M. & Sakiyama-Elbert, S. E. Cell therapy for spinal cord regeneration. Adv. Drug Deliv. 
Rev. 60, 263–276 (2008). 
106. Boddington, S. E. et al. Labeling human mesenchymal stem cells with fluorescent contrast agents: 
the biological impact. Mol. Imaging Biol. 13, 3–9 (2011). 
107. Bulte, J. W. M. In vivo MRI cell tracking: clinical studies. Am. J. Roentgenol. 193, 314–325 (2009). 
108. Lubetzki, C. et al. Gene transfer of rat mature oligodendrocytes and glial progenitor cells with the 
LacZ gene. Ann. N. Y. Acad. Sci. 605, 66–70 (1990). 
 295 
 
109. Mintzer, M. A. & Simanek, E. E. Nonviral vectors for gene delivery. Chem. Rev. 109, 259–302 
(2009). 
110. Krueger, W. H. H., Madison, D. L. & Pfeiffer, S. E. Transient transfection of oligodendrocyte 
progenitors by electroporation. Neurochem. Res. 23, 421–426 (1998). 
111. Guo, Z. et al. Efficient and sustained transgene expression in mature rat oligodendrocytes in primary 
culture. J. Neurosci. Res. 43, 32–41 (1996). 
112. Blits, B. & Bunge, M. B. Direct gene therapy for repair of the spinal cord. J. Neurotraum. 23, 508–
520 (2006). 
113. Jiang, S., Seng, S., Avraham, H. K., Fu, Y. & Avraham, S. Process elongation of oligodendrocytes is 
promoted by the Kelch-related protein MRP2/KLHL1. J. Biol. Chem. 282, 12319–12329 (2007). 
114. Franklin, R. J. M., Quick, M. M. & Haase, G. Adenoviral vectors for in vivo gene delivery to 
oligodendrocytes: transgene expression and cytopathic consequences. Gene Ther. 6, 1360–1367 
(1999). 
115. Hermens, W. T. J. M. C. & Verhaagen, J. Viral vectors, tools for gene transfer in the nervous system. 
Prog. Neurobiol. 55, 399–432 (1998). 
116. Pichon, C., Billiet, L. & Midoux, P. Chemical vectors for gene delivery: uptake and intracellular 
trafficking. Curr. Opin. Biotech. 21, 640–645 (2010). 
117. Ryan, D. A. & Federoff, H. J. Translational considerations for CNS gene therapy. Expert Opin. Biol. 
Ther. 7, 305–318 (2007). 
118. Chen, D., Sung, R. & Bromberg, J. S. Gene therapy in transplantation. Transpl. Immunol. 9, 301–314 
(2002). 
119. O’Leary, M. T. & Charlton, H. M. A model for long-term transgene expression in spinal cord 
regeneration studies. Gene Ther. 6, 1351–9 (1999). 
120. Lentz, T. B., Gray, S. J. & Samulski, R. J. Viral vectors for gene delivery to the central nervous 
system. Neurobiol. Dis. 48, 179–188 (2011). 
121. Maxwell, D. J. et al. Fluorophore-conjugated iron oxide nanoparticle labeling and analysis of 
engrafting human hematopoietic stem cells. Stem Cells 26, 517–524 (2008). 
122. Neve, R. L. & Carlezon, W. A. J. Gene delivery into the brain using viral vectors. 
Neuropsychopharmacology: The fifth generation of progress pp253–262 (2002). 
123. Pritchard, C. D. et al. Establishing a model spinal cord injury in the African green monkey for the 
preclinical evaluation of biodegradable polymer scaffolds seeded with human neural stem cells. J. 
Neurosci. Methods 188, 258–69 (2010). 
124. Wang, M. et al. Bioengineered scaffolds for spinal cord repair. Tissue Eng. Part B Rev. 17, 177–194 
(2011). 
125. Teng, Y. D. et al. Functional recovery following traumatic spinal cord injury mediated by a unique 
polymer scaffold seeded with neural stem cells. Proc. Natl. Acad. Sci. USA 99, 3024–3029 (2002). 
126. Bliss, T. M., Andres, R. H. & Steinberg, G. K. Optimizing the success of cell transplantation therapy 
for stroke. Stroke 37, 275–294 (2011). 
 296 
 
127. Li, J.-Y., Christophersen, N. S., Hall, V., Soulet, D. & Brundin, P. Critical issues of clinical human 
embryonic stem cell therapy for brain repair. Trends Neurosci. 31, 146–153 (2008). 
128. Okamura, R. M. et al. Immunological properties of human embryonic stem cell-derived 
oligodendrocyte progenitor cells. J. Neuroimmunol. 192, 134–144 (2007). 
129. Srinivas, M. et al. Imaging of cellular therapies. Adv. Drug Deliv. Rev. 62, 1080–1093 (2010). 
130. Berman, S. C., Galpoththawela, C., Gilad, A. A., Bulte, J. W. M. & Walczak, P. Long-term MR cell 
tracking of neural stem cells grafted in immunocompetent versus immunodeficient mice reveals 
distinct differences in contrast between live and dead cells. Magn. Reson. Med. 65, 564–574 (2011). 
131. Soenen, S. J. H., Himmelreich, U., Nuytten, N. & De Cuyper, M. Cytotoxic effects of iron oxide 
nanoparticles and implications for safety in cell labelling. Biomaterials 32, 195–205 (2011). 
132. Marszałł, M. P. Application of magnetic nanoparticles in pharmaceutical sciences. Pharm. Res. 28, 
480–3 (2011). 
133. Yiu, H. H. P. Engineering the multifunctional surface on magnetic nanoparticles for targeted 
biomedical applications: a chemical approach. Nanomedicine (Lond.) 6, 1429–1446 (2011). 
134. Hofmann-Amtenbrink, M., Hofmann, H. & Montet, X. Superparamagnetic nanoparticles - a tool for 
early diagnostics. Swiss Med. Weekly 140, w13081 (2010). 
135. Berry, C. C. Progress in functionalization of magnetic nanoparticles for applications in biomedicine. 
J. Phys. D: Appl. Phys. 42, 224003 (2009). 
136. Aliaga, M. E., Carrasco-Pozo, C., López-Alarcón, C., Olea-Azar, C. & Speisky, H. Superoxide-
dependent reduction of free Fe(3+) and release of Fe(2+) from ferritin by the physiologically-
occurring Cu(I)-glutathione complex. Bioorg. Med. Chem. 19, 534–541 (2011). 
137. Kress, G. J., Dineley, K. E. & Reynolds, I. J. The relationship between intracellular free iron and cell 
injury in cultured neurons, astrocytes, and oligodendrocytes. J. Neurosci. 22, 5848–55 (2002). 
138. Mornet, S., Vasseur, S., Grasset, F. & Duguet, E. Magnetic nanoparticle design for medical diagnosis 
and therapy. J. Mater. Chem. 14, 2161 (2004). 
139. Olariu, C. I. et al. Multifunctional Fe3O4 nanoparticles for targeted bi-modal imaging of pancreatic 
cancer. J. Mater. Chem. 21, 12650 (2011). 
140. Pankhurst, Q. A., Thanh, N. K. T., Jones, S. K. & Dobson, J. Progress in applications of magnetic 
nanoparticles in biomedicine. J. Phys. D: Appl. Phys. 42, 224001 (2009). 
141. Dobson, J. Magnetic micro- and nano-particle-based targeting for drug and gene delivery. 
Nanomedicine (Lond.) 1, 31–37 (2006). 
142. McBain, S. C., Yiu, H. H. P. & Dobson, J. Magnetic nanoparticles for gene and drug delivery. Int. J. 
Nanomed. 3, 169–180 (2008). 
143. Frank, J. A. et al. Clinically applicable labeling of Mammalian and Stem Cells by Combining 
Superparamagnetic Iron Oxides and Transfection Agents. Radiology (2003). 
144. Sasaki, H. et al. Therapeutic effects with magnetic targeting of bone marrow stromal cells in a rat 
spinal cord injury model. Spine (Phila Pa 1976) 36, 933–938 (2011). 
 297 
 
145. Vaněček, V. et al. Highly efficient magnetic targeting of mesenchymal stem cells in spinal cord 
injury. Int. J. Nanomedicine 7, 3719–3730 (2012). 
146. Shubayev, V. I., Pisanic, T. R. 2nd & Jin, S. Magnetic nanoparticles for theragnostics. Adv. Drug 
Delivery Rev. 61, 467–477 (2009). 
147. Debbage, P. & Jaschke, W. Molecular imaging with nanoparticles: giant roles for dwarf actors. 
Histochem. Cell Biol. 130, 845–875 (2008). 
148. Tartaj, P., Del Puerto Morales, M., Veintemillas-Verdaguer, S., Gonzalez-Carreno, T. & Serna, C. J. 
The preparation of magnetic nanoparticles for applications in biomedicine. J. Phys. D: Appl. Phys. 
36, R182–R197 (2003). 
149. Fang, C. & Zhang, M. Multifunctional magnetic nanoparticles for medical imaging applications. J. 
Mater. Chem. 19, 6258–6266 (2009). 
150. Wang, Y. X., Hussain, S. M. & Krestin, G. P. Superparamagnetic iron oxide contrast agents: 
physicochemical characteristics and applications in MR imaging. Eur. Radiol. 11, 2319–2331 (2001). 
151. Nitin, N., LaConte, L. E. W., Zurkiya, O., Hu, X. & Bao, G. Functionalization and peptide-based 
delivery of magnetic nanoparticles as an intracellular MRI contrast agent. J. Biol. Inorg. Chem. 9, 
706–712 (2004). 
152. Ben-Hur, T. et al. Serial in vivo MR tracking of magnetically labeled neural spheres transplanted in 
chronic EAE mice. Magn. Reson. Med. 57, 164–71 (2007). 
153. Zhu, J., Wu, X. & Zhang, H. L. Adult neural stem cell therapy: expansion in vitro, tracking in vivo 
and clinical transplantation. Curr. Drug. Targets 6, 97–110 (2005). 
154. Focke, A. et al. Labeling of human neural precursor cells using ferromagnetic nanoparticles. Magn. 
Reson. Med. 60, 1321–1328 (2008). 
155. Bulte, J. W. M. et al. Neurotransplantation of magnetically labeled oligodendrocyte progenitors: 
Magnetic resonance tracking of cell migration and myelination. Proc. Natl. Acad. Sci. U. S. A. 96, 
15256–15261 (1999). 
156. Shapiro, E. M., Skrtic, S. & Koretsky, A. P. Sizing it up: cellular MRI using micron-sized iron oxide 
particles. Magn. Reson. Med. 53, 329–338 (2005). 
157. Modo, M. et al. Tracking transplanted stem cell migration using bifunctional, contrast agent-
enhanced, magnetic resonance imaging. Neuroimage 17, 803–811 (2002). 
158. Kircher, M. F., Mahmood, U., King, R. S., Weissleder, R. & Josephson, L. A multimodal 
nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor 
delineation. Cancer Res. 63, 8122–8125 (2003). 
159. Ben-Hur, T., Einstein, O. & Bulte, J. W. Stem cell therapy for myelin diseases. Curr. Drug Targets 6, 
3–19 (2005). 
160. Kim, J., Kim, P.-H., Kim, S. W. & Yun, C.-O. Enhancing the therapeutic efficacy of adenovirus in 
combination with biomaterials. Biomaterials 33, 1838–50 (2012). 
161. Plank, C., Zelphati, O. & Mykhaylyk, O. Magnetically enhanced nucleic acid delivery. Ten years of 
magnetofection - Progress and prospects. Adv. Drug Deliv. Rev. 63, 1300–1331 (2011). 
 298 
 
162. Buerli, T. et al. Efficient transfection of DNA or shRNA vectors into neurons using magnetofection. 
Nat. Protoc. 2, 3090–3101 (2007). 
163. Pickard, M. R., Barraud, P. & Chari, D. M. The transfection of multipotent neural precursor/stem cell 
transplant populations with magnetic nanoparticles. Biomaterials 32, 2274–84 (2011). 
164. Pickard, M. R. & Chari, D. M. Enhancement of magnetic nanoparticle-mediated gene transfer to 
astrocytes by “magnetofection”: effects of static and oscillating fields. Nanomedicine (Lond.) 5, 217–
232 (2010). 
165. Godbey, W. T. & Mikos, A. G. Recent progress in gene delivery using non-viral transfer complexes. 
J. Control. Release 72, 115–125 (2001). 
166. Bergen, J. M., Park, I.-K., Horner, P. J. & Pun, S. H. Nonviral approaches for neuronal delivery of 
nucleic acids. Pharm. Res. 25, 983–998 (2008). 
167. Luo, D. & Saltzman, W. M. Enhancement of transfection by physical concentration of DNA at the 
cell surface. Nat. Biotechnol. 18, 893–895 (2000). 
168. Bunnell, B. A., Muul, L. M., Donahue, R. E., Blaese, R. M. & Morgan, R. A. High-efficiency 
retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. 
Proc. Natl. Acad. Sci. USA 92, 7739–7743 (1995). 
169. Plank, C. et al. The magnetofection method: using magnetic force to enhance gene delivery. Biol. 
Chem. 384, 737–747 (2003). 
170. Mah, C. et al. Microsphere-mediated delivery of recombinant AAV vectors in vitro and in vivo. Mol. 
Ther. 1, S239 (2000). 
171. Plank, C., Scherer, F., Schillinger, U. & Anton, M. Magnetofection: enhancement and localization of 
gene delivery with magnetic particles under the influence of a magnetic field. J. Gene. Med. 2, 24 
(2000). 
172. McBain, S. C. et al. Magnetic nanoparticles as gene delivery agents: enhanced transfection in the 
presence of oscillating magnet arrays. Nanotechnology 19, 405102 (2008). 
173. Fouriki, A., Farrow, N., Clements, M. A. & Dobson, J. Evaluation of the magnetic field requirements 
for nanomagnetic gene transfection. Nano Rev. 1, 1–5 (2010). 
174. Creusat, G. et al. Proton sponge trick for pH-sensitive disassembly of polyethylenimine-based siRNA 
delivery systems. Bioconjug. Chem. 21, 994–1002 (2010). 
175. Suh, J., Wirtz, D. & Hanes, J. Efficient active transport of gene nanocarriers to the cell nucleus. Proc. 
Natl. Acad. Sci. USA 100, 3878–3882 (2003). 
176. Van der Aa, M. A. E. M. et al. The nuclear pore complex: the gateway to successful nonviral gene 
delivery. Pharm. Res. 23, 447–459 (2006). 
177. Brunner, S. et al. Cell cycle dependence of gene transfer by lipoplex, polyplex and recombinant 
adenovirus. Gene Ther. 7, 401–407 (2000). 
178. Kim, J.-B. et al. Enhanced transfection of primary cortical cultures using arginine-grafted PAMAM 
dendrimer, PAMAM-Arg. J. Control. Release 114, 110–117 (2006). 
 299 
 
179. Bettinger, T., Carlisle, R. C., Read, M. L., Ogris, M. & Seymour, L. W. Peptide-mediated RNA 
delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids 
Res. 29, 3882–3891 (2001). 
180. Zanta, M. A., Belguise-Valladier, P. & Behr, J.-P. Gene delivery: A single nuclear localization signal 
peptide is sufficient to carry DNA to the cell nucleus. Proc. Natl. Acad. Sci. USA 96, 91–96 (1999). 
181. Kyrtatos, P. G. et al. Magnetic tagging increases delivery of circulating progenitors in vascular 
injury. JACC. Cardiovasc. Interv. 2, 794–802 (2009). 
182. Yanai, A. et al. Focused magnetic stem cell targeting to the retina using superparamagnetic iron 
oxide nanoparticles. Cell Transplant. 21, 1137–1148 (2012). 
183. Schäfer, R. et al. Functional investigations on human mesenchymal stem cells exposed to magnetic 
fields and labeled with clinically approved iron nanoparticles. BMC Cell Biol. 11, 22 (2010). 
184. MacDougall, I. C. Evolution of IV iron compounds over the last century. J. Ren. Care 35, 8–13 
(2009). 
185. Laurent, N., Sapet, C., Le Gourrierec, L., Bertosio, E. & Zelphati, O. Nucleic acid delivery using 
magnetic nanoparticles: the Magnetofection technology. Ther. Deliv. 2, 471–482 (2011). 
186. Scherer, F. et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro 
and in vivo. Gene Ther. 9, 102–109 (2002). 
187. Baryshev, M., Vainauska, D., Kozireva, S. & Karpovs, A. New device for enhancement of liposomal 
magnetofection efficiency of cancer cells. World Acad. Sci. Eng. Tech. 58, 306–309 (2011). 
188. Yiu, H. H. P., McBain, S. C., Lethbridge, Z. A. D., Lees, M. R. & Dobson, J. Preparation and 
characterization of polyethylenimine-coated Fe3O4-MCM-48 nanocomposite particles as a novel 
agent for magnet-assisted transfection. J. Biomed. Mater. Res. A 92, 386–392 (2010). 
189. Petri-Fink, A., Chastellain, M., Juillerat-Jeanneret, L., Ferrari, A. & Hofmann, H. Development of 
functionalized superparamagnetic iron oxide nanoparticles for interaction with human cancer cells. 
Biomaterials 26, 2685–2694 (2005). 
190. Musyanovych, A. et al. Criteria impacting the cellular uptake of nanoparticles: A study emphasizing 
polymer type and surfactant effects. Acta Biomater. 7, 4160–4168 (2011). 
191. Al-Ali, S. Y. & Al-Hussain, S. M. An ultrastructural study of the phagocytic activity of astrocytes in 
adult rat brain. J. Anat. 188, 257–262 (1996). 
192. Nguyen, K. B. & Pender, M. P. Phagocytosis of apoptotic lymphocytes by oligodendrocytes in 
experimental autoimmune encephalomyelitis. Acta Neuropathol. 95, 40–46 (1998). 
193. Noske, W., Lentzen, H., Lange, K. & Keller, K. Phagocytotic activity of glial cells in culture. Exp. 
Cell Res. 142, 437–445 (1982). 
194. Triarhou, L. C., Cerro, M. D. E. L. & Herndon, R. M. Ultrastructural evidence for phagocytosis by 
oligodendroglia. Neurosci. Lett. 53, 185–189 (1985). 
195. Walczak, P., Kedziorek, D. a, Gilad, a a, Lin, S. & Bulte, J. W. M. Instant MR labeling of stem cells 
using magnetoelectroporation. Magn. Reson. Med. 54, 769–774 (2005). 
196. Gratton, S. E. A. et al. The effect of particle design on cellular internalization pathways. Proc. Natl. 
Acad. Sci. USA 105, 11613–11618 (2008). 
 300 
 
197. Cannon, G. J. & Swanson, J. A. The macrophage capacity for phagocytosis. J. Cell Sci. 101, 907–913 
(1992). 
198. Canton, I. & Battaglia, G. Endocytosis at the nanoscale. Chem. Soc. Rev. 41, 2718–2739 (2012). 
199. Conner, S. D. & Schmid, S. L. Regulated portals of entry into the cell. Nature 422, 37–44 (2003). 
200. Swanson, J. A. & Watts, C. Macropinocytosis. Trends Cell Biol. 5, 424–428 (1995). 
201. Mercer, J. & Helenius, A. Gulping rather than sipping: macropinocytosis as a way of virus entry. 
Curr. Opin. Microbiol. 15, 490–499 (2012). 
202. Kumari, S., Mg, S. & Mayor, S. Endocytosis unplugged: multiple ways to enter the cell. Cell Res. 20, 
256–275 (2010). 
203. Chithrani, B. D. & Chan, W. C. W. Elucidating the mechanism of cellular uptake and removal of 
protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 7, 1542–1550 (2007). 
204. Thorek, D. L. J. & Tsourkas, A. Size, charge and concentration dependent uptake of iron oxide 
particles by non-phagocytic cells. Biomaterials 29, 3583–3590 (2008). 
205. Hutter, E. et al. Microglial response to gold nanoparticles. ACS Nano 4, 2595–2606 (2010). 
206. Qiu, Y. et al. Surface chemistry and aspect ratio mediated cellular uptake of Au nanorods. 
Biomaterials 31, 7606–19 (2010). 
207. Weill, C. O., Biri, S. & Erbacher, P. Cationic lipid-mediated intracellular delivery of antibodies into 
live cells. Biotechniques 44, Pvii–Pxi (2008). 
208. Xia, T., Kovochich, M., Liong, M., Zink, J. I. & Nel, A. E. Cationic polystyrene nanosphere toxicity 
depends on cell-specific endocytic and mitochondrial injury pathways. ACS Nano 2, 85–96 (2008). 
209. Xu, M., Zhao, Y. & Feng, M. Polyaspartamide derivative nanoparticles with tunable surface charge 
achieve highly efficient cellular uptake and low cytotoxicity. Langmuir 28, 11310–11318 (2012). 
210. Lin, J., Zhang, H., Chen, Z. & Zheng, Y. Penetration of lipid membranes by gold nanoparticles: 
insights into cellular uptake, cytotoxicity, and their relationship. ACS Nano 4, 5421–5429 (2010). 
211. Wilhelm, C. et al. Intracellular uptake of anionic superparamagnetic nanoparticles as a function of 
their surface coating. Biomaterials 24, 1001–11 (2003). 
212. Verma, A. & Stellacci, F. Effect of surface properties on nanoparticle-cell interactions. Small 6, 12–
21 (2010). 
213. Safi, M., Courtois, J., Seigneuret, M., Conjeaud, H. & Berret, J.-F. The effects of aggregation and 
protein corona on the cellular internalization of iron oxide nanoparticles. Biomaterials 32, 9353–63 
(2011). 
214. Monopoli, M. P. et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo 
biological impacts of nanoparticles. J. Am. Chem. Soc. 133, 2525–2534 (2011). 
215. Walczyk, D., Bombelli, F. B., Monopoli, M. P., Lynch, I. & Dawson, K. A. What the cell “sees” in 
bionanoscience. J. Am. Chem. Soc. 132, 5761–5768 (2010). 
216. Jing, Y. et al. Quantitative intracellular magnetic nanoparticle uptake measured by live cell 
magnetophoresis. FASEB J. 22, 4239–4247 (2008). 
 301 
 
217. Prijic, S. et al. Increased cellular uptake of biocompatible superparamagnetic iron oxide 
nanoparticles into malignant cells by an external magnetic field. J. Membr. Biol. 236, 167–179 
(2010). 
218. Chaudhari, K. R. et al. Opsonization, biodistribution, cellular uptake and apoptosis study of 
PEGylated PBCA nanoparticle as potential drug delivery carrier. Pharm. Res. 29, 53–68 (2011). 
219. Soenen, S. J. H. et al. Intracellular nanoparticle coating stability determines nanoparticle diagnostics 
efficacy and cell functionality. Small 6, 2136–2145 (2010). 
220. Dos Santos, T., Varela, J., Lynch, I., Salvati, A. & Dawson, K. A. Quantitative assessment of the 
comparative nanoparticle-uptake efficiency of a range of cell lines. Small 7, 3341–3349 (2011). 
221. Kim, J.-S. & Yoon, T.-J. Cellular uptake of magnetic nanoparticle is mediated through energy-
dependent endocytosis in A549 cells. J. Vet. Sci. 7, 321–326 (2006). 
222. Pinkernelle, J., Calatayud, P., Goya, G. F., Fansa, H. & Keilhoff, G. Magnetic nanoparticles in 
primary neural cell cultures are mainly taken up by microglia. BMC Neurosci. 13, 32 (2012). 
223. Greene, L. A. & Tischler, A. S. Establishment of a noradrenergic clonal line of rat adrenal 
pheochromocytoma cells which respond to nerve growth factor. Proc. Natl. Acad. Sci. USA 73, 
2424–2428 (1976). 
224. Connolly, J. L., Green, S. A. & Greene, L. A. Comparison of rapid changes in surface morphology 
and coated pit formation of PC12 cells in response to nerve growth factor, epidermal growth factor, 
and dibutyryl cyclic AMP. J. Cell Biol. 98, 457–465 (1984). 
225. Pisanic, T. R. 2nd, Blackwell, J. D., Shubayev, V. I., Fiñones, R. R. & Jin, S. Nanotoxicity of iron 
oxide nanoparticle internalization in growing neurons. Biomaterials 28, 2572–2581 (2007). 
226. American Type Culture Collection Standards Development Organization Workgroup ASN-0002 Cell 
line misidentification: the beginning of the end. Nat. Rev. Cancer 10, 441–448 (2010). 
227. Nardone, R. M. Curbing rampant cross-contamination and misidentification of cell lines. 
Biotechniques 45, 221–227 (2008). 
228. Buehring, G. C., Eby, E. A. & Eby, M. J. Cell line cross-contamination: how aware are Mammalian 
cell culturists of the problem and how to monitor it? In Vitro Cell. Dev. Biol. Anim. 40, 211–5 (2004). 
229. Bubeník, J. Cross-contamination of cell lines in culture. Folia Bio. (Praha) 46, 163–164 (2000). 
230. Rojas, A. Cell line cross-contamination: who wins? J. Biol. Chem. 286, le20 (2011). 
231. MacLeod, R. A. F. et al. Widespread intraspecies cross-contamination of human tumor cell lines 
arising at source. Int. J. Cancer 83, 555–563 (1999). 
232. Freshney, R. I. Cell line provenance. Cytotechnology 39, 55–67 (2002). 
233. Parks, G. Manual of Animal Technology. The Canadian Veterinary Journal pp374 (2009). 
234. Freshney, R. I. Culture of Animal Cells: A Manual of Basic Technique. (John Wiley & Sons, Inc.: 
2005).doi:10.1002/cii.8 
235. Hughes, P., Marshall, D., Reid, Y., Parkes, H. & Gelber, C. The costs of using unauthenticated, over-
passaged cell lines: how much more data do we need? BioTechniques 43, 575–586 (2007). 
 302 
 
236. Nel, A., Xia, T., Mädler, L. & Li, N. Toxic potential of materials at the nanolevel. Science 311, 622–
627 (2006). 
237. Hansmann, F. et al. Highly malignant behavior of a murine oligodendrocyte precursor cell line 
following transplantation into the demyelinated and non-demyelinated central nervous system. Cell 
Transplant. 21, 1161–1175 (2012). 
238. Kitada, M. & Rowitch, D. H. Transcription factor co-expression patterns indicate heterogeneity of 
oligodendroglial subpopulations in adult spinal cord. Glia 54, 35–46 (2006). 
239. Abrajano, J. J. et al. Differential deployment of REST and CoREST promotes glial subtype 
specification and oligodendrocyte lineage maturation. PLoS One 4, e7665 (2009). 
240. Pickard, M. R., Jenkins, S. I., Koller, C., Furness, D. N. & Chari, D. M. Magnetic nanoparticle 
labelling of astrocytes derived for neural transplantation. Tissue Eng., Part C 17, 89–99 (2011). 
241. Pickard, M. R. & Chari, D. M. Robust uptake of magnetic nanoparticles (MNPs) by central nervous 
system (CNS) microglia: implications for particle uptake in mixed neural cell populations. Int. J. 
Mol. Sci. 11, 967–981 (2010). 
242. Sharp, J., Frame, J., Siegenthaler, M., Nistor, G. & Keirstead, H. S. Human embryonic stem cell-
derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord 
injury. Stem Cells 28, 152–163 (2010). 
243. Lachapelle, F. et al. Transplanted transgenically marked oligodendrocytes survive, migrate and 
myelinate in the normal mouse brain as they do in the shiverer mouse brain. Eur. J. Neurosci. 6, 814–
824 (1994). 
244. Richter-Landsberg, C. & Heinrich, M. OLN-93: a new permanent oligodendroglia cell line derived 
from primary rat brain glial cultures. J. Neurosci. Res. 45, 161–173 (1996). 
245. Jain, T. et al. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic 
resonance imaging. Biomaterials 29, 4012–4021 (2008). 
246. Jasmin et al. Optimized labeling of bone marrow mesenchymal cells with superparamagnetic iron 
oxide nanoparticles and in vivo visualization by magnetic resonance imaging. J. Nanobiotechnology 
9, 4 (2011). 
247. Ståhlberg, A. et al. Defining cell populations with single-cell gene expression profiling: correlations 
and identification of astrocyte subpopulations. Nucleic Acids Res. 39, 1–12 (2011). 
248. Bouslama-Oueghlani, L., Wehrle, R., Sotelo, C. & Dusart, I. Heterogeneity of NG2-expressing cells 
in the newborn mouse cerebellum. Dev. Biol. 285, 409–421 (2005). 
249. Geppert, M. et al. Uptake of dimercaptosuccinate-coated magnetic iron oxide nanoparticles by 
cultured brain astrocytes. Nanotechnology 22, 145101 (2011). 
250. Yang, Z. et al. A review of nanoparticle functionality and toxicity on the central nervous system. J. 
R. Soc. Interface 7, S411–422 (2010). 
251. Busch, W. et al. Internalisation of engineered nanoparticles into mammalian cells in vitro: influence 
of cell type and particle properties. J. Nanopart. Res. 13, 293–310 (2010). 
252. Chissoe, W. F., Vezey, E. L. & Skvarla, J. J. The use of osmium-thiocarbohydrazide for structural 
stabilization and enhancement of secondary electron images in scanning electron microscopy of 
pollen. Grana 34, 317–324 (1995). 
 303 
 
253. Jongebloed, W. L., Stokroos, I., Kalicharan, D. & Van der Want, J. J. L. Is cryopreservation superior 
over tannic acid/arginine/osmium tetroxide non-coating preparation in field emission scanning 
electron microscopy? Scanning Microsc. 13, 93–109 (1999). 
254. Friedman, P. L. & Ellisman, M. H. Enhanced visualization of peripheral nerve and sensory receptors 
in the scanning electron microscope using cryofracture and osmium-thiocarbohydrazide-osmium 
impregnation. J. Neurocytol. 10, 111–131 (1981). 
255. Grandfield, K. Focused ion beam in the study of biomaterials and biological matter. Adv. Mater. Sci. 
Eng. 2012, 1–6 (2011). 
256. Dunnebier, E., Segenhout, J. & Kalicharan, D. Low-voltage field-emission scanning electron 
microscopy of non-coated guinea-pig hair cell stereocilia. Hear. Res. 90, 139–148 (1995). 
257. McGregor, J. E., Wang, Z., Ffrench-Constant, C. & Donald, A. M. Microscopy of myelination. 
Microscopy: Science, technology, applications and education pp1185–1195 (2010). 
258. Forge, A., Nevill, G., Zajic, G. & Wright, A. Scanning electron microscopy of the mammalian organ 
of corti: assessment of preparative procedures. Scanning Microsc. 6, 521–534 (1992). 
259. Furness, D. N., Mahendrasingam, S., Ohashi, M., Fettiplace, R. & Hackney, C. M. The dimensions 
and composition of stereociliary rootlets in mammalian cochlear hair cells: comparison between 
high- and low-frequency cells and evidence for a connection to the lateral membrane. J. Neurosci. 28, 
6342–6353 (2008). 
260. De la Fuente, J. M., Berry, C. C., Riehle, M. O. & Curtis, A. S. G. Nanoparticle targeting at cells. 
Langmuir 22, 3286–93 (2006). 
261. Gupta, A. K., Berry, C. C., Gupta, M. & Curtis, A. Receptor-mediated targeting of magnetic 
nanoparticles using insulin as a surface ligand to prevent endocytosis. IEEE Trans. Nanobioscience 
2, 255–261 (2003). 
262. Berry, C. C., Wells, S., Charles, S., Aitchison, G. & Curtis, A. S. G. Cell response to dextran-
derivatised iron oxide nanoparticles post internalisation. Biomaterials 25, 5405–5413 (2004). 
263. McCarthy, K. D. & De Vellis, J. Preparation of separate astroglial and oligodendroglial cell cultures 
from rat cerebral tissue. J. Cell Biol. 85, 890–902 (1980). 
264. Florez, L. et al. How shape influences uptake: interactions of anisotropic polymer nanoparticles and 
human mesenchymal stem cells. Small 8, 2222–2230 (2012). 
265. Ang, D. et al. Insights into the mechanism of magnetic particle assisted gene delivery. Acta 
Biomater. 7, 1319–1326 (2011). 
266. Borchert, H. et al. Determination of nanocrystal sizes: a comparison of TEM, SAXS, and XRD 
studies of highly monodisperse CoPt3 particles. Langmuir 21, 1931–1936 (2005). 
267. Rubio, N., Rodriguez, R. & Arevalo, M. A. In vitro myelination by oligodendrocyte precursor cells 
transfected with the neurotrophin-3 gene. Glia 47, 78–87 (2004). 
268. Zhang, S., Li, J., Lykotrafitis, G., Bao, G. & Suresh, S. Size-dependent endocytosis of nanoparticles. 
Adv. Mater. 21, 419–424 (2009). 
269. Tenzer, S. et al. Nanoparticle size is a critical physicochemical determinant of the human blood 
plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 5, 7155–7167 (2011). 
 304 
 
270. Jiang, W., Kim, B. Y. S., Rutka, J. T. & Chan, W. C. W. Nanoparticle-mediated cellular response is 
size-dependent. Nat. Nanotechnol. 3, 145–150 (2008). 
271. Sanchez-Antequera, Y. et al. Magselectofection: an integrated method of nanomagnetic separation 
and genetic modification of target cells. Blood 117, e171–181 (2011). 
272. Summers, H. D. et al. Statistical analysis of nanoparticle dosing in a dynamic cellular system. Nat. 
Nanotech. 6, 170–174 (2011). 
273. Hohnholt, M. C., Geppert, M. & Dringen, R. Treatment with iron oxide nanoparticles induces ferritin 
synthesis but not oxidative stress in oligodendroglial cells. Acta Biomater. 7, 3946–3954 (2011). 
274. Hirrlinger, J., Resch, A., Gutterer, J. M. & Dringen, R. Oligodendroglial cells in culture effectively 
dispose of exogenous hydrogen peroxide: comparison with cultured neurones, astroglial and 
microglial cells. J. Neurochem. 82, 635–644 (2002). 
275. Fisichella, M. et al. Mesoporous silica nanoparticles enhance MTT formazan exocytosis in HeLa 
cells and astrocytes. Toxicol. In Vitro 23, 697–703 (2009). 
276. Berry, C. C., Wells, S., Charles, S. & Curtis, A. S. G. Dextran and albumin derivatised iron oxide 
nanoparticles: influence on fibroblasts in vitro. Biomaterials 24, 4551–4557 (2003). 
277. Cengelli, F. et al. Interaction of functionalized superparamagnetic iron oxide nanoparticles with brain 
structures. J. Pharmacol. Exp. Ther. 318, 108–116 (2006). 
278. Marquis, B. J., Love, S. A., Braun, K. L. & Haynes, C. L. Analytical methods to assess nanoparticle 
toxicity. Analyst 134, 425–439 (2009). 
279. Allen, T. Introduction to electron microscopy for biologists. (Elsevier Inc.: Burlington, MA, USA, 
2008). 
280. Dhawan, A. & Sharma, V. Toxicity assessment of nanomaterials: methods and challenges. Anal. 
Bioanal. Chem. 398, 589–605 (2010). 
281. Bjørnerud, A. & Johansson, L. The utility of superparamagnetic contrast agents in MRI: theoretical 
consideration and applications in the cardiovascular system. NMR Biomed. 17, 465–477 (2004). 
282. Murray, M. & Fischer, I. Transplantation and gene therapy: combined approaches for repair of spinal 
cord injury. Neuroscientist 7, 28–41 (2001). 
283. Filbin, M. T. Recapitulate development to promote axonal regeneration: good or bad approach? 
Philos. Trans. R. Soc. Lond. B. Biol. Sci. 361, 1565–1574 (2006). 
284. Duncan, I. D. Replacing cells in multiple sclerosis. J. Neurol. Sci. 265, 89–92 (2008). 
285. Madhavan, L. & Collier, T. J. A synergistic approach for neural repair: cell transplantation and 
induction of endogenous precursor cell activity. Neuropharmacology 58, 835–44 (2010). 
286. Huang, J. K. et al. Myelin regeneration in multiple sclerosis: targeting endogenous stem cells. 
Neurotherapeutics 8, 650–658 (2011). 
287. Wolswijk, G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of 
oligodendrocyte precursor cells. J. Neurosci. 18, 601–609 (1998). 
288. GIBCO Neon
TM
 Transfection Protocol for GIBCO® Rat Glial Precursor Cells (GPCs). 
http://protocolexchange.community.invitrogen.com/protocol/1036/protocol-1036.pdf  
 305 
 
289. www.lonzabio.com Amaxa Nucleofector Protocol for Rat Oligodendrocytes. Lonzabio protocol  
290. Anitei, M. et al. A role for Sec8 in oligodendrocyte morphological differentiation. J. Cell Sci. 119, 
807–818 (2006). 
291. Fallini, C., Bassell, G. J. & Rossoll, W. High-efficiency transfection of cultured primary motor 
neurons to study protein localization, trafficking, and function. Mol. Neurodegener. 5, 17 (2010). 
292. Sapet, C. et al. High transfection efficiency of neural stem cells with magnetofection. BioTechniques 
50, 187–189 (2011). 
293. Regenberg, A. et al. The role of animal models in evaluating reasonable safety and efficacy for 
human trials of cell-based interventions for neurologic conditions. J. Cereb. Blood Flow Metab. 29, 
1–9 (2009). 
294. Seil, F. J. Tissue culture models of myelination after oligodendrocyte transplantation. J. Neural 
Transplant. 1, 49–55 (1989). 
295. Seil, F. J., Johnson, M. L., Saneto, R. P., Herndon, R. M. & Mass, M. K. Myelination of axons within 
cytosine arabinoside treated mouse cerebellar explants by cultured rat oligodendrocytes. Brain Res. 
503, 111–117 (1989). 
296. Davidson, S. et al. Differential activity by polymorphic variants of a remote enhancer that supports 
galanin expression in the hypothalamus and amygdala: implications for obesity, depression and 
alcoholism. Neuropsychopharmacology 36, 2211–2221 (2011). 
297. Pickard, M. R. & Chari, D. M. Magnetic nanoparticle applications for neural stem cell transplantation 
therapies. Programme of the Fourth Annual Scientific Conference of the UK National Stem Cell 
Network, University of York (2011). 
298. Furlani, E. P. & Ng, K. C. Nanoscale magnetic biotransport with application to magnetofection. 
Phys. Rev. 77, 061094 (2008). 
299. Verwer, R. W. H. et al. Cells in human postmortem brain tissue slices remain alive for several weeks 
in culture. FASEB J. 16, 54–60 (2002). 
300. Choi, J. Y. et al. In vitro cytotoxicity screening of water-dispersible metal oxide nanoparticles in 
human cell lines. Bioprocess Biosyst. Eng. 33, 21–30 (2010). 
301. Gómez-Pinilla, F., Vu, L. & Cotman, C. W. Regulation of astrocyte proliferation by FGF-2 and 
heparan sulfate in vivo. J. Neurosci. 15, 2021–2029 (1995). 
302. Forget, C., Stewart, J. & Trudeau, L.-E. Impact of basic FGF expression in astrocytes on dopamine 
neuron synaptic function and development. Eur. J. Neurosci. 23, 608–616 (2006). 
303. Leclere, P. G. et al. Effective gene delivery to adult neurons by a modified form of electroporation. J. 
Neurosci. Meth. 142, 137–143 (2005). 
304. Chen, C.-J. et al. Identification of a key pathway required for the sterile inflammatory response 
triggered by dying cells. Nat. Med. 13, 851–856 (2007). 
305. Tokumoto, Y. M., Apperly, J. A., Gao, F.-B. & Raff, M. C. Posttranscriptional regulation of p18 and 
p27 Cdk inhibitor proteins and the timing of oligodendrocyte differentiation. Dev. Biol. 245, 224 –
234 (2002). 
 306 
 
306. Hermens, W. T. J. M. C. et al. Transient gene transfer to neurons and glia: analysis of adenoviral 
vector performance in the CNS and PNS. J. Neursoci. Methods 71, 85–98 (1997). 
307. Tang, X. M. et al. Cell cycle arrest induced by ectopic expression of p27 is not sufficient to promote 
oligodendrocyte differentiation. J. Cell Biochem. 76, 270–279 (1999). 
308. Blakemore, W. F. Regeneration and repair in multiple sclerosis: the view of experimental pathology. 
J. Neurol. Sci. 265, 1–4 (2008). 
309. Baron, W. et al. PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of 
proliferation and differentiation by multiple intracellular signaling pathways. Mol. Cell Neurosci. 15, 
314–329 (2000). 
310. Fan, R. et al. Minocycline reduces microglial activation and improves behavioral deficits in a 
transgenic model of cerebral microvascular amyloid. J. Neurosci. 27, 3057–3063 (2007). 
311. Dobson, J. Remote control of cellular behaviour with magnetic nanoparticles. Nat. Nanotechnol. 3, 
139–143 (2008). 
312. Kamau, S. W. et al. Enhancement of the efficiency of non-viral gene delivery by application of 
pulsed magnetic field. Nucleic Acids Res. 34, e40 (2006). 
313. Smith, C.-A. M. et al. The effect of static magnetic fields and tat peptides on cellular and nuclear 
uptake of magnetic nanoparticles. Biomaterials 31, 4392–4400 (2010). 
314. Birgbauer, E., Rao, T. S. & Webb, M. Lysolecithin induces demyelination in vitro in a cerebellar 
slice culture system. J. Neurosci. Res. 78, 157–166 (2004). 
315. Jarjour, A. A., Zhang, H., Bauer, N., Ffrench-Constant, C. & Williams, A. In vitro modeling of 
central nervous system myelination and remyelination. Glia 60, 1–12 (2012). 
316. Johnson, S. L. et al. Synaptotagmin IV determines the linear Ca2+ dependence of vesicle fusion at 
auditory ribbon synapses. Nat. Neurosci. 13, 45–52 (2010). 
317. Jasinska, M. et al. Rapid, learning-induced inhibitory synaptogenesis in murine barrel field. J. 
Neurosci. 30, 1176–1184 (2010). 
318. Bonnici, B. & Kapfhammer, J. P. Spontaneous regeneration of intrinsic spinal cord axons in a novel 
spinal cord slice culture model. Eur. J. Neurosci. 27, 2483–2492 (2008). 
319. Sun, Y.-Y. et al. Glucocorticoid protection of oligodendrocytes against excitotoxin involving 
hypoxia-inducible factor-1alpha in a cell-type-specific manner. J. Neurosci. 30, 9621–9630 (2010). 
320. Abdellatif, A. A. et al. Gene delivery to the spinal cord: comparison between lentiviral, adenoviral, 
and retroviral vector delivery systems. J. Neurosci. Res. 84, 553–567 (2006). 
321. Halfpenny, C. A. Remyelination biology: The neurobiology of oligodendrocyte progenitor cells and 
their potential for myelin repair in Multiple Sclerosis. PhD Thesis (2003). 
322. Kippert, A., Trajkovic, K., Rajendran, L., Ries, J. & Simons, M. Rho regulates membrane transport 
in the endocytic pathway to control plasma membrane specialization in oligodendroglial cells. J. 
Neurosci. 27, 3560–3570 (2007). 
323. Dugas, J. C., Tai, Y. C., Speed, T. P., Ngai, J. & Barres, B. A. Functional genomic analysis of 
oligodendrocyte differentiation. J. Neurosci. 26, 10967–10983 (2006). 
 307 
 
324. Tang, D. G., Tokumoto, Y. M. & Raff, M. C. Long-term culture of purified postnatal 
oligodendrocyte precursor cells. Evidence for an intrinsic maturation program that plays out over 
months. J. Cell Biol. 148, 971–984 (2000). 
325. Simons, M. & Trajkovic, K. Neuron-glia communication in the control of oligodendrocyte function 
and myelin biogenesis. J. Cell Sci. 119, 4381–4389 (2006). 
326. Broughton, S. K. et al. Large-scale generation of highly enriched neural stem-cell-derived 
oligodendroglial cultures: maturation-dependent differences in insulin-like growth factor-mediated 
signal transduction. J. Neurochem. 100, 628–638 (2007). 
327. Zauner, W., Brunner, S., Buschle, M., Ogris, M. & Wagner, E. Differential behaviour of lipid based 
and polycation based gene transfer systems in transfecting primary human fibroblasts: a potential role 
of polylysine in nuclear transport. Biochim. Biophys. Acta 1428, 57–67 (1999). 
328. Barres, B. A. The mystery and magic of glia: a perspective on their roles in health and disease. 
Neuron 60, 430–40 (2008). 
329. Park, J.-Y. et al. On the mechanism of internalization of alpha-synuclein into microglia: roles of 
ganglioside GM1 and lipid raft. J. Neurochem. 110, 400–411 (2009). 
330. Pocock, J. M. & Liddle, A. C. Microglial signalling cascades in neurodegenerative disease. Prog. 
Brain Res. 132, 555–565 (2001). 
331. Nair, A., Frederick, T. J. & Miller, S. D. Astrocytes in multiple sclerosis: a product of their 
environment. Cell Mol. Life Sci. 65, 2702–2720 (2008). 
332. Magistretti, P. J. & Ransom, B. R. Astrocytes. Neuropharmacology: The fifth generation of progress 
pp181–208 (2002). 
333. Iacono, R. F. & Berria, M. I. Cell differentiation increases astrocyte phagocytic activity. A 
quantitative analysis of both GFAP labeling and PAS-stained yeast cells. Medicina (B. Aires) 59, 
171–175 (1999). 
334. Sherwood, C. C. et al. Evolution of increased glia-neuron ratios in the human frontal cortex. Proc. 
Natl. Acad. Sci. USA 103, 13606–13611 (2006). 
335. Jehee, J. F. M. & Murre, J. M. J. The scalable mammalian brain: emergent distributions of glia and 
neurons. Biol. Cybern. 98, 439–445 (2008). 
336. Zhu, X., Bergles, D. E. & Nishiyama, A. NG2 cells generate both oligodendrocytes and gray matter 
astrocytes. Development 135, 145–157 (2008). 
337. De Palma, R. et al. Silane ligand exchange to make hydrophobic superparamagnetic nanoparticles 
water-dispersible. Chem. Mater. 19, 1821–1831 (2007). 
338. Chen, Z. et al. Dual enzyme-like activities of iron oxide nanoparticles and their implication for 
diminishing cytotoxicity. ACS Nano 6, 4001–4012 (2012). 
339. Fleige, G. et al. Magnetic labeling of activated microglia in experimental gliomas. Neoplasia 3, 489–
99 (2001). 
340. Schädlich, A. et al. How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with 
detailed size measurements. Pharm. Res. 28, 1995–2007 (2011). 
 308 
 
341. Bouzier-Sore, A.-K. et al. Nanoparticle phagocytosis and cellular stress: involvement in cellular 
imaging and in gene therapy against glioma. NMR Biomed. 23, 88–96 (2010). 
342. Hillaireau, H. & Couvreur, P. Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol. 
Life Sci. 66, 2873–2896 (2009). 
343. Kumar, A. et al. Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine 6, 64–
69 (2010). 
344. Liu, J. Scanning transmission electron microscopy and its application to the study of nanoparticles 
and nanoparticle systems. J. Electron Microsc. (Tokyo) 54, 251–278 (2005). 
345. Chen, T. et al. Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic 
resonance imaging. ACS Nano 5, 7866–7873 (2011). 
346. Guilhon, E. et al. Spatial and temporal control of transgene expression in vivo using a heat-sensitive 
promoter and MRI-guided focused ultrasound. J. Gene Med. 5, 333–342 (2003). 
347. Johannsen, M., Thiesen, B., Wust, P. & Jordan, A. Magnetic nanoparticle hyperthermia for prostate 
cancer. Int. J. Hyperthermia 26, 790–795 (2010). 
348. Clancy, B., Darlington, R. B. & Finlay, B. L. Translating developmental time across mammalian 
species. Science 105, 7–17 (2001). 
349. Clancy, B., Finlay, B. L., Darlington, R. B. & Anand, K. J. S. Extrapolating brain development from 
experimental species to humans. Neurotoxicology 28, 931–937 (2007). 
350. Jeong, D.-K., Taghavi, C. E., Song, K.-J., Lee, K.-B. & Kang, H.-W. Organotypic human spinal cord 
slice culture as an alternative to direct transplantation of human bone marrow precursor cells for 
treating spinal cord injury. World Neurosurg. 75, 533–539 (2011). 
351. Fukushima, T., Tezuka, T., Shimomura, T., Nakano, S. & Kataoka, H. Silencing of insulin-like 
growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and 
expression of progression-associated gene CD24. J. Biol. Chem. 282, 18634–18644 (2007). 
352. Dinkel, K., Ogle, W. O. & Sapolsky, R. M. Glucocorticoids and central nervous system 
inflammation. J. Neurovirol. 8, 513–528 (2002). 
353. Havrdova, E., Horakova, D., Kovarova, I. & Krasulova, E. Future directions in the treatment of 
Multiple Sclerosis. Casopis Lekaru Ceskych 144, 663–665 (2005). 
354. Jain, T. K., Reddy, M. K., Morales, M. A., Leslie-Pelecky, D. L. & Labhasetwar, V. Biodistribution, 
clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Molec. Pharm. 5, 316–
327 (2008). 
355. Tandon, P. & Nordstrom, R. J. Next-generation imaging development for nanoparticle biodistribution 
measurements. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3, 5–10 (2011). 
356. Rosner, M. H. & Auerbach, M. Ferumoxytol for the treatment of iron deficiency. Expert Rev. 
Hematol. 4, 399–406 (2011). 
357. Schwenk, M. H. Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency 
anemia in patients with chronic kidney disease. Pharmacotherapy 30, 70–79 (2010).  
 
